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Abstract 
 
Apoptotic cells (AC) are able to modulate the immune system, dampening inflammation 
and triggering anti-inflammatory responses by various immune cells as a consequence of 
interaction and uptake. Rituximab (RTX) is an anti-CD20 monoclonal antibody used as a 
treatment in several autoimmune diseases, including rheumatoid arthritis (RA). 
Treatment results in B cell depletion, with B cell apoptosis known to contribute to RTX-
mediated B cell death. However the simple removal of B cells from the system does not 
seem to account for all the beneficial effects of this biologic. We propose that RTX 
treatment in RA results in the re-establishment of temporary tolerance to the system, 
through an apoptotic B cell-dependent mechanism.  
Initial in vitro and in vivo investigations were undertaken to explore the validity of this 
hypothesis. The present work sought to examine the immunomodulatory capacity of 
apoptotic B cells and to determine whether the potential anti-inflammatory effects of 
apoptotic B cells are modulated by RTX, with both in vitro methods and an in vivo 
model of autoimmunity utilized in these studies. The results presented in this thesis 
demonstrate that apoptotic B cells have comparable effects on bone marrow derived 
macrophage (BMDM) phenotype and function in vitro as previously described AC from 
other cellular sources. Surprisingly, in the in vitro assay system used, viable cells had 
the same immunomodulatory effects on BMDM as AC, for all criteria investigated. 
Preliminary studies indicate this may be a promising avenue of inquiry, however further 
work is needed before a conclusion can be reached as to the relative level of 
involvement of apoptotic B cell-mediated tolerance in the improvement seen on RTX 
treatment in RA. 
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F  
 FACS   fluorescence-activated cell sorter 
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 GAD    glutamic acid decarboxylase 
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 MARCO   macrophage receptor with collagenous structure 
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 MFG-E8  milk-fat globule EGF factor 8 
 MFI   mean fluorescence intensity  
 MHC I   major histocompatibility complex class I 
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 MZ   marginal zone 
N 
 NFκB   nuclear factor kappa B 
 NK cell   natural killer cell 
 NHL   non-Hodgkin’s lymphoma 
 NO   nitric oxide 
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 RU   relative units 
S  
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1.1 The Immune System 
The immune system has evolved to protect the body from invasion by pathogens, with 
the ability to recognize and mount an appropriate response to foreign antigens crucial 
for maintaining the health of an individual. In addition to this role in protection, the 
immune system is also responsible for the regulation of tolerance to harmless antigens, 
such as self-antigens. If a breakdown in tolerance occurs, unnecessary inflammatory 
responses are mounted that can result in chronic and detrimental inflammation, known 
as autoimmunity. 
The immune system is comprised of two main branches, the innate immune system and 
the adaptive immune system, which work in close contact with one another. The innate 
immune system mounts the first line of defence, quickly responding to infection, while 
the adaptive immune system offers a slower, but more tailored response to specific 
pathogens, providing immunological memory and allowing an enhanced immune 
response on repeated encounters with a particular antigen. 
1.2 Innate Immunity 
The innate immune system has evolved to detect common, invariant molecular patterns 
expressed by pathogenic microorganisms, termed PAMPs (pathogen-associated 
molecular patterns), a concept originally proposed in the 1980s by Charles Janeway Jr 
[1]. Recognition of these molecular patterns results in the initiation of non-specific 
immune responses, and defects or deficiencies in innate effector mechanisms, such as 
the myeloid cell compartment [reviewed in [2] or complement proteins [reviewed in 
[3], results in recurrent microbial infections of varying severity.  
The cellular component of the innate immune system is comprised of a number of 
distinct cell types: the myeloid cells (monocytes, macrophages and dendritic cells 
(DCs)), the granulocytes (neutrophils, eosinophils and basophils), and mast cells. Innate 
immune cells express a wide range of receptors known collectively as pattern 
recognition receptors (PRRs). PRRs recognise molecular patterns common to microbes, 
and can also recognise altered self-epitopes, such as those exposed during cell death. 
Toll-like receptors (TLRs) play a key 
 role in the recognition of microbial structures, initiating responses to a wide range of 
extracellular and endosomal microbes. TLR4 is expressed on the surface of innate 
effector cells, and as part of the TLR4:MD-2 complex is able to detect 
lipopolysaccharide (LPS) [4], a constituent of the cell membrane of Gram-negative 
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bacteria. TLR7 and TLR8 are localized to endosomes and bind to viral single-stranded 
RNA [5]. Scavenger receptors (SR) encompass a broad range of molecules expressed on 
the surface of macrophages and dendritic cells (DCs), as well as certain endothelial 
cells. SR-A binds to lipoteichoic acid [6], a major constituent of the cell wall of Gram-
positive bacteria, while LOX-1 (lectin-like oxidised LDL-receptor 1) is able to bind both 
Gram-positive and Gram-negative bacterial products [7]. Detection of intracellular 
PAMPs is undertaken by cytosolic PRRs, including NOD-like receptors [8] and RIG-I-like 
receptors [9]. Recognition of pathogens via PRRs results in the initiation of multiple 
responses by innate cells. The production of chemokines recruits additional effector 
cells to sites of inflammation, the secretion of pro-inflammatory cytokines activates 
cells and helps to direct the immune response, and the up-regulation of co-stimulation 
molecules enables initiation of adaptive immune responses. 
The complement cascade, along with collectins and ficolins [reviewed in [10], can be 
seen as the humoral arm of the innate immune response, contributing to the non-
adaptive recognition of pathogens. Activation of the complement cascade results in the 
opsonization of target cells/microbes, mediating the removal of pathogens, through the 
recruitment and modulation of effector cells, the activation of pro-inflammatory 
mediators and direct killing by anti-microbial complexes.  
Innate responses are immediate, but non-clonal. Activation of innate immunity initiates 
microbial clearance and containment, while alerting the adaptive immune response to 
the potential threat. The combination of innate and adaptive immunity generates a 
multifaceted response with the ability to recognize both invariant molecular patterns 
and specific antigens expressed by the pathogen, enabling its effective eradication from 
the system. 
1.3 Macrophages 
Macrophages are a heterogeneous immune cell population, which are present in almost 
all tissues of the body and are one of the main innate immune cells involved in the 
homeostatic clearance of dead and dying cells, a topic that will be discussed in depth 
later in this introduction. They are highly phagocytic cells, constitutively expressing a 
wide range of PRRs, including scavenger receptors, TLRs, phosphatidylserine receptors, 
integrins and complement receptors, enabling the recognition of specific phagocytic or 
endocytic ligands (see sections 1.2 and 1.8).  
It was originally proposed that phagocytic mononuclear cells, including all macrophage 
populations, differentiated from circulating peripheral blood monocytes after migration 
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into the tissues, with this model known as the mononuclear phagocyte system (MPS) 
[11]. More recently, however, it has been demonstrated that this cell type can arise 
through several, distinct developmental pathways. During an immune response, 
circulating monocytes are recruited to sites of inflammation, differentiating into 
inflammatory macrophages, following a developmental pathway in keeping with the 
original model. Multiple tissue resident macrophage populations, however, have been 
shown to consist of both monocyte-derived cells, and cells with embryonic origins able 
to undergo self-renewal in the tissue [12]. Fate-mapping studies have shown that 
Langerhans cells [13], microglia [14], splenic red pulp macrophages, alveolar 
macrophages and certain peritoneal macrophages are established prenatally [15] and 
able to undergo self-renewal in the tissues. Within these populations developmental 
pathways can differ, deriving from both the embryonic yolk sac (i.e. microglia [14]) and 
from the fetal liver (i.e. Langerhans cells [13]). It has been demonstrated that 
peripherally derived macrophages are able to replace self-renewing tissue-resident 
macrophages after experimental ablation of these populations [16], with this tissue re-
population postulated to take place under certain inflammatory settings, however it is 
not clear to what extent this occurs under physiological conditions in vivo.  
Macrophages are highly plastic cells; the effector profile of a macrophage is dependant 
on the stimuli received on activation, resulting in a spectrum of different activated 
populations in vivo [17]. This spectrum of populations can be broadly split into two main 
subsets, based on functional and biochemical differences: the classically activated, M1-
macrophages; and the alternately activated M2-macrophages, with monocyte-derived 
inflammatory macrophages classified as M1-like cells, while tissue resident macrophages 
are more M2-like in their phenotype. It is important to note however, that many 
populations of macrophages both in vitro and in vivo, do not fall fully into either of 
these subsets, with the M1/M2 descriptions offering a broad conceptual framework, 
rather than definitive populations. After differentiation into activated effector cells, 
macrophages retain a level of plasticity, and it has been postulated that the phenotype 
of a macrophage can change over time in response to environmental cues [18]. 
However, several cell surface markers are commonly used to help identify macrophages 
both in vivo and in vitro, including F4/80, CD11b, Ly6C and Ly6G [19] in the murine 
system. Cytokine production and the expression of additional cell-surface markers allow 
discrimination between different sub-populations, with the markers used for 
identification differing between human and murine cells. 
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1.3.1 M1 Macrophages 
Classically activated M1-macrophages arise during cell-mediated immune responses, and 
are the pro-inflammatory macrophage subset. They are involved in resistance against 
microbial infection and tumours, with murine M1 macrophages activated by IFNγ alone, 
or IFNγ in combination with a TLR agonist (e.g. LPS) or other cytokines (TNFα/GM-CSF). 
IFNγ stimulates macrophage antimicrobial and tumoricidal properties; on recognition 
and phagocytosis of pathogens or infected cells, the target is taken up into endocytic 
vacuoles, which become acidified [20], creating an inhospitable environment, and 
facilitating destruction of the contents. If acidification is not sufficient, these vacuoles 
can bind with lysosomes containing microbicidal enzymes, such as hydrolases [21] and 
lysozyme [22]. These activated M1 macrophages can also undergo a respiratory burst, 
resulting in the increased production of nitric oxide (NO) and reactive oxygen species 
that are directly toxic to pathogens, enhancing their killing ability and further 
mediating the removal of microbes [23]. The uptake and destruction of pathogens by M1 
macrophages results in the production of danger signals, such as the pro-inflammatory 
cytokines IL-1β, IL-6, IL-12, IL-23, TNFα and IFNγ, as well as chemokines and growth 
factors. The production of pro-inflammatory signals, combined with the expression of 
high-levels of surface MHC II (major histocompatibility complex class II) and co-
stimulatory molecules characterizes murine M1 macrophages, and enables the effective 
presentation of pathogen-derived epitopes to T cells, augmenting the adaptive immune 
response. 
1.3.2 M2 Macrophages 
Alternately activated M2-macrophages are a heterogeneous group of non-inflammatory 
macrophages, which can be further sub-divided into distinct populations, with each of 
these populations having clear roles within the immune response. 
In the murine system, regulatory M2 macrophages are activated in a two step process, 
generally by a combination of immune complexes and TLR ligands, however other 
factors can also induce their differentiation, including: prostaglandins, apoptotic cells, 
IL-10, TGF-β, glucocorticoids and FcγR (Fc gamma receptor) ligation, with different 
activatory stimuli generating slightly different regulatory populations. Activation by IL-
10 results in the increased expression of FcγRI, II and III, and the scavenger receptor 
MARCO, and enhanced IL-10 production, while inhibiting antigen presentation via the 
down-regulation of MHC II and co-stimulatory molecules [24]. Alternately, regulatory 
macrophage activation by immune complexes and TLR4 ligands results in enhanced IL-10 
production, but with high levels of co-stimulatory molecule expression and efficient 
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antigen presentation to Th2 cells [24]. Despite this, these diverse regulatory 
macrophage populations all have anti-inflammatory roles, involved in the dampening of 
active immune responses and the regulation of inflammation. Regulatory macrophages 
as a whole, are characterized by their enhanced production of the anti-inflammatory 
cytokine, IL-10, coupled with the decreased expression of the pro-inflammatory 
cytokine, IL-12 [17].  
The second group of M2 macrophages are the wound-healing macrophages. This subset 
are activated by IL-4 and IL-13, which are released during tissue injury and by Th2 cells 
as part of type 2 mediated immune responses, such as allergy and parasitic infection. 
Murine M2 macrophages activated through IL-4 and IL-13 up-regulate expression of the 
mannose receptor (CD206) [25], scavenger receptors (SR-A and DC-SIGN) and the C-type 
lectin receptor Dectin-1 [26]. The up-regulation of the arginase gene (ARG1) is a 
prototypical marker for murine macrophage alternative activation, with the expression 
of ARG1 resulting in a shift toward arginase activity [27], directly contributing to the 
production of the extracellular matrix and playing significant roles in tissue repair and 
homeostasis. IL-4 activation of macrophages directly suppresses hallmarks of M1 
macrophage activity, acting to inhibit both the respiratory burst [28] and the production 
of pro-inflammatory cytokines [29]. 
1.4 Adaptive Immunity 
There is huge diversity within the adaptive immune system, enabling the recognition of 
vast numbers of unique epitopes expressed by microorganisms. Adaptive immunity is 
highly specific, allowing recognition of particular pathogens, with subsequent antigen-
specific responses mounted. These responses result in long-standing immunological 
memory to the antigen in question. Effective adaptive immune responses involve 
antigen presentation by APCs, such as DCs and macrophages, and antigen recognition by 
lymphocytes expressing specific cell surface antigen receptors. There are two major 
populations of lymphocytes: the T cell and B cell populations. These cells express 
diverse repertoires of antigen-specific receptors, making this large pool of T and B cells 
highly effective against wide range pathogens.  
T cells are only able to recognize cognate antigen in the context of self-MHC (major 
histocompatibility complex) expressed on the surface of APCs. There are two different 
classes of MHC molecules, MHC class I (MHC I) and MHC class II (MHC II), with 
presentation of a peptide in the context of MHC I resulting in peptide recognition by 
T cells expressing the CD8 co-receptor [30,31], while presentation in the context of 
MHC II results in recognition by T cells expressing the CD4 co-receptor [32]. The 
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different subclasses of T cell have diverse effector mechanisms and functions within the 
immune response. CD8+ T cells are known as cytotoxic T cells, and are capable of direct 
killing of malignant or infected cells in response to activation. Cytotoxic T cells induce 
apoptosis in their target cell by engaging pro-apoptotic receptors on the target cell 
surface, or by the release of cytolytic proteins and enzymes that disrupt the target cell 
membrane and target intracellular apoptotic machinery. The CD4+ T cells are a more 
heterogeneous population, comprised of multiple T helper (Th) cell subsets (Th1, Th2 
and Th17) and the regulatory T cells (Tregs). Th cells exert their effector functions 
through the productions of cytokines, which are able to modulate immune responses, 
directing B cell antibody production and cell-mediated immunity. Each Th subset has a 
distinct role within the immune response, and can be characterized based on the 
production of signature cytokines [33,34]. Unlike the other CD4+ T cell subsets, Tregs 
are anti-inflammatory cells, able to inhibit pro-inflammatory immune responses, both 
by direct cell-contact mechanisms, and the production of anti-inflammatory cytokines 
[35]. 
1.5 B cells 
B cells have multiple immunological functions. They are able to mediate the adaptive 
humoral immune response, through their production of antibodies, and have additional 
roles as APCs. B cell can also secrete a range of cytokines, which are able to either 
suppress or enhance pro-inflammatory responses depending on the particular cytokines 
secreted. B cells are highly specific cells that recognize their cognate antigen through 
surface expressed immunoglobulins (Ig), termed B cell receptors (BcRs). Each B cells has 
a single specificity, expressing multiple copies of the same BcR.  
Naïve B cells can be sub-divided into three distinct populations: B-1 B cells, B-2 B cells 
and MZ (marginal zone) B cells. B-1 B cells are the first B cells to appear during fetal 
development, with conventional follicular B cells (B-2 B cells) arising later [36]. B-1 B 
cells are a self-renewing B cell subset that comprise around 5% of the total B cell 
population, and are found primarily in the peritoneal and pleural cavities, with an 
important role in the defence of these sites. This B cell population can be further 
subdivided based on their surface expression of CD5, with CD5+ B-1 B cells termed B-1a 
cells, while the CD5- subset are classed as B-1b cells [37], with these populations arising 
from different progenitors. All B-1 B cell populations express a restricted B cell receptor 
repertoire compared to the major B-2 B cell population. B-1 cells are involved in early, 
non-adaptive immune responses, directed mainly toward carbohydrate antigens, and are 
able to produce low-affinity ‘natural’ antibodies without the requirement of T cell help. 
However, B-1 cells are also able to rapidly produce specific T-independent antibodies 
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when stimulated, such as their secretion of mucosal IgA in response to commensal 
bacteria in the intestinal mucosa [38]. MZ B cells are also considered to be innate-like B 
cells, residing in the marginal sinus of the spleen, where they are well situated to 
respond to blood-borne pathogens. MZ B cells functionally resemble B-1 B cells, 
expressing a restricted BcR repertoire biased toward common environmental and self-
antigens, and mediate mostly T cell-independent responses. It has been postulated that 
MZ cells may play a role in the presentation of antigen to T cells and NK cells [39]. 
B-2 B cells comprise the largest and most studied population of B cells, and it is the B-2 
subset that will be focused on throughout this thesis. 
1.5.1 Development 
B cells, along with T cells and NK cells, are part of the lymphoid lineage, and originate 
from common lymphoid progenitors. Before birth, B cells can develop in specialized 
microenvironments in the yolk sac, fetal liver, and bone marrow; however, after birth 
B cell development is restricted to the bone marrow, with new B cells continually 
produced throughout life. After development in these specialized niches, B-2 B cells 
migrate to the periphery where they can become activated on recognition of their 
cognate antigen, differentiating into antibody-secreting plasma cells and memory 
B cells, and mounting an active immune response against invading pathogens.  
In the bone marrow, stromal cell signals induce the differentiation of common lymphoid 
progenitors into B cell–specific progenitors, termed pro-B cells. These signals are 
delivered both through direct contact and secreted factors, with the early B-lineage 
growth factor, IL-7, the first environmental factor shown to be crucial for B cell 
development [40].  
At the pro-B cell stage, the ordered rearrangement of immunoglobulin genes begins, 
with the heavy-chain locus rearranged first. Successful heavy-chain rearrangement 
results in the production of an intact µ heavy-chain, and the cessation of gene 
rearrangement. If a productive heavy-chain is not produced after rearrangement of both 
chromosomes, the pro-B cell is eliminated. The production of a functional µ heavy-chain 
enables the expression of the pre-BcR, and the subsequent development of the pro-
B cell into a pre-B cell. In the pre-BcR complex the µ heavy-chain is paired with 
germline-encoded surrogate light chains, consisting of the λ5-like and Vpre-B proteins 
[41], and associates with Igα/Igβ heterodimers, enabling signal transduction through 
this complete pre-B cell receptor. The pre-BcR is expressed transiently [42], and it is 
unknown if pre-BcR signalling is ligand-dependent or the result of pre-BcR complex 
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aggregation, however, signalling through this receptor is essential for the progression of 
the cell along its developmental pathway. On expression of an effective pre-BcR and 
subsequent pre-BcR signalling, the cell undergoes multiple rounds of proliferation, 
giving rise to many resting small pre-B cells, and initiating the rearrangement of the 
light-chain locus [43]. The small resting pre-B cells arising from the same original pre-B 
cell undergo different light chain rearrangement, resulting in a distinct antigen 
specificity and increasing the overall diversity of the B cell repertoire. On 
rearrangement of both the heavy- and light-chain loci, allelic exclusion is employed, 
with rearrangement occurring one allele at a time and as such, only one specificity of 
BcR will be expressed on the cell surface.  
Successful light-chain recombination enables the expression of intact BcR molecules on 
the surface of immature B cells. As the specificity of the expressed BcR is generated 
randomly, there is a possibility that the cell will be auto-reactive. In order to eliminate 
potentially self-reactive cells, the immature B cells undergo the process of central 
tolerance, in which they are exposed to self-antigen. Immature B cells are not fully 
functional, and antigen recognition does not result in activation, but in the removal of 
self-reactive clones, through either clonal deletion, induction of anergy, or receptor 
editing. Receptor editing is a process by which the BcR undergoes secondary light-chain 
rearrangement; if a non-autoreactive BcR is successfully produced the B cell will 
continue on its developmental pathway, if rearrangement results in another self-
reactive BcR the B cell will be eliminated via clonal deletion. Immature B cells that do 
not undergo an interaction with self, or those that have undergone successful receptor 
editing, migrate out of the bone marrow and into the periphery where they recirculate 
throughout the body. Not all auto-antigens are expressed in central lymphoid organs 
however, and as such a number of autoreactive B cells will make it to the periphery 
where they undergo an additional round of tolerance induction in the attempt to rid the 
body of autoreactive cells [44]. 
These newly generated naïve B cells are non-dividing cells, with a very short life span, 
and in the absence of antigen recognition the majority will die by apoptosis within a 
few weeks. Once antigen has been encountered these B cells need to enter lymphoid 
follicles within secondary lymphoid organs, such as the spleen and lymph nodes, in 
order to survive and mature, with the follicles providing the necessary signals for B cell 
survival. However, there is limited space in available in the lymphoid follicles, and so 
newly generated B cells must compete with existing peripheral B cells for space. This 
competition favours existing B cells, which are already established in the stable 
peripheral B cell pool, with the expression of specific cell surface proteins, such as BLyS 
[45], contributing to their survival. 
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Naïve B cells continue to recirculate until they either succumb to cell death, or 
encounter cognate antigen, with BcR stimulation a critical signal for naïve B cell 
survival [46].  
1.5.2 B cell Responses 
B cell activation in response to the majority of antigens requires signals from cognate 
T cells, with these termed T-dependent antigens. To initiate B cell responses to T-
dependant antigens, two stages of B cell activation must occur. The B cell must 
encounter antigen via its BcR, followed by interaction with cognate T cells in the 
lymphoid follicles. B cells are able to recognize antigen associated with DCs, however 
they are also able to interact with free soluble antigen, unlike T cells, which require 
the presentation of antigen in the context of self-MHC molecules. Following antigen 
recognition, the interaction of CD40 on B cells with CD40L expressed on T cells drives 
the B cell into the cell cycle, activating it and initiating antigen-dependent B cell 
development, with the cytokine milieu present at the time of activation influencing 
subsequent B cell differentiation. Activation leads to clonal expansion, generating high 
numbers of effector cells. These effector B cells are short-lived plasma cells, which 
remain in the periphery and are able to produce antibodies, secrete immunomodulatory 
cytokines and function as antigen-specific APCs. Antibody-secreting plasma cells are 
terminally differentiated cells, whose morphology and surface marker expression is 
distinct from that of naïve B cells. Plasma cells have an increased cytoplasmic to 
nuclear ratio, along with the presence of secretory vacuoles and additional rough 
endoplasmic reticulum [47], and down-regulate numerous B cell-specific surface 
molecules, including MHC II, B220 (CD45R), CD19, and CD20, amongst others [48]. These 
effector B cells may differentiate further in germinal centres, undergoing somatic 
hypermutation of their BcRs and subsequent affinity maturation, as well as antibody 
class switching, enhancing the humoral immune response and allowing different 
functions to be carried out by various antibody isotypes. Some of these activated 
germinal centre B cells alter their expression of chemokine receptors [49], obtaining the 
ability to migrate to the splenic red pulp, lymph node medullary cords and the bone 
marrow, where they survive as long-lived plasma cells, able to secrete antibody for 
many months [50]. The eventual formation of a pool of antigen-specific memory B cells 
ensures rapid and massive B cell proliferation on repeated antigen encounter, resulting 
in the generation of enhanced numbers of antigen specific plasma cells and a more 
effective secondary immune response.  
Traditionally, the role of effector B cells has been seen to be the production of large 
amounts of antibodies. However, it is now recognized that along with antibody 
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production, B cells have multiple immunological functions, able to: secrete a broad 
range of cytokines; act as APCs, directly presenting antigen to T cells; and suppress pro-
inflammatory responses both in vitro and in vivo. 
1.5.2.1 Antibody Production 
Although antibodies themselves do not directly remove pathogens, they have a broad 
range of biological activities, mediated through their binding to antigen and 
establishment of effector responses. Multiple antibody isotypes are able to activate the 
complement cascade, resulting in either complement-mediated lysis of the target cell, 
or its complement opsonization, leading to recognition and ingestion by phagocytes 
[51]. Antibodies can also directly opsonize antigens/cells, enhancing uptake by 
phagocytes through interaction of the antibody constant region with FcRs expressed on 
phagocytes. Antibody binding of target cells and subsequent FcR interaction can also 
result in antibody-dependant cell mediated cytotoxicity (ADCC), in which the activity of 
cytotoxic cells is directed toward specific target cells, resulting in uptake and 
destruction by macrophages and direct lysis by NK cells. Antibodies can also directly 
neutralize certain viruses and toxins, binding to the pathogen/pathogenic product, 
blocking their access to, and interaction with, their specific cell-surface receptors. 
1.5.2.2 APC function 
It has been known for many years that the presentation of cognate antigen by B cells to 
primed T cells initiates the direct T-B cell interactions required for these cells to 
become fully activated [52]. However, more recently, activated effector B cells have 
also been implicated as effective APCs, able to prime T cells and initiate their 
activation, with B cells particularly effective at presenting antigen in situations where 
its availability is limited [53]. The important of B cells as APCs has been confirmed in 
vivo, with antigen presentation by B cells shown to be crucial in the induction of several 
autoimmune disease models, including autoimmune arthritis [54], insulin-dependent 
diabetes mellitus [55] and murine lupus [56]. Presentation of antigen by B cells is also 
required for optimal development of memory CD4+ T cells [57]. 
1.5.2.3 Cytokine secretion  
B cells can also contribute to immune responses through the secretion of cytokines, 
with activated B cells able to produce an array of effector cytokines able to influence 
the outcome of the existing immune response. As with CD4+ T helper cells, B cells can 
be classified into subsets according to the cytokine milieu they produce, with 
populations of both effector and regulatory B cell subsets described. Cytokine 
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production by B cells is dependant on both the combination of activatory signals 
received by the cell, and the cytokine milieu present at the time of activation. 
Work by Lund and colleagues has identified two distinct populations of effector B cells 
based on their patterns of cytokine production [58], with these distinct subsets able to 
influence T cell responses.  Co-culture of murine B cells with either Th1 or Th2 cells in 
vitro results in the polarization of the B cell population to either a Be1 or Be2 subset, 
respectively, with the Be1 subset producing high levels of the Th1 cytokines IFNγ and IL-
2, and the Be2 subset producing enhanced IL-4. These subsets have also been identified 
in vivo in mice infected with pathogens known to skew the system to a Type 1 or Type 2 
immune response [58].  
B cells constitutively secrete particular cytokine profiles, however cytokine production 
by B cells can also be altered by stimulation, with signals such as TLR stimulation [59] 
and the activation state of the cell influencing the cytokine profile [60], demonstrating 
the context dependant nature of cytokine production by B cells. 
Populations of regulatory B cells (Bregs) have also been described, with the 
immunomodulatory effect of these cells mediated largely through their production of 
the anti-inflammatory cytokine IL-10. IL-10 inhibits CD4+ T cell polarization, along with 
pro-inflammatory cytokine production and antigen presentation by professional APCs. 
Bregs have been shown to suppress inflammatory responses in multiple disease models, 
including experimental autoimmune encephalitis (EAE) [61], collagen induced arthritis 
(CIA) [62] and colitis [63].  
1.5.3 B cells in Autoimmunity 
B cells play vital roles in helping to rid the body of invading pathogens, however if the 
delicate balance of the immune system is disrupted, and self-tolerance is broken, 
B cells can contribute to the pathology seen in autoimmunity. Auto-antibodies can be 
detected in patients with a variety of autoimmune diseases, including systemic lupus 
erythematosus (SLE) [64] and rheumatoid arthritis (RA) [65]. Auto-reactive B cells 
process and present self-antigens, driving autoimmune T cell responses [66]. 
Dysregulated patterns of cytokine production are seen by B cells from patients with 
autoimmunity, with enhanced production of pro-inflammatory cytokines and diminished 
anti-inflammatory cytokine secretion [67,68]. 
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1.5.3.1 B cells in Rheumatoid Arthritis 
The efficacy of Rituximab (RTX), a B cell depleting monoclonal antibody [69], in 
treating RA has definitively proven the involvement of B cells in the pathogenesis of 
disease. B cell involvement has also been shown to be crucial to several murine models 
of arthritis [54,70,71], and along with the clinical efficacy of RTX, this finding has 
renewed interest in B cells as a key player in RA pathogenesis. Although the 
involvement of B cells in RA pathogenesis is evident, the exact contribution of this 
population is unclear, with these cells are able to play several functional roles in the 
context of autoimmunity.  
In RA, plasma cells produce autoantibodies including rheumatoid factor (RF) and anti-
citrullinated peptides antibodies (ACPA). RA patients can be divided into subsets based 
on the presence or absence of autoantibodies, with 50-80% of RA patients having RF, 
ACPA, or both autoantibodies present in their sera [72]. RF is the classic autoantibody in 
RA and binds the constant region of Immunoglobulin G (IgG) molecules, however the 
presence of RF is not specific for RA [73], and a pathogenic role for RF in RA has yet to 
be identified. Infusion of RF from RA patients into healthy individuals is not able to 
cause even transient synovitis [74], indicating that these autoantibodies, at least by 
themselves, are not pathogenic. Although most ACPA positive patients are also positive 
for RF, ACPA are specific serological markers for RA and are increasingly being used for 
disease diagnosis [75]. ACPA occurrence can be seen several years before the onset of 
RA, and ACPA+ patients differ from ACPA- patients in clinical disease phenotype, as well 
as their associations with environmental and genetic risk factors [76]. ACPA+ disease is 
associated with increased joint damage, low remission rates, more severe disease 
course and a higher frequency of extra-articular disorders compared to ACPA- RA. The 
majority of genetic risk factors identified are associated with ACPA+ disease, with 
confirmed ACPA+ RA susceptibility genes including PTPN22 and TRAF1/C5 [76]. These 
differences in genetic contributions to disease development underline the heterogeneity 
of RA, with ACPA+ and ACPA- RA now considered distinct disease subgroups. 
B cells also produce chemokines, including CXCL13 [77] and eotaxin-1 [78], and pro-
inflammatory cytokines such as IFNγ, IL-4 and IL-6. These cytokines can provide non-
specific help to bystander T cells, potentially adding to an environment already tipped 
toward autoimmunity. B cells also play a major role in the regulation of lymphoid tissue 
architecture through their ability to secrete lymphotoxin, a cytokine essential for the 
formation of lymphoid structures, including ectopic germinal centres, which can be seen 
in approximately 30% of RA patients. 
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B cells are also able to contribute to the T cell response in RA through the expression of 
co-stimulatory molecules crucial for T cell activation, such as CD80/86 and CD40, as 
well as their ability to act as APCs [reviewed in [79], supporting the activation of 
autoreactive T cells.  
1.6 Rituximab 
Rituximab, a genetically engineered chimeric monoclonal antibody (mAb) directed 
toward the B cell cell-surface antigen CD20, was approved by the Food and Drug 
Administration for treatment of refractory or relapsed non-Hodgkin’s lymphoma in 1997. 
In 2001, an open label study was undertaken to assess the efficacy of Rituximab in the 
treatment of RA [80]. This study followed 5 patients with refractory RA for 12-17 
months, with all RTX treated patients achieving the American College of Rheumatology 
50% improvement criteria at 6 months post infusion. Following the success of this study 
several randomized, double-blind, placebo-controlled studies were undertaken  
[81-83], all of which demonstrated the value of RTX as a treatment for RA. In 2006 RTX 
was approved for the treatment of adult patients with active RA who have had an 
inadequate response to anti-TNF therapy [84], and to date is the only selective B cell 
depleting agent approved for use in this autoimmune disease. 
CD20 is a transmembrane phosphoprotein that belongs to the MS4A family of proteins 
[85] and is expressed on all cells of the B cell lineage except pro-B cells and plasma 
cells. CD20 is involved in many cellular signalling events including proliferation, 
activation, and differentiation, and on cross-linking results in apoptosis of the cell [86]. 
CD20 is an attractive target for B cell depletion as it is stable and highly expressed on B 
cells, is lineage specific, and does not circulate in the plasma as a free protein. As a 
result of this, the majority of new B cell depletion therapies under development are 
also targeted toward CD20, such as Tositumomab (B1), a murine IgG2a monoclonal 
antibody approved by the FDA in 2003 for the treatment of follicular non-Hodgkin 
lymphoma [87].  
1.6.1 Mechanisms of B cell Depletion 
Several mechanisms contribute to B cell depletion after RTX treatment: antibody-
dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and 
programmed cell death/apoptosis. Interactions between the Fc portion of the RTX and 
Fc receptors (FcRs) expressed on effector cells result in antibody-dependent cellular 
cytotoxicity (ADCC), a mechanism vital to the efficacy of RTX [88]. CDC has also been 
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shown to play a crucial role in RTX-mediated B cell depletion [89], however, the 
relative contribution of programmed cell death (PCD) following the binding of CD20 by 
RTX is disputed.  
1.6.1.1 Antibody-Dependent Cellular Cytotoxicity 
FcRs are expressed on a variety of effector cells including monocytes, macrophages, and 
NK cells. RTX is a chimeric antibody consisting of murine heavy and light chain variable 
regions and a human IgG1 constant region [reviewed in [90], and can be bound by 
members of the Fc-gamma receptor (FcγR) sub-family. When RTX interacts with CD20 on 
the surface of B cells the Fc region is able to associate with FcγRs on effector cells, with 
destruction of the opsonised B cell, either by phagocytosis or the release of toxic 
granules from the effector cell resulting [reviewed in [91].  
Studies using tumour cell lines and human tumour models have demonstrated that anti-
CD20 antibodies trigger ADCC both in vitro and in vivo [92]. However, a paper by 
Harjunpaa et al highlights the need for caution in extrapolating results gained in tumour 
cell lines to other cell lines, or indeed primary B cells. On in vitro co-culture of phorbol 
myristate acetate (PMA) activated peripheral blood leukocytes (PBL) and HF-1.3.4 
lymphoma cells, enhanced lymphoma cell lysis is seen on addition of RTX [93]. However 
when Raji lymphoma cells were included in the cultures in place of the HF-1.3.4 cells, 
comparable levels of ADCC were seen to occur in the presence and absence of RTX [93].  
Allelic polymorphisms of FcγRIIIa have been suggested as a determining factor for RTX 
efficacy [94]. It has been found that patients with the FcγRIIIa receptor 158V allotype, 
where valine (V) is encoded at the amino acid position 158 rather than phenylalanine, 
have a greater probability of experiencing a clinical response after RTX treatment for 
non-Hodgkin’s lymphoma. This has led to the postulation that given the right 
polymorphism there is increased ADCC activity against lymphoma cells, suggesting that 
ADCC is an important mechanism of B cell depletion in vivo, at least in the setting of 
lymphoma. However the authors of the study point out that the association between the 
FcγR polymorphism and clinical response may be due to another genetic polymorphism 
in linkage disequilibrium with the FCGR3A gene.  
1.6.1.2 Complement Dependent Cytotoxicity 
The IgG constant region of RTX allows the antibody to be bound by complement proteins 
in vivo, making Rituximab highly effective at activating the classical pathway of 
complement [91]. This activation leads to the formation of membrane attack complexes 
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on the surface of RTX-opsonized B cells and subsequent cell lysis. The classical 
complement pathway also generates C3b proteins, which directly bind to, and opsonise 
B cells, resulting in phagocytosis and destruction of the cell.  
The expression of complement-regulating proteins, such as CD59, has been associated 
with resistance to anti-CD20 therapy in some studies, with CD59 expressing cell lines 
shown to be resistant, either fully or partially, to RTX induced CDC in vitro, whereas 
CD59- cell lines are susceptible to CDC-mediated cell death [95]. Treatment of the CD59 
expressing ARH-77 cell line with anti-CD59 neutralizing antibody significantly increases 
CDC in vitro [95], with similar results seen in a range of lymphoma cell lines [93]. Other 
studies however, have found that the expression of complement-regulatory proteins 
does not relate to the outcome of treatment with RTX. Weng and colleagues analyzed 
the expression of the complement inhibitors CD46, CD55 and CD59 on pre-treatment 
tumour cells in 29 patients who were then treated with Rituximab. No significant 
difference was seen in the levels of pre-treatment complement inhibitors expressed in 
any of the response groups (full, partial or non-response to treatment), demonstrating 
that complement inhibitor expression does not necessarily predict clinical outcome 
after RTX treatment [96], contradicting evidence that CDC is a major mechanism of RTX 
action. Furthermore, effective B cell depletion with anti-CD20 antibodies has also been 
observed in mice with genetic deficiencies in the complement proteins C3, C4 and C1q, 
[88] and anti-CD20 antibodies engineered with mutations in the Fc region to prevent 
C1q binding were no more or less effective at depleting B cells in vivo than their non-
mutated counterparts [97].  
However, a study by Meerten et al examining the relative contributions of ADCC and 
CDC in RTX-mediated depletion may explain these conflicting results. Peripheral blood 
monocytes were co-cultured with a human CD20 (hCD20) expressing T cell line, CEM-
CD20, in which the expression levels of hCD20 can be altered, and RTX in the presence 
or absence of serum. Serum contains complement proteins, and therefore in the 
presence of serum both ADCC and CDC will take place, whereas in the absence of serum 
CDC will be inhibited. Using this experimental set up the authors were able to 
demonstrate that cell sensitivity to CDC correlates to the level of CD20 expression by a 
cell, with those cells not sensitive to CDC being cleared by ADCC and vice versa [98]. 
1.6.1.3 Programmed Cell Death (Apoptosis) 
CD20 has been postulated to play a role in B cell survival [86], and it is thought that 
binding of anti-CD20 antibodies to CD20 molecules on the cell surface could initiate 
cell-signalling cascades, affecting several signalling pathways, and ultimately result in 
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B cell apoptosis. It has been suggested that CD20 molecules are indirectly associated 
with src-family kinases due to their constitutive association with lipid rafts in the cell 
membrane, and on cross-linking with anti-CD20 antibodies trans-activation of the src-
kinases can occur initiating signalling cascades ultimately resulting in apoptosis [99] 
(Figure 1.1). However, the importance of programmed cell death as an in vivo 
mechanism of RTX-mediated B cell depletion is still disputed.  
Studies have been undertaken utilising hCD20 x VavBcl-2 double transgenic (tg) mice, an 
“apoptosis resistant” mouse model with B cells that express human CD20, enabling the 
direct investigation of RTX rather than a mouse homologue. Beers and colleagues 
demonstrate that B cells from this mouse strain are no less susceptible to RTX-mediated 
B cell depletion than non-resistant hCD20tg targets [100], indicating that the induction 
of apoptosis is not a key effector mechanism of B cell depletion. However, other 
investigators have shown that the anti-apoptotic factor Bcl-2 is down-regulated in 
multiple tumour cell lines on treatment with Rituximab in vitro [101]. Although these 
results may be due to the use of tumour cell lines and therefore are not transferable to 
normal B cells in vivo, other studies also dispute the claim that apoptosis is not a 
mechanism of B cell depletion. RTX has been shown to up-regulate the expression of 
Raf-1 kinase inhibitor (RKIP), a negative regulator of two major cell survival pathways: 
the NFκB and ERK1/2 pathways, in Ramos and Daudi cells, leading to the down-
regulation of the anti-apoptotic protein Bcl-xl [102,103], and the sensitization of these 
cells to apoptosis. In a study by Byrd et al reductions in the levels of certain anti-
apoptotic factors were noted in patients with chronic lymphocytic leukaemia after 
treatment with RTX [104]. No changes in the levels of Bcl-2 or Bax were observed in this 
study, however the levels of two other anti-apoptotic proteins, Mcl-1 and XIAP, 
diminished notably after treatment [104]. These finding support the idea that apoptosis 
plays a role in B cell depletion by Rituximab, and could explain why Beers et al saw no 
change when modulating the expression of Bcl-2, as this particular anti-apoptotic factor 
may not be involved in the pathway of apoptosis initiated by anti-CD20 infusion. In vivo 
activation of caspase-9, caspase-3 and cleavage of poly(ADP-ribose) polymerase (PARP) 
have also been observed in chronic lymphocytic leukaemia patients treated with RTX, 
indicating activation of the mitochondrial pathway of apoptosis in RTX-induced  B cell 
depletion.  
1.6.2 Clinical Efficacy of Rituximab in Autoimmunity 
Many of the suggested mechanisms for the efficacy of RTX as a treatment for 
autoimmune diseases centre on the depletion of pathogenic B cells, with the removal of 
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these inflammatory effectors directly helping to return immunological balance to a 
system otherwise tipped to autoimmunity.  
It was initially hypothesised that the depletion of autoreactive B cells would lead to a 
reduction in the serum autoantibody titre of patients and an improvement of disease. 
However, it has since been seen in multiple studies there is little correlation between 
changes in titres of autoantibodies and disease activity, with this finding true of both RA 
[81] and SLE [105]. In RA, titres of RF, a well-recognized prognostic factor for aggressive 
disease [69], can decrease within the first few weeks after RTX treatment [81], 
however, as a pathogenic role for RF has yet to be elucidated, this reduction in serum 
levels cannot definitively be said to account for the clinical outcomes seen after RTX 
treatment. RTX treatment has also been shown to be effective in RA patients who are 
RF sero-negative [82], and so it may be hypothesised that the reduction of RF on 
treatment with Rituximab cannot be responsible for RTX efficacy in RA. 
Studies in animal models however have highlighted a direct role for the removal of 
pathogenic B cells in the amelioration of symptoms in autoimmunity. B cell depletion 
has been shown to suppress disease in a mouse model of proteoglycan-induces arthritis 
by lessening the autoantibody response and reducing the numbers of autoreactive 
T cells present [71], underlining a role for pathogenic B cells as APCs during 
autoimmune responses. Work by Barr et al has demonstrated that the removal of IL-6 
producing pathogenic B cells by B cell depletion therapy is responsible for the 
improvements seen after treatment in a multiple sclerosis model [68], highlighting the 
role of B cells as potent cytokine producing cells, with their production of pro-
inflammatory cytokines able to contribute to disease pathology. 
Several theories focusing on the indirect effects of RTX treatment on the immune 
system, rather than the removal of pathogenic B cells, have also been put forward. In 
the ‘immune complex decoy hypothesis’, Taylor and Lindorfer have suggested that the 
therapeutic efficacy of RTX treatment may be due to the recognition of RTX-opsonized 
B cells as immune complexes by FcγR-expressing effector cells in vivo [106]. The authors 
postulate that the formation of large numbers of these RTX-B cell immune complexes in 
the blood and lymphatic system would divert FcγR-expressing effector cells (i.e. 
monocytes, macrophages and neutrophils) away from interacting with inflammatory 
immune complexes deposited in inflamed tissues, resulting in the reduction of tissue 
damage. 
Another theory, put forward by Silverman and Boyle in 2008, is the ‘B cell roadblock 
hypothesis’ [107]. This theory attributes the clinical efficacy of RTX to the blockade of 
   
35 
B cell trafficking. The authors propose that by ridding the system of pathogenic B cells, 
additional memory B cells are not able to enter the joint to promote the on-going 
inflammatory response, resulting in the gradual clinical improvement seen on RTX 
treatment. However, this hypothesis does not explain why the clinical effects of RTX 
treatment can in some cases be seen long after B cell repopulation, as following this 
line of thinking, pathogenesis should re-occur on B cell return. It has also been noted in 
multiple studies that not all joint B cells are necessarily depleted on RTX infusion 
[108,109], observations which also conflict with Silverman and Boyle’s proposed theory. 
Although several ideas have been presented as to the method by which RTX exerts its 
clinical efficacy, it is still not fully understood why the depletion of B cells with RTX 
alleviates RA disease symptoms. 
1.7 Cell Death 
Cell death is an essential biological process that is involved in a wide range of 
physiological processes, from embryogenesis and steady state tissue turnover, to 
lymphocyte clonal deletion and the resolution of immune responses. Many forms of cell 
death have been described [110], with apoptosis, necrosis, and autophagy comprising 
the most extensively studies forms of cell death. Cells are classified into these 
categories based on the morphological and biochemical features observed on cell death, 
and their subsequent interactions with phagocytes. 
1.7.1 Necrosis 
Necrosis occurs as a consequence of tissue damage or extreme cellular stress, and was 
originally thought to be an uncontrolled, passive form of cell death. However, more 
recent evidence has shown that under certain conditions programmed necrosis can take 
place, resulting in a form of regulated cell death devoid of the activation of caspases, a 
family of specialized proteases critical to apoptotic cell death [reviewed in [111].  
Necrosis is morphologically characterized by a gain in cell volume and the swelling of 
cellular organelles, coupled with lysosomal leakage, and the loss of membrane integrity 
resulting in the release of intracellular contents. Clearance of necrotic cells is slower 
and less efficient than that of apoptotic cells, occurring after the release of 
intracellular material from the dying cell [112]. This release of intracellular material is 
often accompanied by the release of pro-inflammatory cytokines and endogenous 
danger signals, known as DAMPs (damage-associated molecular patterns), including heat 
shock proteins (HSP) [113], uric acid, nucleotides (RNA and DNA), and the chromatin 
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protein HMGB1 (high-mobility group box 1) [114]. The presence of DAMPs can initiate 
inflammation in the absence of infection, and as such, necrosis is generally classed an 
immunogenic form of cell death. However, this is not always the case. Work by Miles et 
al has shown that during both necrotic and apoptotic cell death human neutrophils 
release α-defensins, small anti-inflammatory peptides, with these peptides able to 
inhibit the secretion of pro-inflammatory cytokines from macrophages [115]. The anti-
inflammatory properties of necrotic neutrophils in vivo has also been demonstrated, 
with administration of necrotic neutrophil supernatant able to protect mice from a 
model of peritonitis [115]. These findings reveal that the idea of necrosis as a purely 
inflammatory form of cell death is not necessarily accurate in all circumstances. 
1.7.2 Apoptosis 
Apoptosis is a controlled and highly regulated form of cell death. It is an active process, 
requiring energy in the form of ATP, and is characterized by specific morphological 
changes including cleavage of chromosomal DNA, nuclear condensation and 
fragmentation, and the formation of apoptotic bodies [reviewed in [116]. Although 
morphologically similar, apoptotic cell death describes a heterogeneous group of 
biochemical and functional forms of death, with activation initiated by two separate 
but overlapping pathways, the ‘extrinsic’ and the ‘intrinsic’ pathway.  
The extrinsic pathway of apoptosis is initiated in response to external stimuli received 
by the cell (Figure 1.1). Extrinsic signals include the ligation of pro-apoptotic cell-
surface receptors, such as Fas (CD95), TNFR1 (tumour necrosis factor receptor 1), or 
TRAIL (TNF-related apoptosis-inducing ligand). Ligation of these receptors initiates the 
activation of specialised proteases called caspases, with the cleavage of procaspase-8 
into its active form initiating a cascade of proteolytic activity, resulting in the 
activation of the effector caspases 3, 6 and 7, along with a range of other degradative 
enzymes. These enzymes cause the breakdown of integral cell components, including 
but not limited to: nuclear lamins, which are fibrous proteins required for function of 
the nucleus; enzymes involved in DNA repair, such as PARP; and cytoskeletal proteins, 
leading to the breakdown of the cell and ultimately cell death. 
The intrinsic pathway is initiated from within the cell itself in response to cellular 
stress, such as cellular starvation, growth factor depletion, increased cellular calcium 
concentration or DNA damage (e.g. from ionizing radiation or chemotherapeutic 
agents). This pathway of apoptosis involves the mitochondria of the cell, and is also 
referred to as the ‘mitochondrial pathway’ of apoptosis. Pro-apoptotic members of the 
Bcl-2 family of proteins migrate to the surface of the mitochondria forming 
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mitochondrial apoptosis-induced channels (MAC), releasing cytochrome c into the 
cytoplasm. Cytochrome c then binds to other cytoplasmic proteins to form the 
apoptosome and this protein complex goes on to activate caspase-9, an initiator 
caspase, which induces the same cascade of events as the extrinsic pathway of 
apoptosis, resulting in the death of the cell.  
The formation of apoptotic bodies or blebs is a common feature of both pathways of 
apoptosis, preventing the release of intracellular matter into the surrounding 
environment. These apoptotic bodies, along with non-fragmented apoptotic cells, 
express specific ‘find-me’ and ‘eat-me’ signals (see section 1.8), recruiting phagocytes 
and resulting in their rapid clearance from the system, with uptake generally occurring 
in the absence of pro-inflammatory responses (see section 1.9). 
1.7.3 Autophagy 
Autophagy is the process by which a cell recycles its cellular components, and is 
considered to primarily be a survival mechanism up-regulated in response to stress 
conditions, however it is also postulated to be an alternative cell death pathway. 
Autophagy is a catabolic process, starting with the formation of a flat isolation 
membrane that surrounds a portion of the cytoplasmic material, forming an 
autophagosome. The autophagosomes then undergoes maturation, culminating in its 
fusion with lysosomal vesicles, where they deliver their contents, ready for degradation. 
The catabolites are then transported back into the cell’s cytoplasm, ready for 
incorporation into new cellular components. Autophagy can be sub-dived into three 
forms, dependent on the mode of delivery of the autophagosome’s contents to 
lysosomes: macroautophagy, microautophagy [reviewed in [117] and chaperone-
mediated autophagy [reviewed in [118].  
Autophagy is known to play important roles in embryonic development and tissue 
remodelling, however its role in cell death is disputed. Several studies have shown that 
autophagic cell death occurs under conditions in which apoptosis is inhibited [119,120], 
with ex vivo studies using cells from apoptotic-resistant Bax-/-Bak-/- mice showing that 
the knockdown of essential autophagy gene products protects these cells from 
chemotherapeutic-induced death [120]. A more recent study by Petrovski et al has 
shown that the human breast cancer cell line, MCF-7, undergoes autophagic cell death 
in response to prolonged exposure to continued cell starvation with the clearance of 
autophagic cells resulting in distinct transcriptional responses in phagocytes [121], with 
these findings indicating autophagy is in fact a distinct form of cell death. However, 
other studies have shown that inhibition of autophagy, through various mechanisms, 
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Figure 1.1 Schematic showing a selection of the apoptotic pathways in B cells.  
Apoptosis can be triggered through a variety of mechanisms including ligation of cell surface 
receptors, such as Fas (CD95) and TNFR1, two prototypical apoptosis inducers. Ligation of these 
receptors initiates the activation of caspases. Cleavage of procaspase-8 into active caspase-8 
initiates a cascade of events, resulting in the activation of the effector caspases 3, 6 and 7, along 
with a range of other degradative enzymes. These enzymes cause the breakdown of integral cell 
components (e.g. nuclear lamins, DNA repair enzymes such as PARP, and cytoskeletal proteins), 
resulting in the death of the cell. Caspase 8 can also activate pro-apoptotic proteins belonging to 
the Bcl-2 family, leading to cytochrome c release from the mitochondria and activation of caspase-
9, and effector caspases, also ultimately resulting in cell death. It has been shown that CD20 
molecules constitutively associate with lipid rafts in the cell membrane, and on cross-linking with 
anti-CD20 antibodies can initiate cell-signalling pathways ultimately leading to apoptosis of the 
B cell. 
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results in an increased rate of cell death [122,123], suggesting that autophagy may 
indeed be a pro-survival mechanism activated by dying cells in the attempt to cope with 
sub-optimal conditions, prior to cell death.   
1.8 Recognition and Ingestion of Apoptotic Cells 
Cells undergoing apoptosis are recognized by professional phagocytes (Figure 1.2), such 
as macrophages and immature DCs and rapidly engulfed, with the clearance of 
apoptotic cells (AC) without stimulation of the immune system crucial to the 
maintenance of peripheral self-tolerance. 
Phagocytes are able to recognise AC via the expression of a range of PRRs, which along 
with the recognition of PAMPs, are able to detect changes in the composition of the 
plasma membrane of the AC. These changes are collectively termed ‘ACAMPs’ 
(apoptotic cell-associated molecular patterns) [reviewed in [124], or ‘eat-me’ signals. 
Coupled with the exposure of neo-epitopes by the AC, the down-regulation of a range of 
‘don’t eat-me’ signals normally expressed by healthy cells further encourages the rapid 
uptake of these dying cells by phagocytes. A number of soluble ‘bridging molecules’ are 
also involved in phagocyte binding of AC, adding a further layer of complexity to the 
process. 
One of the most well characterized ACAMPs is the exposure of phosphatidylserine (PS) 
on the outer leaflet of the AC plasma membrane [125]. This change in membrane 
composition occurs very early in the apoptotic process and is an essential ‘eat-me’ 
signal involved in AC uptake [125], with multiple receptors and bridging molecules 
involved in its recognition. Fadok et al found that phagocytes could directly bind PS via 
specific phosphatidylserine receptors [126], however it is only more recently that the 
details of the receptors for PS have been elucidated, with multiple PR receptors now 
identified. The T cell/transmembrane, immunoglobulin, and mucin (TIM) proteins TIM-1, 
TIM-3 [127] and TIM-4 [128] have been shown to specifically bind PS exposed on the 
surface of AC in both humans and mice. These proteins differ in their expression 
patterns, with TIM-3 and TIM-4 expressed on phagocytic APCs and involved in AC uptake 
and cross-presentation of antigens [129]. Other PS receptors have also been identified, 
including CD300a in humans [130]; and RAGE (receptor for advanced glycation end-
products) [131], Stabilin-2 [132], and brain-specific angiogenesis inhibitor 1 (BSAI1) 
[133] in mice. Work by Park et al has shown that BSAI1 binds directly to PS via 
thrombospondin type 1 repeats in its extracellular region, mediating AC engulfment by 
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macrophages both in vitro and in vivo [133]. Over-expression of BSAI1 in the J774 
macrophage cell line results in the enhanced uptake of apoptotic thymocytes in vitro, 
 
Figure 1.2 Schematic detailing the molecules involved in the binding and uptake of 
apoptotic cells by phagocytes. 
Apoptotic cells expose PS (phosphatidylserine) on their outer surface, with the associated PC 
(phosphatidylcholine) internalization. PS is recognized by PS receptors directly, and the adapter 
molecules MFG-E8, GAS-6 and β2-GPI, with MFG-E8 then recognized by the αvβ3 integrin 
(vitronectin receptor), GAS-6 by MER family members and β2-GPI recognized by the β2-GPI 
receptor. In the presence of complement AC become opsonized with iC3b, which is subsequently 
bound by C1q. Binding of C1q by CD91 molecules on phagocytes is mediated by CRT 
(Calreticulin). It has been suggested that modification of surface antigens on AC results in the 
formation of conserved molecular patterns, termed ‘ACAMPs’ (apoptotic cell associated molecular 
patterns), leading to their recognition by phagocytes via collectins such as mannose-binding lectin 
(MBL). CD14 binds MBL, along with modified ICAM-3 (intercellular molecules adhesion molecule 3) 
expressed on the surface of AC. A variety of scavenger receptors are involved in AC adhesion and 
uptake, with newly formed Ox-LDL-like sites on the AC recognized either directly or through the 
use of adaptor proteins such as thrombospondin (TSP-1). On exposure of PS on the AC surface, 
Annexin I is also exposed, allowing recognition by Annexin I receptors expressed by phagocytes. 
Along with expression of apoptotic markers, the viable cell marker CD31 is de-activated, with 
disabled CD31 unable to induce cellular release by phagocytes on homotypic adhesion with active 
CD31. 
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while simultaneous i.p. injection of AC and BSAI1 blocking proteins into mice effectively 
inhibited AC phagocytosis by peritoneal macrophages [133].   
Soluble bridging molecules allow additional, indirect recognition of PS by phagocytes. 
Milk-fat globule EGF factor 8 (MFG-E8) is a protein secreted by subsets of phagocytes, 
including activated macrophages [134]. It is able to bind PS via its C-terminal region and 
associates with the integrins αvβ5 and αvβ3 (the vitronectin receptor) on phagocytes 
[135], stimulating the engulfment of AC [134]. Growth-arrest specific 6 (GAS-6) is an 
abundant plasma protein that can bind to PS, with the closely related protein S also 
able to act as a bridging molecule during PS recognition [136]. Both Gas-6 and protein S 
are recognised by tyrosine-kinase receptors belonging to the TAM family, including 
Tyro3, Axl and Mer, with studies in mice that have a functional Mer knock-out have 
been shown to develop an SLE-like autoimmunity [137]. The serum protein, β2-
glycoprotein I (β2GPI) has also been shown to bind to PS expressed on AC [138], 
however the specific β2GPI-receptor expressed by phagocytes is still not clear, with 
members of the LRP (lipoprotein receptor-related protein) receptor family indicated 
[139]. 
Although a key marker of apoptotic cells, several studies have suggested that PS 
exposure alone is not sufficient to induce AC uptake by phagocytes, and the recognition 
of other ACAMPs in conjunction with PS is needed to initiate AC uptake. Although this 
has not been conclusively shown, the modification of existing surface antigens does 
occur on AC, resulting in the generation of neo-epitopes, with these epitopes also 
detected by phagocytes during uptake.  
Collectins, such as MBL (mannose-binding lectin), SP-A (surfactant protein A), SP-D 
(surfactant protein D) and the complement component C1q bind neo-epitopes expressed 
to the surface of late apoptotic cells, termed ‘collectin-binding sites’ [reviewed in 
[140]. Opsonization of AC by collectins promotes their uptake through subsequent 
interaction with the low-density lipoprotein (LDL)-receptor-related protein (LRP-
1/CD91) and calreticulin (CRT) on the surface of phagocytes [141]. The binding of 
pentraxin-related C-reactive protein (CRP) to AC in parallel with C1q inhibits activation 
of the complement cascade by preventing the formation of the membrane-attack 
complex on the apoptotic cell surface [142], avoiding the initiation of pro-inflammatory 
responses toward AC antigens. 
There is some evidence that that oxidation of the AC surface is an important component 
of their recognition by phagocytes [143], with the formation of oxidized low-density 
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lipoprotein (ox-LDL)-like sites on AC, detected as ‘altered-self’ by phagocytes. 
Recognition can be direct, through a variety of receptors including the scavenger 
receptors SR-A (scavenger receptor A) [144], CD68 [145], and LOX-1 (oxidized low-
density lipoprotein-1) [146], or via the bridging molecule thrombospondin (TSP-1). The 
binding of TSP-1 enables indirect recognition by additional phagocytic scavenger 
receptors, such as the class-B scavenger receptor CD36 and the vitronectin receptor 
[147], with TSP-1 also able to bind to as-yet undefined neo-epitopes on the AC, termed 
‘TSP-1 binding sites’ [reviewed in [140], further promoting the uptake of AC by 
phagocytes. 
Functional alterations in adhesion molecules have also been noted on AC. ICAM-3 
(intercellular adhesion molecule 3/CD50) is a cell adhesion molecule constitutively 
expressed on all leukocytes [reviewed in [148], and is involved in immune regulation via 
its interactions with LFA-1 (leukocyte functional antigen 1). The ICAM-3 expressed by AC 
has a functionally altered first Ig-like domain [149], leading to a switch in binding 
preference from the prototypic receptor LFA-1, to an alternative macrophage receptor, 
mediating interactions between apoptotic leukocytes and macrophages [150]. Another 
cell adhesion molecule, PECAM-1 (platelet endothelial cell adhesion molecule/CD31) is 
also involved in the binding of phagocytes to AC, with CD31 expressed by both viable 
and apoptotic cells. Binding of viable cells by macrophages through the homotypic 
adhesion of surface CD31 initiates CD31-mediated signalling, leading to the active 
detachment of the viable cell [151]. In AC, this CD31-mediated detachment from 
macrophages is disabled, promoting their binding and subsequent uptake by phagocytes 
[151]. 
Along with changes in the specific cell surface molecules expressed by AC helping to 
mediate tethering and uptake by phagocytes, the spatial distribution of these molecules 
is likely to be involved in the differentiation between cell states, as well as the down 
regulation\functional inactivation of ‘don’t eat-me’ signals expressed by viable cells. 
Integrin-associated protein (IAP/CD47) is a cell surface glycoprotein expressed by all 
hematopoietic cells [152], and has been characterized as a marker of self on murine 
cells [153], acting as a ‘don’t eat-me’ signal. CD47 is bound by SIRPα (signal regulatory 
protein alpha) expressed on macrophages, DCs and neutrophils, and sends a negative 
engulfment signal to the phagocyte [153], preventing clearance of the cell. On 
apoptosis, cells down-regulate CD47 expression and are no longer able to stimulate 
SIRPα and the downstream inhibitory signals necessary to avoid phagocytic uptake 
[154]. Complement opsonization of AC also plays a key role in their recognition and 
clearance by phagocytes, with viable cells expressing a range of complement regulators, 
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which inhibit the binding of complement and opsonization of healthy self-cells. CD46 
(membrane cofactor protein) is one such regulator, ubiquitously expressed on all 
nucleated cells. Expression of CD46 is lost on apoptosis, leading to the binding of the 
classical complement components C3b and iC3b, and promoting phagocytosis of the AC 
[155]. 
If AC are not cleared in a timely fashion they undergo secondary necrosis, resulting in 
the release of intracellular material into the surrounding environment and initiating 
pro-inflammatory responses. In certain circumstances, this can lead to a break in 
tolerance to intracellular self-antigens, and chronic pathology, such as in SLE [156].  
1.9 Immune Modulation by Apoptotic Cells 
Due to its role in development and homeostasis, apoptosis has traditionally been 
thought to be intrinsically non-immunogenic, however in the 1990s multiple groups 
demonstrated that the uptake of AC can actively suppress inflammatory responses 
[157,158]. Based on these findings, an extensive body of work has arisen demonstrating 
that the binding and engulfment of AC actively induces a range of anti-inflammatory 
responses by phagocytes, playing a key role in the resolution of adaptive immune 
responses under normal circumstances, and potentially able to re-introduce tolerance 
to the immune system. However, the view that apoptosis results purely in anti-
inflammatory, tolerogenic responses, while necrosis results in pro-inflammatory 
responses, has been shown to be an oversimplification. Recent tumour vaccination 
studies have established that cells can either undergo immunogenic or non-
immunogenic apoptosis depending on the apoptotic stimulus, with immunogenic AC able 
to stimulate an active antigen-specific immune response [159].  
1.9.1 Immunogenic Apoptosis 
The immunogenicity of apoptotic cells has been shown to be dependant on the early 
exposure of CRT on the AC surface [160]. CRT is a Ca2+-binding chaperone that is usually 
located in the lumen of the endoplasmic reticulum (ER) [reviewed in [161]. Surface 
exposure of CRT defines immunogenic AC and acts as an immunogenic ‘eat-me’ signal 
for phagocytes [160]. Several cell death stimuli can induce the exposure of CRT and 
subsequent immunogenic apoptosis, including anthracyclins, UVC exposure and ionizing 
radiation. Immunogenic apoptosis has been most widely studied within the setting of 
cancer therapy, with the efficacy of many chemotherapeutics depending on the 
generation of antigen specific T cell responses. 
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A study by Albert et al looking into the cross-presentation of exogenous antigen by DC 
was one of the first to provide evidence that antigen-specific T cell responses can be 
generated after the acquisition of antigens from apoptotic cells [162]. Human DC 
cultured in vitro with apoptotic influenza-infected monocytes were able to acquire viral 
antigens from the AC and generate influenza-specific cytotoxic T cells that could 
effectively target infected DC [162]. Interestingly, in this system influenza-infected 
necrotic cells were unable to provide sufficient antigen to DC in order to prime 
influenza-specific cytotoxic T cell responses.  
 
Further work has supported the idea of immunogenic apoptosis. Kotera et al have shown 
that the immunization of mice with DC pulsed with either apoptotic or necrotic B16-BL6 
melanoma cells, resulted in the inhibition of melanoma growth [163]. CT26 colon cancer 
cells treated with anthracyclins are rapidly cleared by DC on injection into 
immunocompetent mice, resulting in the priming of anticancer T cell responses that are 
able to prevent the growth of live CT26 cells in vivo [164]. Injection of apoptotic RMA 
cells, a T cell lymphoma cell line, into C57BL/6 mice results in the induction of tumour-
specific cytotoxic T cell responses [165]. Conversely, injection of necrotic RMA cells was 
unable to elicit tumour-specific responses [165], indicating that in this model apoptotic 
cells were more able to elicit inflammatory responses than necrotic cells.  
These findings demonstrate that the dogma of apoptosis being a tolerogenic, anti-
inflammatory process, unable to stimulate pro-inflammatory responses, is an 
oversimplification. However, in many situations this is seen to be the case. 
1.9.2 Non-immunogenic Apoptosis 
Billions of cells undergo apoptosis everyday in an individual without inciting 
inflammatory responses, demonstrating the non-immunogenic nature of physiologically 
occurring apoptosis. Investigation of the immunomodulatory capacity of AC has 
demonstrated that not only does non-immunogenic apoptosis occur without the 
stimulation of pro-inflammatory responses, but that the interactions of AC with 
phagocytes can actively exert anti-inflammatory effects on the system, affecting a wide 
variety of immune responses including cell maturation, antigen presentation and local 
cytokine production. 
Maturation of DC is inhibited upon AC ingestion, preventing their development into 
competent antigen presenting cells. To become fully activated, T cells must recognize 
their cognate antigen in the context of MHC followed by a ‘signal 2’, delivered in the 
form of co-stimulation by the APC or the production of specific cytokines. Immature 
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murine DC are unable to upregulate the co-stimulatory molecule CD86 [166],  after 
phagocytosis of AC, and show a diminished ability to produce pro-inflammatory 
cytokines such as IL-12 [166], resulting in a reduced capacity to stimulate T cell 
activation and subsequent adaptive immune responses.  
Many studies have documented that the uptake of AC by phagocytes has potent anti-
inflammatory effects on innate effector cells. In vitro co-culture of human monocyte-
derived macrophages with AC results in the decreased production of pro-inflammatory 
cytokines, including IL-8, TNFα, and IL-1β, coupled with the increased production of the 
anti-inflammatory cytokine TGF-β [157]. Work by Chong et al has shown that human NK 
cell interaction with apoptotic Jurkat, PLB-985 or CD4+ T cells results in increased TGF-
β secretion in vitro, and that this TGF-β production is able to suppress the generation of 
IFNγ  by stimulated NK cells [167]. AC can also have direct effects on the production of 
inflammatory mediators, with the binding and phagocytosis of AC able to inhibit pro-
inflammatory cytokine gene transcription by macrophages, independent of subsequent 
AC engulfment [168]. This negative feedback response to AC helps to regulate unwanted 
inflammation and may contribute to immune contraction and the termination of 
immune responses. 
Interaction with AC also effects the production of other immune mediators by 
macrophages. On co-culture with AC, macrophages increase production of the anti-
inflammatory prostaglandin PGE2 [157], with concomitant inhibition of pro-inflammatory 
eicosanoids and LPS-induced NO generation also seen [169].  
The anti-inflammatory effects of AC have also been demonstrated in vivo. In a murine 
model of pneumonia, mice with genetic defects in macrophage apoptosis were shown to 
have enhanced recruitment of neutrophils to sites of lung inflammation and increased 
production of inflammatory cytokines, resulting in a greater degree of pulmonary 
inflammation [170]. In this model, intratracheal administration of apoptotic 
macrophages into the lungs was able to decrease the amount of local inflammation to 
levels comparable with wild-type animals [170]. Injection of AC into the peritonea or 
lungs of mice after induction of inflammation at these sites, has also been shown to 
reduce inflammatory infiltrates, as well as stimulate local TGF-β production, enhancing 
the resolution of inflammation [171]. Furthermore, in a murine model of arthritis, i.v. 
injection of apoptotic thymocytes protects mice from arthritis through the generation 
of IL-10-producing regulatory B cells [172], indicating the beneficial effects of AC 
administration in the context of autoimmunity. 
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Interestingly, in a large proportion of the studies looking into the immunosuppressive 
effects of AC, the apoptotic stimuli used should induce immunogenic apoptosis 
according to the reports into CRT exposure [134,160,164]. However, investigators have 
repeatedly demonstrated anti-inflammatory effects of the resultant AC populations. 
These findings indicate that exposure of CRT alone cannot fully account for the 
immunogenicity of AC, with other factors evidently involved in the generation of pro- or 
anti-inflammatory responses to AC. The activation state of the AC at time of death 
[173], the number of AC [165], the phagocyte involved in AC uptake [174], the presence 
of innate immune stimulation at the time of AC uptake [175], the release of soluble 
mediators by AC [176] and the cytokine milieu present at AC uptake [165], have all been 
implicated in the nature of the response to AC. However, in the majority of work 
looking into immunomodulation by AC, the concept of immunogenic vs. non-
immunogenic apoptosis is not discussed, and these disparate finding are not addressed. 
Despite this, a considerable body of evidence supports the idea that AC are able to 
induce anti-inflammatory responses on binding/engulfment by phagocytes both in vitro 
and in vivo, and may have the potential to re-introduce tolerance to the immune 
system. The response of the immune system to AC is highly complex, and further work is 
needed to enable a better understanding of these processes and their regulation in vivo. 
1.10 Hypothesis and Aims 
We hypothesise that RTX treatment in autoimmunity, specifically focusing on RA, may 
re-introduce temporary tolerance to the immune system (Figure 1.3). If on treatment 
with RTX apoptosis of B cells is caused, the B cells will be phagocytosed by APC in a 
non-inflammatory context. The phagocytosed B cell, and any antigens it has 
internalized, will therefore be degraded and presented by the APC in a tolerogenic 
environment. If the B cell had previously taken up self-antigen, specifically the putative 
self-antigen the RA response is directed toward, presentation of this arthritogenic 
antigen in a non-inflammatory, tolerizing environment may result in the re-introduction 
of temporary tolerance to the RA system. 
Li et al have explored the concept of using the in vivo production of AC to re-introduce 
tolerance to self-antigens in the context of autoimmunity, with a murine model of 
type 1 diabetes utilized [177,178]. In these studies, non-obese diabetic (NOD) mice 
were administered plasmid DNA vaccinations encoding a beta cell auto-antigen, 
glutamic acid decarboxylase (GAD), and the pro-apoptotic protein BAX. The vaccination 
induced the synthesis of GAD in target cells, followed by apoptosis of these newly self- 
antigen containing cells. The GAD-BAX vaccinated mice showed a significant reduction 
in diabetes onset compared to both untreated mice, and those treated with a vaccine 
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Figure 1.3 Schematic detailing our hypothesis: Rituximab-mediated B cell apoptosis helps 
to re-introduce tolerance to self-antigens in autoimmunity. 
1-2. Autoreactive B cells encounter self-antigen and internalize it via their BcR. 3. RTX binds to 
CD20 on B cells and induces cell death through apoptosis. 4. The AC resulting from these 
autoreactive B cells contain fragments of previously internalized self-antigen. 5. These AC cleared 
by macrophages, ingesting the apoptotic bodies and the self-antigen they contain. Phagocytosis of 
AC will polarize the macrophage to a regulatory/anti-inflammatory phenotype. 6. The self-antigen 
taken will be processed and presented to T cells by the macrophage via MHC II. The presentation 
of self-antigen in an anti-inflammatory environment will result in T cell tolerization to the self–
antigen, dampening down the inflammatory response seen in RA and introducing a temporary 
tolerance to the system. 
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containing GAD alone. The investigators showed that the GAD containing apoptotic cells 
were phagocytosed by DCs, and hypothesize that the uptake of auto-antigen containing 
AC by dendritic cells was able to re-introduce peripheral tolerance to the autoimmune 
system [177]. Further studies demonstrated that not only can this vaccine construct 
prevent disease onset, it is also able to ameliorate established diabetes in this mouse 
model, with 50% of NOD mice treated with the GAD-BAX vaccine subsequent to disease 
onset showing improvement of symptoms [178]. These studies, although undertaken in a 
diabetes model, prove that the uptake of apoptotic cells containing self-antigen is able 
to modulate the progression of autoimmune disease. As the self-antigen that the 
pathogenic response is directed toward in RA is still unknown, a vaccination approach 
could not be undertaken in this disease setting. However, the RTX-mediated induction 
of apoptosis in auto-antigen containing B cells, may have comparable effects on the 
immune system in RA, helping to re-establish tolerance in a system skewed toward 
inflammation. 
The aim of the current study was to begin to unravel the possibility of this hypothesis. 
The role of apoptotic B cells and their immunomodulatory capacity was focused on, 
with the following questions specifically addressed: 
1. Do apoptotic B cells have the same immunomodulatory capacity as other 
apoptotic lymphocytes? 
2. Does Rituximab binding to B cells affect the way in which they interact with 
other cells of the immune system, both prior to cell death and after B cell 
apoptosis? 
3. Are macrophages able to present antigen they themselves have not directly 
encountered, but that they have acquired as the result of the phagocytosis of 
apoptotic B cells? 
4. Are apoptotic B cells (induced by either irradiation or RTX treatment) able to 
modulate inflammatory responses in vivo? 
  
 
 
 
 
 
Chapter 2: Materials and Methods 
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2.1 Animals 
2.1.1 Mouse strains 
Human CD20 transgenic (hCD20tg) C57BL/6 mice and hCD20tg DBA mice were both bred 
in-house (Central Research Facilities, University of Glasgow, Glasgow, U.K.). Expression 
of the human CD20 gene was detected using polymerase chain reaction (PCR) (see 
2.1.2), and wild-type (WT) littermates were used as controls. WT DBA1/J mice were 
purchased from Charles River. Homozygous C57BL/6 OT-II mice, which express T cell 
receptors (TcR) that recognise the ovalbumin (OVA) peptide 323-339 in the context of I-
Ab, were used as T cell donors for in vitro assays (section 2.3.4). Age matched mice 
were used for all experiments. All animals were maintained under standard animal 
house conditions in accordance with local and home office regulations. 
2.1.2 Genotyping of hCD20tg mice 
Mice expressing the human CD20 gene were identified by genotyping of tail DNA using 
PCR. Mice were genotyped using two different primer pairs designed in-house, one 
specific for human CD20 Exon 2 (Forward: 5’-CACAAGGTAAGACTGCCAAAAATC-3’, 
Reverse: 5’-ATATACAAGCCCCAAAACCAAAAG-3’) and one for the 5’ Bac region (Forward: 
5’-ATTGTTTGAGTGCTCAGCATG-3’, Reverse: 5’–GGGAAAAACAATATTGCCTCC-3’) 
(purchased from Integrated DNA Technologies). In detail, mouse tail-tips were lysed 
using Alkaline Lysis Buffer (see appendix) for 60 minutes at 95oC. The DNA containing 
solution was then neutralized using an equal volume of Neutralization Buffer (see 
appendix). 10µl of this DNA solution was then readied for PCR by addition of Green 
Loading Buffer (Promega), the forward and reverse primers for the gene section being 
investigated, dNTP mix and Taq polymerase (both from Promega), following the 
manufacturer’s instructions. The samples were then loaded onto a 2% Agarose gel, 
consisting of 2g Agarose dissolved in 100ml 1x TAE (see appendix), and run at 100 volts 
for 45-80min. A band of 100kbp for 5’Bac, and 400kbp for Exon 2, indicated the 
presence of the hCD20 transgene. 
2.1.3 Phenotyping of hCD20tg mice 
The presence and expression pattern of the hCD20 protein was verified in mice 
identified as having the human CD20 transgene via PCR genotyping. Blood, spleen and 
LN single cell suspensions (see 2.2.1 and 2.2.2) were analysed via flow cytometry (see 
2.5.1).  
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Cells were stained using readily available anti-human CD20 FACS antibodies, or with 
fluorescently labelled Rituximab (Genetech) (see Tables 2.2 and 2.3). Rituximab (RTX) 
was conjugated to the fluorochrome AlexaFluor-488, using an AlexaFluor-488 Protein 
Labeling Kit from Invitrogen, according to the manufacturers instructions. To label the 
protein, 2mg/ml RTX was diluted in a 1M bicarbonate solution (Invitrogen). The RTX 
mixture was then added to a vial of the AlexaFluor-488 (AF-488) reactive dye, and 
stirred for 1hr at room temperature (RT). The AF-488 labelled RTX (RTX-488) was then 
purified using the purification column provided, separating the RTX-488 conjugate from 
unincorporated dye. Once the fraction containing the RTX-488 conjugate had been 
collected, the absorbance of the conjugate solution was measured using a Nanodrop 
(Thermo Scientific), and the degree of labelling calculated following the manufacturer’s 
instructions. The labelling resulted in a final ratio of 6.9M of dye per mole of antibody, 
falling within the optimal range of 4-9 moles of AF-488 per mole of IgG used.  
2.2 Harvesting, preparation and culturing of cells  
2.2.1 Preparation of single cell suspensions from secondary lymphoid 
organs 
Mice were euthanized using an increasing concentration of carbon dioxide gas (CO2), 
and the spleen, thymus and/or various lymph nodes harvested and placed in complete 
RPMI (cRPMI) medium (see appendix). Single cell suspensions were prepared by passing 
the organs through a 40µm cell strainer (VWR) into cRPMI using the plunger of a sterile 
5ml syringe. The cell suspensions were made up to 5ml with complete RPMI, and 
centrifuged at 450g for 5min. Supernatants were poured off, and the cell pellet 
resuspended. LN cells were then resuspended in 2ml-10ml complete RPMI, without a red 
blood cell (RBC) lysis step being undertaken. To the splenocyte and thymocyte 
suspensions, 1ml of ACK lysis buffer (Gibco, Life Technologies) was added to the 
resuspended pellet to remove RBC contamination. The cells were left to incubate at RT 
for 1min, after which 10ml of cRPMI was added to stop the reaction, and the cells again 
centrifuged at 450g for 5min. The splenocytes and thymocytes were then resuspended 
in 10ml of cRPMI ready for counting. Cells were counted using a haemocytometer, with 
Trypan Blue (Fluka Analytical) staining used to identify viable cells. Cells were then 
resuspended at the desired concentration in the appropriate media ready for further 
use. 
2.2.2 Preparation of single cell suspensions from blood 
Blood samples were taken both from live mice, and directly after euthanization. For live 
animal blood samples, mice were bled from the tail vein, with up to 100µl of blood 
   
52 
collected in heparinised capillary tubes. For blood collection post-mortem, mice were 
euthanized using an increasing concentration of CO2 and blood extracted directly from 
the vena cava into a syringe flushed with 0.25M EDTA. Blood samples were then 
processed in the same manner. An ammonium chloride solution (StemCell) was added at 
10x the volume of the sample and incubated for 10min on ice to remove RBC 
contamination. cRPMI was then added to stop the reaction, the cells centrifuged at 450g 
for 5min, and resuspended in fresh cRPMI ready for counting. Cells were counted using a 
haemocytometer, with Trypan Blue (Fluka Analytical) staining used to identify viable 
cells. Cells were then resuspended at the desired concentration in the appropriate 
media ready for further use. 
2.2.3 Preparation of bone marrow derived macrophages (BMDM) 
Macrophages were prepared from the bone marrow of either WT littermate DBA mice or 
WT littermate C57BL/6 mice. Mice were euthanized and the hind legs removed for bone 
marrow (BM) harvesting. Under sterile conditions, the BM was flushed from both femurs 
and tibias using a 5ml syringe filled with cRPMI. To break up any clumps of BM the cell 
suspension was repeatedly taken up and pushed out of the syringe. The cell suspension 
was then passed through a 40µm cell strainer (VWR), washed in cRPMI, centrifuged and 
counted as described in 2.2.1. For the generation of L929 BMDM the BM cells were 
plated at a concentration of 6x106 – 8x106 cells per 9cm petri dish, in cRPMI 
supplemented with 20% L929 cell supernatant (see 2.2.5.), which was 2x sterile filtered 
before addition to in vitro BM cell cultures. For the generation of GM-CSF BMDM, 10x106 
BM cells were plated at a concentration of 1x106 cells/ml in cRPMI supplemented with 
5ng/ml recombinant murine GM-CSF and 5ng/ml murine IL-3 (both from Peprotech). On 
day 3 the BMDM were given 5ml additional supplemented media. All BMDM were used 6-
7 days after isolation. To remove the adherent BMDM from the petri dishes, all media 
was removed, non-adherent cells washed off, and ice cold PBS added to the plates. This 
was left for 1min and the cells then scraped off using a cell scraper. The resultant cell 
suspension was collected, washed, and resuspended in cRPMI ready for counting and 
subsequent use.  
2.2.4 Isolation of peritoneal macrophages 
Primary macrophages were isolated from the peritoneal cavity of WT littermate 
C57BL/6 mice. Mice were euthanized, and 7ml of PBS + 2mM EDTA was injected into the 
peritoneal cavity through the peritoneal membrane. The abdomen of the mouse was 
then massaged to encourage the detachment of peritoneal macrophages from the 
internal surface of the membrane, and the solution taken up into a clean syringe. The 
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cells were washed with cRPMI, centrifuged at 450g for 5min, resuspended in 5ml cRPMI 
and counted ready for use. 
2.2.5 Culture of the L929 cell line  
The L929 cell line is a murine fibrosarcoma cell line that secretes M-CSF into its cell 
culture supernatant [179]. This supernatant can then be used to supplement cell culture 
media to induce the growth and development of murine bone marrow derived 
macrophages (see 2.2.3).  
To generate the L929 supernatant, L929 cells were cultured in 100ml cRPMI in T150 
flasks (Corning) until they reached confluence, and then for a further 4 days to allow a 
build up of M-CSF in the supernatant. The M-CSF-enriched media was then removed, and 
centrifuged at 450g for 5min to remove any cell debris. The supernatant could then be 
aliquoted and stored at -20oC for future use. 
2.2.6 CD19+ B cell isolation 
hCD20tg mice were euthanized by increasing concentration of CO2, and peripheral LNs 
(cervical, inguinal, popliteal, axillary, brachial and aortic LNs) and spleen were 
extracted, placed in cRPMI, single cell suspensions prepared (see 2.2.1) and the 
suspensions combined. CD19+ B cells could then be isolated using the EasySep Mouse 
B cell Enrichment Cocktail kit (StemCell Technologies) according to the manufacturer’s 
instructions, under sterile conditions. In detail, single cell suspensions were 
resuspended in PBS + 2% FBS, and 5% normal rat serum, at a concentration of 1x108 
cells/ml, and transferred into a sterile 5ml capped FACS tube. The B cell Enrichment 
Cocktail was added to the cell suspension at 50µl/ml and incubated at 4oC for 15min. 
After the incubation period, Biotin Selection Cocktail was added at 100µl/ml, and the 
mix incubated for a further 15min at 4oC. The Magnetic Particles were then added at a 
concentration of 100µl/ml and the cell suspension incubated at 4oC for another 5min. 
The cell suspension was then made up to 2.5ml with PBS + 2% FBS, and placed in an 
EasySep purple magnet for 5min at RT. With the tube still in the magnet, the suspension 
was poured into a fresh tube. This transferred the B cells to the fresh tube, while the 
unwanted cell fraction was retained in the original tube by the magnet. The CD19+ 
B cell suspension was then centrifuged, and the pellet resuspended in 10ml complete 
RPMI, and counted as in 2.2.1, ready for use. 
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2.2.7 CD4+ T cell isolation 
C57BL/6 WT littermates, or C57BL/6 OT-II, mice were euthanized and the spleens 
extracted, placed in cRPMI, and single cell suspensions prepared as described in 2.2.1. 
CD4+ T cells were isolated from the spleens and LNs using the EasySep Mouse CD4+ T cell 
Enrichment kit (StemCell Technologies) according to the manufacturer’s instructions, 
under sterile conditions. In detail, single cell suspensions were centrifuged and 
resuspended in PBS + 2% FBS, with 1mM EDTA, at a concentration of 1x108 cells/ml, and 
transferred in to a sterile 5ml capped FACS tube. Normal rat serum was added to the 
cell suspension at 50µl/ml cells. The CD4+ T cell Enrichment Cocktail was then added to 
the cell suspension at 50µl/ml and incubated at 4oC for 15min. After the incubation 
period, the Biotin Selection Cocktail was added at 100µl/ml, and the mix further 
incubated for 15min at 4oC. The Magnetic Particles were then added at a concentration 
of 100µl/ml and the cell suspension incubated at 4oC for another 5min. The cell 
suspension was then made up to 2.5ml with PBS + 2% FBS, and placed in an EasySep 
purple magnet, without the cap, for 5 minutes at RT. With the tube still in the magnet, 
the cell mix was poured in to a fresh tube. The T cells were transferred to this fresh 
tube, while the unwanted cell fraction was retained in the original tube by the magnet. 
The CD4+ T cell suspension was then centrifuged, and the pellet resuspended in 10ml 
cRPMI, and counted ready for use (see 2.2.1). 
2.2.8 CFSE staining of cells 
Primary B cells, T cells and thymocytes, were stained with CFSE (Carboxyfluorescein 
Diacetate Succinimidyl Ester) (Invitrogen) to allow tracking of the cells by flow 
cytometry. Purified B cells, T cells and/or thymocytes (2.2.6, 2.2.7 and 2.2.1, 
respectively) were washed twice in 20ml PBS and centrifuged at 450g for 5min. The 
cells were resuspended in fresh PBS at a concentration of 1x107 cells/ml. A stock 
solution of 5mM CFSE in DMSO was then added, to give a final concentration of 2.5µM 
CFSE and incubated for 5min at RT, in the dark with shaking. To stop the staining 
reaction and quench any unbound dye, the cells were washed twice in 20ml cRPMI and 
resuspended in fresh media ready for use. 
2.2.9 CellTrace violet staining of cells 
BMDM, prepared as previously described in 2.2.3, were stained with CellTrace Violet 
Cell Proliferation Kit (Invitrogen) according to the manufacturers instructions. In brief, 
cells were resuspended at 1x106 cells/ml in PBS and CellTrace Violet added to the 
suspension at a final working concentration of 5µM. Cells were incubated for 20min at 
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37oC, protected from light. To stop the staining reaction, 5 times the original staining 
volume of cRPMI was added to the cells and incubated for a further 5min. Cells were 
then washed in cRPMI, and resuspended in fresh media ready for use. 
2.2.10 Induction of apoptosis by irradiation 
Peripheral LNs, spleens and thymuses were harvested from mice as previously described 
in 2.2.1. CD19+ B cells were isolated using the EasySep Mouse B cell Enrichment Cocktail 
kit and CD4+ T cells isolated using the EasySep Mouse T cell Enrichment Cocktail kit as 
described in 2.2.6 and 2.2.7, respectively. Cells were then resuspended at 1x106cells/ml 
in cRPMI and irradiated using an XRAD225 x-ray irradiation system (Precision X-ray Inc.). 
Cells were given a dose of 30Gy, and subsequently incubated for 4hr at 37oC, 5% CO2, to 
ensure the majority of cells had undergone apoptosis before use, as confirmed by flow 
cytometry (section 2.5.1.2) 
2.2.11 Induction of apoptosis by Etoposide treatment 
Peripheral LNs, spleens and thymuses were harvested from mice as previously described 
in 2.2.1. CD19+ B cells were isolated using the EasySep Mouse B cell Enrichment Cocktail 
kit and CD4+ T cells isolated using the EasySep Mouse T cell Enrichment Cocktail kit as 
described in 2.2.6 and 2.2.7, respectively. Cells were then resuspended in 10µM 
Etoposide (Sigma) at a concentration of 2x106 cells/ml and incubated overnight at 37oC, 
5% CO2. Cells were washed 3 times in cRPMI prior to subsequent use. Flow cytometry 
was used to confirm majority of cells had undergone apoptosis before use, as described 
in section 2.5.1.2. 
2.3 In vitro assays 
2.3.1 Kinetics of Rituximab internalization 
Fluorescently labelled Rituximab (RTX-488) (see 2.1.3) was used in conjunction with an 
AF-488 quenching antibody (Invitrogen) to investigate the kinetics of RTX internalization 
by hCD20tg B cells in vitro.  
B cells were isolated from hCD20tg C57BL/6 mice (see 2.2.6), resuspended at 
1x106 cells/ml in cRPMI, and 1ml of the cell suspension transferred into 5ml FACS tubes. 
The B cells were then incubated with either 2µg/ml RTX-488 or no stimulation, for 
0min, 15min, 30min, 60min, 3hr, 6hr or 24hr, at 37oC, 5% CO2. To inhibit any further 
RTX internalization after incubation, cells were fixed with either: a 4% Formalin solution 
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for 5min at RT, for flow cytometric analysis; or the Cytofix/Cytoperm kit (BD 
Bioscience) for 30min at RT, for use in fluorescent microscopy.  
For flow cytometric analysis of internalization, half of the cells from each time-point 
were incubated with an anti AF-488 antibody (see 0), which effectively quenches the 
signal from any surface-bound AF-488 [180]. Cells were then run on a FACSCalibur. For 
each time-point, comparison of the MFI of AF-488 between B cells that had had their 
surface AF-488 quenched, and those that had not, allowed the relative level of RTX 
internalization to be determined. 
For fluorescent microscopy, B cells from early time-points were stained with rhodamine-
conjugated phalloidin (section 2.5.2.1), cytospun onto slides (section 2.5.2.2) and 
visualized using an ApoTome Microscope (Zeiss) (section 2.5.2.3). 
2.3.2 BMDM interactions with apoptotic cells  
To allow comparison of the effects of differing apoptotic cells on macrophages, in vitro 
assays were performed in which BMDM were co-cultured with apoptotic cells derived 
from either B cells, T cells or thymocytes.  
L929 BMDM and/or GM-CSF BMDM were prepared from the bone marrow of C57BL/6 WT 
littermates on day 0, and fed on day 3 (see 2.2.3).  
On day 6, the BMDM were plated out at 3x105 cells/ml in cRPMI into 5ml FACS tubes, 
with 1ml of the cell suspension per tube, for later FACS analysis. BMDM were also plated 
out into 96 well, flat bottom plates at 1x106 cells/ml in cRPMI, for later collection of 
supernatants. In some assays 100U IFNγ was added to each BMDM containing tube/well. 
All BMDM were then incubated overnight at 37oC, 5% CO2. Etoposide treated B cells, 
T cells, and thymocytes were also set up on day 6, as described in 2.2.11, and incubated 
overnight to induce apoptosis. Where the Etoposide treated cells were to be used for 
the evaluation of BMDM – AC interaction levels via flow cytometry, the lymphocytes 
were CFSE stained prior to Etoposide treatment (section 2.2.8), to allow later 
identification. Apoptotic lymphocytes to be co-cultured with BMDM to be used for BMDM 
phenotypic analysis were not CFSE stained.  
On day 7, further single cell suspensions of thymocytes, B cells, and T cells were 
prepared (see 2.2.1, 2.2.6 and 2.2.7, respectively), and CFSE stained (see 2.2.8) if 
appropriate to the assay being undertaken. The cells were then resuspended at 
1x106 cells/ml in cRPMI, and half of each newly isolated cell population irradiated to 
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induce apoptosis, as detailed in 2.2.10. After the incubation period, the irradiated and 
non-irradiated lymphocyte preparations were washed and resuspended at 5x106 cells/ml 
in fresh cRPMI. At this stage Etoposide-treated cells were washed extensively to remove 
all Etoposide from the cell suspensions, before also being resuspended at 5x106 cells/ml 
in fresh cRPMI. The FACS tubes containing BMDM were centrifuged at 450g for 5min, the 
media poured off and the cells resuspended in the remaining cRPMI. 300µl of the 
irradiated, non-irradiated or Etoposide-treated cell suspensions were added to the 
appropriate tubes, and 100µl to the desired wells, to give a final ratio of 5:1, AC to 
BMDM. In certain adaptations of the assay, E.coli LPS (Sigma) was added to tubes/wells 
at a concentration of 100ng/ml or 1ng/ml. Co-cultures to be analysed by flow cytometry 
for BMDM – AC interaction levels were incubated for 0, 15, 30 or 60min at 37oC, 5% CO2. 
At the end of the desired length of co-culture, these cells were washed in 3ml ice cold 
PBS + 5mM sodium azide to inhibit any further cell-cell interactions. Cells were then 
FACS stained, fixed, and run on a FACSCalibur (see 2.5.1). The co-cultures set up in 
96 well plates were incubated for 24hr at 37oC, 5% CO2 before having the cell culture 
supernatants removed and frozen down at -20oC, ready for later use in cytokine ELISAs 
(see 2.5.4). Co-cultures to be analysed by flow cytometry in order to determine changes 
in BMDM phenotype were incubated for 6 or 24hr at 37oC, 5% CO2. At the end of the 
desired length co-culture, these cells were washed in 3ml ice cold PBS + 5mM sodium 
azide, before being FACS stained and run on a MACSQuant (see 2.5.1). 
2.3.3 BMDM interactions with pre-treated B cells 
The in vitro assay used to examine the interactions of BMDM with apoptotic cells (see 
2.3.2) was modified to allow investigation of whether RTX binding to B cells has an 
effect on the way B cells, or apoptotic cells originating from these B cells, interact with 
different populations of BMDM under inflammatory and non-inflammatory conditions.  
In detail, BMDM were prepared from the bone marrow of C57BL/6 WT littermates on day 
0, and supplemented with either L929 supernatant or GM-CSF and IL-3, as required. 
BMDM were fed on day 3 (see 2.2.3).  
On day 6, the BMDM were plated out at 3x105 cells/ml in cRPMI into 5ml FACS tubes, 
with 1ml of the cell suspension per tube, for later FACS analysis. BMDM were also plated 
out into 96 well, flat bottom plates at 1x106 cells/ml in cRPMI, for later collection of 
supernatants. All BMDM were then incubated overnight at 37oC, 5% CO2. Also on day 6, 
B cells were isolated from hCD20tg C57BL/6 mice (see 2.2.6), CFSE stained (see 2.2.8), 
resuspended in cRPMI at 1x106 cells/ml, and incubated with either 100µg/ml RTX, 
100µg/ml human polyclonal IgG or no stimulation for 30min at 37oC, 5% CO2. These cells 
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were then washed 2x in cRPMI, Etoposide treated (see 2.2.11) and incubated overnight 
to induce apoptosis.  
On day 7, a further single cell suspension of primary B cells was prepared (see 2.2.6), 
CFSE stained (see 2.2.8), and incubated with RTX or controls, as previously stated. The 
cells were then washed 2x in cRPMI and resuspended at 1x106 cells/ml. Half of each pre-
treated group was irradiated to induce apoptosis, as detailed in 2.2.10. After the 
incubation period, the B cells were washed and resuspended at 5x106 cells/ml in fresh 
cRPMI. At this stage the Etoposide treated B cells were washed a minimum of 3x, and 
resuspended at 5x106 cells/ml in fresh cRPMI. The FACS tubes containing BMDM were 
centrifuged at 450g for 5min, the supernatant poured off and the cells resuspended in 
the remaining media. 300µl of the irradiated, non-irradiated or Etoposide pre-treated 
B cell suspensions were added to the appropriate tubes, and 100µl to the desired wells, 
to give a final ratio of 1:1, 3:1 or 5:1 (B cells:BMDM), as stated. In certain adaptations 
of the assay, E.coli LPS (Sigma) was added to tubes/wells at a concentration of 
100ng/ml or 1ng/ml. Co-cultures to be analysed by flow cytometry for BMDM – B cell 
interaction levels were incubated for 15min – 3hr at 37oC, 5% CO2. At the end of the 
desired length of co-culture, the cell-cell interactions were stopped by washing with 
3ml ice cold PBS + 5mM sodium azide. Cells were then FACS stained for the macrophage 
marker F4/80, fixed, and run on a FACSCalibur (see 2.5.1). The co-cultures set up in 96 
well plates were incubated for 24hr at 37oC, 5% CO2 before having the cell culture 
supernatants removed and frozen down at -20oC, ready for later use in cytokine ELISAs 
(see 2.5.4).  
2.3.4 Secondary presentation of antigen by BMDM 
In vitro assays were developed in the lab to allow investigation of the ability of 
macrophages to present antigen previously internalized by apoptotic cells to T cells, a 
process we have termed ‘secondary presentation’. For this system OVA was used as the 
model antigen, with the activation of OVA-specific T cells isolated from OTII T cell 
receptor (TcR) transgenic mice used as a read out of successful antigen presentation by 
the BMDM. Figure 2.1 gives an overview of the experimental design. 
L929 BMDM were prepared from the bone marrow of C57BL/6 WT littermates on day 0, 
and fed on day 3 (see 2.2.3).  
On day 6, the spleens and peripheral LNs were harvested from hCD20tg C57BL/6 mice 
and the B cells isolated (see 2.2.6). The B cells were then incubated overnight at 37oC, 
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5% CO2 with either a RTX-OVA peptide conjugate protein (RTX:OVA) or control antigens 
at 100µg/ml, 30µg/ml or 15µg/ml.  
The RTX:OVA conjugate was prepared using Sulpho-MBS (Thermo Scientific Peirce), an 
amine-to-sulfhydryl cross-linker, with RTX conjugated to an OVA323-339 peptide that has 
an added cysteine residue at the N-terminus, to allow chemical conjugation. In detail, 
the Sulpho-MBS cross-linker was added to 0.1mM RTX, at a final concentration of 1mM 
and the mixture incubated for 30min at RT. Excess cross-linker was then removed using 
a Zeba Spin Desalting Column (ThermoScientific). OVA323-339 peptide was then added to 
the RTX containing fraction in a 4:1 peptide:protein-NH2 molar ratio, and incubated for 
a further 30min at RT. The RTX:OVA conjugate was run through an Amicon Ultra 100K 
concentrating column (Millipore) to remove any unbound OVA peptide. A Nanodrop 1000 
(ThermoScientific) was used to measure the concentration of the conjugate protein, 
which was stored at 4oC until use. 100µg of RTX:OVA was estimated to contain 50µg of 
RTX and 50µg of OVA peptide. 
Also on day 6, the BMDM were plated out into either 24 well tissue culture plates, or 
96 well plates, at a concentration of 1x106 cells/ml in cRPMI, and 100units of IFNγ added 
to each BMDM containing well and incubated overnight at 37oC, 5% CO2.  
The following day (day 7), the antigen-treated B cells were washed extensively and 
resuspended at 1x106 cells/ml in fresh cRPMI.  These cells were then co-cultured with 
the BMDM, at a ratio of 1:1 (BMDM:B cells), with 100ng/ml E.coli LPS (Sigma), for 3hr at 
37oC, 5% CO2. As a control, wells containing B cells alone were also set up, and 
processed in the same way as the BMDM wells for the remainder of the assay. After co-
culture, all media was removed from the wells and the BMDM washed extensively to 
remove any un-phagocytosed B cells. 1ml fresh cRPMI was then added to the wells ready 
for overnight BMDM - OTII T cell co-culture. OTII T cells were isolated, as detailed in 
2.2.7, and resuspended at 1x106 cells/ml in cRPMI. 1x106 OTII T cells were added to 
appropriate wells, with a final volume of 2ml per well, and incubated overnight at 37oC, 
5% CO2.  
On day 8, cells from the 24 well plates were stained for flow cytometric analysis to 
allow investigation of the expression levels of CD69, an early activation marker of 
T cells (see 2.5.1). 
On day 10, supernatants were collected from the 96 well plates for use in IL-2 cytokine 
ELISAs (see 2.5.4), and the cells used for in vitro proliferation assays (see 2.5.3). 
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Figure 2.1  Secondary presentation Assay Protocol 
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2.4 Animal models 
2.4.1 Rituximab treatment of mice 
A single dose of Rituximab (RTX) (Genetech) was administered intravenously (i.v.) at 
100µg/mouse. In the case of RTX treatment of collagen-induced arthritis (CIA), the 
monoclonal antibody was administered either on day -4 or 0, with day 0 being the day 
of CIA induction. In the case of RTX treatment of healthy hCD20tg C57/B6 mice, RTX 
was administered on day 0, with mice euthanized on day 7, and the extent of B cell 
depletion analysed by FACS analysis (see 2.5.1). ChromPure whole human IgG (Jackson 
Laboratories) was used as a control. 
2.4.2 Adoptive cell transfers 
Spleen and LN cells were harvested from either hCD20tg DBA mice or WT littermates (as 
detailed in 2.2.1) and the B cells isolated (see 2.2.6). Purified viable B cells were then 
transferred into WT DBA mice, with 5x106 cells transferred via i.v. injection in to the 
tail vein. In the case of apoptotic cell adoptive transfers, B cells were irradiated to 
induce apoptosis (as described in 2.2.10), and either 5x106 or 0.5x106 apoptotic cells 
transferred per mouse, via i.v. injection into the tail vein. 
2.4.3 Collagen induced arthritis 
Collagen induced arthritis (CIA) [181] was induced by intra-dermal (i.d.) injection of an 
emulsion of 100µg of either chicken collagen type II (chicken CII) (Chondrex), or bovine 
collagen type II (CII) (Chondrex, MD Bioscience or Sigma, as stated) with 200µg 
Complete Freund’s Adjuvant (CFA) on day 0. CFA was prepared by resuspending 100mg 
of Mycobacterium tuberculosis H37 Ra (Difco Laboratories) in 25ml of Incomplete 
Freund’s Adjuvant (Sigma) to give a 4mg/ml CFA solution. Mice were boosted on day 21 
by i.p. injection of 100µg CII in PBS. In certain CIA runs RTX treatment was given (see 
2.4.1), and/or adoptive transfers of B cells or apoptotic cells performed (as detailed in 
2.4.2).  
Disease was monitored by the measurement of paw/ankle swelling using calipers, and 
both a 16-point and 24-point scale clinical scoring system. The 16-point scale monitors 
general inflammation of the paw as shown in Table 2.1. The 24-point score monitors 
joint inflammation, with each inflamed joint being assigned a score of 1, and the 
maximum score per paw being 6 (5 digits plus wrist/ankle). 
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Table 2.1 16-Point Clinical Scoring System for CIA  
Score Description   
0 Normal  
1 Redness  
2 Swelling of one joint (wrist/ankle or digit) 
3 Swelling of two or more joints  
4 Severe swelling (all joints)   
 
B cell responses were assessed by serum ELISA (as detailed in 2.5.5) on day 40-45, and 
T cell responses measured by in vitro proliferation assays (as described in 2.5.3).  
2.4.3.1 Analysis of radiographic pathology in CIA 
For some CIA runs, post-mortem x-rays were taken of the hind paw to determine the 
level of radiographic pathology incurred during the model. Paws were flattened in 
histology cassettes, fixed with formalin for 7-14 days and x-rays taken using the Kodak 
Fx-Pro. Images were captured using an exposure time of 2.5min at 35KVP, with the f-
stop set to 4, and illumination correction was applied. The images were then scored for 
radiological bone damage, with a maximal score of 27 possible. The scoring system 
employed was based on a method developed by collaborators at Cardiff University and 
Prince Charles Hospital, Cardiff. In detail, the 5 metacarpophalangeal (MCP) joints, 
along with the base of the 1st metatarsal bone were scored for erosions, osteopenia and 
evidence of periostial reactions, while the 2nd distal tarsal was scored for joint space 
loss with adjacent bone and osteopenia. The joint space between the 4th and 5th distal 
tarsal and fibulare, as well as that between the intermedium and centrale, were also 
scored for loss of definition and osteopenia. A score of 1 was assigned for evidence of 
each parameter, and a score of 0 in the absence of evidence. An overview of the joints 
scored and representative images of a healthy and an arthritic paw are given in Chapter 
7, Figure 7.12. 
2.4.4 Delayed type hypersensitivity responses 
Mice were immunized subcutaneously (s.c.) with an emulsion of 100µg of ovalbumin 
(OVA) (Sigma) with Complete Freunds Adjuvant (CFA) on day 0. On day 14 mice were re-
challenged with 100µg of heat aggregated ovalbumin (HAO) s.c. in the footpad 
[182,183]. Control mice received PBS instead of either OVA/CFA or HAO, or were left 
naive.  
To make the HAO, OVA was resuspended at 20mg/ml in PBS and heat-inactivated in a 
water bath for 2hr at 80oC. The suspension was then centrifuged at 450g for 5min, and 
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the supernatant discarded. The pellet was then washed in cold PBS, resuspended at a 
final concentration of 20mg/ml, aliquoted and stored at -20oC. Prior to use the HAO was 
thawed, and a syringe used to disperse any visible clumps.  
To assess the model, mice were monitored for inflammation, with paw thickness 
measured at 24 and 48hr post HAO challenge. T cell responses were measured by in 
vitro proliferation assays (as described in 2.5.3) as well as IL-2 cytokine ELISAs (see 
section 2.5.4). 
2.5 Analysis of responses 
2.5.1 Flow cytometric analysis 
Peripheral LNs, mesenteric LNs, peyers patches and spleen were analysed by flow 
cytometry, as well as peritoneal lavage and blood samples. Cells from in vitro assays 
were also analysed.  
2.5.1.1 Basic extracellular staining  
For cell surface staining, 3x105 – 1x106 cells were transferred to 5ml FACS tubes, washed 
with 1ml FACS buffer (see appendix) and centrifuged at 450g for 5min. The cell pellet 
was resuspended, 100µl of a 1:100 dilution of Fc Block (BD Bioscience) added and the 
cells incubated for 5-15min at 4oC. Antibodies for extracellular staining were diluted in 
FACS buffer and 50µl of this mix added to each tube and incubated for 20min at 4oC in 
the dark. An overview of the FACS antibodies and dilutions used are given in Tables 2.2 
and 2.3. Cells were then washed with 1ml of FACS buffer and centrifuged at 450g for 
5min. Where a biotin-conjugated primary antibody was used for cell surface staining, a 
further staining step involving a fluorochrome-labelled streptavidin was required. The 
streptavidin was diluted in FACS buffer and 50µl of this mix added to each tube and 
incubated for 20min at 4oC in the dark. After the final staining step, cells were washed 
with 1ml of FACS buffer, centrifuged at 450g for 5min, and resuspended in 300µl FACS 
buffer ready to be run on either a FACSCalibur (BD Bioscience) or a MACSQuant 
(Miltenyi) as stated. Samples that were not run immediately were fixed for later 
analysis. Cells to be fixed were resuspended in 250µl Cytofix/Cytoperm (BD Bioscience) 
and incubated for 20min at 4oC in the dark. Cells were then washed twice with 1ml 
1x perm wash solution (BD Bioscience), once with 1ml FACS buffer, and resuspended in 
300µl FACS buffer ready to be run. All FACS data were analyzed using FlowJo software 
(TreeStar). 
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2.5.1.2 Detection of apoptosis via FACS 
AnnexinV-FITC, 7-AAD and Cell Via-Probe (all BD Bioscience) staining was used to detect 
the kinetics of apoptosis of B cells in response to various in vitro treatments. B cells 
were isolated from either C57BL/6 hCD20tg mice or WT littermates (as detailed in 
2.2.6), and resuspended in cRPMI. Cells were then either incubated with 100µg/ml RTX, 
irradiated (see 2.2.10), or Etoposide-treated (see 2.2.11) depending on the conditions 
being investigated. At various time-points after the initial treatment, 1x106 cells were 
transferred into 5ml FACS tubes ready for staining. Cells were then washed once with 
1ml FACS buffer (see appendix), and twice more with 1ml 1x AnnexinV buffer 
(eBioscience). The cells were then resuspended in 100µl of 1x AnnexinV buffer, and 5µl 
of AnnexinV-FITC added per tube, before incubation at 4oC for 30min. Cells were 
washed with 1ml of AnnexinV buffer, centrifuged at 450g for 5min, and resuspended in 
300µl AnnexinV buffer ready to be run on either a FACSCalibur (BD Bioscience) or a 
MACSQuant (Miltenyi) as stated. 10min prior to the cells being run, 10µl of 7-AAD or Cell 
Via-Probe solution was added to each tube. This solution was not removed before the 
running of samples. 
2.5.1.3 Acid stripping of surface staining 
Acid stripping was employed to remove bound fluorochromes from the surface of cells 
previously stained for flow cytometric analysis. Single cell suspensions were prepared as 
stated in 2.2.1, and stained with either cell surface lineage markers or RTX-488 (see 
2.5.1.1). After staining cells were washed in 1ml FACS buffer, the supernatant poured 
off and the cells resuspended in the remaining buffer. 500µl-1ml 0.5M sodium 
chloride + 0.2M acetic acid was added to relevant tubes and incubated at 4oC for either 
4min or 10min depending on the protocol in use. Cells incubated for 4min were then 
washed twice with 2ml TBS (see appendix), once with 1ml FACS buffer and then 
resuspended in 300µl FACS Buffer. Cells that were incubated for 10min were then 
washed twice with 2ml TBS, followed by two more acid incubations with TBS washes in 
between each, for a total of 3 or 4 acid incubations, as stated. After the final acid 
incubation step, cells were washed twice more with 2ml TBS, once with 1ml FACS buffer 
and then resuspended in 300µl FACS Buffer. All acid stripped cells were analyzed on a 
FACSCalibur. 
2.5.1.4 Quenching of surface staining using Trypan Blue 
Trypan Blue was utilized to quench the signal from surface-bound fluorochromes on 
cells previously stained for flow cytometric analysis. Single cell suspensions were 
prepared at stated in 2.2.1, and stained with cell surface lineage markers (see 2.5.1.1). 
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Table 2.2 Anti-human antibodies 
Target Fluorochrome Clone Dilution/ 
Concentration Supplier 
     
CD20 v450 L27 1:40 BD Biosciences 
CD20 FITC 2H7 1:40 BD Biosciences 
CD20 PE 2H7 1:40 BD Biosciences 
CD20 PECy5 2H7 1:40 BD Biosciences 
CD20 APC 2H7 1:40 BD Biosciences 
CD20 AF-488 Rituximab 1-2µg/test Conjugated in Lab 
     
 
Table 2.3 Anti-mouse antibodies 
Target Fluorochrome Clone Dilution Supplier 
     
CD3e FITC 145-2C11 1:200 BD Pharmingen 
CD3e PE 145-2C11 1:200 BD Pharmingen 
CD3e APC 145-2C11 1:200 BD Pharmingen 
CD4 FITC H129.19 1:200 BD Pharmingen 
CD5 PE 53-7.3 1:200 eBioscience 
CD11b v450 M1/70 1:200 BD Horizon 
CD11b APC-Cy7 M1/70 1:200 BD Pharmingen 
CD11c PE-Cy7 HL3 1:200 BD Pharmingen 
CD19 PerCP-Cy5.5 1D3 1:200 BD Pharmingen 
CD19 APC 1D3 1:200 BD Pharmingen 
CD19 PE-Cy7 1D3 1:200 BD Pharmingen 
CD21 FITC 7G6 1:200 BD Pharmingen 
CD23 PE B3B4 1:200 BD Pharmingen 
CD24 PE M1/69 1:200 BD Pharmingen 
CD40 PE 3/23 1:200 BD Pharmingen 
CD45 APC 30-F11 1:200 eBioscience 
CD69 PE H1.2F3 1:200 eBioscience 
CD69 PE-Cy5 H1.2F3 1:200 eBioscience 
CD86 FITC GL1 1:200 BD Pharmingen 
CD206 AF647 C068C2 1:200 BioLegend 
B220 PEcy7 RA3-6B2 1:200 eBioscience 
Biotin PE Streptavidin 1:1000 eBioscience 
DO11.10 TcR APC KJ1.26 1:200 BD Pharmingen 
F4/80 PE BM8 1:400 BioLegend 
F4/80 APC BM8 1:200 eBioscience 
GR1 
(Ly6C/Ly6G) APC RB6-8C5 1:100 BD Pharmingen 
IgD FITC 11.26c.2a 1:200 BD Pharmingen 
IgD APC 11-26 1:200 eBioscience 
IgM PE R6-60.2 1:200 BD Pharmingen 
Ly6C PerCP Al-21 1:100 BD Pharmingen 
MHC I-Ab PE-Cy7 AF6-120.1 1:200 BioLegend 
MHC I-Aq Biotin KH116 1:200 BD Pharmingen 
         
 
 
   
66 
After staining cells were washed in 1ml FACS buffer, the supernatant poured off and the 
cells resuspended in the remaining buffer. 500µl/1ml 0.4% Trypan Blue (Sigma) was then 
added to relevant tubes, and incubated for either 1min or 2min, as stated. Cells were 
washed 2 times in 3ml cRPMI, once with 1ml FACS Buffer, and resuspended in 300µl 
FACS buffer before running on a FACSCalibur. 
2.5.1.5 Quenching of surface AlexaFluor-488 staining 
An anti-AF-488 quenching antibody (Invitrogen) was used after B cell incubation with 
RTX-488 to quench the signal emitted from surface bound RTX-488. B cells were 
incubated with RTX-488 for various time-points and then fixed (see 2.3.1). After this 
fixation step, 1ml FACS buffer was added to the tubes and centrifuged at 450g for 5min. 
Cells were then washed in 1ml FACS buffer, followed by 1ml of sodium phosphate buffer 
(see appendix), and resuspended in 100µl sodium phosphate buffer. 5µl anti-AF-488 
antibody was added to each tube, and incubated at 4oC for 20min. After incubation, 
cells were washed in 1ml of sodium phosphate buffer and resuspended in 300µl of 
sodium phosphate buffer ready to be run on a FACSCalibur. 
2.5.2 Fluorescent Microscopy 
2.5.2.1 Phalloidin staining 
A proportion of the B cells used to investigate the kinetics of RTX internalization (see 
2.3.1) were stained with rhodamine-conjugated phalloidin (Sigma), a high-affinity F-
actin probe, to enable detection of the cell membrane by fluorescence microscopy. 
To do this, 3x105 Cytofix/Cytoperm fixed B cells were washed twice with 1ml 1x perm 
wash solution (BD Bioscience), and resuspended in 200µl perm wash. The B cells were 
then stained with 50µg/ml rhodamine-phalloidin and incubated for 30min at RT. Cells 
were washed 3 times with 1ml 1x perm wash solution and resuspended at 
5x104 cells/75µl FACS buffer, ready to be cytospun onto slides (see section 2.5.2.2) and 
visualized (see 2.5.2.3). 
2.5.2.2 Cytospins 
Samples for analysis by fluorescent microscopy were cytospun onto slides. Single cell 
suspensions were resuspended in FACS buffer at 5x104 cells/75µl, with 75µl transferred 
onto a Superfrost Plus microscope slide (VWR) using a cytospin (450g for 5mins). Slides 
were left to dry, before the mounting using Vectashield mounting media containing DAPI 
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(Vector). Cover slips were sealed using clear nail varnish, and slides were stored at          
-20oC in the dark until visualisation on an ApoTome Microscope (Zeiss). 
2.5.2.3 Visualization of cells 
All slides were visualized using an ApoTome Microscope (Zeiss). 
2.5.3 Proliferation assays 
To measure the relative ability of lymphocytes to proliferate in response to a particular 
antigen, the incorporation of radioactive tritiated-thymidine (3H-thymidine) into newly 
synthesized cells was determined.  Mice were euthanized and single cell suspensions 
prepared, as described in 2.2.1. Cells were added to a 96 well plate at a concentration 
of 3x105 – 5x105 cells/well. Cells were incubated with cRPMI alone or media 
supplemented with OVA or CII, depending on the antigen used initially. OVA was added 
at concentrations of 1mg/ml and 500µg/ml, while CII was added at either 30µg/ml or 
60µg/ml. Plates were incubated for 72-96hr at 37°C, 5% CO2 before pulsing with 
12.5µl 3H-thymidine per well, for an additional 16hr. PMA and Ionomycin stimulation of 
cells (at 5ng/ml and 350ng/ml, respectively) was used as a positive control, and plates 
were incubated for 24hr at 37oC, 5% CO2 before pulsing with 12.5µl 3H-thymidine for a 
further 16hr. The cells were then harvested onto filter mats (Perkin Elmer) using a 
Harvester 96 - Mach III cell harvester (Tomtec). Once the filter mats had dried, they 
were placed in MicroBeta sample bags (Perkin Elmer), scintillation fluid added (Wallac), 
and analysed using a Betaplate scintillation counter (Wallac). 
2.5.4 Cytokine ELISAs 
2.5.4.1 Sandwich ELISAs 
Cytokine expression was tested in in vitro culture supernatants. ELISAs were carried out 
according to the manufacturer’s protocols (Table 2.4). In general, 96-well half volume 
high-binding plates (Fisher Scientific) were coated with capture antibody in 
recommended coating buffer (see appendix) and incubated overnight at 4oC. Plates 
were then washed 3-5 times with phosphate-buffered saline + 5% Tween (PBST) (see 
appendix), and blocked with blocking buffer (see appendix) for 1hr to inhibit non-
specific antibody binding. Plates were washed a following 3-5 times with PBST. The 
standards and samples were then added in triplicate and the plates incubated for 2hr at 
RT. For TGF-β ELISAs all samples were acid activated prior to addition to the ELISA plate 
in order to activate any latent TGF-β1 present. To do this, 20µl 1N HCl was added to 
100µl of sample and incubated at RT for 10min. The samples were then neutralized with 
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20µl of 1N NaOH. Depending of the cytokine being investigated certain samples were 
diluted in assay diluent (see appendix) before addition to the plate. After the sample 
incubation plates were washed 5x with PBST. Depending on the kit in use, at this stage 
either a working detector solution, made up of the detection antibody and streptavidin-
HRP, was added, or the detection antibody alone. Both of these were left for an hour at 
RT. For the plates where only the detection antibody was added, after another wash 
step, streptavidin-HRP was added for 30min at RT. Once the plates had been incubated 
with both the detection antibody and streptavidin-HRP, either together or alone, plates 
were washed a further 7 times and TMB substrate added to wells in order to develop the 
plates. This was left for between 2-30min depending on the cytokine in question. The 
reaction was then stopped using 4N sulphuric acid, and plates read at 450nm. 
Table 2.4 Cytokine ELISAs 
Cytokine Company Detection Range 
   
Mouse IL-1β BD Bioscience 31.25 – 2000 pg/ml 
Mouse IL-6 BD Bioscience 15.62 – 1000 pg/ml 
Mouse IL-10 BD Bioscience 31.25 – 2000 pg/ml 
Mouse IL-12 eBiosciences 4.69 – 300 pg/ml 
Mouse TNFα BD Bioscience 15.62 – 1000 pg/ml 
Mouse TGF-β eBiosciences 15.62 – 1000 pg/ml 
      
 
 
 
2.5.4.2 Competitive binding ELISAs 
Prostaglandin E2 expression was tested in in vitro culture supernatants by competitive 
binding ELISAs (Cayman Chemicals), which were carried out according to the 
manufacturer’s instructions, with all kit reagents reconstituted/diluted in Ultra Pure 
water (Cayman Chemicals). Samples, either neat or diluted in cell culture medium 
(cRPMI), and standards diluted in cRPMI were added to pre-coated plates, with 50µl 
each of Prostaglandin E2 AChE Tracer and Prostaglandin E2 monoclonal antibody (both 
supplied with the kit) directly added to the sample containing wells. Relevant control 
wells were also set up at this time according to the manufacturers protocol, the plates 
covered, and incubated for 18hr at 4oC. Plates were then washed 5 times with 1x wash 
buffer, and 200µl of the developer, Ellman’s Reagent, added to each well (both 
supplied with the kit). The plates were then covered with plastic film and developed at 
RT, in the dark, with shaking for 60-90min. Ellman’s Reagent cannot over-develop, and 
so no stop solution was added to these ELISAs before the plates were read at 405nm. 
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2.5.5 Serum ELISAs 
Levels of type II collagen (CII) specific IgG1 and IgG2a, as well as total IgG and total 
IgG1, were tested in the serum of mice used in collagen-induced arthritis (CIA) models 
(as detailed in 2.4.3). Serum ELISAs were developed in house. As with cytokine ELISAs, 
96-well half volume high-binding plates (Fisher Scientific) were used. For total IgG and 
IgG1 ELISAs plates were coated with goat anti-mouse IgG (Southern Biotech) at 5ug/ml 
in PBS and incubated at 4oC overnight. For CII-specific IgG1 and IgG2a plates were 
coated with either ELISA grade chicken collagen, or ELISA grade bovine collagen, at 
5ug/ml in 1x collagen diluent (all from Chondrex), and incubated overnight at 4oC. 
Plates were then washed 4 times with PBST (see appendix), and blocked with PBS + 
3% BSA for 1hr at RT. Plates were washed a following 4 times with PBST, and serum 
samples and standards added, and the plates incubated for 2hr at RT.  
Table 2.5 gives an overview of the standards and their dilutions, as used for each serum 
ELISA. For CII-specific serum ELISAs commercially available standards are not available, 
and so a dilution range of pooled sera from CIA animals was used to create standard 
curve values, with a scale of ‘relative units’ (RU) used for analysis. Multiple dilutions of 
each serum sample were included in the assay to ensure a final result that fell within 
the standard curve.  
Table 2.5 Serum ELISA standards 
ELISA Standard Range/Dilution 
   
Total IgG Polyclonal IgG 1.56 - 100ng/ml 
Total IgG1 Polyclonal IgG1 0.62 - 40ng/ml  
CII IgG1 Pooled sera 1:3000 - 1:2187000 
CII IgG2a Pooled sera 1:3000 - 1:2187000 
      
 
After the sample incubation, plates were washed 4x with PBST. The appropriate 
secondary antibody, diluted 1:3000 in PBS + 1% BSA, was then added to the plate and 
incubated for 1hr at RT. Anti-IgG HRP (Southern Biotech), was used as the secondary 
antibody for total IgG ELISAs. Anti-IgG1 HRP (Bethyl) was used as the secondary 
antibody for both the total IgG1, and CII-specific IgG1 ELISAs, while anti-IgG2a HRP (BD 
Bioscience) was used for the CII-specific IgG2a ELISAs. Plates were washed a further 4 
times in PBST, and TMB substrate added to every well in order to develop the plates. 
This was left for between 1-10min, until the standard curve could be visualized. The 
reaction was then stopped using 4N sulphuric acid, and plates read at 450nm. 
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2.6 Statistical analyses 
The GraphPad Prism computer program was used to perform all statistical analyses, 
with different analyses utilised depending on the data being investigated. When 
comparing two sets of data, either a T-test or a Mann-Whitney test was used, depending 
on the distribution of the data. A One-way ANOVA (or non-parametric equivalent) was 
used for the comparison of three or more data groups in experiments with only one 
variable factor. A post-test was employed if overall significance was detected, with 
Bonferroni’s test used. A two-way ANOVA was used for the comparison of three or more 
data groups in experiments with two variable factors (i.e. the CIA model). Figure 
legends state the statistical test used for each set of data. p values of 0.05 or less were 
considered to be statistically significant, with * = p<0.05, ** = p<0.01, *** =  p<0.001. 
Data in graphs are shown as means ± SD. 
  
 
 
 
 
 
Chapter 3: Macrophage Interactions with 
Apoptotic Cells 
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3.1 Introduction 
Cell death is a crucial biological process that is pivotal in regulating steady state tissue 
turnover and homeostasis, as well as playing a major role in the resolution of immune 
responses, with three main forms of cell-death existing: apoptosis, necrosis, and 
autophagy. Cells can be placed into each of these categories depending on the 
morphological and biochemical features observed on cell death, and their subsequent 
interactions with phagocytes. 
Apoptosis is a controlled and highly regulated form of cell death, characterized by 
cleavage of chromosomal DNA, nuclear condensation and fragmentation, and the 
formation of apoptotic bodies that prevent the release of intracellular matter into the 
surrounding environment. AC are rapidly cleared from the system by phagocytes, in the 
absence of pro-inflammatory responses. Apoptosis can be activated by two pathways: 
the ‘intrinsic’ pathway, which is initiated from within the cell itself in response to 
severe cell stress, DNA damage, or the loss of cell survival factors; and the ‘extrinsic’ 
pathway, which is initiated in response to external stimuli received by the cell in the 
form of the ligation of pro-apoptotic receptors expressed on the cell’s surface, such as 
Fas and TRAIL. Both pathways of apoptosis are active processes requiring energy in the 
form of ATP, and result in the activation of specialised proteases called caspases, 
leading to the breakdown of integral cell components and cell death.  
Necrosis occurs as a consequence of tissue damage or extreme cellular stress, and is 
characterized by swelling of cellular organelles, coupled with lysosomal leakage, and 
the loss of membrane integrity. Originally thought to be an uncontrolled, passive form 
of cell death, evidence had shown that certain forms of programmed necrosis take 
place, resulting in regulated caspase-independent mechanisms of cell death. Clearance 
of necrotic cells is slower and less efficient than that of apoptotic cells, occurring after 
the release of intracellular material from the dying cell [112], inducing inflammatory 
responses in the surrounding environment. 
Autophagy is a catabolic process that can be involved cell survival, as well as cell death, 
through the recycling of cellular components in response to cell starvation, with 
important roles in embryonic development and tissue remodelling. Autophagic cell 
death results from prolonged exposure to continued cell starvation, and is associated 
with extensive vacuolization of the cytoplasm [121], with specific proteins involved in 
the formation of large autophagic vesicles. The clearance of autophagic cells results in 
distinct transcriptional responses in phagocytes [121], leading to pro-inflammatory  
outcomes. 
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Millions of cells undergo apoptosis every day, and so the rapid clearance of AC without 
stimulation of the immune system is crucial to maintaining peripheral tolerance to self. 
If not cleared in a timely fashion, apoptotic cells will undergo secondary necrosis, 
leading to the release of intracellular material into the surrounding environment, which 
in certain circumstances can lead to in a break in tolerance to intracellular self-
antigens, and chronic pathology, such as in SLE [156]. 
The non-inflammatory clearance of AC is dependent on the interaction of AC with 
phagocytes during cell tethering and uptake, with changes in the surface membrane 
composition of the AC detected, as well as functional alterations in adhesion molecules 
(i.e. ICAM-3 [149]) and inhibitory molecules (i.e. CD31 [151]), collectively termed 
‘ACAMPs’ [reviewed in [124]. One of the most well characterized changes undergone by 
AC is the exposure of PS on the cell surface [184], with this change in membrane 
composition being a key “eat-me” signal involved in AC uptake [125]. Phagocytes are 
able to recognise PS directly via specific PS receptors on their surface, or via soluble 
adaptor proteins that allow additional, indirect recognition of PS by phagocytes. MFG-E8 
[134], β2-glycoprotein I [138] and GAS-6 [136], are all able to bind exposed PS on the AC 
surface, with each adaptor molecule then recognized by its specific receptor on the 
phagocyte. Alongside alterations in membrane composition, modification of existing 
surface antigens occurs on AC, resulting in the generation of neo-epitopes, however, 
the specifics of these processes are not yet fully understood. Collectins, such as MBL 
and the complement component C1q bind to the surface of late apoptotic cells, 
promoting uptake through subsequent interaction with CD91 and CRT on the surface of 
phagocytes [141], with ACAMPs thought to be the target for this interaction. Oxidization 
of the AC surface results in the formation of ox-LDL-like neo-epitopes on the AC 
surface, which can be recognized directly by scavenger receptor A (SR-A) [144] and 
LOX1 [146], and also act as TSP-1 binding sites, allowing indirect recognition by 
additional phagocytic scavenger receptors. Changes in the specific cell surface 
molecules expressed by AC help to mediate tethering and uptake by phagocytes, 
however certain molecules considered to be markers of AC, are also exposed on viable 
cells (i.e. PS), and as such the spatial distribution of these molecules is likely to be 
involved in the differentiation between cell states.  
Clearance of apoptotic cells was originally thought to occur simply in the absence of 
pro-inflammatory signals, however in the late 1990s, work by Voll et al showed that the 
uptake of AC can actively suppress inflammatory responses [158], with apoptotic 
peripheral blood lymphocytes shown to induce increased production of the anti-
inflammatory cytokine IL-10 and decreased production of the pro-inflammatory 
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cytokines TNFα, IL-1β and IL-12 by human monocytes on stimulation with LPS. Over the 
past two decades, a huge body of work has arisen that supports this finding that AC are 
able to modulate the immune system, actively promoting anti-inflammatory responses 
in a range of phagocytes. Ingestion of AC by immature DC results in a diminished ability 
to produce pro-inflammatory cytokines such as IL-12, and inhibition of DC maturation 
[166], with immature murine DC that ingest apoptotic neutrophils unable to upregulate 
the co-stimulatory molecule CD86, resulting in a reduced capacity to stimulate T cell 
proliferation [166]. Cytokine production by NK cells is also affected by interaction with 
AC. In vitro co-culture of human NK cells and apoptotic Jurkat, PLB-985 or CD4+ T cells 
results in significant increases in TGF-β production by the NK cells, with this TGF-β 
production able to suppress further IFNγ secretion by the NK cells in response to 
stimulation [167]. Along with modulating cytokine production by innate immune cells, 
uptake of AC by phagocytes has also been shown to alter secretion of other immune 
mediators, and angiogenic growth factors [185]. Co-culture of apoptotic Jurkat T cells 
with murine peritoneal macrophages results in increased production of anti-
inflammatory prostaglandins such as PGE2, with concomitant inhibition of pro-
inflammatory eicosanoids and LPS-induced NO generation [169]. The immunomodulatory 
effects of AC have also been confirmed in vivo. In a murine model of CIA, intravenous 
injection of apoptotic thymocytes, up to one month before arthritis induction, was able 
to protect mice from disease and led to increased secretion of IL-10 by CD4+ T cells on 
in vitro re-stimulation [172], indicating the ability of AC to alter adaptive cell function 
as well as innate cell function.  
This body of evidence supports the idea that AC are able to induce anti-inflammatory 
responses on binding/engulfment by phagocytes both in vitro and in vivo, and may have 
the potential to re-introduce tolerance to the immune system. We hypothesize that 
treatment with Rituximab in the context of RA may re-introduce a temporary tolerance 
to the immune system, caused, at least in part, by the generation of large numbers of 
apoptotic B cells (Figure 1.3). If on treatment with RTX, apoptosis of B cells is caused, 
the B cells will be cleared by APCs, with the binding and engulfment of AC inducing a 
range of anti-inflammatory responses in the APC. As that uptake of apoptotic B cells by 
phagocytes will be in a non-inflammatory context, peptides resulting from B cell 
degradation will be presented by the APC in a ‘tolerogenic’ context. If the ingested 
B cell has previously taken up self-antigen, specifically the putative self-antigen the RA 
response is directed toward, presentation of this antigen in a non-inflammatory, 
tolerizing environment, may result in the re-introduction of temporary tolerance to the 
RA system. Although the effects of uptake of a variety of different AC have been 
investigated, apoptotic B cells have not been used as the model AC for any of these 
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studies.  For that reason, as an initial step to understanding the potential validity of our 
hypothesis, the immunosuppressive effects of apoptotic B cells were examined, and 
specifically whether apoptotic B cells have the same immunomodulatory capacities as 
other, more commonly studied AC. To do this, in vitro assays were set up in which bone 
marrow derived macrophages (BMDM) were co-cultured with a variety of apoptotic cells, 
allowing direct comparison of the outcomes of co-culture. Primary murine B cells, 
T cells and thymocytes were utilized, with apoptosis inducted either by x-irradiation or 
Etoposide-treatment of cells. 
Chapter objectives: 
• To investigate whether BMDM and apoptotic B cells undergo similar levels of 
interaction as BMDM and other AC 
• To explore whether the interaction of BMDM and apoptotic B cells alters BMDM 
phenotype, specifically their antigen presenting potential and activation 
• To determine whether the interaction of BMDM and apoptotic B cells results in 
changes in the BMDM function 
3.2 Results 
3.2.1 Induction of apoptosis by irradiation 
Apoptosis is a naturally occurring form of programmed cell death, however it can be 
also induced by various external stimuli. To assess whether AC originating from different 
populations of lymphocytes interact differently with macrophages, primary B cells, 
T cells and thymocytes isolated from C57BL/6 mice were used as model AC, with 
apoptosis induced ex vivo by ionizing radiation. Ionizing-radiation comprises several 
different type of radiation, with gamma-irradiation [186-188] and x-irradiation [189-
191] both repeatedly used in the literature to induce apoptosis. Throughout this thesis 
x-irradiation was utilized to induce apoptosis, due to access to an XRAD225 x-ray 
irradiation system.  
Lymphocytes are known to be particularly radiosensitive compared to other cell types, 
however on irradiation cell death in lymphocytes does not occur immediately, but after 
a latent period [192], with the length varying depending on both the radiation dose and 
culture conditions. If left for prolonged periods of time apoptotic cells will undergo 
secondary necrosis. For use in co-culture with BMDM, a population of apoptotic, but not 
necrotic, irradiated lymphocytes was desired, along with a population of still viable 
non-irradiated lymphocytes, and so the optimal length of lymphocyte incubation post 
treatment was determined.  
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To do this, spleens were harvested from mice, single cell suspensions prepared and the 
B cells isolated. The B cells were then divided into two groups, resuspended at 1x106 
cells/ml in cRPMI, and one group irradiated. Both groups were then incubated for 
varying lengths of time, as stated. The time points begin after B cell separation ex vivo, 
and indicate the length of incubation after irradiation, starting at 0hr. Cell were then 
stained with AnnexinV and 7-AAD, and analysed by flow cytometry to allow detection of 
live, apoptotic and dead cells (see Table 3.1). AnnexinV is a calcium-dependent 
phospholipid-binding protein that specifically binds to phosphatidylserine (PS), while 7-
AAD is a fluorescent intercalator that emits a signal on binding to DNA. Viable cells, 
which have intact cell membranes, will exclude 7-AAD and do not express sufficient 
levels of PS on their surface to result in a detectable AnnexinV signal, resulting in a 
double negative population of cells. During apoptosis, the cell membrane remains 
intact, however PS becomes exposed on its outer surface. As such, apoptotic cells stain 
positive for AnnexinV, but are 7-AAD-. In dead cells and necrotic cells (including those 
undergoing secondary necrosis), membrane integrity is lost, allowing 7-AAD to enter the 
cell and bind to DNA, resulting in a 7-AAD+ population. Due to the loss of membrane 
integrity necrotic and dead cells will also be AnnexinV+ as the protein will be able to 
enter these cells, and bind to PS constitutively expressed on the inner leaflet of cell 
membranes. 
Table 3.1 Detection of cell viability by FACS 
FACS Stains 
 
Annexin V 7-AAD 
   
Viable Cells - - 
Apoptotic Cells + - 
Necrotic Cells + + 
      
 
At the 0hr time-point comparable levels of live, apoptotic and dead B cells were seen in 
both the irradiated and non-irradiated groups, with the proportion of dead cells 
remaining comparable at all time-points investigated (Figure 3.1a-d). However, by the 
3hr time-point substantially less viable cells were present in the irradiated cell 
population (36.1±12.6%) compared to the non-irradiated cells (66.8±4.2%) (Figure 3.1b), 
with this reduction in viable cells in the irradiated cell population coupled with an 
increased proportion of apoptotic cells (irr: 50.5±9.3% vs. non-irr: 23.7±4.3%) (Figure 
3.1c). At the 6hr and 8hr time point this pattern continued, with considerably more 
apoptosis observed in the irradiated cell population when compared to the non-
irradiated cells (6hr – irr: 71.7±1.4% vs. non-irr: 40.7±4.1%, 8hr – irr: 82.3±2.7% vs. non-
irr: 58.1±7%). Although markedly more apoptosis was seen in the irradiated cell
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Figure 3.1 Induction of B cell apoptosis by irradiation 
Single cell suspensions wells were prepared from the combined spleen and LNs of WT C57BL/6 
mice, and either irradiated or left non-irradiated. Cells were then incubated for varying time-points 
and stained with 7-AAD and Annexin V, and analysed by flow cytometry to allow detection of live, 
dead and apoptotic cells. (A) Representative FACS plots showing the gating used to differentiate 
live, dead and apoptotic cells at each of the time points and for each treatment group, with viable 
cells 7-AAD-AnnexinV-, apoptotic cells 7-AAD-AnnexinV+ and dead cells staining double positive for 
7-AAD and AnnexinV. (B) Graph of pooled data showing the percentages of live non-irradiated or 
irradiated B cells over a 24hr period of in vitro culture. (C) Graph of pooled data showing the 
percentages apoptotic non-irradiated or irradiated B cells over a 24hr period of in vitro culture. 
(D) Graph of pooled data showing the percentages late apoptotic/dead non-irradiated or irradiated 
B cells over a 24hr period of in vitro culture. (n=1, 3 replicates)  
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populations at the 6 and 8hr time-points, after 6hr of culture a substantial proportion of 
apoptotic cells were also observed in the non-irradiated cell population, with only 
34.5±5.7% of B cells viable at 6 hours, 22±7.8% at 8hr and 3.5±2.6% at 24hr (Figure 
3.1b). At the 24hr time-point, the proportions of live and dead cells were again 
comparable between the two groups. 
These findings demonstrate that x-irradiation of murine B cells induces substantial 
levels of apoptosis, with a significant increase in the proportion of apoptotic cells 
observed between 3-8hr after irradiation, compared to non-irradiated cells. However, 
after 6hr, the non-irradiated cells also began to undergo high levels of apoptosis. As 
such, to ensure a large apoptotic population in the irradiated group while maintaining a 
mostly viable cell population in the non-irradiated cells, it was decided that both 
irradiated and non-irradiated cells would be used in BMDM co-cultures after 3-4hr of 
incubation. 
3.2.2 Interactions of L929 BMDM with irradiated apoptotic cells 
In vitro assays were performed to investigate whether AC originating from different 
populations of lymphocytes interact differently with macrophages. Murine BMDM were 
grown for 6 days in media supplemented with M-CSF-containing L929 supernatant (L929 
BMDM), and half the cells stimulated overnight with 100U IFNγ. Thymocytes were 
isolated from C57BL/6 mice, with B cells purified from the spleens, and T cells from 
peripheral LNS. All lymphocytes were CFSE-stained, and half of the cells from each 
lymphocyte population were irradiated to induce apoptosis, with viable cells used for 
comparison, and all cells incubated for 4hr. The L929 BMDM incubated overnight with 
IFNγ were further stimulated with 10ng/ml LPS (activated L929 BMDM). All BMDM were 
mixed with CFSE-stained viable or irradiated B cells, T cells or thymocytes, at a ratio of 
5:1 (lymphocytes:BMDM) and co-cultured for 15min. The co-cultures were then stained 
for the macrophage lineage marker F4/80 and the resultant levels of cell-cell or cell-AC 
interaction were analyzed by flow cytometry. 
In the samples tested, viable cells were gated on using forward scatter (FSC) and side 
scatter (SSC), and within this population the F4/80+ cells were defined as BMDM. 
F4/80+CFSE+ cells were deemed to be BMDM undergoing interactions with CFSE-stained 
lymphocytes/AC, with the F4/80+CFSEhi populations also investigated independently 
(Figure 3.2a).  
When L929 BMDM were co-cultured with either viable or irradiated cells, the vast 
majority of the BMDM population became CFSE+ for all conditions investigated (Figure 
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3.2b-d). Within the CFSE+ population of BMDM, two distinct sub-populations were 
detected, a CFSEhi and CFSElo population. When the CFSEhi population of L929 BMDM was 
investigated, differences between the co-culture conditions became apparent. On co-
culture of BMDM with irradiated lymphocytes in the absence of stimulation, a 
significantly higher percentage of CFSEhi BMDM were present in the BMDM + irradiated 
thymocyte condition (20.9±3.6%) compared to the BMDM co-cultures with irradiated 
B cells, or irradiated T cells (7.4±1.4% and 7.7±2.9%, respectively) (Figure 3.2d). When 
activated BMDM were utilized in the co-cultures, significantly more CFSEhi BMDM were 
detected after co-culture with irradiated B cells (29.3±2.4%), compared to the un-
stimulated BMDM co-cultured with irradiated B cells (7.4±1.4%). Viable cells were used 
in BMDM co-cultures for comparison, with lower levels of interaction between BMDM and 
viable lymphocytes expected, compared to irradiated lymphocytes. Comparable levels 
of CFSEhi BMDM were seen on co-culture of viable or irradiated T cells with either un-
stimulated BMDM (8.6±2.3% and 9.1±0.7%, respectively) or activated BMDM (7.7±2.9% 
and 9.3±0.3%, respectively). When viable or irradiated thymocytes co-cultures were 
compared, similar levels of CFSEhi BMDM were also observed when both un-stimulated 
and activated BMDM were utilized for the co-cultures. However, co-culture of L929 
BMDM with viable B cells resulted in unexpectedly high proportions of CFSEhi BMDM. Co-
culture of un-stimulated BMDM with viable B cells resulted in a substantially greater 
percentage of CFSEhi BMDM compared to those co-cultured with irradiated B cells 
(42.1±8.9% vs. 7.4±1.7%), and also when compared to either viable T cells or 
thymocytes (42.1±8.9% vs. 8.6±2.3% and 25.3±12.5%, respectively). The levels of 
interaction seen with viable B cells was also markedly increased when activated BMDM 
were utilized in the co-culture conditions (66.5±1.2% CFSEhi), compared to un-
stimulated BMDM. 
To begin to understand whether BMDM co-culture with AC in this sytem resulted in any 
immunomodulatory effects on the BMDM, the production of IL-10 and TNFα by activated 
L929 BMDM was quantified after co-culture with AC. Co-culture with irradiated B cells, 
T cells or thymocytes had no effect on IL-10 production, compared to BMDM cultured 
alone (3813±521pg/ml) (Figure 3.3a), with viable cells also having no effect on IL-10 
levels. Co-culture of activated L929 BMDM with irradiated T cells or thymocytes resulted 
in a slight decrease in TNFα production (2654±222pg/ml and 2389±234pg/ml, 
respectively), compared to activated BMDM (3919±584pg/ml). The data also indicate a 
decrease in TNFα secretion after co-culture with irradiated B cells (3059±987pg/ml) 
(Figure 3.3b). Unexpectedly, co-culture with viable B cells, T cells and thymocytes also 
seemedly decreased production of TNFα (1978±238pg/ml, 2389±234pg/ml, and 
2798±234pg/ml, respectively).  
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Figure 3.2 Interaction of L929 BMDM with irradiated apoptotic cells 
Murine BMDM were grown in cRPMI supplemented with M-CSF containing L929 supernatant. 
BMDM were co-cultured with CFSE stained viable or irradiated primary B cells, T cells or 
thymocytes for 15min in the presence or absence of 100U IFNγ and 10ng/ml LPS, and analyzed by 
flow cytometry. (A) Gating strategy used to define CFSE+ and CFSEhi BMDM. First panel: SSC vs. 
FSC. Second panel: SSC vs. F4/80. Third panel: CFSE vs. F4/80. (B) Representative FACS plots 
showing the levels of interaction seen between un-stimulated L929 BMDM and viable and 
irradiated lymphocytes. Panels: CFSE vs. F4/80. (C) Representative FACS plots showing the 
levels of interaction seen between IFNγ + LPS stimulated L929 BMDM and viable and irradiated 
lymphocytes. (D) Graph of pooled data showing the percentage of CFSE+ BMDM. (E) Graph of 
pooled data showing the percentage of CFSEhi BMDM. (No stim: n=2 from 2 independent 
experiments, LPS+IFNγ: n=1)  
   
81 
 
Figure 3.3 Cytokine production by activated L929 BMDM after co-culture with apoptotic cells 
Murine BMDM were grown in cRPMI supplemented with L929 cell supernatant. BMDM were 
stimulated with 100U IFNγ overnight, and on d7 adherent cells were co-cultured overnight with 
viable or irradiated primary B cells or thymocytes, in the presence of 10ng/ml LPS. Cytokine 
production by L929 BMDM was quantified using ELISAs. (A) Graph showing IL-10 production 
(pg/ml). (B) Graph showing TNFα production (pg/ml). (n=1, 3 replicates)  
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These findings demonstrate that, the proportion of L929 BMDM undergoing elevated 
cell-cell interactions after co-culture with irradiated apoptotic cells varied between the 
different conditions, with the pattern of interaction altered by the BMDM activation 
state. The co-culture of L929 BMDM with viable cells resulted in unexpectedly high 
proportions of elevated cell-cell interactions, regardless of the activation state of the 
BMDM, with significantly more CFSEhi BMDM detected in the co-cultures containing 
viable B cells compared to the other viable cell conditions. On quantification of 
cytokine production by BMDM after co-culture, TNFα production decreased, while no 
change in IL-10 concentration was detected, for all AC investigated. Surprisingly, in this 
assay system co-culture of BMDM with viable cells had the same modulatory effects on 
BMDM cytokine production as co-culture with AC, for all cell types investigated. 
3.2.3 Investigation of the CFSEhi and CFSElo populations of L929 
BMDM after co-culture 
As shown, culture of L929 BMDM with CFSE-stained lymphocytes resulted in two distinct 
CFSE+ BMDM populations, a CFSEhi population and a CFSElo population. It was theorized 
that the CFSE signal in the CFSElo BMDM group could potentially be due to the uptake of 
free CFSE that had leached into the cell culture media from CFSE-stained lymphocytes 
by BMDM. To determine whether this was the case, L929 BMDM were co-cultured with 
either CFSE-stained thymocytes or CFSE-stained thymocyte conditioned media. The 
CFSE-stained thymocyte conditioned media was produced by culturing viable or 
irradiated CFSE-stained thymocytes in cRPMI for 4hr, with the supernatant from these 
cultures collected and used for BMDM co-culture. The CFSE signal of the BMDM was then 
analyzed by flow cytometry. 
In the samples tested, viable cells were gated on using FSC and SSC, and within this 
population the F4/80+ cells were defined as BMDM. Within this F4/80+ population, the 
proportion of CFSE+ cells was investigated, with BMDM cultured in cRPMI alone used to 
set the CFSE-/CFSE+ gate (Figure 3.2a). L929 BMDM that were co-cultured with either 
viable or irradiated thymocytes showed a large increase in CFSE signal, with over 95% of 
BMDM detected as CFSE+ after co-culture (Figure 3.4b, c). However L929 BMDM co-
cultured with the CFSE-stained thymocyte conditioned media showed no increase of 
CFSE signal above background.  
Once it was confirmed that both the CFSEhi and CFSElo BMDM populations were in some 
way interacting with CFSE-stained AC/lymphocytes, rather than free CFSE, additional 
analysis of the flow cytometry data was undertaken in an attempt to further understand 
the interactions taking place. To do this, the CFSEhi and CFSElo populations of BMDM 
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were gated on individually (Figure 3.5a) and the FSC vs. SSC profiles of these subsets 
compared. When an overlay was produced comparing the CFSEhi BMDM and CFSElo BMDM 
populations resulting from co-culture of un-stimulated L929 BMDM with either irradiated 
or viable lymphocytes (Figure 3.5b), it can be seen that the CFSEhi BMDM generally have 
a higher FSC than the CFSElo BMDM, with these results replicated in the conditions 
containing stimulated BMDM. This reveals that the CFSEhi BMDM are larger in size than 
the CFSElo BMDM, indicating these cells are potentially undergoing interactions with 
whole cells or complete AC. The CFSElo population, on the other hand, may in some way 
be taking up small amounts of CFSE from the stained cells, or undergoing interactions 
with small apoptotic blebs or cell debris, or rather than whole cells, however without 
further work this cannot be conclusively stated. 
3.2.4 Induction of apoptosis by Etoposide treatment 
In the literature, many different methods of inducing apoptosis in vitro are utilized, 
including irradiation [157], chemotherapeutic treatment [168,193], and the culture of 
cells in the absence of survival factors [194]. There is a growing body of work 
demonstrating that different methods of apoptosis induction give rise to AC with varying 
characteristics, resulting in altered responses to these AC by other cells of the immune 
system [reviewed in [195]. As uptake of viable cells had the same effects on BMDM 
function as uptake of AC in this system, it was decided to investigate the interactions of 
BMDM with another form of AC in an attempt to obtain results more closely resembling 
those in the published literature. Etoposide is a topo-isomerase inhibitor, with in vitro 
treatment of cells resulting in damage to cellular DNA and subsequent apoptosis [196]. 
Etoposide-treated lymphocytes were added to the co-culture assay system to allow 
comparison of the interaction of BMDM with these AC to the interactions of BMDM with 
irradiated AC. Before the use of Etoposide-treated AC in the co-culture system, the 
kinetics of cell death after Etoposide-treatment was determined.  
To do this, spleens and LNs were harvested from C57BL/6 mice, combined, and the 
B cells isolated. The B cells were then resuspended in 10µM Etoposide and incubated for 
up to 24hr. The time points begin after B cell separation ex vivo, and indicate the 
length of Etoposide-treatment, starting at 0hr. An aliquot of cells was removed at each 
time-point and stained with 7-AAD and Annexin V, before analysis by flow cytometry to 
allow detection of live, apoptotic and necrotic/dead cells at each time-point.  
At the 0hr time-point the majority of B cells were still viable (76.1±0.9%), with a 
moderate level of apoptotic cells (15.4±0.1%) and negligible levels of dead cells 
detected (4±0.1%) (Figure 3.6a and b). Similar proportions of viable, apoptotic and dead 
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Figure 3.4 Co-culture of BMDM with CFSE+ thymocyte conditioned media does not result in 
an increased CFSE signal within the BMDM population 
Murine L929 BMDM were co-cultured with CFSE-stained viable or irradiated thymocytes, or CFSE-
stained thymocyte conditioned media, for 15min and analyzed via flow cytometry. (A) The gating 
strategy used to identify L929 BMDM in samples. First panel: SSC vs, FSC. Second panel: SSC 
vs. F4/80. Third panel: CFSE vs. F4/80. (B) Representative FACS plots showing CFSE staining of 
BMDM after co-culture with either viable or irradiated thymocytes, or CFSE-stained thymocyte 
conditioned media. Panels: CFSE vs. F4/80. (C) Graph of pooled data showing the percentage of 
CFSE+ BMDM. (n=1, 3 replicates) 
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Figure 3.5 The CFSEhi population of BMDM have a greater forward scatter profile than 
CFSElo BMDM after co-culture 
Murine BMDM were grown in cRPMI supplemented with M-CSF containing L929 supernatant. On 
d7 adherent cells were co-cultured with CFSE stained viable or irradiated primary B cells, T cells or 
thymocytes for 15min and analyzed by flow cytometry. (A) Gating strategy to identify CFSEhi and 
CFSElo BMDM. First panel: SSC vs, FSC. Second panel: SSC vs. F4/80. Third panel: CFSE vs. 
F4/80. (B) Representative images showing overlays of the forward scatter and side scatter 
properties of the CFSEhi and CFSElo BMDM subsets. Panels: SSC vs. FSC. (n=1, 3 replicates) 
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Figure 3.6 Induction of B cell apoptosis by Etoposide treatment 
B cells were isolated from the combined spleen and LNs of WT C57BL/6 mice and cultured in 
10µM Etoposide. Cells were then incubated for 0, 3, 6, 8 or 24hr, stained with 7-AAD and 
Annexin V and cell viability analysed by flow cytometry. (A) Representative FACS plots showing 
the gating used to differentiate live, dead and apoptotic cells at each of the time points. Panels: 7-
AAD vs. Annexin V, with viable cells 7-AAD-AnnexinV-, apoptotic cells 7-AAD-AnnexinV+ and dead 
cells 7-AAD+ and AnnexinV-. (B) Graph of pooled data showing the percentages of live, apoptotic 
and dead cells over a 24hr period of in vitro culture. (n=1, 3 replicates)  
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cells were seen at the 3 and 6hr time-points. After 8hr of Etoposide treatment a large 
increase in the number of double positive cells was seen, with 43.9±8.1% of the B cells 
7-AAD+Annexin+, with a concomitant decrease in viable cells (21.9±2%) and a similar 
percentage of apoptotic cells (24.9±6.9%). At the 24hr time-point, very few cells were 
still viable (8.2±1.2%) with a slight increase in apoptotic cells indicated (33.9±3%), and a 
high proportion of dead cells (49±2.9%). 
In accordance with the available protocols on Etoposide-treatment of cells and these 
findings, cells were incubated overnight in 10µM Etoposide to allow sufficient 
proportions of cells to undergo apoptosis, prior to use in co-culture assays. 
3.2.5 Interactions of L929 BMDM with irradiated or Etoposide-treated 
apoptotic cells 
In vitro assays were performed to investigate whether the agent used to induce 
apoptosis affects the interactions between AC and L929 BMDM, and whether this effect 
is consistent when using AC originating from different lymphocyte populations. To do 
this, murine BMDM were grown for 7 days in media supplemented with M-CSF-containing 
L929 supernatant. The day before co-culture, B cells, T cells and thymocytes were 
isolated from C57BL/6 mice, CFSE-stained and incubated overnight with 10µM Etoposide 
to induce non-immunogenic apoptosis. On the day of co-culture, additional B cells, T 
cells and thymocytes were isolated from C57BL/6 mice, CFSE-stained, and half of the 
cells from each newly isolated lymphocyte population were irradiated to induce 
immunogenic apoptosis, and the irradiated and non-irradiated cells incubated for 4hr. 
The L929 BMDM were mixed with either viable, irradiated or Etoposide-treated B cells, 
T cell or thymocytes, at a ratio of 1 BMDM:5 lymphocytes, and co-cultured for 15min. 
The co-cultures were then stained for the macrophage lineage marker F4/80, and levels 
of cell-cell or cell-AC interaction analyzed by flow cytometry. 
CFSE+ and CFSEhi BMDM were gated on as described in Figure 3.2a. No difference was 
seen in the proportion of CFSE+ BMDM on co-culture with either irradiated or viable 
lymphocytes, or Etoposide-treated thymocytes (Figure 3.7). However, co-culture of 
BMDM with Etoposide-treated B cells or T cell resulted in a decrease in the proportion of 
CFSE+ BMDM (73.7±1.5% and 66.7±8.7%, respectively), compared to all other conditions.  
No difference in the proportion of CFSEhi BMDM was seen when BMDM were co-cultured 
with either irradiated (5.6±1.1%), Etoposide-treated T cells (2.2±0.1%,), or viable T cells 
(8.8±0.7%). However, Etoposide-treatment of thymocytes resulted in a slightly reduced 
proportion of CFSEhi BMDM after co-culture (13±1.3%), compared to co-culture with 
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irradiated thymocytes (23±3%) or viable thymocyte (24.8±2.2% CFSEhi BMDM). Although 
the Etoposide-treated thymocytes showed reduced levels of interaction with the L929 
BMDM compared to the other thymocyte treatments investigated, this condition still 
resulted in a notably greater proportion of CFSEhi BMDM compared to the other 
Etoposide-treated lymphocytes (BMDM+Etop. B cells: 5.2±0.1%, BMDM+Etop. T cells: 
2.2±0.1%). This pattern of increased interaction of thymocytes compared to the other 
lymphocyte populations investigated was also reflect in the irradiated conditions, with a 
greater proportion of CFSEhi BMDM resulting from co-culture with irradiated thymocytes 
than with either irradiated B cell or irradiated T cells (23±3% vs. 11.2±1.2% and 
5.6±1.1%, respectively). When the CFSEhi BMDM population was examined after co-
culture of L929 BMDM with viable lymphocytes, as seen in the previous assay, either 
similar or enhanced levels of interaction were seen within each lymphocyte group, 
compared to its apoptotic counterparts, although this increase was far subtler in the 
T cell and thymocyte populations. On co-culture of viable B cells with BMDM, 40.6±2.3% 
of BMDM were CFSEhi, significantly more than either of the apoptotic B cell conditions 
(BMDM+irr B: 11.2±1.2% and BMDM+Etop. B: 5.2±0.1%), or indeed, the viable T cell or 
thymocytes co-cultures (8.4±0.7% and 24.8±2.2%, respectively). 
These findings show that under the experimental conditions used, apoptotic thymocytes 
undergo increased interactions with L929 BMDM compared to apoptotic B cells or 
T cells, regardless of the method of apoptosis induction. In both the B cell and 
thymocyte populations, Etoposide-treatment resulted in a reduced levels of interaction 
with BMDM, compared to their irradiated counterparts, with no difference in BMDM-
T cell interaction observed between the apoptotic stimuli. Surprisingly, BMDM co-
culture with viable B cells resulted in a significantly higher proportion of cell-cell 
interaction than any of the other conditions investigated. 
3.2.6 Changes in L929 BMDM phenotype after co-culture with 
irradiated or Etoposide-treated apoptotic cells 
To determine whether cell-cell interactions between L929 BMDM and different 
populations of AC can alter BMDM phenotype, the expression levels of a range of surface 
markers was investigated. L929 BMDM-AC co-cultures were set up as before, in the 
presence or absence of 1ng/ml LPS stimulation. The co-cultures were incubated for 
either 6 or 24hr before being analysed by flow cytometry.  
The effect of 1ng/ml LPS stimulation on the antigen-presenting potential and activation 
of the L929 BMDM was investigated; with the expression of MHC II, CD86, CD40, CD69 
and CD206 examined. Expression levels were normalized, with expression of the marker 
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Figure 3.7 L929 BMDM show enhanced cell-cell interactions with viable B cells 
Murine BMDM were grown in cRPMI supplemented with M-CSF containing L929 supernatant. On 
d7 adherent cells were co-cultured with CFSE stained viable, irradiated, or etoposide treated 
primary B cells, T cells or thymocytes for 15min and analyzed by flow cytometry. 
(A) Representative FACS plots showing the levels of interaction seen between L929 BMDM and 
apoptotic lymphocytes. Panels: CFSE vs. F4/80. (B) Graph of pooled data showing the percentage 
of CFSE+ BMDM. (C) Graph of pooled data showing the percentage of CFSEhi BMDM. (n=1, 
3 replicates)  
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by BMDM at 6hr without LPS stimulation used as the control population. MHC II is used 
by professional APCs, such as macrophages, to present antigen, with ligation of the co-
stimulatory molecules CD86 and CD40 involved in defining the outcome of antigen 
recognition. On stimulation with 1ng/ml LPS MHC II expression by the BMDM was 
decreased at 6hr (75±16% of that on control BMDM) compared to un-stimulated BMDM, 
however by 24hr more MHC II was expressed by the BMDM + LPS (41±4% vs. 57±18%) 
(Figure 3.8a). At 6hr CD86 expression was increased on low-level LPS stimulation 
(96±13% vs. 137±24%), however by 24hr no difference could be detected between the 
stimulated and un-stimulated BMDM (Figure 3.8b). CD40 expression was unchanged by 
LPS stimulation at 6hr, however a dramatic increase was observed at the 24hr time-
point after stimulation, with expression increasing to 774±108% of that on control BMDM 
(Figure 3.8c).  
The expression of two macrophage activation markers was also explored. CD69 is an 
early activation marker, with its up-regulation indicating cell activation [197]. CD206, 
also commonly know as the mannose receptor, is a C-type lectin receptor that is mainly 
expressed on the surface of regulatory subsets of macrophages. Expression of both CD69 
and CD206 was enhanced by stimulation with LPS at both the 6 and 24hr time-points 
(Figure 3.8d, e). At 6hr CD69 expression on BMDM+LPS was 2498±961% of control 
expression, and at 24hr was 3059±1074% compared to 240±210% on the un-stimulated 
BMDM. CD206 expression was 193±16% of the control on BMDM+LPS at 6hr, while at 24hr 
it was 86±4% of the control compared to 48±3% on the un-stimulated BMDM. 
The effect of BMDM-AC co-culture on the antigen-presenting potential of the BMDM was 
investigated; with the expression of MHC II, CD86 and CD40 examined. At the 6hr time-
point, co-culture of L29 BMDM with Etoposide-treated B cells or thymocytes, in the 
absence of LPS, had no effect on the expression of MHC II, CD86 or CD40, compared to 
L929 BMDM cultured under the same conditions alone (Figure 3.9a-c, left panels), 
however co-culture with irradiated B cells induced significant up-regulation of all three 
markers. MHC II expression increased to 176±38% of that on control BMDM, CD86 to 
148±39% and CD40 to 156±11%. Co-culture of L929 BMDM with irradiated thymocytes 
resulted in the up-regulation of the co-stimulatory molecules CD86 (148±39% of control) 
and CD40 (169±41% of control), however no change in MHC II expression was seen. 
Interestingly, viable B cells also induced enhanced expression of these molecules, with 
CD86 increased to 138±9% and CD40 146±27% of control levels. Viable thymocyte co-
culture however, had no effect on the expression of these molecules. In the presence of 
low-level LPS, no change in CD86 or CD40 expression was seen in any co-culture 
condition, however co-culture with Etoposide-treated thymocytes or viable B cells 
increased the expression of MHC II by L929 BMDM (136±18% of control and 156±30% of 
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control, respectively). At the 24hr time-point MHC II expression was significantly up-
regulated on L929 BMDM co-cultured with any of the apoptotic cells investigated in the 
absence of LPS (BMDM+irr B: 146±7%, BMDM+irr thy: 153±25%, BMDM+Etop. B: 137±7%, 
BMDM+Etop. thy: 147±23% of control expression) (Figure 3.9a, right panel). 
Interestingly, co-culture with viable B cell or thymocytes also induced up-regulation of 
MHC II, with levels increasing to 134±14% of the control on co-culture with viable 
B cells, and to 136±21% on co-culture with viable thymocytes. In the presence of low-
level LPS, no change in MHC II expression was observed at the 24hr time-point, with 
levels of CD86 also staying equivalent to controls, both in the presence and absence of 
LPS (Figure 3.9b, right panel). CD40 expression was enhanced after 24hr of L929 BMDM 
co-culture with irradiated B cells in the absence of low-level LPS, with expression 
increasing to 128±6% of that of control cells, however no change was seen in the other 
apoptotic cell co-cultures (Figure 3.9c, right panel). Enhanced expression of CD40 was 
also induced after co-culture of L929 BMDM with viable B cells, with surface levels 
increasing to 129±10% of controls. 
The expression of activatory and regulatory markers was explored in order to help 
determine whether the co-culture of BMDM with different AC has an effect on 
macrophage polarization. At 6hr, co-culture with all AC investigated, except the 
irradiated B cells, had no effect on CD69 expression in the absence of low-level LPS 
(Figure 3.10a – left panel) Co-culture with irradiated B cells resulted in the up-
regulation of CD69 to 222±115% of control expression. In the presence of LPS, L929 
BMDM co-culture with Etoposide-treated thymocytes resulted in the down-regulation of 
CD69 expression, with levels decreasing to 58±5% of baseline. No other BMDM-AC co-
culture resulted in the modulation of CD69 at 6hr in the presence of LPS. Co-culture 
with viable B cell or thymocytes also resulted in no change in CD69 expression at 6hr, in 
the presence or absence of low-level LPS. At this time-point, in the absence of LPS, 
CD206 expression by BMDM was comparable for co-culture conditions investigated, 
however the data indicates a decrease in expression on co-culture with irradiated or 
viable B cells, however this was not significant (Figure 3.10 – left panel). Addition of 
low-level LPS to the irradiated B cells or thymocytes, or Etoposide-treated B cells co-
cultures had no effect on CD206 expression by BMDM, however on co-culture with 
Etoposide-treated thymocytes, expression decreased to 63±5% of baseline. At the 24hr 
time-point a decrease from baseline in the expression of both CD69 and CD206 was seen 
in all co-culture conditions (apoptotic and viable cells) in the presence of low-level LPS 
(Figure 3.10a and b – right panels). In the absence of LPS, co-culture of L929 BMDM with 
irradiated B cells resulted in the increased expression of CD69 to 202±89% of baseline, 
however irradiated thymocytes, Etoposide-treated cells nor viable cells had any effect 
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on CD69 expression. Co-culture with both irradiated B cells and Etoposide-treated 
thymocytes induced a decrease in CD206 expression at 24hr in the absence of LPS, with 
BMDM co-cultures with irradiated B cells expressing 72±6% of baseline CD206 and those 
co-cultured with Etoposide-treated thymocytes expressing 78±7%. The other apoptotic 
cells had no effect on CD206 expression, however co-culture with viable B cells was also 
able to down-regulate its expression, with 72±4% of baseline expression at 24hr. Viable 
thymocytes did not have the same effect as viable B cells, and no change in CD206 
expression was observed in this co-culture condition. 
These data indicate that different AC populations can have differing effects on L929 
BMDM phenotype under certain in vitro culture conditions, with these differences 
seeming to be greater after short-term culture. However, in the presence of low-level 
LPS, the differences in the effects of the four populations of AC on BMDM phenotype 
were greatly reduced at the 6hr time-point, and totally eliminated at 24hr. 
3.2.7 Changes in L929 BMDM function after co-culture with irradiated 
or Etoposide-treated apoptotic cells 
To determine whether the interaction of L929 BMDM with AC had functional effects on 
the BMDM, the production of soluble immune mediators by BMDM was investigated after 
overnight co-culture with AC. Sandwich ELISAs were utilized to quantify the levels of 
pro-inflammatory (IL-12, TNFα, and IL-6) and anti-inflammatory (IL-10 and TGF-β) 
cytokines present in the cell culture supernatants, while a competitive binding ELISA 
was used to quantify production of the prostaglandin PGE2, a physiologically abundant 
eicosanoid known have immunomodulatory properties. 
When co-cultured alone, un-stimulated L929 BMDM produced minimal levels of IL-12 
(20±5pg/ml), TNFα (32±4pg/ml) and IL-6 (20±6pg/ml) (Figure 3.11a-c – left panels). On 
co-culture with AC, no effect was seen on the production of IL-12 (Figure 3.11a – left 
panel), however levels of TNFα and IL-6 were decreased, resulting in levels of secretion 
below the minimum detection limit of the assays used (15.6pg/ml for both assays) 
(Figure 3.11b and c – right panels). Viable cells had the same effects on pro-
inflammatory cytokine production as AC for all cytokines investigated. On the addition 
of 1ng/ml LPS to the culture system, L929 BMDM produced increased levels of IL-12 
(133±18g/ml), TNFα (134±14pm/ml) and IL-6 (2182±97pg/ml) (Figure 3.11a-c – right 
panels) compared to those cultured in the absence of LPS. Co-culture with AC had no 
effect on the production of IL-12 or TNFα production by LPS treated BMDM, compared to 
the L929 BMDM cultured alone in the same conditions. Surprisingly, the data indicate a 
reduction in TNFα secretion by L929 BMDM after co-culture with either viable B cells  
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Figure 3.8 Stimulation of L929 BMDM with LPS alters their phenotype 
Murine BMDM were grown in cRPMI supplemented with M-CSF containing L929 supernatant. On 
d7 adherent cells were stimulated with 1ng/ml LPS. After 6hr and 24hr incubations cells were 
stained for expression of molecules involved in antigen presentation and cell activation and 
analyzed by flow cytometry. Expression levels of cell surface markers were normalized, with 
expression of the marker by BMDM at 6hr without LPS stimulation used as the control population. 
Graphs showing the normalized MFIs for (A) MHC II (B) CD86, (C) CD40, (D) CD69, and (E) 
CD206. White bars = BMDM alone, striped bars = BMDM alone + 1ng/ml LPS. (n=2, data from 2 
independent experiments with 3 replicates each)  
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Figure 3.9 Co-culture with viable or apoptotic cells alters the antigen-presenting potential of 
L929 BMDM 
Murine BMDM were grown in cRPMI supplemented with M-CSF containing L929 supernatant. On 
d7 adherent cells were co-cultured with viable, irradiated, or Etoposide-treated primary B cells or 
thymocytes, in the presence or absence of 1ng/ml LPS. After 6hr and 24hr of co-cultures cells were 
stained for expression of molecules involved in antigen presentation and analyzed by flow 
cytometry. Expression levels of cell surface markers were normalized, with expression of the 
marker by BMDM alone without used as the control population. Graphs showing the normalized 
MFIs of (A) MHC II, (B) CD86, and (C) CD40. White symbols = BMDM alone, black symbols = 
BMDM + B cells, grey symbols = BMDM + thymocytes. (n=2, data from 2 independent 
experiments)  
   
95 
 
 
 
 
Figure 3.10 Co-culture with viable or apoptotic cells alters L929 BMDM activation 
Murine BMDM were grown in cRPMI supplemented with M-CSF containing L929 supernatant. On 
d7 adherent cells were co-cultured with viable, irradiated, or Etoposide-treated primary B cells or 
thymocytes, in the presence or absence of 1ng/ml LPS. After 6hr and 24hr of co-cultures cells were 
stained for expression of molecules involved in cell activation and analyzed by flow cytometry. 
Expression levels of cell surface markers were normalized, with expression of the marker by 
BMDM alone without used as the control population. Graphs showing the normalized MFIs for 
(A) CD69 and (B) CD206. White symbols = BMDM alone, black symbols = BMDM + B cells, grey 
symbols = BMDM + thymocytes. (CD69 n=2, with data from 2 independent experiments, CD206 
n=1, data from a single experiment)  
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(62±19pg/ml) or thymocytes (103±25pg/ml). Co-culture of L929 BMDM with viable, 
irradiated or Etoposide-treated cells in the presence of 1ng/ml LPS resulted in an 
increase in IL-6 production (5313±858pg/ml), compared to BMDM cultured alone, 
however with the number of repeats undertaken, signifiance was not reached in any 
condition. 
IL-10 secretion by L929 BMDM was not affected by co-culture with AC in the presence or 
absence of LPS, as compared to secretion by BMDM alone (no LPS: 104±90pg/ml, LPS: 
1888±987pg/ml), with viable cells also having no effect (Figure 3.12a). No change in the 
production of TGF-β by L929 BMDM after co-culture with AC was detected, in either the 
presence or absence of LPS (Figure 3.12b). However the results gained from the TGF-β 
ELISAs were extremely variable, and therefore a subtle change in levels could have been 
obscured. 
Production of PGE2 by L929 BMDM in response to co-culture with AC was also 
investigated. PGE2 can be secreted by macrophages in response to a range of stimuli 
[157,198,199], and the addition of exogenous PGE2 has been shown to be able to 
regulate cytokine production by macrophage populations [157,200,201]. A competitive 
binding ELISA was used to quantify PGE2 levels, and as such, all concentrations were 
normalized to the media only control and expressed as a change in PGE2 concentration 
above this background (Δ PGE2).  
Co-culture of the L929 BMDM with all AC populations resulted in a marked increase in 
PGE2, compared to BMDM cultured alone (47±4 pg/mlΔ PGE2) (Figure 3.12c). Although 
this increase was seen on co-culture of L929 BMDM with all AC, more PGE2 was secreted 
by the BMDM on co-culture with irradiated cells, compared to those co-cultured with AC 
from the same origin which had undergone Etoposide-treatment (L929+irr B: 
362±25pg/ml vs. L929+Etop. B: 271±27pg/ml Δ PGE2, and L929+irr thy: 376±22pg/ml vs. 
L929+Etop. thy: 101±17pg/ml Δ PGE2). Co-culture with viable B cells and thymocytes 
also resulted in increased PGE2 secretion, with 304±6pg/ml and 280±23pg/ml Δ PGE2, 
respectively. 
These data confirm that AC are able to modulate cytokine production by L929 BMDM, 
with both pro-and anti-inflammatory cytokine production altered on overnight co-
culture with AC, regardless of the activation state of the BMDM. Secretion of PGE2 by 
L929 BMDM was significantly increased after co-culture with all AC populations. All AC 
investigated induced similar effects on the BMDM, with the AC origin and route of 
apoptosis induction seemingly immaterial to the outcome of co-culture. Interestingly,
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Figure 3.11 Pro-inflammatory cytokine production by L929 BMDM after co-culture 
Murine BMDM were grown in cRPMI supplemented with L929 cell supernatant. On d7 adherent 
cells were co-cultured overnight with viable, irradiated, or etoposide treated primary B cells or 
Thymocytes, in the presence or absence of 1ng/ml LPS. Cytokine production by L929 BMDM was 
quantified using ELISAs. (A) Graph of IL-12 produced (pg/ml). Left column: no LPS, Right column: 
+ LPS. (B) Graph of TNFα produced (pg/ml). Left column: no LPS, Right column: + LPS. (C) Graph 
of IL-6 production (pg/ml). Left column: no LPS, Right column: + LPS. (n=1, 3 replicates)  
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Figure 3.12 Anti-inflammatory cytokine and PGE2 production by L929 BMDM after co-culture 
Murine BMDM were grown in cRPMI supplemented with L929 cell supernatant. On d7 adherent 
cells were co-cultured overnight with viable, irradiated, or etoposide treated primary B cells or 
thymocytes, in the presence or absence of 1ng/ml LPS. Cytokine and PGE2 production by L929 
BMDM were quantified using ELISAs. (A) Graph of IL-10 produced (pg/ml). Left column: no LPS, 
Right column: + LPS. (B) Graph of TGF-β produced (pg/ml). Left column: no LPS, Right column: + 
LPS. (C) Graph of PGE2 produced (pg/ml) in the presence of LPS. (IL-10 and TGF-β n=2, from 2 
independent experiments, PGE2 n=1)  
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under the experimental conditions used, viable cells showed the same 
immunomodulatory properties as apoptotic cells, with affects on both cytokine and 
PGE2 production.  
3.2.8 Comparison of interactions of L929 BMDM and GM-CSF BMDM 
with apoptotic cells 
There are multiple methods of in vitro maturation that can be used to generate 
macrophage populations from bone marrow cells, and depending on the method chosen 
considerable variability is seen in the resultant macrophage phenotype. Macrophages 
are highly plastic cells, with a spectrum of activated phenotypes, however these can be 
broadly split into two main subsets – the classically activated, M1-macrophages, and the 
regulatory/wound-healing M2-macrophages [17]. BMDM generated using M-CSF- 
containing L929 cell supernatant are considered to be ‘M2-like’ macrophages [202], 
resembling non-inflammatory, regulatory macrophages found in vivo, while those 
generated using GM-CSF are considered to be more like an M1 macrophage. 
After observing the interactions of L929 BMDM with apoptotic cells, we wanted to 
investigate whether similar patterns of interaction would result from co-culture of AC 
with a more inflammatory population of macrophages. To do this, BMDM were generated 
in media supplemented with GM-CSF and IL-3 (GM-CSF BMDM), giving rise to a 
population of M1-like macrophages [202], and the previous co-culture experiments 
repeated using this BMDM population: mature, adherent GM-CSF BMDM were co-cultured 
with CFSE-stained viable, irradiated or Etoposide-treated B cell or thymocytes for 
15min, at a ratio of 5 lymphocytes/AC:1 BMDM. The decision was made to no longer 
include T cell co-culture conditions in this assay, due to technical issues with the 
method of T cell purification. 1ng/ml LPS stimulation was added to certain conditions 
during the co-cultures, and L929 BMDM included for comparison. As before, interaction 
levels were analyzed by flow cytometry (Figure 3.13a). 
No difference was seen in the proportion of CFSE+ GM-CSF BMDM observed after co-
culture with either irradiated B cells or thymocytes (Figure 3.13b – left panel). A 
reduction in CFSE+ BMDM was observed when GM-CSF BMDM were co-cultured with 
Etoposide-treated B cells or thymocytes in the absence of LPS, compared to the co-
cultures with irradiated lymphocytes (GM-CSF+Etop. B: 58.2±14.8%% and GM-
CSF+Etop. thy: 60.7±13% vs. GM-CSF+irr B: 98.1±2.1% and GM-CSF+irr thy: 95.7±3%). 
When GM-CSF BMDM were co-cultured with Etoposide-treated B cells in the presence of 
LPS, a decrease in the proportion of CFSE+ BMDM was also seen compared to all other 
conditions. Viable B cells and thymocytes were included as a control, with the resultant 
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levels of CFSE+ BMDM comparable to those seen after co-culture with irradiated cells, 
both in the presence and absence of LPS. The levels of CFSE+ L929 BMDM were more 
consistent than that of the CFSE+ GM-CSF BMDM. A decrease in the proportion of CFSE+ 
L929 BMDM was observed on co-culture with Etoposide-treated B cells in the absence of 
LPS (73.3±21.1%) (Figure 3.13b – right panel).  
On investigation of the population of GM-CSF BMDM undergoing elevated AC interactions 
(CFSEhi BMDM), it could be seen that regardless of the origin of the AC, or the mode of 
apoptosis induction, a similar proportion of CFSEhi GM-CSF BMDM were observed after 
co-culture in the absence of LPS (GM-CSF+irr B: 3.6±2.3%, GM-CSF+irr thy: 5±0.7%, GM-
CSF+Etop. B: 2.5±0.6%, GM-CSF+Etop. thy: 3.8±0.4%) (Figure 3.13c – left panel). Similar 
levels of CFSEhi GM-CSF BMDM were also detected after co-culture with viable B cells 
and thymocytes, in the absence of LPS. On addition of LPS into the BMDM-AC co-culture 
system, no differences were seen in the proportion of CFSEhi GM-CSF BMDM after co-
culture with any of the AC investigated, or with viable thymocytes. However, co-culture 
of GM-CSF BMDM with viable B cells in the presence of LPS resulted in a slight increase 
in CFSEhi BMDM (12.8±0.5% CFSEhi), compared to all other co-culture conditions. 
Although an increase in the percentage of CFSEhi BMDM was observed after co-culture 
with viable B cells, the levels of CFSEhi BMDM were still relatively low. As with the GM-
CSF BMDM, co-culture of L929 BMDM with all AC resulted in comparable percentages of 
CFSEhi BMDM, however co-culture with viable B cells resulted in a significantly increased 
proportion of CFSEhi L929 BMDM compared to all other conditions (no LPS: 50.8±21.8%, 
+ LPS: 52.3±20% CFSEhi) (Figure 3.13c – right panel). The percentages of CFSEhi L929 
BMDM after co-culture were consistently higher than those observed in the GM-CSF 
BMDM co-cultures, regardless of the culture conditions.  
Together these findings show that in this experimental set up GM-CSF BMDM undergo 
lower levels of interaction with AC than L929 BMDM, however, the pattern of interaction 
within the two BMDM populations is similar. The method used to induce apoptosis 
affected the overall interaction levels seen, with Etoposide-treated cells tending to 
undergo less interaction with BMDM. Within each BMDM population, similar levels of 
enhanced interaction were observed in all co-cultures incorporating apoptotic B cells 
and thymocytes, in the presence and absence of LPS, with viable thymocyte also 
showing similar levels of interaction with BMDM. Surprisingly, the co-culture of GM-CSF 
BMDM or L929 BMDM with viable B cells resulted in a significant increase in the 
proportion of CFSEhi BMDM, compared to the AC-containing co-cultures. 
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Figure 3.13 L929 BMDM show enhanced cell-cell interactions compared to GM-CSF BMDM 
Murine BMDM were grown in cRPMI supplemented with either M-CSF containing L929 supernatant 
or recombinant murine GM-CSF + IL-3. On d7 adherent cells were co-cultured with CFSE stained 
viable, irradiated, or Etoposide-treated primary B cells or thymocytes for 15 minutes, in the 
presence or absence of 1ng/ml LPS and analyzed by flow cytometry. (A) Representative FACS 
plots showing the levels of interaction seen between the GM-CSF BMDM or L929 BMDM and the 
apoptotic lymphocytes. Panels: CFSE vs. F4/80. (B) Graph of pooled data showing the percentage 
of CFSE+ GM-CSF BMDM (left) and L929 BMDM (right). (C) Graph of pooled data showing the 
percentage of CFSEhi GM-CSF BMDM (left) and L929 BMDM (right).  (L929 BMDM n=3, from 3 
independent experiments, GM-CSF BMDM n=2, from 2 independent experiments). Statistics used: 
One Way ANOVA followed by Bonferroni’s post test, with * = p<0.05, ** = p<0.01 and 
*** = p<0.001. 
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3.2.9 Changes in GM-CSF BMDM function after co-culture with 
apoptotic cells 
To determine whether the interaction of GM-CSF BMDM with AC had any functional 
effect on the BMDM, the production of soluble mediators by GM-CSF BMDM after 
overnight culture with AC was investigated. The levels of the cytokines IL-12, TNFα, IL-
6, IL-10, and TGF-β present in the cell culture supernatants were quantified by ELISA, 
with a competitive binding ELISA used to quantify production of PGE2.  
Unlike the L929 BMDM, in the absence of LPS stimulation, no TNFα, IL-6 or IL-10 could 
be detected in any condition containing GM-CSF BMDM (data not shown). The L929 
BMDM secreted detectable levels of all three of these cytokines when cultured alone 
(Figures 3.11 and 3.12). In the absence of LPS, a decrease in IL-12 production was 
observed on co-culture of GM-CSF BMDM with either irradiated (GM-CSF+irr B: 
12±5pg/ml, GM-CSF+irr thy: 16±8pg/ml) or Etoposide-treated cells (GM-CSF+Etop. B: 
8±4pg/ml, GM-CSF+Etop. thy: 11.8±6.7pg/ml), compared to the BMDM cultured alone 
(99±30pg/ml) (Figure 3.14a – left panel). This finding differed from that seen on co-
culture of L929 BMDM with AC in the absence of LPS, in which no change in IL-12 was 
seen compared to BMDM cultured alone (Figure 3.11). Interestingly, co-culture with 
viable cells also resulted in a reduction of IL-12 secretion (GM-CSF+B: 9±4pg/ml, GM-
CSF+thy: 12±5pg/ml). In the presence of LPS, co-culture of GM-CSF BMDM with AC had 
no effect on the levels of IL-12 (Figure 3.14a – right panel), IL-6 (Figure 3.14c) or IL-10 
secretion (Figure 3.15a), compared to BMDM cultured alone, with viable cells also 
having no effect on the production of these cytokines. Co-culture of L929 BMDM with AC 
in the presence of LPS also had no effect on IL-12 or IL-10 secretion (Figure 3.12), 
however co-culture with AC increased IL-6 production by these BMDM (Figure 3.11). A 
marked decrease in TNFα was detected on co-culture, with GM-CSF BMDM cultured 
alone producing 42±7pg/ml TNFα, while TNFα sectretion by BMDM co-cultured with 
either AC or viable cells dropped below the 15.6pg/ml detection limit of this assay 
(Figure 3.14b). As with L929 BMDM (Figure 3.12), no change in the production of TGF-β 
was detected on co-culture of GM-CSF BMDM with AC, in either the presence or absence 
of LPS (Figure 3.15b), however the results gained from this ELISA were extremely 
variable and therefore a subtle change in levels could have been obscured. 
Production of PGE2 by GM-CSF BMDM in response to co-culture with AC was also 
investigated. When GM-CSF BMDM were cultured in the absence of LPS, no PGE2 was 
detectable above background in any condition (data not shown), mirroring the results 
seen with L929 BMDM. In the presence of LPS, co-culture of GM-CSF BMDM with 
irradiated B cells or thymocytes resulted in an increase in PGE2 (98±35pg/ml and 
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117±20 pg/ml Δ PGE2, respectively), compared to the GM-CSF BMDM cultured alone 
(17±5pg/ml Δ PGE2) (Figure 3.14c). GM-CSF BMDM co-culture with Etoposide-treated 
cells did not affect the levels of PGE2 (21±8pg/ml Δ PGE2). Co-culture of GM-CSF BMDM 
with viable B cells and thymocytes also induced an increase in PGE2 production 
compared to BMDM alone, with a 66±16pg/ml Δ PGE2 and 95±22pg/ml Δ PGE2 seen, 
respectively. This pattern of PGE2 production differed from that of the L929 BMDM. GM-
CSF BMDM cultured alone in the presence of LPS produced markedly less PGE2 than L929 
BMDM cultured in the same conditions (17±5pg/ml Δ PGE2 vs. 47±4 pg/ml Δ PGE2), with 
co-culture of L929 BMDM with either AC or viable cells resulting in a substantial increase 
in PGE2 (Figure 3.12c). 
These data confirm that AC are able to modulate immune-mediator production by M1-
like GM-CSF BMDM, with both pro-inflammatory cytokine and PGE2 production altered on 
overnight co-culture with AC. All AC investigated induced similar effects on cytokine 
production by GM-CSF BMDM, with the AC origin and route of apoptosis induction 
seemingly immaterial to the outcome of co-culture, however GM-CSF BMDM production 
of PGE2 was only increased by co-culture with AC induced by irradiation, not Etoposide-
treatment. Interestingly, under the experimental conditions used, co-culture with 
viable cells had the same immunomodulatory effects on cytokine secretion by GM-CSF 
BMDM as apoptotic cells, however viable cell co-culture had varying effects on PGE2 
production by the BMDM. 
3.3 Discussion 
• As an initial step to understanding the potential validity of our hypothesis, we 
used an in vitro assay to examine the immunosuppressive effects of apoptotic B 
cells, with a focus on whether apoptotic B cells have the same 
immunomodulatory capacities as other more commonly studies AC. 
• Apoptotic B cells underwent similar levels of interaction with macrophages as 
the other apoptotic cells examined, and had comparable ability to alter 
macrophage phenotype and function. These findings show that apoptotic B cells 
have the same capacity to modulate the immune response as other more 
commonly studied AC.  
• Unexpectedly, BMDM underwent increased levels of interaction with viable 
B cells, compared to other viable lymphocyte populations and all AC 
investigated. All the viable cell populations investigated were able to 
recapitulate the AC-driven modulation of macrophage phenotype and function, 
with further work needed to fully understand this result. 
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Figure 3.14 Pro-inflammatory cytokine production by GM-CSF BMDM after co-culture 
Murine BMDM were grown in cRPMI supplemented with recombinant murine GM-CSF and IL-3. 
On d7 adherent cells were co-cultured overnight with viable, irradiated, or Etoposide-treated 
primary B cells or thymocytes, in the presence or absence of 1ng/ml LPS. Cytokine production by 
GM-CSF BMDM was quantified using ELISAs. (A) Graph of IL-12 produced (pg/ml). Left column: 
no LPS, Right column: + 1ng/ml LPS. (B) Graph of TNFα produced (pg/ml) in the presence of LPS. 
(C) Graph of IL-6 production (pg/ml) in the presence of LPS. (n=1, 3 replicates)  
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Figure 3.15 Anti-inflammatory cytokine and PGE2 production by GM-CSF BMDM after co-
culture 
Murine BMDM were grown in cRPMI supplemented with recombinant murine GM-CSF and IL-3. 
On d7 adherent cells were co-cultured overnight with viable, irradiated, or etoposide treated 
primary B cells or Thymocytes, in the presence or absence of 1ng/ml LPS. Cytokine and PGE2 
production by GM-CSF BMDM were quantified using ELISAs. (A) Graph of IL-10 produced (pg/ml) 
in the presence of LPS. (B) Graph of TGF-β produced (pg/ml). Left column: no LPS, Right column: 
+ 1ng/ml LPS. (C) Graph of PGE2 produced (pg/ml) in the presence of LPS. (IL-10 and TGF-β n=2, 
from 2 independent experiments, PGE2 n=1)  
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• These preliminary results support our hypothesis, and indicate that the RTX-
mediated generation of large numbers of apoptotic B cells in vivo would be able 
to dampen down inflammation, and potentially help halt the progression of 
autoimmunity. 
On co-culture of BMDM with either irradiated or viable CFSE-stained lymphocytes, the 
vast majority of BMDM became CFSE+, with two distinct CFSE+ BMDM populations 
detected: a CFSEhi population and a CFSElo population. It had been expected that co-
culture would result in a single CFSE+ BMDM population (BMDM interacting with 
lymphocytes) and a CFSE- BMDM population (BMDM not interacting with lymphocytes). As 
this was not the case, the cause of the two CFSE+ populations was sought.  
It was initially speculated that uptake of free CFSE in the media by the BMDM could 
account for the CFSElo BMDM population. However both the CFSEhi and CFSElo BMDM 
populations were shown to be interacting directly with lymphocytes rather than free 
CFSE, as co-culture of BMDM with CFSE-stained thymocyte conditioned media alone did 
not result in a detectable CFSE signal in the BMDM population. In co-cultures resulting in 
large proportions of CFSEhi BMDM, a step-wise increase in CFSE staining is seen within 
this population, while the CFSElo population shows a more homogenous pattern of CFSE 
staining and no clear separation from the unstained BMDM, indicating an overall 
population shift. This staining pattern suggests that the CFSEhi BMDM may be undergoing 
specific, high-level interactions with/uptake of whole cells or AC, as interaction with 
each additional CFSE-stained cell would result in a clear increase in CFSE signal. In 
contrast, the staining seen within the CFSElo BMDM population could be the result of 
interaction with/uptake of small apoptotic blebs or cell debris, resulting in a more 
homogenous spread of CFSE staining. When the relative sizes of the CFSEhi and CFSElo 
BMDM were compared it could be seen that the CFSEhi population of BMDM have high 
forward scatter properties compared to the CFSElo BMDM population signifying that they 
are larger cells, and indicating that these BMDM have either already ingested or are in 
the process of taking up CFSE-stained AC, resulting in this size increase. The CFSEhi 
BMDM also had moderate-to-high side scatter properties compared to the CFSElo BMDM 
population, indicating increased cell granularity, which may be a result of the formation 
of intracellular vesicles due to AC uptake. These finding support the idea that the CFSEhi 
BMDM are undergoing specific interactions with whole cells/AC.  
On further investigation of the results, it is, however, unlikely the CFSElo population are 
interacting with small apoptotic blebs. In preparation of the CFSE-stained thymocyte 
conditioned medium used to prove the necessity of CFSE-stained cells in co-culture to 
get a CFSElo BMDM population, thymocyte samples were centrifuged at 450g to pellet 
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the cells, and the supernatants removed to use as conditioned media. Although this 
speed is sufficient to pellet cells, it is not fast enough to pellet small apoptotic blebs 
and high-speed ultra-centrifugation of the samples would be required. Therefore, if the 
CFSElo BMDM population resulted from the interaction of BMDM with CFSE+ apoptotic 
blebs, the CFSElo BMDM population would also have been present after incubation in 
conditioned media, however this was not the case. These findings led to the supposition 
that the staining seen in this CFSElo BMDM population was due to a type of low-level 
CFSE uptake directly from the stained cells. Without further investigation into this 
BMDM population, a definite conclusion as to the cause of this BMDM subset could not be 
made, and such work was too much of a digression from the aims of this thesis to 
pursue, however several routes of thinking were explored in an attempt to offer a 
potential explanation. 
Trogocytosis is the process by which immune cells are able to extract surface molecules 
from other immune cells, incorporating them into their own cell membrane, and can 
occur within minutes of cell-cell interactions [reviewed in [203]. Trogocytosis entails 
the transfer of complete membrane fragments, rather than the transfer of individual 
molecules, resulting in the simultaneous transfer of target and non-target molecules 
[204]. It was hypothesized that transfer of small volumes of CFSE-stained cytosol from 
the lymphocytes to the BMDM may have occurred via trogocytosis of molecules from the 
lymphocyte cell surface, resulting in a CFSElo BMDM population. However, on closer 
inspection of the literature, it was ascertained that this process could not explain the 
findings in the present co-culture assays. Trogocytosis by phagocytes, also termed 
‘shaving’ or ‘antigenic modulation’, has been shown to be dependent on Fc-receptor 
interactions with antibody opsonized target cells [205]. Antibodies bound to the surface 
of opsonized target cells create antibody-antigen complexes that can be recognized by 
FcR expressed on phagocytes, such as monocytes/macrophages, leading to the removal 
of complete antibody-antigen complexes and associated membrane fragment. The 
shaving of RTX-CD20 complexes from the surface of B cells by monocytes is a well 
documented examples of this process [206]. Non antibody-dependent mechanisms of 
trogocytosis also exist, however these are dependent either on specific ligand 
recognition by NK cells [207], or cognate antigen interaction by B cells [208] and T cells 
[204], with no antibody-independent mechanisms documented for phagocytes. As such, 
this potential explanation of CFSE transfer was found to be invalid. 
Another potential theory put forward to explain the CFSElo BMDM population was the 
transfer of small amounts of CFSE to the BMDM via inter-cellular membrane nanotubes. 
These nanotubes, also called tunneling nanotubes (TNT), occur commonly between 
immune cells in vitro allowing the exchange of intracellular proteins and lipids between 
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cells, and are postulated to have in vivo roles in immune defense and developmental 
processes, as well as the spread of pathogens and cancer progression [reviewed in [209]. 
TNT can form within a few minutes of culture [210], with increased cell proximity 
resulting in greater numbers of nanotubes present between cells [211]. TNT connect a 
wide variety of cells including macrophages [212], B cells [213], T cells [214] and 
dendritic cells (DCs) [211], with characterization of these nanotubes revealing variations 
in formations, structure and functional properties between cells types, and even within 
single cell populations [212]. The diffusion of fluorescent marker proteins between the 
cytoplasm of cells via TNT has previously been observed. On co-injection of Lucifer 
Yellow and Texas red dextran into individual THP-1 cells the fluorescent markers 
transferred to TNT-connected cells within 60 seconds of injection, with Lucifer Yellow 
consistently detectable in several connected cells, while Texas dextran red was 
intermittently detectable in adjacent cells [211]. These findings support the theory that 
small amounts of CFSE may have been transferred to the BMDM from TNT-connected 
lymphocytes in the co-culture assays presented in this chapter, with the length of time 
of co-culture used sufficient to allow TNT formation and CFSE transfer. However, in 
disagreement with this theory, the permeability to small cytoplasmic molecules does 
not seem to apply to all TNT. Studies in the rat pheochromocytoma cell line, PC12, 
demonstrate that neither the small molecule calcein, nor cytoplasmically expressed 
green fluorescent protein, were transferred in detectable amounts between TNT-
connected cells [210]. None of the literature in this area of research specifically 
investigates either the potential of CFSE to transfer between TNT-connected cells, or 
nanotubes formation between the mixture of cells included in our co-culture conditions, 
and as such it cannot be conclusively stated one way or the other whether TNT are 
responsible for the CFSElo BMFM population, however they do offer a promising potential 
explanation. 
The proportion of CFSEhi BMDM observed after co-culture varied between the different 
AC conditions, although these differences were minor, and as such may not be 
biologically relevant. It is interesting to note however, that in all BMDM co-cultures 
containing apoptotic T cells, consistently low proportions of CFSEhi BMDM were observed 
compared to the other co-culture conditions investigated, regardless of the BMDM 
activation state. This result was also seen when viable T cells were included in the 
assays, and may indicate that the BMDM are less able to interact with T cells in the 
absence of antigen, compared to other cell populations. However further work would 
need to be undertaken to explore this suggestion before a firm conclusion could be 
made, with a much larger range of cell types investigated in the co-culture conditions. 
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Unexpectedly, the co-culture of BMDM with viable B cells consistently resulted in the 
highest proportions of CFSEhi BMDM. One potential explanation for the results of BMDM-
viable cell co-culture in the present assays could be the presence of apoptotic material 
in the so-called ‘viable cell’ conditions. Although apoptosis was not intentionally 
induced in these conditions, cells cultured in vitro in the absence of specific growth 
factors have a finite life span, and some level of spontaneous apoptosis will have 
occurred. This idea is supported by the observation that the BMDM, especially the L929 
BMDM, undergo increased high-level interactions with the ‘viable’ B cells, compared to 
either the ‘viable’ T cells or thymocytes, as it is known that B cells are particularly 
prone to spontaneous cell death in culture [215]. Consequently, it would be expected 
that a larger proportion of the cells in the viable B cell condition would be apoptotic, or 
expressing very early apoptotic markers (ACAMPs) compared to the other ‘viable’ 
conditions, resulting in increased interactions with the BMDM. Although a proportion of 
cells in these non-irradiated conditions will be apoptotic, in order to discriminate from 
the other treatment groups and maintain consistency with the rest of the chapter, this 
un-treated group will still be referred to as the viable group. It has been shown that the 
irradiated conditions contain a greater proportion of apoptotic cells compared to the 
viable cell conditions (Figure 3.1), however the increased interaction may be a result of 
the type of apoptosis undergone by the cells, rather than the overall amount. There is a 
growing body of evidence detailing differences in the forms of apoptosis resulting from 
various induction stimuli, with the interactions of these AC with cells of the immune 
system resulting in distinct responses [reviewed in [216]. Therefore, the form of cell 
death resulting from a lack of survival factors in the viable conditions could differ from 
that induced by x-irradiation, leading to the expression of diverse ACAMPs, which would 
be recognized by different receptors on the BMDM leading to altered levels of 
interaction with these distinct forms of AC. Indeed, consistently lower interaction levels 
were observed with Etoposide-treated AC compared to irradiated AC, and although 
minor, this difference in interaction levels could also indicate an altered ability of these 
BMDM to interact with AC induced via different cell death stimuli. If this is the case, it 
could explain why the non-irradiated viable cell conditions show high levels of 
interaction with the BMDM, and are able to modulate BMDM function in the same ways 
as the irradiated cultures. However, differences in the kinetics of the BMDM-viable 
cell/BMDM-AC interactions may also go some way to explain this finding. In the assays 
utilized in this chapter, BMDM were co-cultured with either viable or irradiated B cells 
for 15min resulting in a higher level of BMDM-viable B cell interaction observed. In 
chapter 4 of this thesis (Figures 4.6 and 4.9) BMDM were co-cultured either viable or 
irradiated B cells for 3hr, and it can be seen that comparable proportions of CFSEhi 
BMDM resulted from these co-cultures, indicating that the increased levels of 
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interaction seen with viable B cells after 15min may be due to the time-point 
investigated, rather than an intrinsic characteristic of BMDM-viable B cell interactions. 
In the literature an assortment of different macrophages populations have been used to 
investigate the immunomodulatory effects of AC uptake [157,217-219]. As such, it was 
examined whether BMDM-AC interaction in these co-culture assays differed, depending 
on the type of macrophage used, and if utilizing a different population would give rise 
to results more in keeping with those predicted, based on the published literature. To 
do this, the interaction of AC with GM-CSF BMDM was explored. There is substantial 
variability in macrophage phenotypes associated with the various methods of BMDM 
generation, with a large body of work looking into the phenotype and function of these 
different subsets. Generation of BMDM using recombinant GM-CSF produces an M1-like 
population of macrophages, which resemble the classically activated, inflammatory 
population of cells found in vivo, with M1 macrophages characterized by their ability to 
secret pro-inflammatory cytokines and their expression of MHC II and CD86. 
Recombinant GM-CSF can also be used to generate bone marrow-derived dendritic cells 
[220], with cells generated using these similar protocols commonly categorized as 
immature DCs, and as such there is some disagreement in the literature as to whether 
GM-CSF induced cells are indeed macrophages, or dendritic cells. However, work by Lari 
and colleagues has demonstrated the ability of GM-CSF generated BMDM to differentiate 
into osteoclasts, the bone resorbing cells of the body [221]. Osteoclasts arise in vivo 
from the fusion of monocytes and/or macrophages, resulting in the formation of large 
multinucleated cells, capable of producing lytic enzymes and acids that degrade bone 
[reviewed in [222]. The ability to generate osteoclasts from GM-CSF BMDM indicates 
that these cells have not committed to the DC lineage, and this ability, along with the 
expression of common macrophage surface markers such as CD11b, the M-CSF receptor 
and F4/80 by these cells [202] can be taken as conformation that this cell population 
are in fact a macrophage subset. As a side note, there is currently some debate as to 
whether macrophages and DCs are separate cell populations at all, or if instead, DCs are 
a specialized macrophage subset adapted for antigen presentation [223-225], in which 
case the GM-CSF generated cells could theoretically be both DCs and macrophages, 
however this possibility will not be explored here.  
M-CSF-containing L929 supernatant produces a more regulatory, M2-like phenotype of 
macrophages. M2 macrophages can be distinguished by their expression of the IL-4 
receptor, high level expression of scavenger receptors, CD206 (the mannose receptor) 
[25], and C-type lectins (CLECs) [reviewed in [226], with this enhanced expression of 
PRRs facilitating the binding of both pathogens and apoptotic cells by this macrophage 
population. 
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In the in vitro assays undertaken, lower levels of interaction were seen between 
AC/viable cells and GM-CSF BMDM compared to L929 BMDM, regardless of the cell type 
or the method used to induce apoptosis. M2-like L929 BMDM have been shown to be 
highly phagocytic, in comparison to GM-CSF BMDM [227], and so the reduced interaction 
of GM-CSF BMDM with AC during co-culture can be attributed to intrinsic cell 
characteristics, rather than a consequence of the assay. Differences in expression of 
PRRs, as well as cell adhesion molecules, will influence the relative ability of these 
BMDM populations to interact with other cells. Studies looking at human monocyte-
derived macrophages have shown differences in the morphology, expression of cell 
surface markers and suppressive activity of macrophages differentiated using M-CSF 
compared to those differentiated using GM-CSF. M-CSF macrophages are elongated, 
spindle-like cells expressing all 3 FcγRs (CD16, CD32 and CD64), as well as the αvβ5 
integrin and high levels of CD14, and show enhanced IL-10 production. GM-CSF 
macrophages however, show weak IL-10 production, indicating limited suppressive 
function, and have a round, fried egg-like morphology. These M1 macrophages express 
only 2 types of FcγR (CD32 and CD64), express αvβ3 rather than αvβ5, and express 
minimal CD14 [228]. Although focused on human macrophages, these results highlight 
the differences in the expression of surface molecules involved in cell-cell interactions 
by M-CSF and GM-CSF differentiated macrophages. The effects of these colony 
stimulating factors on murine macrophage phenotype and function have also been 
shown, with culture of peritoneal macrophages in the presence of recombinant M-CSF 
resulting in the marked increase in the synthesis and stable surface expression of the 
macrophage scavenger receptor (MSR) [229], as well as an increase in surface expression 
of the complement receptor, CR3. In this study, M-CSF also enhanced specific peritoneal 
macrophage functions, as demonstrated by the enhanced uptake of fluorescently 
labeled lipoprotein, an MSR ligand, and increased cation-independent adhesion to 
serum-treated tissue culture plastic [229].   
In an attempt to understand the outcomes of the BMDM-AC interactions observed, the 
effect of co-culture on L929 BMDM antigen presenting potential and activation was 
investigated. To do this, the relative expression levels of a range of cell surface markers 
were compared using flow cytometry. Very few differences were detected in the L929 
BMDM on co-culture with AC of different origins, but from the same apoptotic treatment 
group. The only notable phenotypic difference after co-culture was the expression of 
CD69, with L929 BMDM co-cultured with irradiated B cells in the absence of LPS 
expressing substantially more of this early activation marker than those co-cultured 
with irradiated thymocytes, however this finding was variable. This increased 
expression was unexpected, as although not demonstrated in macrophages, it has 
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previously been shown that AC are able to inhibit the expression of CD69 on activated 
T cells in vitro [230].  
When the overall ability of AC to modulate L929 BMDM phenotype was compared to 
BMDM cultured alone, it could be seen that levels of co-stimulatory molecules expressed 
by the BMDM incubated with AC were unchanged, with MHC II expression increased in 
the absence of LPS in all conditions containing AC. Previous work by Barker et al has 
shown that co-culture of L929 BMDM with apoptotic neutrophils does not alter 
expression levels of the co-stimulatory molecules CD40, CD80 or CD86 by BMDM [219], 
although in this study MHC II expression also showed no change on co-culture [219]. 
Alternately, work looking at murine red pulp macrophages has demonstrated an up-
regulation of both MHC II and CD86 after interaction with apoptotic thymocytes [231], 
indicating that different populations of macrophages respond differently to AC in terms 
of their expression of MHC II and co-stimulatory molecules. As such, the expression 
pattern of these markers by L929 BMDM on AC co-culture is likely due to the 
macrophage population used. The BMDM used in both the present study and that by 
Barker et al [219], were generated using L929 supernatant, however bone marrow was 
harvested from BALB/c mice in the work of Barker et al, and from C57BL/6 mice in the 
present work, which could account for the differences seen. 
The expression of CD69 and CD206 on L929 BMDM was also investigated. When 
expression levels by BMDM co-cultured with AC were compared to BMDM cultured alone, 
a small decrease in the expression of CD69 was observed in the presence of 1ng/ml LPS, 
regardless of the cell type or apoptotic stimuli, with the same reduction in expression 
seen in CD206. As the decrease was minor it is hard to know whether this level of 
variation would be biologically relevant, but if so, these results indicate that in the 
present assay system co-culture of BMDM with AC is able to down-regulate LPS-induced 
BMDM activation, but does not skew the population to a more M2-like population, as 
would be indicated by increased CD206 expression.  
The ability of AC to modulate the secretion of soluble immune-mediators by 
macrophages has been extensively documented, and ELISAs were undertaken to 
determine whether the BMDM-AC interactions observed were having functional effects 
on the BMDM in terms of the production of soluble immune mediators. All AC 
investigated had the same effects on cytokine production by L929 BMDM, with the levels 
of IL-12, TNFα, IL-6, IL-10 and TGF-β investigated. Unexpectedly, in our co-culture 
assays, viable cells had the same effects on cytokine secretion by L929 BMDM as AC for 
all cell types tested. Decreased production of both TNFα and IL-6 could be detected 
after AC/viable cell co-culture, however no change in the production of IL-12, IL-10 or 
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TGF-β was observed in any condition. These finding do not fully fit with the concept of 
AC suppression of macrophage inflammatory responses, however within the published 
body of work there is a level of variability. On co-culture with apoptotic neutrophils, 
human monocyte-derived macrophages down-regulate their production of the pro-
inflammatory cytokines IL-8, TNFα, and IL-1β, and increase production of the anti-
inflammatory cytokine TGF-β, however no detectable difference in IL-10 secretion is 
seen [157,232]. An increase in TGF-β production, with concomitant inhibition of TNFα, 
nitric oxide and iNOS (inducible nitric oxide synthase) production is seen in both 
classically activated murine peritoneal macrophages and the RAW 264 macrophage cell 
line on co-culture with apoptotic Jurkat T cells [169]. AC uptake by the murine 
macrophage cell line J774 markedly decreases their ability to secrete TNFα, as well as 
the chemokines MIP-1α, MIP-2, and CXCL1 (previously called KC) on LPS-stimulation, 
with TGF-β production also increased [218]. Interestingly, in this study, along with the 
production of chemokines and pro-inflammatory cytokines, the production of the anti-
inflammatory cytokine IL-10 was also mildly suppressed [218].  
When cytokine production by GM-CSF BMDM after AC co-culture was investigated, a 
different pattern of modulation was observed than that seen in the L929 BMDM 
population. Unlike the L929 BMDM, a decrease in IL-12 production was seen, however no 
change in the production of IL-6 was detected after co-culture of GM-CSF BMDM. As with 
the L929 BMDM, co-culture with viable cells had the same effects on cytokine secretion 
by GM-CSF BMDM as co-culture with AC. The GM-CSF and L929 BMDM used in these 
assays have arisen from the same precursors, but differentiated in response to different 
growth factors, reflecting the ability of macrophages in vivo to develop into different 
populations depending on their environment. The disparity in the functional outcome of 
co-culture between the two BMDM populations demonstrates the intrinsic differences 
between these different macrophage subsets, reflecting their varied roles during an 
immune response. 
PGE2 production by the BMDM was also examined. The addition of exogenous PGE2 to 
human monocyte-derived macrophages in culture has been shown to suppress 
inflammatory cytokine production [157], with the production of PGE2 by macrophages 
after uptake of AC thought to help regulate the inhibition of pro-inflammatory cytokine 
production in an autocrine manner. In the current co-culture system, an increase in 
PGE2 production was seen on co-culture of both L929 and GM-CSF BMDM with AC, 
however the expected concomitant decrease in inflammatory cytokines was not 
observed. This finding indicates that only under certain conditions is PGE2 sufficient to 
inhibit the release of pro-inflammatory cytokines by macrophages after interaction with 
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AC. Viable cells had the same ability as AC to modulate PGE2 production by the L929 
BMDM, however their effect on GM-CSF BMFM was more variable, as was the effect of 
the AC investigated. 
Within each treatment group the different AC had comparable effects on cytokine 
secretion and PGE2 production by the BMDM. Inducers of apoptosis stimulate cell death 
through particular biochemical pathways, with different pathways involved depending 
on the initial stimulus, and so it is not surprising that AC induced through the same 
mechanism, in the same environment, have similar effects on phagocytes. Although this 
result was seen repeatedly in these co-culture assays, there is evidence indicating that 
in vivo this would not always be the case, with other factors able to override the 
influence of apoptosis induction. For example, the activation state of AC is able to 
influence the responses of DC in vitro [173]. Ingestion of apoptotic resting peripheral 
blood mononuclear cells (PBMCs) does not provide maturation signals to human 
monocyte-derived DC, however uptake of apoptotic activated PBMCs is able to induce 
the expression of the maturation markers CD80, CD83 and CD86 by the DC, as well as 
production of pro-inflammatory cytokines [173]. In this study gamma-irradiation was 
used to induce apoptosis in both the resting and activated PBMC groups, demonstrating 
that although the mechanisms of apoptosis induction plays a key role in the response of 
the immune system to AC, other factors are also at play. Murine macrophages that 
phagocytose AC in the presence of Toll-like receptor (TLR) ligands have been shown to 
have a different cytokine profile than those that encounter either stimulus alone, 
demonstrating that the environment in which AC are encountered can influence the 
subsequent response by phagocytes [175]. 
Viable cells were originally included in the assay a control; as no antigen is present in 
the current assay system, considerable viable cell-BMDM interaction was not expected.  
However, throughout the work undertaken in this chapter viable cells were found to 
have the same immunomodulatory capacity as AC, with viable B cells showing higher 
levels of interactions with both L929 and GM-CSF BMDM than any of the AC populations 
investigated. This was an unexpected finding. In vivo secretion of TGF-β in inflamed 
peritonea of ICR mice is enhanced by clearance of apoptotic Jurkat cells, but not viable 
Jurkat cells, administered intraperitoneally [171]. In this model, peritoneal and lung 
macrophages also showed a significant increase in the uptake of apoptotic cells 
compared to viable cells on investigation of peritoneal or bronchoalveolar lavage fluid 
cytospins [171]. As such, the results seen in the present work do not fit with the 
available literature. As discussed previously, the interaction of BMDM with the viable 
cells, and their effects on BMDM function may be due to AC contamination within this 
condition. However, another theory could also be proposed. Unlike BMDM, which are 
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generated in vitro, macrophages in vivo do not exist in isolation; they are part of a 
system in which both apoptotic and viable cells are continually present. If non-specific 
cell-cell interactions take place in vivo as a part of normal cell encounters, such as 
through the interaction of cell adhesion molecules, any potential effects interaction 
with viable cells may have on macrophages would have already occurred. Therefore, 
the administration of exogenous viable cells, such as in the study mentioned above, 
would not be expected to have additional influence on the macrophage phenotype or 
activity, and as such no change would be detected. Within this interaction model, the 
administration of additional AC could still impact macrophage responses. Under steady 
state conditions, AC are rapidly cleared from the system and as a result, macrophages 
would not be expected to encounter large numbers of AC simultaneously. The 
introduction of a large number of AC at the same time could tip the balance from 
immunologically silent AC clearance by phagocytes, to an actively anti-inflammatory 
form of clearance, skewing macrophage phenotype and subsequent function. Based on 
this theory, it could therefore be suggested that the present in vitro findings regarding 
the action of viable cells on BMDM are an artefact of the assay system utilized, as the 
BMDM included in the co-culture conditions had never previously encountered any cells 
other than BMDM, and so interaction with viable cells had demonstrable effects. 
Whereas in vivo, macrophages will have already undergone interactions with viable cells 
prior to any baseline measurement taken. If this theory were correct, it would be 
expected that similar results would be gained from other in vitro assays comparing 
viable cell and AC co-culture conditions. 
Although the majority of work looking into the effects of AC uptake by phagocytes does 
not include viable cell controls, a small number do. Fadok et al have shown that the in 
vitro co-culture of murine macrophages and apoptotic thymocytes results in a higher 
phagocytic index, compared to that when viable thymocytes were included in co-culture 
conditions, with this score taking into account both the percentage of macrophages that 
had phagocytosed cells and the average number of cells per macrophage, [125]. Co-
culture of RAW macrophages with apoptotic Jurkat cells induces increased TGF-β 
secretion and an accompanied inhibition of TNFα production, however co-culture with 
viable Jurkat cells has no effect on cytokine production by RAW cells [169], however in 
these studies viable cells do not influence macrophage. Although these studies do not 
initially support the hypothesis proposed, it is interesting to note that neither utilizes 
BMDM. In the first, thioglycollate elicited peritoneal macrophages were examined, a 
population of macrophages that have developed in vivo, while the second used the 
macrophage RAW cell line rather than primary cells. As a result, the results gained in 
these studies are not directly comparable to those in the present body of work. 
   
116 
However, further work is needed to understand the interactions observed between 
BMDM and viable cells in the present co-culture assays, and to explore whether viable 
cells are able to modulate macrophage phenotype and function under conditions not 
explored with the current assay system. 
Together these findings indicate that under the experimental conditions used, AC of 
different origins have similar levels of interaction with BMDM and do not greatly differ 
in their ability to alter macrophage phenotype or function. However, in all conditions 
investigated, viable cells show the same ability as AC to modulate macrophage 
phenotype and function, adding a layer of complexity to the previous literature, and 
warranting further investigation. 
  
 
 
 
 
 
Chapter 4: The Effects of Rituximab on B cell 
– Macrophage Interactions 
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4.1 Introduction 
Many cell populations are known to be involved in the pathogenesis of RA, with a role 
for B cells being highlighted by the success of the biologic RTX, a monoclonal antibody 
(mAb) that depletes B cells [69]. Although the involvement of B cells in RA pathogenesis 
is now evident, the exact contribution of B cells is still unclear, as these cells are able 
to perform multiple roles in the context of autoimmunity, including the production of 
autoantibodies [54], the secretion of pro-inflammatory cytokines, the expression of co-
stimulatory molecules crucial for T cell activation [233], as well as being able to act as 
APCs [54]. To help enable a better understanding of the part B cells play in RA disease 
pathogenesis, the mode of action of effective agents targeted at this cell population 
needs to be elucidated.   
RTX was originally developed and approved for use in the treatment of B cell lymphoma 
[91], but is now commonly used to treat RA patients after failure of anti-TNF therapies. 
Rituximab targets CD20, a transmembrane phosphoprotein that belongs to the MS4A 
family of proteins [234], which is expressed on the cells of the B cell lineage; with the 
exception of pro-B cells and plasma cells. Treatment with anti-CD20 mAb results in 
rapid and prolonged B cell depletion [reviewed in [106] and improvement of disease 
symptoms, with the effects of treatment on occasion lasting long after B cell 
repopulation had occurred.  
Three mechanisms contribute to RTX-mediated B cell depletion: antibody-dependent 
cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and apoptosis. 
It is widely accepted that interactions between the Fc portion of the anti-CD20 mAb and 
FcRs expressed on effector cells resulting in ADCC are vital to the efficacy of RTX [88]. 
CDC has also been shown to play a central role in B cell depletion after RTX treatment 
[93], acting in synergy with ADCC. Cell sensitivity to CDC correlates to the level of CD20 
expression by B cells [98], with those cells not sensitive to CDC being cleared by ADCC 
and vice versa. The role of RTX-mediated apoptosis in B cell depletion has been shown 
by multiple groups [235-237], however there is some disagreement as to its contribution 
in vivo [238], with many B cells lines refractory to RTX-mediated apoptosis [239,240].  
Although there is clear consensus that RTX treatment ameliorates RA activity, the 
mechanisms by which it exerts its beneficial effect remains unclear. We hypothesize 
that one of these mechanisms of action may be the re-introduction of a temporary 
tolerance to the immune system, both through the generation of large numbers of 
apoptotic cells and the indirect effects of RTX-mediated B cell depletion on other cells 
of the immune system. On infusion with RTX, B cells present in the peripheral blood are 
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quickly depleted [241], however clearance of B cells from secondary lymphoid organs is 
a slower process [242], with residual B cell populations often left in secondary and 
tertiary lymphoid organs after infusion [243,244]. This means that B cells, potentially 
with surface-bound or internalized RTX, can be present in the system for considerable 
lengths of time before being cleared, and during this time these cells are able to 
interact with other cells of the immune system. 
It has recently been shown by Kamburova and colleagues that in vitro culture of human 
T cells with RTX-treated B cells results in a skewing of the T cell population to a Th2-
like phenotype, as demonstrated by an increase in expression of the Th2-associated 
markers CCR4 and GATA3, and enhanced IL-4 production [245]. Further in vivo studies 
have shown that a single dose of RTX is able to alter the phenotype and function of non-
depleted B cells present in secondary lymphoid organs after treatment [244]. LN were 
collected during renal transplant surgery from patients that had previously undergone 
RTX treatment, and the LN mononuclear cells isolated using density gradient 
centrifugation. On stimulation with αCD40 and IL-21 ex vivo, the B cells from RTX-
treated patients showed decreased levels of IgM production, compared to those from 
non-RTX-treated controls, coupled with increased expression of mRNA for activation-
induced cytidine deaminase, an enzyme involved in class switch recombination, 
indicating that RTX treatment can have a direct effect on B cell signaling cascades and 
subsequently, B cell function. In this study the authors also demonstrated that in vitro 
stimulation of T cells with the LN B cells from RTX-treated patients resulted in a weaker 
Th17 response, compared to stimulation with non-RTX-treated B cell controls, as 
measured by intracellular cytokine production [244]. These findings demonstrate that 
RTX stimulation of B cells can directly affect B cell function, as well as the interactions 
of these cells with other immune effector cells, prior to their clearance from the 
system. 
The focus of the work in this chapter is to explore whether RTX binding to B cells can 
affect the way B cells interact with APCs. To do this, in vitro assays were performed 
utilizing primary hCD20tg B cells and murine BMDM, grown in media supplemented with 
either M-CSF-containing L929 supernatant, or GM-CSF and IL-3. The B cells were labelled 
with CFSE and incubated with RTX, before extensive washing to remove free antibody. 
In certain versions of the assay, B cells from each pre-treatment were irradiated, 
allowing comparison of the effects of viable and apoptotic RTX pre-treated B cells. 
BMDM were mixed with the CFSE-stained viable or irradiated pre-treated B cells and co-
cultured, with flow cytometry used to determine the resultant levels of cell-cell 
interaction, and ELISAs undertaken to look at alterations in cytokine production. 
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Chapter objectives: 
• To investigate whether BMDM undergo altered levels of interaction with RTX 
pre-treated B cells, compared to untreated or IgG pre-treated B cells 
• To visualize the type of interactions BMDM and RTX pre-treated B cells undergo, 
and examine whether these differ from those between BMDM and untreated or 
IgG pre-treated B cells  
• To explore whether the interaction of BMDM with RTX pre-treated B cells has an 
effect on BMDM function and phenotype 
4.2 Results 
4.2.1 Optimisation of Rituximab internalisation protocol 
Before the effects of RTX on B cell – macrophage interactions were explored, a better 
understanding of the kinetics of RTX internalisation by hCD20tg B cells in vitro was 
sought. To do this, RTX conjugated to AlexaFluor488 (RTX-488) was used, allowing 
analysis of RTX uptake by flow cytometry. In order to differentiate between total bound 
RTX-488 and internalized RTX-488, a method of removing cell surface staining was 
sought. This would enable the levels of internalized RTX to be determined, as well as 
calculation of the relative levels of surface bound RTX. 
Cells were stained with either anti CD3-FITC, anti CD3-PE anti CD19-PerCPCy5.5 or anti-
CD19-APC and two different methods to remove cell surface fluorescence examined; 
incubation with trypan blue to quench any surface signal [246-248], and acid stripping 
of the surface bound antibody [249,250]. To quench the fluorescent signal, stained cell 
samples were incubated with 0.4% trypan blue for 2min at either 4oC or RT. When 
incubated at either 4oC or RT, no decrease in signal was seen for any of the four 
fluorochromes tested, as determined by the MFI values for each fluorochrome (Figure 
4.1a).  
A range of acid stripping protocols are documented in the literature, and two different 
methods were were explored. In the first, cells were incubated with 1ml 0.5M NaCl + 
0.2M acetic acid for 4min at 4oC, prior to washing and FACS analysis (acid strip 1), 
whereas in the second they were incubated with 0.5M NaCl + 0.2M acetic acid for 
10min, washed, and again incubated with acid and washed two further times, before 
being analysed by flow cytometry (acid strip 2). For the second protocol either 0.5ml or 
1ml of acid was used, with certain samples incubated at 4oC and others at RT. A 
substantial decrease in surface fluorescence was observed for all fluorochromes tested 
with the first acid strip protocol used, with 54±2% of the original FITC, 1±0% of the PE, 
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24±0% of the PerCPCy5.5 and 35±3% of the APC signal present after treatment compared 
to stained, un-stripped samples (Figure 4.1a). A substantial reduction in surface 
fluorescence was also observed for all fluorochromes tested when the second acid strip 
protocol was used, regardless of the volume of acid or incubation temperature (Figure 
4.1a). For both the PE and APC signal, the method of acid stripping did not alter the 
final level of surface fluorescence seen, with the majority of PE and APC staining 
removed by all acid strip protocols tested. However, for FITC the acid strip 2 protocol 
with 1ml of acid at RT was markedly less able to reduce surface fluorescence than the 
other three variations of the acid strip 2 protocol, with 73±11% of the original signal 
remaining compared to 37±2% after the acid strip 2 protocol with 1ml acid at 4oC, 
34±0.4% after the acid strip 2 protocol with 0.5ml of acid at 4oC, and 44±1% after using 
the acid strip 2 protocol with 0.5ml of acid at RT. The acid strip 1 protocol was 
considerably more effective at reducing the PerCPCy5.5 signal than the acid strip 2 
protocol with 0.5ml of acid at 4oC, with only 24±0% of the original signal remaining after 
treatment, compared to 48±0.7%. 
The effect of both trypan quenching and acid stripping on cell viability was also 
investigated. The trypan quenching protocol used, along with the acid strip 1 protocol, 
had no adverse effects on cell viability compared to the un-treated stained cells, as 
determined by flow cytometry. Examination of the cells FSC and SSC was used to detect 
viable cells (Figure 1b), with trypan quenching at 4oC resulting in 67±0.7% of the total 
cell population viable, trypan quenching at RT resulting in 64±0.1% and the acid strip 1 
protocol resulting in 68±3% (Figure 4.1c). However, when the acid strip 2 protocol, 
which employed multiple rounds of acid incubations, considerable decreases in the 
proportion of viable cells was seen, ranging from 23±6% of the total cells remaining 
viable cells down to only 4±0% (Figure 4.1b, c). 
The acid strip 1 protocol showed potential as a method of removal of surface bound 
RTX-488, however it was decided to investigate a further method to inhibit cell surface 
fluorescence. This decision was made for two reasons: firstly, a high level of surface 
FITC remained after treatment, which could obscure true internalization values; and 
secondly, acid stripping affects antibodies of all fluorochromes, and therefore the use 
of this protocol would mean that no other antibodies could be used alongside the RTX-
488. Incubation of pre-stained cells with an anti-AlexaFluor488 (anti-488) antibody 
allows specific quenching of any AF488 surface signal [180]. Primary hCD20tg B cells 
were incubated with RTX-488 for 20min before being incubated with the anti-488 
antibody for a further 20min, and analyzed by flow cytometry. In order to determine 
the optimal volume of anti-488 antibody needed to quench the RTX-488 signal an 
antibody titration was undertaken.  
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In the samples tested, viable B cells were gated on using FSC and SSC, and within this 
population, those that had interacted with RTX were defined as FSCintRTX-488+ cells, as 
shown in Figure 4.2a. Incubation with the anti-488 antibody did not alter the overall 
proportion of RTX+ B cells (Figure 4.2b), however a considerable decrease in the 
intensity of the AF488 staining could be seen (Figure 4.2c). B cells incubated with RTX-
488 alone had an MFI of 254±0, whereas, when the cells were incubated with RTX-488 
followed by 5µl anti-488 their MFI was 35±0.5, with RTX-488 followed by 10µl anti-488 it 
was 31±0.4, with RTX-488 followed by 15µl it was 33±0.1 and with RTX-488 followed by 
20µl anti-488 it was 30±0.6 (Figure 4.2d). Cell viability was not affected by anti-488 
incubation (data not shown). 
As an outcome of these investigations, it was decided to utilize the anti-488 quenching 
antibody in the studies of RTX internalization by hCD20tg B cells, rather than trypan 
quenching or acid stripping. 
4.2.2 RTX internalisation by hCD20tg B cells and cell survival 
To investigate the kinetics of RTX internalization by hCD20tg B cells, primary B cells 
were isolated from the combined spleen and LNs of an hCD20tg C57BL/6 mouse and 
incubated with RTX-488 for 0min, 15min, 30min, 1hr, 3hr, 6hr and 24hr. Half of the 
cells from each time-point were then incubated with anti-488 antibody, to quench the 
surface RTX-488 signal, with the difference in MFIs between the anti-488 treated and 
untreated groups used to calculate relative RTX internalization over time. 
In the samples tested, viable B cells were gated on using FSC and SSC, and within this 
population those that had interacted with RTX were defined as FSCintRTX-488+ cells, as 
shown in Figure 4.3a. At the early time-points, incubation with the anti-488 antibody 
resulted in a decrease in the percentage of RTX-488+ B cells (0min: 6.3±2.1% vs. 
1.9±0.5%, 15min: 94.5±0.3% vs. 47.2±3.9%, 30min: 95.5±0.2% vs. 83.2±2.3%), however 
from 1hr onwards, incubation with anti-488 antibody did not alter the overall proportion 
of RTX-488+ B cells (Figure 4.3b and c). After 30min of incubation, maximal binding of 
RTX-488 to B cells in this system was achieved, as evidenced by the increasing total MFIs 
seen at the 0min (86±11) and 15min (192±4) time-points, compared to the consistent 
total MFIs of the later time-points (30min: 283±4, 1hr: 300±2, 3hr: 290±3, 6hr: 292±5, 
and 24hr: 236±11) (Figure 4.3d). The amount of internalized RTX-488 remained at 
baseline levels for the first 30min, with MFIs comparable to the 0min time point (0min: 
51±7, 15min: 41±0.6, 30min: 53±1). After 3hr of culture the majority of bound RTX had 
been taken up by the B cells (external MFI: 76±3.1 vs. internal MFI: 215±2.5) and
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Figure 4.1 Acid stripping of cells removes surface fluorescence but has adverse effects on 
cell viability 
Spleens and LN were isolated from WT DBA mice, combined, and FACS stained with either anti 
CD3-FITC, anti CD3-PE, anti CD19-PerCPCy5.5 or anti CD19-APC. The signal of the surface 
staining was then either quenched by incubation with trypan blue for 2min, or was stripped using 
one of two acid stripping protocols: acid strip 1 cells - incubated with 1ml 0.5M NaCl + 0.2M acetic 
acid for 4min at 4oC; and acid strip 2 cells - incubated with 0.5M NaCl + 0.2M acetic acid for 3x 
10min. Volumes and temperatures are indicated in the figure. Cell samples were then analyzed by 
flow cytometry. (A) Graphs showing the levels of surface staining for each fluorochrome tested 
after removal protocols undertaken, normalised to the MFI of stained cells. (B) Representative 
FACS plots showing cell viability after staining removal protocols undertaken. Panels: SSC vs. 
FSC. (C) Graph of pooled data showing the percentage of viable cells after the various trypan 
quenching and acid stripping protocols. (n=2, data from 2 independent experiments)  
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Figure 4.2 Titration of anti-448 antibody 
Spleens and LN were isolated from an hCD20tg C57BL/6 mouse, combined, and incubated with 
RTX-488 for 20min. Cells were then incubated with the anti-488 antibody for 20min before being 
analyzed by flow cytometry. (A) FACS plots demonstrating the gating strategy used to define RTX+ 
B cells. First panel: SSC vs. FSC. Second panel: RTX-488 vs. FSC. (B) Representative dot plots 
showing the percentage of RTX+ B cells after treatment with 5µl, 10µl, 15µl or 20µl of anti-488 
antibody. Panels: RTX-488 vs. FSC. (C) Representative histograms showing the levels of RTX-488 
staining after treatment with varying amounts of anti-488 antibody. (D) Graph of pooled data 
showing the reduction in the levels of RTX staining (MFI) after treatment with anti-488 antibody 
compared to un-treated cells. RTX-488 = RTX-AlexaFluor488 conjugate, anti-488 = anti-
AlexaFluor488 antibody. (n=2)  
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remained so for the length of the study (6hr - external MFI: 49±6 vs. internal MFI: 
243±2, 24hr - external MFI: 38±12 vs. internal MFI: 198±7). 
To visualize the internalization of RTX by hCD20tg B cells, primary B cells were isolated 
from the spleen and LNs of an hCD20tg C57BL/6 mouse and incubated with RTX-488 for 
either 0, 15 or 30min. Cells were then stained with rhodamine-conjugated phalloidin, a 
fluorescent F-actin probe, to allow visualization of the cell cytoskeleton, and slides 
prepared with DAPI added to label the nuclei of the cells. The slides were then analyzed 
using a Zeiss ApoTome, at x63 magnification. At the initial 0min time-point no RTX-488 
staining can be seen on the B cell (Figure 4.4). By the 15min time-point RTX-488 has 
bound the B cell, as indicated by its co-localization with phalloidin at the cell surface, 
seen in the composite image. This co-localization continues after 30min of culture, with 
a more distinct area of RTX-488 binding visible. Unfortunately, due to the small amount 
of cytoplasm found in B cells it was not possible to differentiate between surface-bound 
and internalized RTX using this method, as all bound RTX appeared at the surface co-
localized with phalloidin, and a distinct internal or external signal could not be 
detected. As such, investigation was not continued to the later time-points. 
It has previously been shown that addition of RTX to in vitro cultures of human B cells, 
does not increase the occurrence of cell death, either through apoptosis or necrosis 
[245]. We wanted to confirm this finding with hCD20tg B cells, and so the effect of RTX 
on hCD20tg B cell survival in vitro was investigated. To do this, primary B cells were 
isolated from the spleen and LNs of hCD20tg C57BL/6 mice and incubated with either 
RTX or IgG, or left un-treated, up to 24hr. The B cells were then stained with ViaProbe 
(7-AAD solution) and Annexin V to assess the levels of cell death at each time-point, and 
analysed by flow cytometry (Figure 4.5). 
The proportions of live, dead and apoptotic cells were comparable for RTX-treated 
hCD20tg B cells and control cells at all time-points investigated, with viable B cells 
defined as ViaProbe-AnnexinV- double negative cells, apoptotic cells as ViaProbe-
AnnexinV+, and dead/necrotic cells a double positive for ViaProbe and AnnexinV (Figure 
4.5a). At the 8hr time-point the majority of B cells were viable regardless of treatment 
(nt: 66.5±1.3%, RTX: 71.1±0.4%, IgG: 68.8±1%), however by 24hr in culture only a small 
proportion of B cells were still viable (nt: 6±0.6%, RTX: 12.8±0.6%, IgG: 8.3±1.7%), with 
the majority of cells staining ViaProbe-Annexin V+ (nt: 77.2±8.1%, RTX: 73.4±1.6%, IgG: 
76.4±4.4%), indicating they were undergoing apoptosis (Figure 4.5b-d).  
These findings demonstrate that over time, RTX is removed from the surface of hCD20tg 
B cells via its internalization, with the majority of bound RTX located within the cell 
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Figure 4.3 RTX is internalized by hCD20tg B cells 
The spleen and LNs of an hCD20tg C57BL/6 mouse were combined, and B cells isolated and 
incubated with RTX-488 for 0min, 15min, 30min, 1hr, 3hr, 6hr or 24hr as shown. Half of the cells 
from each time-point were then incubated with anti-488 antibody to remove the surface RTX-488 
signal and the difference in MFIs between the anti-488 treated and untreated groups used to 
assess RTX internalization. (A) FACS plots demonstrating the gating strategy used to define RTX+ 
B cells. First panel: SSC vs. FSC. Second panel: RTX-488 vs. FSC. (B) Representative dot plots 
showing the percentage of RTX+ B cells in untreated samples and samples treated with anti-488 
antibody, at each time point. Panels: RTX-488 vs. FSC. (C) Graph of pooled data showing the 
percentage of RTX-488+ B cells in the treated and untreated group at each time point. (D) Graph 
showing the relative levels of internalized and surface RTX at each time-point over a 24hr period. 
(n=1, 3 replicates) Statistics used: One-way ANOVA performed on complete data set in (C), 
followed by Bonferroni’s post test, with * = p<0.05 and *** = p<0.001. 
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Figure 4.4 Visualization of Rituximab binding to hCD20tg B cells  
B cells were isolated from the spleen and LNs of an hCD20tg C57BL/6 mouse and incubated with 
RTX-488 for 0min, 15min or 30min, as shown. Cells were then stained with DAPI and phalloidin, 
cytospun on to slides and visualised using a Zeiss ApoTome (magnification: x63). Column 1: DAPI 
staining. Column 2: RTX-488 staining. Column 3: phalloidin staining. Column 4: Composite image, 
with DAPI in blue, RTX-488 in green and phalloidin in red. 
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Figure 4.5 Incubation with RTX does not alter B cell survival in vitro 
B cells were isolated from the combined spleen and LNs of hCD20tg C57BL/6 mice and incubated 
with RTX or controls for 0min, 30min, 3hr, 6hr, 8hr or 24hr, as shown. Cells were then stained with 
ViaProbe (7-AAD solution) and Annexin V, and analysed by flow cytometry to allow detection of 
live, dead and apoptotic cells. (A) Representative FACS plots showing the gating used to 
differentiate live, dead and apoptotic cells at each of the time points and for each treatment group. 
Panels: ViaProbe vs. Annexin V, with viable cells ViaProbe-AnnexinV-, apoptotic cells ViaProbe-
AnnexinV+ and dead cells ViaProbe+ and AnnexinV+. (B) Graph showing the percentages of live, 
dead and apoptotic un-treated B cells over a 24hr period of in vitro culture. (C) Graph showing the 
percentages of live, dead and apoptotic RTX-treated B cells over a 24hr period of in vitro culture. 
(D) Graph showing the percentages of live, dead and apoptotic IgG-treated B cells over a 24hr 
period of in vitro culture. (n=1, 3 replicates) 
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after 3hr. These results also reveal that RTX treatment of hCD20tg B cells in vitro does 
not effect cell survival as compared to un-treated hCD20tg B cells. 
4.2.3 B cell ingestion by L929 BMDM 
In vitro assays were then performed to investigate whether RTX binding to B cells has an 
effect on the way B cells, or apoptotic cells originating from these B cells, interact with 
L929 BMDM in vitro. Murine BMDM were grown for 7 days in media supplemented with M-
CSF-containing L929 supernatant, before being stimulated overnight with IFNγ. Primary  
B cells were purified from the combined spleens and LNs of hCD20tg C57BL/6 mice, and 
incubated with either RTX or controls for 30min, before extensive washing to remove 
free antibody. Half of the cells from each pre-treatment were irradiated to induce 
apoptosis, and all B cells incubated for 4hr. Adherent L929 BMDM were mixed with CFSE-
stained viable or irradiated RTX pre-treated B cells, in the presence of LPS, at a ratio of 
1 BMDM:1 B cell, and co-cultured for 3hr. In previous in vitro assays undertaken to 
investigate the interaction of L929 BMDM with AC (Chapter 3) cells were co-cultured for 
15min, however the length of co-culture was increased for this adaptation of the assay 
to allow time for the BMDM to phagocytose the pre-treated B cells, therefore enabling 
the investigation of the later effects of these interactions. The levels of cell-cell 
interaction were analyzed by flow cytometry. 
In the samples tested, viable cells were gated on using FSC and SSC, and within this 
population the F4/80+ cells were defined as BMDM. Within this F4/80+ population, CFSE+ 
cells were deemed to be BMDM undergoing interactions with CFSE-stained B cells, as 
shown in Figure 4.6a. When co-cultured with viable B cells, L929 BMDM showed 
significantly higher levels of interaction with RTX pre-treated hCD20tg B cells compared 
to IgG pre-treated B cells (28.4±1.6% CFSE+ BMDM vs. 16.5±7.8%). The results also 
indicated a higher level of interaction with RTX pre-treated viable B cells compared to 
un-treated viable B cells, however this finding was not significant (Figure 4.6b and c). 
When co-cultured with irradiated pre-treated B cells, significantly higher cell-cell 
interactions occurred between the L929 BMDM and the RTX pre-treated cells, compared 
to both the untreated and IgG-treated cells, with 38.8±1.9% CFSE+ L929 BMDM in the RTX 
pre-treated co-cultures compared to 31.4±3.9% CFSE+ L929 BMDM in the un-treated co-
cultures, and 25.2±3.3% CFSE+ L929 BMDM in the IgG pre-treated co-cultures (Figure 4.6b 
and c). 
To determine whether the enhanced cell-cell interaction between L929 BMDM and RTX 
pre-treated B cells had any functional effect on the BMDM, the levels of IL-10 and TGF-β 
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in the cell culture supernatants were investigated. IL-10 and TGF-β are both anti-
inflammatory cytokines, with an increase in production of these mediators indicating a 
skewing of the macrophage population to a more regulatory phenotype. No change in IL-
10 production was seen on co-culture of L929 BMDM with RTX pre-treated viable 
(495±77pg/ml IL-10) or irradiated B cells (535±118pg/ml) compared to the BMDM alone 
(327±113pg/ml) (Figure 4.7a). However, a significant increase in IL-10 production was 
seen on co-culture of L929 BMDM with viable IgG pre-treated (673±7pg/ml IL-10) and 
irradiated IgG pre-treated B cells (554±30pg/ml IL-10) compared to BMDM cultured 
alone. No change in TGF-β production was seen on co-culture of L929 BMDM with any of 
the pre-treated B cells compared to the BMDM cultured alone (Figure 4.7b). 
These findings indicate that RTX binding to B cells does have an effect on the way 
B cells directly interact with L929 BMDM, and this effect continues even once the B cell 
has undergone apoptosis. These data also show that under the conditions studied, this 
increase in L929 BMDM interaction with RTX pre-treated B cells does not influence 
output of anti-inflammatory cytokines by the BMDM. 
4.2.4 Comparison of interaction of pre-treated B cells with BMDM and 
peritoneal macrophages  
To assess whether the activation status of the BMDM would influence their interaction 
with pre-treated B cells, the previous assay was repeated with a range of activated 
BMDM. L929 BMDM were generated as described previously and then divided into four 
separate groups: one stimulated with both IFNγ and LPS (BMDM+IFNγ+LPS), one with IFNγ 
alone (BMDM+IFNγ), one with LPS alone (BMDM+LPS), and one group left un-stimulated 
(BMDM). Primary peritoneal macrophages were isolated from WT C57BL/6 mice and 
included for further comparison. The BMDM and peritoneal macrophages were co-
cultured at a 1:1 ratio with pre-treated B cells for 3 hr, as before, and cell-cell 
interactions analyzed by flow cytometry.  
In the samples tested, BMDM undergoing interactions with pre-treated B cells were 
gated on, as shown previously (Figure 4.6a). A similar series of gating was used to 
identify CFSE+ peritoneal macrophages, with viable cells gated on using FSC and SSC, 
and macrophages defined as the live F4/80+ cells. CFSE+F4/80+ cells were considered to 
be peritoneal macrophages undergoing cell-cell interactions with pre-treated B cells 
(Figure 4.8). 
The activation state of the L929 BMDM did not affect their ability to interact with pre-
treated viable or irradiated B cells, with similar levels of CFSE+ BMDM seen in all culture 
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Figure 4.6 L929 BMDM show higher levels of cell-cell interaction with RTX pre-treated 
B cells compared to un-treated B cells 
Murine BMDM were grown for 7 days in cRPMI supplemented with M-CSF containing L929 
supernatant. Adherent cells were stimulated with 100U IFNγ and 100ng/ml LPS, before co-culture 
with CFSE stained viable or irradiated pre-treated B cells, at a ratio of 1:1 for 3hr, and interaction 
levels analyzed by flow cytometry. (A) FACS plots showing the gating strategy used to identify 
CFSE+ BMDM. First panel: SSC vs. FSC. Second panel: SSC vs. F4/80. Third panel: CFSE vs. 
F4/80. (B) Representative FACS plots showing levels of BMDM interaction with pre-treated viable 
and irradiated B cells. Panels: CFSE vs. F4/80. (C) Graph of pooled data showing the percentage 
of CFSE+ BMDM after co-culture with pre-treated viable and irradiated B cells. nt: no pretreatment, 
RTX: Rituximab. (n=2, data representative of 2 separate experiments) Statistics used: One-way 
ANOVA performed on full data set in (C), followed by Bonferroni’s post test, with * = p<0.05, 
** = p<0.01, and *** = p<0.001 
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Figure 4.7 Co-culture of BMDM with RTX pre-treated B cells does not alter IL-10 or TGF-β  
production by BMDM 
Murine L929 BMDM stimulated with 100U IFNγ and 100ng/ml LPS were co-cultured with viable or 
irradiated pre-treated B cells overnight, cell culture supernatants were collected, and IL-10 and 
TGF-β production investigated by ELISA. (A) Graph of pooled data showing the levels of IL-10 
(pg/ml). (B) Graph of pooled data showing the levels of TGF-β (pg/ml).  (IL-10 n=1, data from a 
single experiment, TGF-β n=2, data from 2 independent experiments) Statistics used: One Way 
ANOVA performed on each data set in (A) and (B), followed by Bonferroni’s post test, with 
* = p<0.05, and ** = p<0.01.  
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conditions (Figure 4.9a). Although the data indicates an increase in interaction between 
RTX pre-treated viable B cells and BMDM of several activation states compared to 
controls, only when the L929 BMDM were stimulated with LPS alone was this increase 
significant, with 38.8±1.5% CFSE+ BMDM compared to 29.4±2% CFSE+ BMDM when co-
cultured with un-treated viable B cells, and 27.3±1.9% CFSE+ BMDM when co-cultured 
with IgG pre-treated viable B cells (Figure 4.9b). The interaction of peritoneal 
macrophages with RTX pre-treated B cells did not differ from that of controls, however 
overall the peritoneal macrophages did show considerably higher levels of interaction 
with all B cells conditions compared to the BMDM, regardless of B cell viability or pre-
treatment (Figure 4.9b and c). An overall average of 68.7±3.6% of peritoneal 
macrophages were CFSE+ on co-culture with viable B cells, while 67.2±2.9% of peritoneal 
macrophages were CFSE+ after co-culture with irradiated B cells. 
These data demonstrate that the activation state of the BMDM used in these assays does 
not have an effect on the level of cell-cell interaction detected, however primary 
peritoneal macrophages show substantially higher levels of interaction with both un-
treated and pre-treated B cells compared to L929 BMDM. Although peritoneal 
macrophages demonstrated differences in interaction levels, and could be argued to be 
a more physiologically relevant tool for investigation, the decision that BMDM would be 
used in further studies was made. This was primarily due to the low numbers of 
peritoneal macrophages that can be isolated, making large scale or repeated in vitro 
studies difficult. It was also decided to use BMDM that had not been stimulated with 
either IFNγ or LPS, as this additional step had no effect on the levels of interaction seen 
between the BMDM and pre-treated B cells.  
4.2.5 Kinetics of early interactions between L929 BMDM and pre-
treated B cells 
Although no difference was seen in the levels of interaction between BMDM and the pre-
treated B cells at the 3hr time-point, studies looking into L929 BMDM interactions with 
viable and apoptotic cells (Chapter 3) indicated that variations in interaction could be 
detected at time-points as early as 15min. Due to these findings, it was decided to look 
into the early kinetics of the L929 BMDM-pre-treated B cell interactions. In vitro assays 
were performed as before with un-stimulated L929 BMDM and RTX pre-treated hCD20tg 
B cells used, but with co-cultures set up for 15, 30 or 60min. The cell ratio used in the 
co-cultures was also altered to 3 B cells:1 BMDM, in at attempt to draw out any 
differences between the B cell pre-treatments that may not have been observable with 
lower B cell numbers.   
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Figure 4.8 Gating strategy for analysis of CFSE+ peritoneal macrophages 
Primary peritoneal macrophages were isolated from WT C57BL/6 mice, co-cultured with CFSE 
stained pre-treated B cells and analyzed for their CFSE signal. The dot plots demonstrate the 
gating strategy used to define peritoneal macrophages and identify the CFSE+ subset. First panel: 
SSC vs. FSC. Second panel: CFSE vs. F4/80. 
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Figure 4.9 Peritoneal macrophages show substantially higher levels of interaction with pre-
treated B cells compared to BMDM, regardless of activation state 
Murine BMDM were grown in cRPMI supplemented with M-CSF containing L929 supernatant. On 
d7, adherent cells (BMDM) or freshly isolated primary murine peritoneal macrophages, were co-
cultured with CFSE stained viable or irradiated pre-treated B cells, at a ratio of 1:1 for 3hr and 
interaction levels analyzed by flow cytometry. 100U IFNγ and/or 100ng/ml LPS was added to 
certain conditions, as shown. (A) Representative FACS plots showing levels of interaction between 
pre-treated, viable or irradiated B cells, and BMDM with or without IFNγ and/or LPS, or peritoneal 
macrophages. Panels: CFSE vs. F4/80. (B) Graphs of pooled data showing the percentage of 
CFSE+ BMDM or peritoneal macrophages after co-culture with viable or irradiated pre-treated 
B cells. RTX: Rituximab. (n=1, 3 replicates) Statistics used: One-way ANOVA performed on each 
full data set in (B) and (C), followed by Bonferroni’s post test, with ** = p<0.01. 
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In the samples tested CFSE+ BMDM were gated on as described previously (Figure 4.6a). 
With the addition of a higher proportion of pre-treated B cells in the co-cultures, the 
percentage of CFSE+ BMDM increased dramatically, resulting in a near completely CFSE+ 
BMDM population for all co-culture conditions investigated (Figure 4.10a, b, d and e). 
Within these co-cultures, a distinct CFSEhi BMDM population became evident and an 
additional CFSEhi gate was introduced (gating rationale detailed in section 3.2.2). It can 
be seen that on co-culture of BMDM with viable pre-treated B cells a substantially higher 
level of interaction occurred between the BMDM and RTX pre-treated cells as early as 
15min in culture, compared to the IgG pre-treatments (RTX pre-treatment: 75.8±1.8% 
CFSEhi BMDM vs. IgG pre-treatment: 46.4±1.6% CFSEhi BMDM) (Figure 4.10c). The RTX 
pre-treated B cells also showed a higher level of interaction with the BMDM, compared 
to the un-treated B cells, however with the numbers of samples looked at the increase 
was not significant. This pattern of enhanced interaction between RTX pre-treated 
B cells and BMDM continued at 30 and 60min. After 30min of co-culture with RTX pre-
treated B cells 75±3.5% of BMDM were CFSEhi, a significantly higher proportion than in 
the un-treated B cell co-cultures (47.5±1.7% CFSEhi BMDM) or the IgG pre-treated co-
cultures (52.7±3% CFSEhi BMDM). After 60min of co-culture, BMDM interaction with RTX 
pre-treated B cells was still significantly higher than that of BMDM with un-treated 
B cells (RTX pre-treated: 59.9±3.7% CFSEhi BMDM v. un-treated: 46.3±2.8% CFSEhi BMDM). 
The BMDM also showed a higher level of interaction with the RTX pre-treated B cells 
compared to the IgG pre-treated B cells, however this increase was not significant. 
When co-cultured with irradiated pre-treated B cells, the BMDM showed significantly 
higher levels of cell-cell interaction with the RTX pre-treated B cells, compared to 
controls, at all early time-points investigated (Figure 4.10f), although overall 
interaction levels were lower than those seen for BMDM with viable B cells. After 15min, 
37.5±3.7% of BMDM co-cultured with RTX pre-treated irradiated B cells were CFSEhi, 
compared to 11.3±3.1% of BMDM cultured with un-treated irradiated B cells and 
13.8±3.4% of BMDM cultured with IgG pre-treated irradiated B cells. After 30min 
interaction levels stayed consistent, with the BMDM showing significantly higher levels 
of interaction with the RTX pre-treated irradiated B cells (48.2±0.1% CFSEhi BMDM), 
compared to those with either un-treated (13.3±1%), or IgG pre-treated (19.4±3.7%), 
B cells. This pattern also continued after 60min of co-culture (RTX pre-treated: 
39.4±4.1% CFSEhi BMDM vs. un-treated: 23.2±0.7% CFSEhi BMDM and IgG pre-treated: 
26.2±2.1% CFSEhi BMDM). 
To further explore the interactions going on between the L929 BMDM and pre-treated 
B cells, and whether surface cell-cell adhesion or B cells internalization was occurring, 
fluorescent microscopy was utilized. CFSE stained, pre-treated viable B cells, were co-
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cultured with CellTracker Violet labelled L929 BMDM for 15, 30 or 60min. The cells were 
then fixed to slides using a cytospin and visualized using a Zeiss ApoTome. The type of 
interaction the B cells were undergoing was categorized as either no interaction, 
surface cell-cell interactions or internalization (Figure 4.11), with the categories 
defined as follows: no interaction – the B cell is not in contact with any BMDM; cell-cell 
interaction – the B cell is in contact with one or more BMDM with the cytoplasm of the 
BMDM seen to be interacting with the B cell; internalization – the B cell is >80% 
surrounded by BMDM cytoplasm.  
After 15min of co-culture, the nature of the interaction between the B cells and L929 
BMDM was not influenced by B cell pre-treatment, with the majority of B cells from all 
pre-treatments undergoing cell-cell surface interactions (un-treated: 70±14.6%, RTX 
pre-treated: 88.2±6.9%, IgG pre-treated: 69.2±10.4%) (Figure 4.12a). After 30min of co-
culture, the predominant form of BMDM-B cells interaction was still surface cell-cell 
interactions for all B cell pre-treatments (un-treated: 79.9±6.3%, RTX pre-treated: 
71.3±10.7%, IgG pre-treated: 84.5±1.8%), however a notably larger proportion of RTX 
pre-treated B cells had been taken up by the BMDM (18±2.1%), compared to both the 
un-treated B cells (1.7±3), and the IgG pre-treated B cells (4.2±2.7%) (Figure 4.12b). 
After 60min of co-culture, the majority of un-treated and IgG pre-treated B cells were 
undergoing cell-cell interactions with the BMDM (79.1±12% and 60.9±12.9%, 
respectively), however far fewer RTX pre-treated B cells were undergoing this type of 
interaction (37.3±16.4%) (Figure 4.12c). At this later time-point, the majority of the 
RTX pre-treated cells were internalized by the BMDM, with a significant increase in the 
internalization of RTX pre-treated B cells seen over the time points investigated (15min: 
4.3±5.5%, vs. 60min: 47.9±18.5%).  
These results confirm the earlier findings in this chapter that RTX pre-treatment of 
B cells affects the way viable and apoptotic B cells interact with L929 BMDM. RTX pre-
treatment of B cells results in a higher levels of overall BMDM-B cell interaction and 
increased uptake of B cells by BMDM. These data also show that this increased 
interaction happens soon after L929 BMDM encounter the RTX pre-treated B cells, with 
cell-cell interactions seen within 15min of co-culture. 
4.2.6 Comparison of ingestion of pre-treated B cells by GM-CSF and 
L929 BMDM 
As discussed in the previous chapter (section 3.2.8), multiple methods of in vitro 
maturation can be used to generate murine BMDM, with considerable variability seen in 
the resultant macrophage phenotype. BMDM generated using L929 cell supernatant are 
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Figure 4.10 Viable and irradiated RTX pre-treated B cells show a significantly higher level of 
interaction with L929 BMDM 
Murine BMDM were grown in cRPMI supplemented with M-CSF containing L929 supernatant. On 
d7 adherent cells were co-cultured with CFSE stained viable or irradiated pre-treated primary 
B cells 15, 30 or 60min, at a ratio of 1 BMDM:3 B cells. Interaction levels were analyzed by flow 
cytometry. (A) Representative FACS plots showing the levels of interaction seen between L929 
BMDM and viable pre-treated viable B cells, co-cultured for either 15, 30 or 60min. Panels: CFSE 
vs. F4/80. (B) Graph of pooled data showing the percentage of CFSE+ BMDM after co-culture with 
viable pre-treated viable B cells. (C) Graph of pooled data showing the percentage of CFSEhi 
BMDM after co-culture with viable pre-treated viable B cells. (D) Representative FACS plots 
showing the levels of interaction seen between L929 BMDM and irradiated pre-treated B cells, co-
cultured for either 15, 30 or 60min. Panels: CFSE vs. F4/80.  (E) Graph of pooled data showing the 
percentage of CFSE+ BMDM after co-culture with viable pre-treated irradiated B cells. (F) Graph of 
pooled data showing the percentage of CFSEhi BMDM after co-culture with irradiated pre-treated 
viable B cells. (n=1, 3 replicates) Stats used: One Way ANOVA performed on each full data set in 
(B) (C) (E) and (F), followed by Bonferroni’s post test, with  * = p<0.05, and ** = p<0.01. 
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Figure 4.11 Scoring guide for L929 BMDM - B cell interactions 
Murine BMDM were grown in cRPMI supplemented with M-CSF containing L929 supernatant. On 
d7, adherent cells were stained with CellTracker violet and co-cultured for 15, 30 or 60min with pre-
treated primary hCD20tg B cells labelled with CFSE. The cells were fixed to slides using a cytospin 
and visualized using a Ziess ApoTome (magnification x63). Interactions between pre-treated B 
cells and BMDM were visualized and the type of interaction the B cells were undergoing was 
categorized as either: no interaction, surface cell-cell interactions or internalization. The categories 
were defined as follows: no interaction – the B cell is not in contact with any BMDM; cell-cell 
interaction – the B cell is in contact with one or more BMDM with the cytoplasm of the BMDM seen 
to be interacting with the B cell; internalization – the B cell is >80% surrounded by BMDM 
cytoplasm. First row: composite images, with CellTracker violet stained BMDM in blue and CFSE 
stained B cells in green. Second row: CellTracker violet stained BMDM. Third row: CFSE stained 
B cells. Scale bar = 10µm. 
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Figure 4.12 Categorizing L929 BMDM interactions with pre-treated B cells 
Pre-treated primary hCD20tg B cells were labelled with CFSE, and co-cultured with CellTracker 
violet stained L929 BMDM for 15, 30 or 60min. The cells were fixed to slides using a cytospin and 
visualized using a Ziess ApoTome (magnification x63). (A) Graph showing the percentage of un-
treated B cells undergoing no interactions, cell-cell interactions or internalization at 15, 30 and 
60min. (B) Graph showing the percentage of RTX pre-treated B cells undergoing no interactions, 
cell-cell interactions or internalization at 15, 30 and 60min. (C) Graph showing the percentage of 
IgG pre-treated B cells undergoing no interactions, cell-cell interactions or internalization at 15, 30 
and 60min. (n=1) Statistics used: One-way ANOVA (Kruskal Wallis) performed on each interaction 
category for each treatment group over time, with *= p<0.05. 
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considered to resemble non-inflammatory, regulatory macrophages found in vivo, while 
BMDM generated using GM-CSF and IL-3 are considered to be a more inflammatory 
population of macrophages. After observing the effect of RTX pre-treatment on B cell 
interactions with L929 BMDM, it was decided to investigate whether RTX pre-treatment 
of B cells had similar effects on their interactions with GM-CSF BMDM. To do this, the 
previous co-culture experiments were repeated using GM-CSF BMDM population. Mature, 
adherent GM-CSF BMDM were co-cultured with CFSE-stained viable or irradiated pre-
treated B cells for 15min, at a ratio of 5:1 (B cells:BMDM). In the previous assays 
undertaken in which BMDM were co-cultured with pre-treated B cells, a cell ratio of 1:1 
was initially used, with this increased to 3:1 (B cells:BMDM) in an attempt to draw out 
any differences between the conditions. These assay were undertaken in parallel to 
those done in Chapter 3, in which a 5:1 (AC:BMDM) ratio was consistently utilised. In 
order to bring these two sections into line, it was decided to use a ratio of 
5 B cells:1 BMDM for all future co-culture assays including pre-treated B cells. 1ng/ml 
LPS stimulation was added to certain conditions during the co-cultures, and L929 BMDM 
used for comparison. As before, interaction levels were analyzed by flow cytometry. 
The proportions of CFSE+ GM-CSF BMDM were consistent throughout the conditions 
investigated, and so analysis was limited to the CFSEhi population (Figure 4.13a). A 
significantly greater percentage of CFSEhi GM-CSF BMDM could be seen on co-culture 
with RTX pre-treated viable B cells compared to controls (RTX pre-treatment: 19.9±2.2% 
vs. no-treatment: 8.6±2.1%, and IgG pre-treated: 6.6±1%) (Figure 4.13b). When co-
cultured in the presence of 1ng/ml LPS, this pattern of interaction between GM-CSF 
BMDM and pre-treated viable B cells was unaltered, with significantly more interaction 
seen between the GM-CSF BMDM and the RTX pre-treated viable B cells (20.8±3%), 
compared to the levels seen on co-culture with either the un-treated B cells (13.8±1.9%) 
or the IgG pre-treated B cells (8.4±2.6%). When irradiated B cells were used in the co-
cultures conditions with GM-CSF BMDM, RTX pre-treatment again significantly increased 
the proportion of CFSEhi GM-CSF BMDM, both in the presence of LPS (RTX pre-treatment: 
22.3±3.6% vs. un-treated: 10.8±1.7% and IgG pre-treated: 9.8±1.2%) and the absence 
(RTX pre-treatment: 21.8±3% vs. un-treated: 8.2±1.5% and IgG pre-treated: 8.7±1.3%) 
(Figure 4.13c). 
As with the previous co-culture studies undertaken utilizing L929 BMDM, the overall 
proportion of CFSE+ L929 BMDM was consistent throughout all conditions (Figure 4.14a), 
however enhanced cell-cell interactions were seen between the L929 BMDM and RTX 
pre-treated B cells (CFSEhi L929 BMDM). Significantly higher proportions of CFSEhi L929 
BMDM could be seen on co-culture with RTX pre-treated B cells, compared to controls, 
when either viable or irradiated B cells were used for co-culture, and the presence of 
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LPS did not alter this pattern of interaction (viable B cells - RTX pre-treated: 55.1±3.7% 
vs. un-treated: 36±4.5% and IgG pre-treated: 38.5±3%, irradiated B cells - RTX pre-
treated: 57.3±5.6% vs. un-treated: 35.8±6.7% and IgG pre-treated: 36.2±4.9%) (Figure 
4.14b and c). 
Although the same pattern of interaction was seen on co-culture of BMDM and pre-
treated B cells, regardless of the method of BMDM generation (GM-CSF vs.L929), 
differences were seen in the relative proportions of the BMDM population undergoing 
interactions. When co-cultured with RTX pre-treated viable B cells in the absence of 
LPS, 19.9±2.2% of GM-CSF BMDM were CFSEhi, while 55.1±3.7% of L929 BMDM stained 
CFSEhi, with considerably lower percentages of CFSEhi BMDM consistently observed in all 
conditions containing GM-CSF BMDM, compared to the equivalent co-culture condition 
containing L929 BMDM.  
To determine whether cell-cell interactions between BMDM and RTX pre-treated B cells 
had an effect on the BMDM phenotype, the levels of IL-10 and IL-12 in the cell culture 
supernatants were investigated. The relative levels of production of these cytokines can 
give an indication of the phenotype of the macrophages present, with M1 cells 
producing high levels of IL-12 and minimal IL-10, while M2 cells produce moderate to 
high levels of IL-10, and very little IL-12 [17]. On culture of GM-CSF BMDM alone or with 
either viable or irradiated pre-treated B cells in the absence of LPS, no IL-10 could be 
detected for any of the conditions investigated (Figure 4.15a). On addition of LPS, the 
GM-CSF BMDM produced moderate levels of IL-10, however co-culture with pre-treated 
viable B cells did not alter the levels compared to GM-CSF BMDM cultured alone 
(179±18pg/ml IL-10), with GM-CSF co-cultured with un-treated B cells producing 
127±12pg/ml, with RTX pre-treated B cells producing 147±40pg/ml IL-10 and those co-
cultured with IgG pre-treated B cells producing 126±27pg/ml IL-10 (Figure 4.15a, left 
panel). Co-culture with irradiated pre-treated B cells in the presence of LPS also did not 
alter the amounts of IL-10 secreted by the GM-CSF BMDM compared to those cultured 
alone (un-treated irradiated B cells: 170±63pg/ml IL-10, RTX pre-treated irradiated 
B cells: 171±76pg/ml IL-10, and IgG pre-treated irradiated B cells: 176±50pg/ml) (Figure 
4.15a, right panel). As with the GM-CSF BMDM, no IL-10 production by L929 BMDM could 
be detected in the absence of LPS (Figure 4.15b). On addition of LPS, the L929 BMDM 
produced high levels of IL-10 (1065±202pg/ml), however the addition of pre-treated B 
cells, either viable or irradiated, did not alter IL-10 production by the BMDM. When IL-
12 production by GM-CSF BMDM was investigated, it was seen that on culture of the 
BMDM alone, in the absence of LPS minimal levels of this cytokine were produced 
(36±11pg/ml), and that co-culture with either viable or irradiated pre-treated B cells 
had no effect on IL-12 production (Figure 4.15c). On addition of LPS, the amount of
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Figure 4.13 Viable and irradiated RTX pre-treated B cells show a significantly higher level of 
interaction with GM-CSF BMDM in the presence or absence of LPS 
Murine BMDM were grown in cRPMI supplemented with GM-CSF and IL-3. On d7 adherent cells 
were co-cultured with CFSE stained viable or irradiated, pre-treated primary B cells for 15min, at a 
ratio of 1 BMDM:5 B cells, in the presence or absence of 1ng/ml LPS. Interaction levels were 
analyzed by flow cytometry. (A) Representative FACS plots showing the levels of interaction seen 
between GM-CSF BMDM and viable pre-treated B cells, co-cultured for either 15, 30 or 60min. 
Panels: CFSE vs. F4/80. (B) Graph of pooled data showing the percentage of CFSEhi GM-CSF 
BMDM after co-culture with viable pre-treated B cells. (C) Graph of pooled data showing the 
percentage of CFSEhi GM-CSF BMDM after co-culture with irradiated pre-treated B cells. (Viable 
B cells n=1, irradiated B cells n=2) Statistics used: One Way ANOVA performed on each full data 
set in (B) and (C), followed by Bonferroni’s post test, with *** = p<0.001. 
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Figure 4.14 Viable and irradiated RTX pre-treated B cells show a significantly higher level of 
interaction with L929 BMDM in the presence or absence of LPS 
Murine BMDM were grown in cRPMI supplemented with M-CSF containing L929 supernatant. On 
d7 adherent cells were co-cultured with CFSE stained viable or irradiated pre-treated primary 
B cells for 15min, at a ratio of 1 BMDM:5 B cells, in the presence or absence of 1ng/ml LPS. 
Interaction levels were analyzed by flow cytometry. (A) Representative FACS plots showing the 
levels of interaction seen between L929 BMDM and viable pre-treated B cells, co-cultured for either 
15, 30 or 60min. Panels: CFSE vs. F4/80. (B) Graph of pooled data showing the percentage of 
CFSEhi L929 BMDM after co-culture with viable pre-treated B cells. (C) Graph of pooled data 
showing the percentage of CFSEhi L929 BMDM after co-culture with irradiated pre-treated B cells. 
(n=1) Statistics used: One Way ANOVA performed on each full data set in (B) and (C), followed by 
Bonferroni’s post test, with *** = p<0.001. 
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Figure 4.15 Cytokine production by GM-CSF and L929 BMDM after co-culture with pre-
treated B cells 
Un-stimulated and 1ng/ml LPS stimulated murine GM-CSF BMDM or L929 BMDM were co-
cultured with viable or irradiated pre-treated B cells overnight, cell culture supernatants collected, 
and IL-10 and IL-12 production quantified by ELISA. (A) Graph showing IL-10 production by GM-
CSF BMDM after co-culture with viable or irradiated pre-treated B cells, in the presence and 
absence of LPS. (B) Graph showing IL-12 production by GM-CSF BMDM after co-culture with 
viable or irradiated pre-treated B cells, in the presence and absence of LPS. (C) Graph showing IL-
10 production by L929 BMDM after co-culture with viable or irradiated pre-treated B cells, in the 
presence and absence of LPS. (D) Graph showing IL-12 production by L929 BMDM after co-
culture with viable or irradiated pre-treated B cells, in the presence and absence of LPS. (n=1, 
3 replicates)  
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IL-12 secreted by GM-CSF BMDM cultured alone increased markedly to 426±44pg/ml. Co-
culture of GM-CSF BMDM with either viable or irradiated pre-treated B cells in the 
presence of LPS did not alter the levels of IL-12. Similar levels of IL-12 were produced 
by L929 BMDM cultured in the presence of LPS, with 551±66pg/ml IL-12 detected (Figure 
4.15d). No difference in the levels of IL-12 produced by L929 BMDM were observed on 
co-culture with either viable or irradiated pre-treated B cells, in the presence of LPS. 
Together these findings show that in this experimental set up, GM-CSF BMDM undergo 
lower levels of interaction with B cells than L929 BMDM, however both L929 and GM-CSF 
BMDM experience enhanced cell-cell interaction with RTX pre-treated B cells. It was 
also established that in both inflammatory and non-inflammatory conditions, the 
increased interactions observed between the BMDM and RTX pre-treated B cells had no 
effect on the levels of IL-10 or IL-12 produced, indicating that the increased interaction 
does not affect the phenotype of either population of BMDM. 
4.2.7 Effects of type-I and type-II anti-CD20 antibody pre-treatment on 
the interaction of B cells with BMDM  
Anti-CD20 antibodies are defined as either type-I or type-II antibodies, dependent on 
their ability to redistribute CD20 into lipid rafts upon binding, with type-I antibodies, 
such as RTX, able to induce this redistribution of CD20. Type-II antibodies, such as 
Tositumomab (B1), do not have this effect on CD20, and it has been shown that binding 
of B cells by type-II antibodies results in far less modulation of CD20 from cell surface, 
compared to type-I anti-CD20 antibodies [251]. We wanted to explore whether the 
ability of RTX to redistribute CD20 played a role in the increased interactions observed 
between L929 BMDM and RTX pre-treated B cells. To do this, the previous BMDM co-
culture assay was repeated, with viable CFSE-stained B cells incubated with either the 
type-I murine RTX antibody (mRTX), the type-II murine Tositumomab antibody (mB1), 
murine polyclonal IgG (mIgG) or left un-treated. These pre-treated B cells were then co- 
cultured with L929 BMDM for 15min, at a 5:1 ratio (B cells:BMDM) and the resultant 
interaction levels analyzed by flow cytometry.  
 
The proportions of CFSE+ L929 BMDM were consistent throughout the conditions 
investigated, and so analysis was limited to the population of L929 BMDM undergoing 
elevated levels of B cell interaction – the CFSEhi BMDM population (Figure 4.16a). As seen 
throughout the chapter with standard RTX, co-culture of L929 BMDM with mRTX treated 
B cells resulted in a significantly larger proportion of CFSEhi BMDM, compared to those 
co-cultured with either un-treated or IgG pre-treated B cells (Figure 4.16b) (mRTX pre-
treated: 44.7±2.3% CFSEhi BMDM vs. un-treated: 28.6±8.8% CFSEhi BMDM and IgG pre-
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Figure 4.16 Comparison of the effects of type-I and type-II anti-CD20 antibodies on the 
interaction of BMDM and pre-treated B cells 
Murine BMDM were grown in cRPMI supplemented with M-CSF containing L929 supernatant. On 
d7 adherent cells were co-cultured with CFSE stained viable pre-treated primary B cells for 15min 
at a ratio of 1 BMDM:5 B cells. Interaction levels were analyzed by flow cytometry. 
(A) Representative FACS plots showing the levels of interaction seen between L929 BMDM and 
viable B cells either given no pre-treatment (nt) or pre-treated with murine RTX (mRTX), murine 
Tositumomab (mB1) or murine polyclonal IgG (IgG). Panels: CFSE vs. F4/80. (B) Graph of pooled 
data showing the percentage of CFSEhi L929 BMDM after co-culture with pre-treated B cells (n=1) 
Statistics used: One Way ANOVA performed on complete data set, followed by Bonferroni’s post 
test, with a value of p<0.05 considered significant and  * = p<0.05. 
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treated: 30±2.2% CFSEhi BMDM) Co-culture of L929 BMDM with mB1 treated B cells 
resulted in a significantly larger proportion of CFSEhi BMDM (50.8±2.5%), compared to 
those co-cultured with either un-treated or IgG pre-treated B cells. However, no 
difference was seen in the proportion of L929 BMDM with B cells pre-treated with either 
mRTX or mB1. 
This study demonstrates that in this assay system, both type-I and type-II anti-CD20 
antibody pre-treatment of B cells have the ability to enhance their interactions with 
L929 BMDM, and that the type of anti-CD20 antibody used does not influence these 
interactions. 
4.3 Discussion 
• In this chapter we went on to investigate the ability of RTX treatment to alter B 
cell interactions with other cells prior to depletion, and the possibility that 
these altered interactions could regulate responses by macrophages.  
• RTX pre-treated B cells underwent increased levels of interaction with BMDM, 
resulting in the enhanced phagocytosis of RTX-coated B cells. This increased 
interaction and uptake did not affect BMDM function, as determined by cytokine 
production.  
• These findings show that RTX bound B cells do not modulate BMDM cytokine 
responses. Investigation of a wider range of BMDM functional outcomes would 
enable us to determine whether other biologically relevant changes are 
occurring after these interactions. 
For the in vitro assays primary B cells isolated from our in-house colony of hCD20tg 
C57BL/6 mice were used. Work by Beers et al has shown that hCD20tg B cells internalize 
surface hCD20 on binding of an IgG2a version of Rituximab (Rit-m2a), resulting in an 
accumulation of internalized antibody, with approximately 50% of their surface hCD20 
internalized after 2hr in culture, and around 80% internalized by 6hr [100]. However, 
work by Beum and colleagues utilizing the standard IgG1 form of RTX and the 38C13-
CD20+ B cell line demonstrated a far slower rate of internalization, with less than 25% of 
surface RTX having undergone internalization after 2hr, as determined by flow 
cytometry [252]. Due to the discrepancies seen in RTX internalization between different 
CD20+ cell populations, and the variations in protocols used, the details of RTX 
internalization by hCD20tg B cells were investigated prior to co-culture assays being 
undertaken.  
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Flow cytometry was used to examine the RTX-mediated internalization of CD20 from the 
surface of hCD20tg B cells, with a fluorescently labeled conjugate comprising of the 
standard IgG1 form of RTX and AlexaFluor488, utilized. After incubation of hCD20tg B 
cells with RTX-488, quenching of cell surface fluorescence allowed differentiation of the 
signal from internalized RTX-488 from that of total RTX-488, allowing the signal from 
the surface bound RTX to be calculated, giving relative values for internal vs. surface 
bound RTX. To enable this type of analysis, removal of cell surface fluorescence is 
required. Trypan blue quenching [246-248,253,254], and acid stripping protocols 
[249,250,255-257] were investigated on a range of commercially available FACS 
antibodies. Trypan quenching resulted in very little decrease in the signal of the 
antibodies tested, with acid stripping protocols showing moderate to high success in the 
removal of cell surface fluorescence. However, before attempted optimization of the 
acid stripping protocol was pursued, a specific AlexaFluor-488 quenching antibody was 
tested [180]. Incubation of RTX-488 labeled B cells with the anti-488 antibody resulted 
in the dramatic reduction of AF488 MFI, with no detrimental effect on cell viability, and 
so it was decided to utilize this approach of removal of AF488-specific cell surface 
fluorescence in the RTX internalization studies. 
On incubation of hCD20tg B cells with the standard IgG1 form of RTX, a similar rate of 
RTX internalization was observed compared to that seen by Beers et al on incubation of 
hCD20tg B cells with the IgG2a form of RTX [100]. With the conditions used for the 
current study, maximal surface binding of hCD20 by RTX was not achieved until after 
1hr of culture, as evidenced by the increasing total MFI seen up to this time. The 
decrease in the percentage of B cells measuring RTX-488+ after treatment with the anti-
488 antibody at 0–30min indicates that at these time points a significant proportion of 
B cells had not yet internalized any fluorescently labeled RTX, while from the 1hr time-
point onwards, the percentage of RTX-488+ B cells was consistent before and after 
treatment with anti-488 antibody, implying that after this time some level of RTX 
internalization had occurred in all B cells. After one hour in culture the majority of 
bound RTX was still present on the surface of the hCD20tg B cells, however from 3hr 
onwards >75% had been internalized. A small decrease in internal fluorescence was seen 
at 24hr, indicating that degradation of the RTX-488 conjugate may have begun. 
Fluorescent microscopy confirmed the flow cytometric data, illustrating the increase in 
total RTX-488 binding observed over the first 30min of culture. 
Along with ADCC and CDC, one of the mechanisms of RTX-mediated B cell depletion is 
the direct induction of apoptosis in B cells. If the in vitro incubation of hCD20tg B cells 
with RTX resulted in an increased number of apoptotic B cells compared to controls, any 
differences seen in the interactions of BMDM and RTX pre-treated B cells could 
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theoretically be attributed to the increased apoptotic cells present, rather than to the 
RTX pre-treated B cells.  Previous work by Kamburova et al has shown that addition of 
RTX alone to in vitro cultures of human B cells does not increase the occurrence of cell 
death, with the presence of complement proteins as well as RTX required for cell death 
to occur [245]. In the present cultures of hCD20tg B cells no increase in B cell death 
observed in cultures incubated with RTX compared to controls, with the majority of 
cells still viable after 8hr in culture, in line with previous findings. 
Once the interaction of hCD20tg B cells with RTX was elucidated, in vitro B cell-BMDM 
co-culture assays were undertaken. It has previously been shown that RTX stimulation 
alters B cell interaction with T cells, resulting in the skewing of T cell populations to 
more Th2-like [245] and less Th17-like [244] phenotypes, as well changing the subclass 
of immunoglobulin produced by B cells [244]. With the current assay we wanted to 
explore whether RTX binding to B cells has an effect on their interactions with 
macrophages, with BMDM used as the model macrophage. 
In the co-culture assays undertaken, when cultured at a BMDM-B cell ratio of 1:1, 
increased interaction between L929 BMDM and CFSE-labeled RTX pre-treated B cells was 
evident compared to controls, but not necessarily significant. The levels of interaction 
between peritoneal macrophages and pre-treated B cells were also investigated, with 
peritoneal macrophages showing a far greater level of B cell interaction compared to 
that of the L929 BMDM. Mouse peritoneal macrophages are comprised of two main 
subsets: an ‘immature’ population that are F4/80+, express high levels of FcRs and 
demonstrate an elevated phagocytic capacity; and a smaller ‘mature’ population, with 
a reduced expression of F4/80 and FcRs, and a diminished phagocytic capacity [258]. 
Although all cells isolated from the peritoneal cavity were included in the co-culture 
conditions, analysis was limited to the F4/80+ population to exclude skewing of the 
results by non-macrophage cell types. However, by focusing on the F4/80+ population, 
the analysis was concentrated on the ‘immature’, highly phagocytic peritoneal 
macrophage subset, which could explain the increased levels of CFSE+ macrophages seen 
compared to the BMDM investigated. Comparison of murine F4/80+ peritoneal 
macrophages to murine splenic macrophages has also highlighted the enhanced 
phagocytic capacity of this macrophage population. In a study by Liu et al, the ability of 
peritoneal macrophages to take-up red blood cells and T cells during in vitro co-culture 
was significantly greater than splenic macrophages [259]. These peritoneal macrophages 
were shown to express lower levels of MHC II and co-stimulatory molecules, but higher 
levels of the pattern recognition receptors TLR2 and TLR4, compared to the splenic 
macrophages [259]. These results indicate that peritoneal macrophages may be 
specialized for the recognition and clearance of pathogens and other stimuli, while 
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other subsets of macrophages, such as splenic macrophages, are more proficient at the 
presentation of antigen and stimulation of effector responses. Although in the present 
in vitro assay, the interactions of peritoneal macrophages were being compared to 
BMDM, this previous work demonstrates the enhanced phagocytic capacity of peritoneal 
macrophages compared to other macrophage subsets. 
Another explanation for the increased interaction seen between the peritoneal 
macrophages and B cells, compared to that of the L929 BMDM and B cells is the differing 
origin of these cell populations. Macrophages express a wide array of PRRs allowing 
detection of AC, with different macrophage populations expressing different 
combinations of these receptors. Much work is still needed to fully understand the 
relative contribution of these receptors to AC uptake and their influence on subsequent 
cellular responses, however recent work however has shown that tissue-resident and 
monocyte-derived macrophages express different PS receptors [260], with tissue-
resident macrophages more efficient at clearing AC in a murine model of thioglycollate-
induced peritonitis [260]. Tissue-resident macrophages have also been shown to 
sequester bridging molecules required for AC uptake by inflammatory monocyte-derived 
macrophages, effectively limiting their contribution to AC clearance [260]. This 
difference in AC uptake was proposed by the authors to be a ‘sorting system’ for AC, 
helping to maintain tolerance by encouraging non-inflammatory AC uptake by M2-like 
tissue-resident macrophage populations, rather than immunogenic uptake by 
inflammatory macrophage populations. Murine F4/80+ peritoneal macrophages have 
been shown to be tissue-resident self-renewing cells, and the population is maintained 
independent of circulating monocytes [15]. L929 BMDM, on the other hand, are 
generated from bone marrow precursors, following the MPS model of development, and 
more closely emulate inflammatory monocyte-derived macrophages found in vivo. As 
such, the increased level of interaction seen in co-cultures containing the peritoneal 
macrophages may not be due to their maturation state, but rather due to their role as 
tissue-resident macrophages, predominantly focused around tissue homeostasis and 
repair [reviewed in [261], and including the enhanced uptake of AC. 
When the peritoneal macrophages were co-cultured with the various pre-treated B cells 
conditions no difference in the interaction levels was observed, however this may have 
been due to the small numbers of repeats undertaken. Isolating substantial numbers of 
peritoneal macrophages proved to be challenging, and although a difference may have 
emerged with further investigation, it was decided to move away from the use of this 
primary cell population. This study also highlighted that IFNγ and/or LPS stimulation of 
the BMDM, and therefore the activation state of the BMDM, had no effect on the levels 
of interaction seen in the vast majority of conditions. This confirmed previous work by 
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Leidi et al, in which it was shown that IFNγ and LPS treatment of human monocyte-
derived macrophages had no effect on the uptake of RTX pre-treated B-CLL (B-chronic 
lymphocytic leukemia) cells by this macrophage population [227].  
In an effort to enhance any differences between the pre-treatments, the ratio of B cells 
to BMDM in the co-cultures was increased. When higher ratios of B cells to L929 BMDM 
(3:1 or 5:1) were used, the majority of BMDM from all conditions were CFSE+ after co-
culture, indicating some level of B cell interaction had occurred in all conditions. 
However in these higher ratio co-cultures a distinct CFSEhi population also became 
apparent, as seen in the co-culture assays undertaken in Chapter 3. The CFSElo 
population of BMDM in these higher ratio cultures was postulated to be due to the 
transfer of CFSE via tunneling nanotubes, although this cannot conclusively be stated 
without further investigation. As the rational for this theory was presented in depth in 
Chapter 3 (section 3.3), it will not be discussed here. However, as a result of this 
theory, it was decided that in these cultures the CFSEhi BMDM population would more 
accurately represent the BMDM undergoing prolonged, and therefore potentially more 
influential, cell-cell interactions, or those with ingested B cells, and as such it is the 
CFSEhi population that has been focused on for analysis.  
A significant increase in the proportion of CFSEhi L929 BMDM was consistently observed 
when co-cultured with RTX pre-treated B cells, compared to controls, with this increase 
seen over a variety of time-points, ranging from 15min - 3hr of co-culture. To expand on 
the data acquired by flow cytometry, fluorescent microscopy was utilized to visualize 
the early interactions between the L929 BMDM and pre-treated B cells, and explore 
whether the enhanced interaction of RTX pre-treated B cells with BMDM observed was 
due to increased cell-cell adhesion, or whether increased phagocytosis of B cells was 
also involved. No differences were seen between conditions at the earliest time point, 
however by 30min of co-culture a substantial increase in the percentage of 
phagocytosed RTX pre-treated B cells was visible compared to the other B cell 
conditions, with this increase in uptake also apparent at the 60min time-point. The 
enhanced phagocytosis observed may be a RTX-specific event, however it could also be 
due to the opsonization of the B cells by RTX, regardless of RTX specificity or function. 
Cells can undergo opsonization by antibodies of a range of specificities, as well as 
complement components, with this coating of the cell targeting it for clearance by 
phagocytes. Macrophages express a variety of cell surface receptors to allow them to 
detect these opsonized cells, including members of the Fcγ family of receptors, which 
bind the Fc portion of IgG molecules, promoting the uptake and subsequent destruction 
of antibody opsonized cells. Antibodies of the IgG1 and IgG3 subclasses are the most 
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efficient for promoting phagocytosis, with RTX an IgG1 antibody. Therefore, along with 
any specific signals that may arise from RTX binding to B cells, the cell will also be 
detected as an opsonized cell by phagocytes. As the IgG used for the control B cell pre-
treatment was a polyclonal IgG preparation, it would not bind to the B cells in any 
substantial amount due to the mix of antibody specificities present in the preparation, 
and as a result these cells should not become opsonized. The RTX internalization studies 
undertaken in this chapter demonstrate that on B cell incubation with RTX, the majority 
of bound RTX is present on the surface of the cell at all time-points from 15min – 1hr, 
effectively opsonizing the cell. By the 3hr time-point almost 75% of the bound RTX was 
internalized by the B cell, however the amount of surface RTX remaining may have been 
enough to allow recognition as an opsonized cell by the BMDM. The kinetics of 
phagocytosis observed in the present microscopy study fits with that of opsonized cells, 
with almost no B cell uptake by L929 BMDM at 15min, low levels at 30min, and an 
substantial proportion seen after 60min of co-culture.  
In an attempt to dissect whether this increased phagocytosis of RTX pre-treated B cells 
was a RTX-specific effect or was just due to antibody opsonization, the monoclonal 
antibody Tositumomab (B1) was used as an additional B cell pre-treatment. 
Tositumomab is a type-II anti-CD20 antibody, and does not cause the redistribution of 
CD20 into lipid rafts, as opposed to type-I anti-CD20 antibodies, such as RTX. In a range 
of in vitro cellular assays using human peripheral blood cells and a variety of B cell 
lines, Tositumomab has been shown to be a potent inducer of ADCC, compared to RTX, 
but less capable of stimulating CDC [240] and shown to be ineffective at recruiting 
complement components [262]. In SCID mice adoptively transferred with the EHRB 
B cell line, complement depletion prior to antibody infusion had no effect on B1-
mediated B cell depletion, whereas RTX-mediated depletion was markedly reduced in 
the absence of complement proteins [262]. Although RTX and B1 are both anti-CD20 
antibodies, the different mechanisms of B cell clearance that result from RTX and B1 
treatment indicates these mAbs have differing modes of action within the body. On 
comparison of L929 BMDM interaction with RTX and B1 pre-treated B cells it could be 
seen that pre-treatment with either antibody resulted in significantly more interaction 
with BMDM versus the untreated or IgG pre-treated B cells. However, no difference was 
seen between the levels of interaction resulting from RTX or B1 pre-treatment, 
demonstrating that the increased BMDM-RTX pre-treated B cell interactions are likely 
not a result of a RTX-specific effect. These results indicate that the enhanced 
interactions may be due to B cell opsonization, however they may due to a CD20-
mediated effect. As both RTX and B1 are anti-CD20 antibodies, it is possible that the 
binding of these antibodies to their target molecule induces a change in the B cell, 
enhancing its ability to interact with the BMDM. The addition of a further co-culture 
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condition, containing B cells pre-treated with an antibody specific for different B cell 
surface marker, such as CD19, would help to dissect whether this is the case, or 
whether B cell opsonization by any specificity of antigen would have the same effect on 
interaction levels. 
To investigate whether RTX pre-treated B cells also undergo enhanced interaction with 
a more inflammatory population of macrophages, the interaction of pre-treated B cells 
with GM-CSF BMDM and L929 BMDM was compared. There is substantial variability in 
macrophage phenotypes associated with the various methods of BMDM generation, with 
a large body of work looking into the phenotype and function of these different subsets, 
while generation of BMDM using recombinant GM-CSF produces an M1-like population of 
macrophages, which resemble the classically activated, inflammatory cell population 
found in vivo. Generation of BMDM using L929 supernatant results in a more regulatory, 
M2-like population of macrophages.  
As with L929 BMDM, the M1-like GM-CSF BMDM undergo enhanced cell-cell interactions 
with RTX pre-treated B cells compared to controls. However, in the in vitro assay 
undertaken, lower levels of interaction were seen between B cells and the GM-CSF 
BMDM. The M2-like L929 BMDM have previously been shown to be highly phagocytic in 
comparison to GM-CSF BMDM [227], and as such, reduced uptake of B cells during co-
culture by GM-CSF BMDM could be attributed to intrinsic cell characteristics, rather than 
a consequence of the assay.  
Interestingly, at the 15min time-point, co-culture of either GM-CSF or L929 BMDM with 
irradiated pre-treated B cells did not alter the levels of cell-cell interaction observed, 
when compared to co-culture with viable pre-treated B cells. Only during the 3hr co-
cultures of L929 BMDM and pre-treated B cells was an increase in BMDM interaction with 
irradiated pre-treated B cells observed, compared to that seen in the equivalent viable 
pre-treatment conditions. One of the chief roles of macrophages in vivo is the rapid 
clearance of apoptotic cells from the system, and as apoptosis of the B cells is the 
outcome of irradiation, it might be expected that the interaction levels seen between 
BMDM and the irradiated B cells would consistently be greater than those between 
BMDM and viable B cells. The comparable levels of interaction seen after short-term co-
culture are not restricted to viable/apoptotic B cells, as work in the previous chapter 
looking into BMDM–AC interactions also demonstrates comparable levels of interaction 
between BMDM and viable or apoptotic T cells, and viable or apoptotic thymocytes. 
Although these findings initially seem to disagree with previous work in the apoptotic 
field, this is not necessarily the case. At the early 15min time-point, BMDM and viable 
B cells underwent surface interactions, as detailed by the fluorescent microscopy study 
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undertaken in this chapter, however these interactions would not necessarily lead to 
phagocytosis of these B cells. Work by Brown et al has demonstrated that THP-1 
macrophages will bind both viable and apoptotic neutrophils through homotypic 
adhesion of CD31 expressed on the surface of the cells, however subsequent CD31-
mediated signalling results in active detachment of the viable, but not apoptotic 
neutrophils [151]. These results demonstrate that macrophage recognition of a cell as 
either viable or apoptotic occurs through surface interactions, prior to the ingestion of 
those cells that are detected as being apoptotic.  
Cell adhesion molecules (CAMs) could also mediate the interactions seen between viable 
B cells and BMDM. CAMs are surface expressed proteins responsible for cell-cell 
interactions, as well as leukocyte migration and homing in vivo. Adhesion molecules can 
be classified into three main groups: selectins, integrins and the immunoglobulin 
superfamily; and are classified depending on their molecular structure. B cells and 
macrophages express various integrins and immunoglobulin superfamily members, with 
many of these molecules acting as ligands for one another. For example, the 
immunoglobulin superfamily member ICAM-3 (intercellular adhesion molecule-3) is 
constitutively expressed by all leukocytes [reviewed in [148], and is able to interact 
with LFA-1 (leukocyte functional antigen-1) expressed by both B cells and macrophages. 
Another immunoglobulin superfamily member, ICAM-1, is expressed at low levels by 
resting B cells and macrophages, however on activation with inflammatory cytokines its 
expression is up-regulated, whereupon it can interact with LFA-1 [263], as well as the 
integrin Mac-1 (αMβ2) [264], expressed by macrophages. 
This initial stage of cell recognition by macrophages could account for the equivalent 
BMDM interaction levels with viable and apoptotic B cells seen after 15min of co-
culture, but the increased BMDM interaction with apoptotic B cells seen after 3hr. Very 
few studies into apoptotic cells directly compare the rate or amount of AC interaction 
to that of viable cells, with none found looking at as early a time-point, however the 
increased interaction of BMDM and apoptotic B cells after 3hr of co-culture fits with the 
previous literature found [125,151]. However, as discussed in Chapter 3, these results 
may potentially be explained by the BMDM interacting with contaminating apoptotic 
B cells in the ‘viable’ B cell conditions. If this is indeed the case, a multitude of 
receptors could be involved with the BMDM-B cell interactions seen. On apoptosis, cells 
expose a variety of neo-epitopes collectively termed ACAMPs, with phagocytes able to 
recognize these directly through PRRs, or indirectly through adaptor molecules (Figure 
1.2).  
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In an attempt to ascertain whether the increased cell-cell interactions observed had any 
functional outcome, ELISAs were undertaken to investigate the levels of pro- and anti-
inflammatory cytokines produced by the BMDM after overnight co-culture. We 
hypothesize that one of the mechanisms of action of RTX may be the re-introduction of 
a temporary tolerance to the immune system through indirect effects of RTX-mediated 
B cell depletion on other cells of the immune system, such as an effect on the 
interactions of RTX-bound B cells prior to their clearance from the system. To re-
introduce tolerance, an anti-inflammatory environment would need to be established as 
a result of RTX treatment in order to halt the already present systemic inflammation 
seen in RA. Macrophages are hugely plastic cells, and are able to alter their phenotype 
in response to different environmental stimuli, with the anti-inflammatory cytokines IL-
10 and TGF-β both produced by macrophages under certain conditions, contributing the 
resolution of inflammation. Quantification of cytokine secretion, in combination with 
the identification of specific surface markers, can also be used to categorize 
macrophages into particular subgroups, with the levels of IL-10 and IL-12 secreted 
commonly used to help in the identification of macrophage subsets. Each subset 
produces different ratios of these mediators: classically activated, inflammatory 
macrophages are known to produce high levels of pro-inflammatory IL-12 and low levels 
of IL-10; whereas regulatory macrophages produce high levels of the anti-inflammatory 
cytokine IL-10, while down-regulating their production of IL-12; and wound-healing 
macrophages produce low levels of both IL-10 and IL-12 [reviewed in [17]. By 
quantifying the levels of cytokines produced by the BMDM in response to RTX pre-
treated B cells, it is possible to start to discern whether RTX binding to B cells alters the 
signals received by BMDM on cell-cell interaction, and alterations in the production of 
these mediators could indicate a skewing of the BMDM to a more anti-inflammatory 
phenotype. 
The levels of IL-10 and IL-12 produced by the GM-CSF and L929 BMDM cultured alone in 
the presence of LPS were in line with those expected. The M1-like GM-CSF BMDM 
produced minimal levels of IL-10 and high levels of IL-12, while the M2-like L929 BMDM 
produced high levels of IL-10, with comparatively low levels of IL-12. However, no 
change in IL-10, IL-12 or TGF-β production could be seen on co-culture of either BMDM 
population with RTX pre-treated B cells, compared to BMDM cultured alone, and this 
was true when either viable or irradiated B cells were used for the co-cultures. 
Although not conclusive, the data generated from these cytokine ELISAs indicates that 
the interaction of RTX pre-treated B cells with BMDM does not enhance anti-
inflammatory functions by the macrophages, or induce a change in phenotype in these 
cells.  
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There is some disparity in the literature as to whether RTX treatment has a widespread 
effect on cytokine levels. In a study looking at the response to a single dose of RTX by 
dialysis-dependent renal failure patients, levels of serum TGF-β were seen to increase 
after treatment in patients receiving high-dose RTX, although the results were highly 
variable and a small sample size used. Moreover, an increase in the pro-inflammatory 
cytokine IL-6 was also documented in the majority of these patients [265].  A longer-
term study in RA patients, looking at serum cytokine levels after B cell depletion 
therapy, showed that multiple rounds of RTX treatment progressively reduced serum 
levels of the inflammatory cytokines IL-15 and IL-17A [266]. Findings by Bouaziz and 
colleagues however, show that B cell depletion in C57BL/6 mice using anti-murine CD20 
antibodies does not alter serum cytokine levels [267]. Levels of IL-1, IL-2, IL-4, IL-5, IL-
6, IL-10, IL-12, IL-13, IL-17, TNFα, IFNγ, GM-CSF, and TGF-β1 were measured for 7 days 
post RTX treatment, and compared to serum collected from the mice prior to depletion, 
with no change seen in the levels of any cytokine investigated [267]. Recent work in 
which a single intra-operative dose of RTX was given to renal transplant patients, 
supported the finding of a lack of systemic effect of B cell depletion on cytokine 
production by immune cells [268]. In this study, the amounts of IL-1β, IL-6, IL-17, IL-22, 
TNFα, and IFNγ produced ex vivo by peripheral blood mononuclear cells isolated before 
or after RTX-treatment were investigated, with levels unchanged up to one month after 
treatment [268]. Although these papers highlight the variation in the literature as to the 
effects of RTX-mediated B cell depletion on serum cytokine production, the work in this 
chapter shows that co-culture of RTX pre-treated B cells and BMDM does not modulate 
the production of IL-10, IL-12 or TGF-β under the experimental conditions used. 
Interestingly, apoptotic B cells had no effect on cytokine production by BMDM, 
regardless of RTX pre-treatment. The immunosuppressive effects of AC on cytokine 
production have repeatedly been demonstrated under a range of conditions 
[157,171,218,232,248].  None of the studies in the literature utilize B cells as the model 
AC, however work from Chapter 3 of this thesis demonstrates that BMDM interactions 
with AC of different origins do not greatly differ, and so it can be assumed that these 
results could be extrapolated to apoptotic B cells. As such the finding that apoptotic 
B cells had no effect on BMDM was unexpected; however it is a finding replicated in 
previous work from this thesis (Chapter 3). As this has been a consistent finding with the 
co-culture assay used, regardless of the origin of AC, it can be classified as an artefact 
of the particular experimental protocol utilized, rather than an intrinsic trait of 
apoptotic B cells. 
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In summation, these findings demonstrate that RTX pre-treatment of B cells results in 
increased levels of interaction with both GM-CSF and L929 BMDM at early time-points, 
leading to enhanced phagocytosis of RTX-coated B cells compared to un-treated B cells. 
This increased interaction does not affect BMDM phenotype or function as determined 
by the production of IL-10, IL-12 and TGF-β. However, the possibility of alterations in 
BMDM phenotype and function not detected by the particular assays utilized cannot be 
ruled out. 
  
 
 
 
 
 
Chapter 5: Secondary Presentation of 
Antigens 
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5.1 Introduction 
In order for a protein antigen to be recognized by T cells it must first be broken down 
into its composite peptides, and these peptides presented on an MHC (major 
histocompatbility complex) molecule expressed on the surface of another cell, ready for 
recognition by antigen-specific T cells. There are two different types of MHC molecule: 
MHC I molecules, expressed by nearly all nucleated cells of the body, with the highest 
levels expressed on lymphocytes; and MHC II molecules, expressed primarily on APCs. 
Presentation of a peptide in the context of MHC I results in peptide recognition by 
T cells expressing the CD8 co-receptor [30,31], known as cytotoxic T cells, while 
presentation in the context of MHC II results in recognition by T cells expressing the CD4 
co-receptor [32], known as T helper (Th) cells, with these different subclasses of T cell 
having distinct effector mechanisms and roles within the immune response. 
MHC I molecules predominantly present cytosolic peptides, these being either 
endogenous peptides arising from proteins found within the cell, or proteins resulting 
from cytosolic pathogens such as viruses. Peptides from the cytosol are transported into 
the endoplasmic reticulum, where those that are of the correct size and express the 
appropriate binding motifs are loaded onto newly synthesized MHC I molecules. Once a 
stable peptide:MHC I complex is formed, it is transported to the cell surface and 
presented, ready for recognition by antigen-specific CD8+ T cells. Although classically 
known for the presentation of peptides deriving from the cytosol of a cell, MHC I 
molecules are also able to present antigens originating from other cells, a process 
known as cross-presentation [reviewed in [269]. Proteins taken up into vesicles from the 
cells surroundings can undergo retrograde transport, whereby they are actively 
transported into the cell cytosol from an enclosed vesicle. Once in the cytosol the 
proteins are degraded into peptides by the proteosome, and transported back in to the 
ER ready for loading onto MHC I molecules and subsequent presentation. 
MHC II molecules primarily present exogenous antigen located within an APC’s vesicular 
system, such as antigens that have been taken up by phagocytosis, endocytosis or 
macropinocytosis, or pathogens that reside and replicate within the vesicles of cells. 
Once these proteins are enclosed in intracellular vesicles, called endosomes, they are 
degraded by proteases, which become activated on acidification of the early endosome. 
The acidified peptide-containing endosome then binds to a lysosome containing MHC II 
molecules, to form the MHC II compartment, and it is within this compartment that it is 
thought peptide loading takes place. With the help of accessory molecules, stable 
peptide:MHC II complexes are formed, and these complexes are transported to the cell 
surface where they are presented, ready for recognition by CD4+ T cells. MHC II 
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molecules can also undertake a form of cross-presentation, in which endogenous 
cytosolic proteins and organelles are delivered to the lysosomes for degradation via the 
process of autophagy, ultimately resulting in their presentation by MHC II molecules 
[reviewed in [270]. Autophagy is a constitutive process, however it is enhanced in 
response to cellular stress, and functions to enhance cell survival through the re-use of 
nutrients already present in the cell, as well as broadening the spectrum of responses to 
intracellular pathogens. 
Antigen presentation by MHC molecules is a crucial step in both the activation and 
tolerization of the adaptive immune response, and it is the expression of co-stimulatory 
molecules on the APC that define the outcome of antigen recognition by adaptive 
immune cells. On the binding of a T cell to its specific antigen in the context of self-
MHC, the cell becomes primed, but it is only once it has received a second signal from 
activatory co-stimulatory molecules expressed by the APC, in the presence of specific 
cytokines, that it will become activated and differentiate into an effector cell. This 
interaction induces T cells to differentiate into effector cells by increasing IL-2 
production resulting in enhanced cellular proliferation, as well as inducing the up-
regulation of cell surface molecules involved in the resultant T cell differentiation. 
MHC I restricted CD8+ T cells become cytotoxic T cells, capable of rapid clonal 
expansion in response to activation and the direct killing of malignant or infected cells 
[reviewed in [271]. Depending on the cytokine milieu present at the time of activation, 
CD4+ T cells can develop into either Th1, Th2, Th17 or Tregs. Each subset has distinct 
effector functions and roles within the immune response, and can be characterized 
based on the production of signature cytokines. Th1 cells are known to produce a range 
of pro-inflammatory cytokines, such as IFNγ, and are involved in cell-mediated 
immunity, via the activation of macrophages, and induce IgG production by B cells, 
while Th2 cells secrete the cytokines IL-4, IL-5, IL-6, IL-10 and IL-13 and are 
predominantly involved in non-inflammatory immune responses and the clearance of 
parasites [reviewed in [33]. Th17 cells are the most recently characterized CD4+ T cell 
subset, and are often the first to be generated in response to infection, producing 
cytokines, such as IL-17, that activate local cells and recruit neutrophils [34,272]. 
Regulatory T cells that develop in the periphery from naïve CD4+ T cells in the presence 
of TGF-β and IL-10 are termed inducible Tregs (iTregs) [35], as opposed to natural Tregs 
(nTregs), which develop in the thymus. These iTregs are able to inhibit pro-
inflammatory immune responses, both by direct cell-contact mechanisms, and the 
production of anti-inflammatory cytokines. 
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If the second co-stimulatory signal is not given, or inhibitory rather than activatory co-
stimulation molecules are bound, tolerance to the specific antigen results. CTLA-4 is an 
inhibitory receptor expressed on the surface of T cells, and has a high affinity for the 
co-stimulatory molecules CD80/CD86. Ligation of CD80/CD86 by CTLA-4 blocks the 
interaction of these activatory molecules with CD28 expressed on the T cell surface, 
resulting in the T cell encountering cognate antigen in the absence of further activatory 
signals. If antigen is recognised by T cells in the absence of co-stimulatory signals, the 
recognising T cell will either undergo clonal deletion, via activation-induced cell death, 
or become anergic, a state in which the cell can no longer be stimulated by cognate 
antigen. Both of these mechanisms act to induce a state of peripheral tolerance toward 
the antigen in question.  
This control of activation vs. tolerance at the time of antigen recognition is vital to the 
maintenance of peripheral tolerance to harmless self-antigen. When this control 
mechanisms breaks down, the result is an active, highly detrimental response toward 
self, leading to the development of autoimmune disorders. Systemic lupus 
erythematosus (SLE) is a chronic autoimmune disease in which increased levels of 
apoptotic lymphocytes [273], coupled with defects in the clearance of apoptotic cells 
[156], results in the release of cell material ultimately leading to a break in tolerance 
to intracellular self-antigens. Autoantibodies directed toward double stranded DNA are 
characteristic of SLE, and are implicated in the pathogenesis of disease. Type I 
diabetes, another common autoimmune disease, results from a loss of tolerance toward 
antigens expressed by the pancreatic β-cells [274], the insulin producing cells of the 
body, resulting in their immune-mediated destruction [reviewed in [275].  
The presentation of both self and non-self antigens happens continually, throughout the 
body, and is a well-characterized process. The majority of studies looking into antigen 
presentation focus on the ‘direct’ presentation of antigens, i.e. those that derive from 
proteins the cell has directly encountered, either through infection or uptake, or those 
that are constitutively expressed within the cell. The aim of the work in this chapter 
was to investigate whether an APC could present antigen it has not directly 
encountered, but derives from a protein taken up by another cell prior to that cell 
being phagocytosed by the APC, a process we have termed ‘secondary presentation’.  
We hypothesize that Rituximab may re-introduce temporary tolerance to the immune 
system. If on treatment with Rituximab apoptosis of B cells is caused, the B cells will be 
phagocytosed by APCs in a non-inflammatory context. As previously discussed, apoptosis 
occurs regularly as a normal part of tissue turnover and homeostasis, and in order to 
prevent autoimmunity, the immune system is tolerized against antigens found on the 
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surface of apoptotic cells, with AC having been shown repeatedly to have 
immunosuppressive effects on the immune system [158,166-169]. The phagocytosed B 
cell, and any antigens it has internalized, will be degraded, and the resultant peptides 
presented by the APC in a tolerogenic context. If the B cell had previously taken up self-
antigen, specifically the putative self-antigen the RA response is directed toward, 
presentation of this arthritogenic antigen in a non-inflammatory, tolerizing 
environment, may result in the re-introduction of temporary tolerance to a system in 
the midst of chronic inflammation.  
As a step to understanding the integrity of this hypothesis, we wanted to examine 
whether APCs are able to achieve secondary presentation of antigen previously taken up 
by B cells. To do this, an in vitro assay was developed involving BMDM, primary hCD20tg 
B cells and transgenic OVA-specific primary T cells [276], with OVA used as the model 
antigen. As hCD20tg B cells are polyclonal, B cell receptor (BcR) mediated uptake of 
OVA will not occur in the majority of these cells, and so a way to ensure uptake of 
sufficient amounts of OVA by B cells was needed. It has been shown by Beers et al that 
RTX is internalized by B cells after binding to CD20 [100], and so to overcome this 
problem, the immunodominant OVA323-339 peptide [277] was chemically conjugated to 
rituximab (RTX:OVA) (as described in section 1.3.4.). By conjugating the OVA peptide to 
RTX, the OVA will be taken up on internalization of RTX, resulting in an accumulation of 
peptide inside early endosomes within the B cells. This internalized OVA could then 
potentially by taken up by the macrophages on phagocytosis of the B cells, and 
presented to the OVA-specific T cells, by these BMDM. Activation of the T cells, isolated 
from OTII T cell receptor (TcR) transgenic mice, can then be used as a read out of 
successful secondary antigen presentation by the BMDM, with Figure 5.1 giving an 
overview of the assay protocol. 
Chapter objectives: 
• To develop an in vitro assay to investigate whether BMDM are able to achieve 
secondary presentation of antigen previously taken up by B cells 
• To explore the functional effect of this secondary presentation on antigen-
specific T cells 
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Figure 5.1 Schematic of the secondary presentation assay 
An overview of the in vitro assay used to assess whether BMDM can successfully present antigen 
previously taken up by B cells. BMDM were generated and co-cultured for 3h with primary hCD20tg 
B cells, which had been pre-treated with 30µg/ml of RTX, RTX conjugated to OVA peptide 
(RTX:OVA), OVA peptide alone (OVAp), or OVA protein (OVApro). The BDMD were washed, to 
remove the B cells, and co-cultured overnight with OVA-specific T cells. T cell activation was used 
as a measure of successful antigen presentation, and was assessed by flow cytometry. Cytokine 
production, and cellular proliferation after co-culture were also examined. 
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5.2 Results 
5.2.1 Activation of T cells by secondary presentation of antigen by 
BMDM 
In vitro assays were performed to assess whether macrophage phagocytosis of B cells 
that have previously encountered antigen can result in the successful presentation of 
this antigen. To do this, primary hCD20tg B cells were cultured with 30µg/ml of RTX 
chemically conjugated to OVAp (RTX:OVA), with un-treated B cells, and those cultured 
with either RTX alone or OVA323-339 peptide (OVAp) alone included as negative controls. 
The conditions containing un-treated B cells, or B cells cultured with RTX, do not 
contain OVA at any stage, and therefore no OVA-specific T cell activation should occur.  
In the conditions containing B cells cultured with OVAp, no interaction was expected 
between the polyclonal B cell population and the peptide, and therefore the peptide 
should not be available for the BMDM to present to the OVA-specific T cells later in the 
assay. Half of the cells from each pre-treatment were irradiated to induce apoptosis, 
and all B cells incubated for 4hr, before extensive washing to remove free antigen, and 
co-cultured with BMDM for 3hr. The BMDM were washed to remove any un-bound B cells, 
and co-cultured overnight with OVA-specific OTII T cells to allow activation to occur. 
CD69 up-regulation by OTII T cells was used as a measure of T cell activation, as 
assessed by flow cytometry.  
In the cell samples tested, viable lymphocytes were gated on using FSC and SSC, and 
within this population T cells were defined as CD3+CD4+ cells, with CD69 expression on 
this population quantified (Figure 5.2a). The level of T cell activation observed in the 
un-treated B cell condition (BMDM+B(nt)) was used as a measurement of background 
activation. No OVA was present at any point in this condition and no T cell activation, or 
subsequent up-regulation of CD69, should take place in the absence of OVA. When 
OTII T cells were co-cultured with BMDM incubated with B cells pre-treated with 
RTX:OVA (BMDM+B(RTX:OVA)), the data indicates an increased expression of CD69 by 
the T cells (17.1±3.6%  CD69+), with the 2 separate peaks seen in the FACS histograms 
for CD69 (Figure 5.2b) demonstrating the presence of two T cell populations with 
distinct CD69 expression profiles. On addition of RTX alone into the secondary 
presentation assay, no T cell activation above background was seen, with only 4.2±0.2% 
of OTII T cells co-cultured with BMDM+B RTX pre-treated B cells (BMDM+B(RTX)) 
expressing CD69. Surprisingly, when co-cultured with BMDM incubated with B cells pre-
treated with OVAp (BMDM+B(OVAp)), 75.4±4.1% of OTII T cells expressed CD69 on their 
surface (Figure 5.2b). This was a sizable increase compared to the T cells from the 
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BMDM+B(nt) condition, in which only 5.1±0.3% of OTII T cells expressed CD69 after co-
culture. On co-culture of OVA-specific T cells with BMDM incubated with irradiated 
apoptotic B cells (BMDM+apopB) pre-treated with RTX:OVA (BMDM+apopB(RTX:OVA)) an 
up-regulation of CD69 by the T cells was also seen, with 16.4±0.6% of T cells expressing 
CD69, compared to background expression levels of 5.9±0.5% in the BMDM+apopB(nt) 
group (Figure 5.2c). No up-regulation of CD69 by the OTII T cells was observed in the 
BMDM+apopB(RTX), compared to background levels. As with the condition containing 
viable B cells pre-treated with RTX:OVA, co-culture of OTII T cells with BMDM incubated 
with apoptotic B cells pre-treated with OVAp resulted in an up-regulation of CD69 by 
the T cells, with 85.6±4% staining positive for CD69. 
Within the CD69+ OTII T cell population, the level of surface CD69 expression was 
investigated. The MFI of CD69 showed an increase above background for both the 
BMDM+B(RTX:OVA) and BMDM+apopB(RTX:OVA) groups (Figure 5.3a and b). CD69 MFI for 
the BMDM+B(RTX:OVA) T cells was 358±122, compared to 91±0.1 in the BMDM+B(nt) 
condition, and 287±67 for the BMDM+apopB(RTX:OVA) T cells, compared to background 
levels of 101±18 on the T cells from the BMDM+apopB(nt) group. Substantial increases in 
OTII T cell CD69 MFI were also seen in both the BMDM+B(OVAp) and BMDM+apopB(OVAp) 
groups (Figure 5.3a and b), with a CD69 MFI of 989±61 and 716±103, respectively. 
For this preliminary study, both irradiated and non-irradiated B cells were utilized as 
the antigen supply for the BMDM. Substantial activation of T cells was seen when co-
cultured with BMDM previously incubated with irradiated B cells pre-treated with 
30µg/ml RTX:OVA (BMDM+apopB(RTX:OVA)) (Figure 5.2c), as well as when non-
irradiated, viable, B cells with the same pre-treatment were used as the BMDM antigen 
supply (Figure 5.2b). The levels of surface CD69 expressed on CD69+ T cells from these 
treatment groups was also similar, with a CD69 MFI of 287±67 for the T cells from the 
BMDM+apopB(RTX:OVA) group, and a CD69 MFI of 358±122 on those from the 
BMDM+B(RTX:OVA) group (Figure 5.3a and b).  
These data indicate that OVA-specific OTII T cells can be activated by the addition of 
RTX:OVA into the secondary presentation assay system, with this activation occurring 
when either viable or irradiated B cells are utilized. As a result of these findings, it was 
decided to remove the irradiated B cell groups from any further assays undertaken, as 
this additional condition did not add anything to the understanding of the system. 
Contrary to expectations, the addition of OVAp into this in vitro system also induced 
substantial activation of OTII T cells. 
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Figure 5.2 Activation of T cells by secondary presentation of antigen by BMDM 
OTII T cells were co-cultured overnight with BMDM, which had been incubated with pre-treated 
viable or apoptotic B cells. Cells were then stained for flow cytometry, and analyzed using a 
FACSCalibur, with CD69 expression used as a marker of T cell activation. (A) The gating strategy 
used to identify T cells. First panel: SSC vs. FSC. Second panel: CD4 vs. CD3. (B) Representative 
FACS plots (CD4 vs. CD69) and histograms (% of Max vs. CD69) showing levels of OTII T cell 
activation after co-culture with BMDM previously incubated with pre-treated viable B cells (BMDM + 
B), and graph of pooled data showing the percentage of CD69+ T cells after co-culture. Grey 
histogram = co-cultures with BMDM previously incubated with un-treated B cells. 
(C) Representative FACS plots (CD4 vs. CD69) and histograms (% of Max vs. CD69) showing 
levels of OTII T cell activation after co-culture with BMDM previously incubated with pre-treated 
apoptotic B cells (BMDM + apop.B), and graph of pooled data showing the percentage of CD69+ T 
cells after co-culture. nt: no pre-treatment, RTX: Rituximab, RTX:OVA: RTX conjugated to OVA 
peptide, OVAp: OVA peptide. (n=1, 3 replicates)  
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Figure 5.3 Level of activation of T cells after secondary presentation of RTX:OVA by BMDM 
OTII T cells were co-cultured overnight with BMDM, which had been incubated with pre-treated 
viable or apoptotic B cells. Cells were then stained for flow cytometry, and analyzed using a 
FACSCalibur, with CD69 expression used as a marker of T cell activation. (A) Graph of pooled 
data showing the CD69 MFI of CD69+ OTII T cells after co-culture with BMDM previously incubated 
with pre-treated viable B cells (BMDM + B). (B) Graph of pooled data showing the CD69 MFI of 
CD69+ OTII T cells after co-culture with BMDM previously incubated with OVAp pre-treated 
apoptotic B cells (BMDM+ apop.B). nt: no pre-treatment, RTX: Rituximab, RTX:OVA: RTX 
conjugated to OVA peptide, OVAp: OVA peptide. (n=1, 3 replicates)  
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5.2.2 Activation of OTII T cells after secondary presentation of 
differing concentrations of RTX:OVA by BMDM 
To assess whether increased OTII T cell activation could be achieved by the addition of 
higher concentrations of RTX:OVA into the secondary presentation assay, the previous 
assay was repeated with some minor changes. Non-irradiated hCD20tg B cells were used 
in co-cultures with BMDM, and these B cells were pre-treated with RTX:OVA at either 
30µg/ml or 100µg/ml. Un-treated B cells and those pre-treated with OVA peptide 
(OVAp) at either 15µg/ml or 30µg/ml were again included, with an additional B cell pre- 
treatment of OVA protein (OVApro) at either 30µg/ml or 100µg/ml included as a further 
control group. OVA-specific T cells only become activated on recognition of the 
immunodominant peptide fragment of the OVA protein in the context of the correct 
MHC II molecule, and therefore in the conditions containing OVApro, processing of the 
protein would need to occur before successful presentation can result. No uptake of the 
protein by the polyclonal B cell population would be expected, and as such no peptide 
fragments should be available for the BMDM to present to the OVA-specific T cells later 
in the assay. After initial co-culture of pre-treated B cells with BMDM, the BMDM were 
washed to remove any un-bound B cells, and co-cultured overnight with OVA-specific 
OTII T cells, as done previously. Again, CD69 up-regulation was quantified by flow 
cytometry, as outlined in Figure 5.2a. 
A similar level of background T cell activation was seen in the BMDM+B(nt) group for this 
study as in the preliminary experiment, with 9.5±1.2% of T cells expressing CD69 after 
co-culture, with an MFI of 102±3 (Figure 5.4b). When used at 30µg/ml, no significant 
activation above background was seen on T cells from the BMDM+B(RTX:OVA) condition, 
with 15.4±2.7% expressing CD69. However, the levels of expression of CD69 on these 
cells was significantly increased compared to the BMDM+B(nt) group (MFIs: 294±12 vs. 
102±3, respectively). OVApro pre-treatment of B cells was included as an additional 
control (BMDM+B(OVApro)), and when used at 30µg/ml no significant activation of 
T cells was seen, with 22.6±0.4% expressing CD69, and an MFI of 203±17. As with the 
previous assay, significant up-regulation of CD69 was seen in the BMDM+B(OVAp) group, 
with 83.9±1.8%  of T cells positive for CD69, and an MFI of 878±105. When used at 
100µg/ml, the RTX:OVA pre-treatment resulted in significant activation of OTII T cells 
compared to the BMDM+B(nt) group, with 26.9±3.4% of T cells from the 
BMDM+B(RTX:OVA) condition expressing CD69, with an MFI of 437±29. Interestingly, 
when B cells were pre-treated with 100µg/ml OVApro, comparable levels of T cells 
activation were seen in the BMDM+B(OVApro) condition as were seen in the 
BMDM+B(RTX:OVA) condition, with 37.9±2.9% of T cells from the BMDM+B(OVApro) CD69 
positive, and an MFI of 301±13. This activation is reflected in the 2 distinct populations 
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Figure 5.4 Activation of OTII T cells after secondary presentation of differing concentrations 
of RTX:OVA by BMDM 
OTII T cells were co-cultured overnight with BMDM, which had been incubated with viable B cells 
pre-treated with different concentrations of a Rituximab-OVA peptide conjugate (RTX:OVA), or 
controls. Cells were then stained for flow cytometry, and analyzed using a FACSCalibur, with CD69 
expression used as a marker of T cell activation. (A) Representative FACS plots (CD4 vs. CD69) 
and histograms (% of Max vs. CD69) showing OTII T cell activation after co-culture with BMDM 
previously incubated with pre-treated viable B cells. (B) Graphs of pooled data showing the 
percentage of CD69+ T cells after co-culture, and the MFI of CD69 on CD69+ T cells. (n=1, 3 
replicates) Statistics used: One-way ANOVA performed on each compete data set (% and MFI), 
followed by Bonferroni’s post test, with * = p<0.05, and *** = p<0.001. 
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seen in the FACS histograms for both of these conditions (Figure 5.4a). A lesser dose of 
15µg/ml OVAp pre-treatment was also included in the study. Even with this reduced 
concentration of OVAp used for B cell pre-treatment, activation of OTII T cell was seen, 
with 82.3±0.6% expressing CD69 and an MFI of 831±98. 
These data show that OVA-specific T cells can be activated by addition of a RTX:OVA 
conjugate into this in vitro assay system, indicating that successful presentation of OVA 
derived from the RTX:OVA conjugate by BMDM is occurring. Interestingly, in this system 
OVA-specific T cells can also be activated by pre-treatment of the hCD20tg B cells with 
OVAp or OVApro, indicating that this polyclonal B cell population must be taking up OVA 
in sufficient amounts for subsequent secondary presentation by BMDM to occur. 
5.2.3 Comparison of activation of OVA-specific T cells after secondary 
presentation of RTX:OVA by B cells or BMDM  
To investigate whether the activation of OVA-specific T cells by RTX:OVA in this assay 
system was due to successful secondary antigen presentation by BMDM, or was actually 
due to the direct presentation of antigen by any residual pre-treated B cells still present 
in the system, additional B cells only controls were added. For this revised assay, non-
irradiated primary hCD20tg B cells were pre-treated overnight with: RTX:OVA at either 
30µg/ml or 100µg/ml; OVApro at either 30µg/ml or 100µg/ml; OVAp at either 15µg/ml 
or 30µg/ml; or left un-treated. These B cells were then either incubated with BMDM for 
3h, or incubated alone. As before, all conditions were washed, and the remaining BMDM 
co-cultured overnight with OVA-specific OTII T cells. CD69 up-regulation by the T cells 
was used as a measure of T cell activation as assessed by flow cytometry, with T cell 
proliferative responses and cytokine production also quantified.  
In the cell samples tested, lymphocytes were gated on using FSC and SSC, and within 
this population the T cells were defined as CD3+CD4+ cells. The expression of CD69 on 
this cell population was then investigated (Figure 5.5). In the conditions that did not 
have BMDM added, no activation of T cells was detected by flow cytometry in any pre-
treatment group compared to the un-treated B cell group (B(nt)) (Figure 5.6a and c). In 
the T cell co-cultures with BMDM that had been incubated with pre-treated B cells, 
significant increases in the levels of CD69+ T cells were observed when B cells were pre-
treated with 100µg/ml of the RTX:OVA conjugate (100µg/ml BMDM+B(RTX:OVA) - 
44±8.6% CD69+ T cells, MFI: 443±81), when compared to the BMDM+B(nt) group (12.1±6% 
CD69+ T cells, MFI: 99±4) (Figure 5.6b and c). A significant increase in CD69+ T cells was 
also seen in both the 30µg/ml and 15µg/ml BMDM+B(OVAp) group (30µg/ml – 74.3±18.8% 
CD69+ T cells, MFI: 856±362, 15µg/ml - 58.4±32.2% CD69+ T cells, MFI: 781±439). When 
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comparisons were made between the BMDM+B co-cultures in which significant T cell 
activation occurred, and the equivalent pre-treatment groups from the B cell only 
conditions, the proportion of T cells expressing CD69, as well as the levels of CD69 up-
regulation, were significantly higher in the BMDM+B co-cultures (Figure 5.6c). 
To determine if the up-regulation of CD69 on the OVA-specific T cells was a good 
reflection of the levels of activation taking place within this population, T cell 
proliferative responses were investigated. The cytokine IL-2 functions as a T cell growth 
factor, and is produced in an autocrine manner by T cells on the binding of antigen to 
the TcR, or by activation with mitogens [278]. IL-2 binding by T cells induces the up-
regulation of the IL-2 receptor, resulting in a positive feedback loop stimulating the 
growth and proliferation of T cells [279,280]. In view of this, IL-2 production by T cells 
can be used as an indirect measurement T cell proliferation. Cell culture supernatants 
were collected after either BMDM–T cell co-culture, or B cell-T cell co-culture, and 
ELISAs used to quantify the levels of IL-2 present. A significant increase in IL-2 
concentration was seen in the 100µg/ml BMDM+B(RTX:OVA) T cell co-cultures 
(42±6pg/ml), compared to the  BMDM+B(nt) group (2±1pg/ml) (Figure 5.7a). Significant 
increases in IL-2 levels were also seen in both the 30µg/ml and 15µg/ml BMDM+B(OVAp) 
groups, with 374±15pg/ml and 347±3pg/ml of IL-2 detected, respectively. In the B cell-
T cell co-cultures, no significant increase in IL-2 was observed in the B(RTX:OVA) 
conditions compared to the B(nt) co-cultures (2±1pg/ml). A significant increase in IL-2 
production was observed in the 100µg/ml B(OVAp) group (111±61pg/ml), however the 
levels of IL-2 production were notably lower than those detected for the equivalent pre-
treatment in which BMDM were present (111±61pg/ml IL-2 vs. 374±15pg/ml IL-2).  
T cell proliferative responses were also measured directly by quantifying the 
incorporation of radioactive tritiated-thymidine (3H-thymidine) into newly synthesized 
cells over a set time-period. In the BMDM+B conditions, significantly more proliferation 
was seen in T cells that had been co-cultured with BMDM incubated with B cells pre-
treated with 100µg/ml RTX:OVA (7948±4558 CPM), compared to those from the 
BMDM+B(nt) group (221±208 CPM) (Figure 5.7b). In the direct B cell-T cell co-cultures, 
significant proliferation was seen only in T cells from the 30µg/ml B(OVAp) group 
(1289±565 CPM) compared to the T cells co-cultured with B cells that had received no 
pre-treatment (36±24 CPM). Although T cell proliferation did occur in co-cultures not 
containing BMDM, the maximal response seen in the direct B cell co-cultures was far less 
than that observed in the BMDM containing co-cultures (30µg/ml B(OVAp): 1289±565 
CPM; vs. 100µg/ml BMDM+B(RTX:OVA): 7948±4558 CPM), indicating a lower level of 
T cell activation in these conditions.  
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In an attempt to characterize the specific T cell response resulting from secondary 
antigen presentation in this assay, the levels of IFNγ, IL-10 and IL-17A in the cell culture 
supernatants were investigated. Naïve CD4+ T cells can differentiate into several 
distinct effector cell subsets, and these subsets can be distinguished based on their 
pattern of cytokine expression. IFNγ was used as a marker of Th1 cells [281], IL-10 as a 
marker of iTregs [35], and IL-17 for Th17 [34,272]. No significant increases in either IFNγ 
or IL-10 production were seen in any BMDM-T cell co-culture condition (Figure 5.8a and 
b). The data indicates increased IFNγ levels in the 100µg/ml BMDM+B(RTX:OVA) group 
(293±22pg/ml), however this was not significant when compared to the BMDM+B(nt) co-
culture (185±32pg/ml). No IFNγ or IL-10 was detectable in any of the direct B cell-T cell 
co-cultures, regardless of the B cell pre-treatment (data not shown). A significant 
increase in the level of IL-17A was seen on co-culture of the OVA-specific T cells with 
100µg/ml BMDM+B(RTX:OVA) compared to the BMDM+B(nt) group, with 55±7pg/ml IL-
17A vs. 28±9pg/ml IL-17A (Figure 5.8c). No change in IL-17A levels were detected in any 
of the B cell-T cell co-cultures, with baseline levels similar to those detected in the 
BMDM-T cell co-cultures (B(nt): 30±10pg/ml IL-17A; BMDM+B(nt): 28±9pg/ml IL-17A). 
With the experimental protocol used, BMDM are able to successfully present antigens to 
T cells that they themselves have not directly taken up. BMDM presented OVA, derived 
from a B cell ingested RTX:OVA conjugate, to OVA-specific T cells resulting in the 
activation of these cells as evidenced by their up-regulation of CD69, increased 
production of IL-2, and enhanced cellular proliferation. BMDM were also able to present 
immunogenic OVA epitopes to T cells, with these epitopes derived from OVApro taken 
up by B cells that were subsequently engulfed by BMDM. This presentation resulted in 
the activation of these OVA-specific T cells as evidence by their up-regulation of CD69, 
however, no change in the levels of IL-2 or cellular proliferation were detected. 
5.3 Discussion 
• An in vitro assay was developed in order to investigate whether self-antigen 
taken up by autoreactive B cells could be presented by other APCs after 
phagocytosis of the B cells. 
• We found that successful secondary presentation of antigen by BMDM was 
possible. 
• These findings are a first step toward understanding this type of antigen 
presentation and demonstrate that this is an interesting line of investigation to 
pursue, with further work allowing us to answer the question of whether 
tolerance or activation would result from such antigen presentation in vivo. 
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Figure 5.5 Gating strategy for analysis of CD69 up-regulation on OTII T cells 
Primary T cells were isolated from OTII mice, co-cultured overnight with B cells or BMDM pre-
incubated with B cells, and their surface expression of CD69 analysed via flow cytometry. (A) 
Representative dot plots demonstrating the gating strategy used to define total T cells and CD69+ T 
cells in T cell-B cell co-cultures. First panel: SSC vs. FSC. Second panel: CD4 vs. CD3. Third 
panel: CD4 vs. CD69. (B) Representative dot plats demonstrating the gating strategy used to 
define total T cells and CD69+ T cells in T cell-BMDM co-cultures. First panel: SSC vs. FSC. 
Second panel: CD4 vs. CD3. Third panel: CD4 vs. CD69.  
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Figure 5.6 Comparison of activation of OVA-specific T cells after direct presentation of 
RTX:OVA by B cells, or secondary presentation by BMDM  
Primary OTII T cells were co-cultured overnight with pre-treated B cells, or BMDM incubated with 
pre-treated B cells. Cells were then stained for flow cytometry, and analyzed using a FACSCalibur, 
with CD69 expression used as a marker of T cell activation. (A) Representative FACS plots (CD4 
vs. CD69) and histograms (% of Max vs. CD69) showing levels of OTII T cell activation after co-
culture with pre-treated B cells. (B) Representative FACS plots (CD4 vs. CD69) and histograms (% 
of Max vs. CD69) showing levels of OTII T cell activation after co-culture with BMDM incubated 
with pre-treated B cells. (C) Graphs of pooled data showing the percentage of CD69+ T cells after 
co-culture, and the MFI of CD69 on CD69+ T cells. (n=2, from 2 independent experiments) 
Statistics used: One-way ANOVA performed on each complete data set (% and MFI), followed by 
Bonferroni’s post test, with * = p<0.05, and *** = p<0.001. 
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Figure 5.7 Proliferative responses of OTII T cells after direct presentation of RTX:OVA by 
B cells, or secondary presentation by BMDM  
OTII T cells were co-cultured with pre-treated B cells, or BMDM incubated with pre-treated B cells 
for 72hr. (A) Graphs showing IL-2 production (pg/ml) after co-culture, as determined by ELISA. (B) 
Graphs showing cellular proliferation, as quantified by the incorporation of 3H-thymidine into newly 
synthesized cells after co-culture. CPM = counts per minute. (IL-2 ELISA n=1, proliferation assay 
n=2 with data from 2 independent experiments) Statistics used: One-way ANOVA performed on 
each complete data set (BMDM+B cells IL-2 production, B cells IL-2 production, BMDM+B cells 
proliferation, B cell proliferation) followed by Bonferroni’s post test, with * = p<0.05, ** = p<0.01, 
and *** = p<0.001. 
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Figure 5.8 T cell responses to secondary presentation of RTX:OVA by BMDM  
OTII T cells were co-cultured directly with pre-treated B cells, or BMDM incubated with pre-treated 
B cells for 72hr. Cell culture supernatants were then collected and cytokine production investigated 
by ELISA. (A) Graph showing the levels of IFNγ production (pg/ml) after co-culture with BMDM 
incubated with pre-treated B cells. (B) Graph showing the levels of IL-10 production (pg/ml) after 
co-culture with BMDM incubated with pre-treated B cells. (C) Graph showing the levels of IL-17A 
production (pg/ml) after co-culture with BMDM incubated with pre-treated B cells (left panel) or after 
direct co-culture with pre-treated B cells (right panel). (n=1) Statistics used: One-way ANOVA 
performed on each complete data set (BMDM+B cells IFNγ production, BMDM+B cells IL-10 
production, BMDM+B cells IL-17A production, B cells IL-17A production), followed by Bonferroni’s 
post test, with * = p<0.05, and ** = p<0.01. 
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Many hypotheses have been put forward to explain how RTX treatment exerts its 
beneficial effects in RA, however a definitive answer has yet to be reached, and it is 
probable that there will not be one mechanism alone. We hypothesize that one of the 
potential mechanisms of action is that RTX re-introduces temporary tolerance to the 
immune system. If APCs are able to present antigen that they themselves have not 
directly taken up, this could lead the presentation of self-antigen endocytosed by auto-
reactive B cells, prior to RTX-mediated depletion, by APCs in an anti-inflammatory 
setting after ingestion of antigen-containing auto-reactive B cells undergoing apoptosis 
as a result of RTX treatment.  
In our assay, hCD20tg B cells were pre-treated with a RTX:OVA conjugate as way to 
ensure the internalization of OVA by a large proportion of the polyclonal B cell 
population. These cells were then incubated with BMDM, which were subsequently co-
cultured with OVA-specific T cells, with the activation and proliferation of the 
transgenic T cells used as a read out of successful antigen presentation.  
OVA peptide (OVAp) was used as a control throughout the secondary presentation 
assays, with OVA protein (OVApro) also used in the majority of assays. hCD20tg B cells 
are polyclonal, and therefore only a fraction of the cells isolated from a naïve hCD20tg 
mouse will be specific for OVA. As such, it was expected that sufficient amounts of 
either OVAp or OVApro would not be taken up by the B cells to allow substantial 
secondary presentation by BMDM, and therefore these conditions were intended as 
negative controls. When OVAp was used as the B cell pre-treatment, extremely high 
levels of OVA-specific T cell activation after BMDM-T cell co-culture were consistently 
observed for both concentrations of peptide tested. These results could not be 
attributed to an unusually high proportion of OVA-specific B cells within the B cell 
populations used, as the same B cell preparations were utilized for all conditions within 
an experiment. Therefore, if a particularly high percentage of OVA-specific B cells were 
present, this would be reflected in the activation rates seen with OVA protein pre-
treatment, and this was not the case. A possible explanation for the increase of T cell 
activation in response to B cell pre-treatment with OVAp is that empty MHC molecules 
expressed on the surface of the B cells directly bound the immunogenic OVA peptide 
present in the culture media. Each MHC molecule has the ability to bind to multiple 
different peptides containing the correct anchor residues [282] and as such, the OVAp 
could be bound by a much higher proportion of B cells, including non-OVA-specific B 
cells within the population. It has previously been shown that empty MHC I [283] and 
MHC II [284] molecules are able to directly bind extracellular peptides, with work by 
Santambrogio et al demonstrating that immature DCs express numerous empty MHC 
class II molecules on their surface, and that these are capable of loading antigen 
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directly from the extracellular medium and presenting it to T cells in vitro [285]. It is 
thought that this mechanism of antigen binding by APCs may allow a more diverse range 
of peptides to be presented to T cells, without the need for intracellular antigen 
processing. Although direct peptide binding by MHC has been demonstrated in vitro, it 
is not thought to readily occur in B cells under physiological conditions, with MHC II 
molecules that are not antigen loaded in the endosomal compartment retained within 
the cell, and subsequently degraded [286]. It would also not be expected that B cells 
would express substantial numbers of empty class I molecules, as it has been shown that 
although empty MHC I molecules expressed on the cell surface are able to directly bind 
peptide in vitro, these empty molecules are unstable, with a very short half life at 
physiological temperatures [287]. Antigen binding induces a conformational change 
stabilizing the molecule, resulting in prolonged expression of the MHC:peptide complex 
on the cell surface [287]. Although this is the case under physiological conditions, work 
by Hidde Ploegh’s group has revealed that at a range of reduced, non-physiological 
temperatures there is an increase in the levels of empty MHC I molecules expressed by 
cells [288,289]. In these studies, using the murine lymphoma cell lines RMA and RMA-S, 
it was found that culturing both cell lines at temperatures ranging from 19-33oC resulted 
in a marked increase in the expression of correctly folded class I molecules, and that on 
addition of exogenous influenza-derived peptide to the cultures the cells could be 
sensitized to antigen-specific cytotoxic T cell-mediated killing [289]. At reduced 
temperatures these empty class I molecules were stably expressed, however, if the cells 
were subsequently incubated at 37oC the expressed empty class I molecules rapidly lost 
their peptide binding capacity and disappeared from the cell surface, with only those 
molecules that had formed MHC:peptide complexes remaining [288]. These findings 
could explain the ability of the hCD20tg B cells to directly bind OVAp, as prior to their 
incubation with antigen the B cells are kept at room temperature during certain initial 
stages of the assay. As room temperature in a lab is generally regulated to be ~20-25oC, 
this would fall well within the temperature range shown to induce expression of empty 
class I molecules on the surface of cells, and therefore could result in MHC I up-
regulation on the surface of the B cells. Although the cultures were promptly 
transferred to 37oC for overnight incubation after addition of antigen, direct binding of 
peptide by empty MHC I in lower temperature cultures has been shown to be a rapid 
process, with addition of peptide to RMA-S cells immediately before transfer to 37oC 
sufficient to rescue surface MHC molecules from destruction [288]. Therefore, the 
overnight incubation of B cells at 37oC would not interfere with the direct binding of 
OVAp by expressed empty MHC, resulting in the presence of sufficient peptide during 
the B cell-BMDM co-cultures to allow subsequent secondary presentation to OVA-specific 
T cells.  
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Another possible explanation for the interaction of the polyclonal B cells with OVAp is 
its uptake by macropinocytosis. Unlike other APCs, which take up antigens non-
specifically from their surrounding environment, B cells take up antigen for presentation 
via antigen-specific B cell receptor (BcR) mediated endocytosis [290], enabling them to 
focus the immune response to specific targets. Although this method of antigen uptake 
seems to be the most relevant in a physiological setting, it has been shown that B cells 
are also able to ingest antigen non-specifically, via macropinocytosis [290]. In the 
present culture system, the uptake of OVAp by polyclonal hCD20tg B cells could be due 
to a non-specific, fluid-phase uptake process, such as macropinocytosis. When pre-
treated with high enough concentrations of OVAp, these B cells are able to undergo 
sufficient levels of this non-specific antigen uptake to allow subsequent secondary 
presentation by BMDM.  
When 30µg/ml OVApro was used as the B cell pre-treatment, no activation of OVA-
specific T cells was seen above background levels, as detected by flow cytometry, IL-2 
ELISA and proliferation assay. On 100µg/ml OVApro B cell pre-treatment, fairly 
consistent levels of moderate T cell activation were seen after BMDM-T cell co-culture. 
In the present culture system, it is proposed that the uptake of OVApro by polyclonal 
hCD20tg B cells is due macropinocytosis, as discussed in regard to OVAp uptake.  
Presentation of OVA peptide derived from the RTX:OVA conjugate was observed in this 
assay system when B cells were pre-treated with 100µg/ml RTX:OVA prior to incubation 
with BMDM, with this successful presentation demonstrated by the up-regulation of the 
early activation marker CD69 [291] on OVA-specific T cells after BMDM-T cell co-culture. 
The levels of T cell activation detected in the RTX:OVA conditions were expected to be 
substantially greater than those observed in the OVApro conditions, however this was 
not the case, and comparable CD69 up-regulation by T cells was detected. The RTX:OVA 
conjugate was developed as a delivery mechanism to target OVA into the hCD20tg 
B cells, allowing the use of this population of polyclonal B cells in the system. However, 
after undertaking the assay it was clear that secondary presentation of OVA resulted 
when B cells were pre-treated with either RTX:OVA or OVApro, raising the question of 
whether this delivery mechanism was indeed necessary. In the BMDM+B conditions, 
increases in CD69 expression by OVA-specific T cells resulted from B cell pre-treatment 
with either RTX:OVA or OVApro, however out of the two conditions, only with the use of 
RTX:OVA was significant T cell proliferation, IL-2 production or IL-17A production 
detected. These differences indicate that the presentation of OVA derived from 
RTX:OVA or OVApro resulted in different responses by the OVA-specific T cell 
population. This difference may have been due to the relative amounts of OVA 
presentation in these conditions. Processing of both RTX:OVA and OVApro would need to 
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occur before presentation of the immunogenic OVA peptide could take place. If the 
RTX:OVA conjugate is easier to process than the complete OVA protein, this could result 
in an increase in the amount of processed OVA peptide present in the BMDM. With more 
processed peptide available for presentation, enhanced expression of MHC:OVAp 
complexes on the BMDM surface and a subsequent increase in OVA-specific T cell 
activation may result. If this is indeed the case, then increasing the concentration of 
OVApro used in the B cell pre-treatment would result in comparable levels of T cell 
activation and cytokine production, compared to those from the RTX:OVA conditions, 
negating the need for the conjugate protein delivery mechanism. However, the 
differences observed between these conditions may be due to the different processing 
and presentation of these antigens by the BMDM, although without further investigation 
this cannot be known. It is also unclear at this stage whether a potential difference in 
the processing/presentation of OVAp derived from these two sources would have any 
relevance to the process currently under investigation, and therefore even if inherent 
differences did exist, the use of the RTX:OVA conjugate may still be unnecessary in this 
particular setting. 
After the initial secondary presentation assays were undertaken, the question was 
raised as to whether the T cell activation observed after BMDM-T cell co-culture was 
due to secondary presentation of antigen by the BMDM, or whether residual B cells 
remained in the culture system at the time of co-culture, and the activation seen was a 
result of direct presentation by these contaminating B cells. In an attempt to clarify the 
route of presentation taking place, B cell only controls were set up. BMDM were not 
added to these conditions, but in all other respects they were treated in the exact same 
way as the counterpart BMDM+B conditions, with the resultant T cell activation 
quantified after T cell co-culture, as before. No significant T cell activation detected in 
any of the B cell only controls, regardless of the pre-treatment used, indicating that the 
activation seen in the BMDM+B conditions is indeed due to secondary antigen 
presentation by the BMDM, rather then direct B cell presentation. Although this control 
does not conclusively rule out direct presentation by B cells, as non-internalized B cells 
bound to the surface of adherent BMDM in the BMDM+B conditions may be responsible 
for some of the activation seen in these cultures via direct antigen presentation, it does 
strongly indicate this is the case. 
Several reasons for the lack of direct presentation seen in the B cell only conditions can 
be suggested, depending on the B cell pre-treatment in question. If working under the 
assumption that OVAp interacts with the polyclonal B cell population by being directly 
bound by empty MHC molecules expressed on the surface of the B cells, minimal direct 
presentation by B cells may seem to conflict with this idea. However, the apparent lack 
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of T cell activation in these conditions could be explained within the context of this 
theory. Some level of T cell activation is seen in the OVAp pre-treated B cell-T cell 
cultures, with an increase in CD69 expression, IL-2 production and T cell proliferation 
observed, it is just in comparison to the BMDM co-cultures that this level of activation 
appears minimal. Resting B cells are known to be poor antigen presenting cells [292], 
and although the direct binding of antigen to B cell MHC was not investigated in these 
studies, the disparity in T cell activation levels in the secondary presentation assay may 
purely reflect the intrinsic antigen presenting capacity of B cells versus macrophages. 
Another potential cause of this reduced level of direct presentation of OVAp may be to 
do with the MHC restriction of the OVA-specific T cells used in the assay. If on culture in 
reduced temperatures, the B cells up-regulate MHC I molecules rather than MHC II 
molecules, and these class I proteins directly bind OVAp present in the media, the 
resultant MHC:peptide complex will only be detectable by MHC I-restricted CD8+ T cells 
[30,31]. As the OVA-specific T cells used for the secondary presentation assays were 
isolated using a CD4+ T cell isolation kit, there will be no CD8+ T cells in the assay to 
detect this antigen presentation, and therefore even if OVAp-expressing B cells were 
present in this condition, CD4+ T cell activation would not occur. In contrast, in the 
BMDM conditions the uptake of B cells and any bound OVAp would result in their 
targeting to the exogenous antigen processing pathway, leading to the presentation of 
OVAp on MHC II molecules, and allowing its recognition by CD4+ OVA-specific T cells.  
In the context of either OVAp or OVApro uptake by macropinocytosis, the reduced direct 
presentation observed may be due to the route of peptide uptake. Antigen that has 
been taken up by B cells via macropinocytosis rather than BcR-mediated endocytosis 
may not enter the antigen processing pathway, therefore inhibiting subsequent peptide 
presentation by the B cells. This does not seem to be the case however, with work by 
Chesnut et al demonstrating that uptake of the KLH antigen by polyclonal B cells can 
result in the activation of KLH-specific T hybridoma cells, as demonstrated by increase 
T cell production of IL-2 [293]. Although demonstrating that successful peptide 
presentation by B cells is possible after macropinocytosis of antigen, this study 
highlights the reduced capacity of B cells to induce T cell activation after this form of 
antigen uptake, compared to other populations of APCs. In the secondary presentation 
assays utilized in this chapter, all cells were cultured at a 1:1 ratio, and this low 
number of B cells:T cells in the direct co-culture conditions may explain the lack of 
T cell activation. Potentially, if the number of OVAp or OVApro pre-treated B cells 
included in the co-cultures were increased, higher levels of T cells activation would be 
detected. Another possible explanation focuses on the viability of the B cells. In the 
initial secondary presentation assays undertaken, conditions containing both non-
irradiated and irradiated B cells were included. On examination of the results it was 
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seen that similar levels of T cell activation were seen in the corresponding pre-
treatments regardless of which B cell group was included in the assay, and so it was 
decided that only non-irradiated B cells would be used in future. Although the B cells 
used for the remainder of the assays had not undergone irradiation, B cells do not 
survive well in culture without the addition of specific survival factors. After overnight 
antigen pre-treatment in the absence of survival factors, the majority of B cells would 
be either apoptotic or dead in both the irradiated and non-irradiated conditions, with 
only a small percentage of viable cells present, as demonstrated in Chapter 3, Figure 
3.1. As such, even if the numbers of OVAp or OVApro pre-treated B cells included in the 
B cell-T cell co-cultures was sufficient to theoretically result in T cell activation, the 
B cells may not have been healthy enough to successfully present antigen.  
In order to fully dissect the contribution of direct antigen presentation by B cells in this 
assay system, further studies would need to be undertaken. The addition of a B cell 
marker into the FACS panel used to gauge T cell activation would enable the detection 
of contaminating B cells remaining in the BMDM+B conditions. Internalized B cells would 
not be accessible to antibody without prior cell permeabilization, and therefore any 
B cell staining seen could be attributed to un-ingested, surface bound B cells with the 
potential to directly present antigen. Microscopy could also be used to visualize the 
specific cell-cell interactions going on, either by labelling each cell population with a 
different stain, such as CFSE, prior to their use in the assay, or by utilizing antibodies 
specific for distinct cell surface markers before visualization. These approaches would 
both help to characterize the cell populations present in the final co-culture stages of 
the assay, and their involvement in the interactions taking place. Use of a fluorescently 
labelled antigen, coupled with visualization of cells via microscopy, could be used to 
directly trace the route of antigen presentation, and conclusively define the 
contributions of direct vs. secondary presentation on the activation of OVA-specific 
T cells.  
Although it cannot be conclusively stated that secondary antigen presentation is fully 
responsible for all the T cells activation seen in the BMDM+B conditions, it is reasonable 
to conclude that this presentation mechanism is involved in this system when B cells are 
pre-treated with the RTX:OVA conjugate. On binding of the RTX to hCD20 expressed on 
the B cell, the conjugate will be taken up via the CD20 internalization pathway, rather 
than by BcR-mediated internalization, the usual route for antigen-specific endocytosis 
by B cells [294]. It has been shown in a variety of B cell lines that internalization of 
CD20:RTX complexes results in their trafficking to early endosomes and subsequently 
lysosomes, as visualised by confocal microscopy [100]. The fusion of acidified 
endosomes with lysosomes is a key step in the processing pathway of exogenous 
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antigens, exposing them to lysosomal proteases and resulting in the generation of 
peptides [295], which can then to be loaded onto newly synthesized MHC II molecules. 
Theoretically, once located in B cells lysosomes, the RTX:OVA conjugate could be 
broken down into its constituent peptides, where it may encounter and be loaded onto 
empty class II molecules to be presented on the cell surface. However, there is no 
direct evidence that the RTX internalization pathway intersects the exogenous antigen-
processing pathway at any stage. The movement and fusion of endosomes and lysosomes 
within the cell is highly regulated, and is dependent on the expression of specific Rab 
and SNARE (soluble NSF attachment protein receptor) proteins on the surface of the 
endosome [reviewed in [296]. Endosomes express different members of the Rab and 
SNARE families of proteins dependant on their role within the cell, and their final target 
destination [reviewed in [297]. It is thought that peptide loading onto class II molecules 
occurs in the MIIC compartment, a particular type of MHC II containing lysosome, 
however this has not yet been clearly defined [reviewed in [298]. Thus, although it is 
known that CD20:RTX complexes traffic into lysosomes where they are degraded and 
MHC II molecules reside in lysosomes prior to antigen loading, until the specific 
lysosomes involved are defined, or the potential intersection of these pathways is 
directly studied, it cannot be said whether empty MHC II molecules would encounter the 
internalized RTX:OVA conjugate. Although direct presentation of the constituent OVA 
peptide by the B cell after this form of internalization is theoretically possible, it seems 
unlikely to have occurred. In the B cell only conditions pre-treated with RTX:OVA no 
indication of any T cell activation was observed at either concentration investigated. In 
the BMDM+B conditions, any RTX:OVA contained within the B cell or bound to its surface 
will be digested by the phagocyte in the same manner as all other exogenous antigens 
on phagocytosis of the B cell, and therefore will be easily accessible for loading on to 
MHC II molecules and subsequent presentation. Because of this, it seems reasonable to 
conclude that successful secondary presentation by BMDM has occurred in this assay 
system, and that the T cell activation seen could not be solely attributed to direct 
antigen presentation by possible contaminating B cells.  
Although the concept of secondary antigen presentation has not previously been 
investigated in its own right, published work looking into varying aspects of the immune 
response touches on this presentation pathway, providing further evidence that this 
may be a naturally occurring mechanism of antigen presentation. In a study looking into 
cross-presentation of exogenous antigens to CD8+ T cells by dendritic cells (DC), Alfaro 
et al demonstrate that DC can successfully present OVA protein contained within 
neutrophils, to both CD4+ and CD8+ OVA-specific T cells [299]. In this study murine 
neutrophils were cultured in vitro with OVA protein, followed by co-culture with murine 
DCs. The DCs were then exposed to OVA-specific OTI (CD8+) and OTII (CD4+) T cells. 
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T cell proliferation, as measured by CFSE dilution 72hr later, was used as a marker of 
successful OVA presentation, with cell division observed in both the CD4+ and CD8+ 
T cells co-cultured with DC that had been incubated with neutrophils preloaded with 
OVA, indicating secondary presentation had occurred in this system. The authors also go 
on to examine whether this type of secondary presentation can result in successful 
T cell activation in an in vivo setting. To do this, C57BL/6 mice were injected with CFSE 
stained OTI T cells, and the following day injected in the footpad with H-2d neutrophils 
either preloaded with OVA or untreated, and H-2b DCs. As OTI T cells can only see OVA 
peptide in the context of H-2b, the use of neutrophils from a H-2d background removed 
the possibility of direct presentation of OVA to the transgenic T cells by the preloaded 
neutrophils. Draining lymph nodes and spleens were harvested 72 hours later, and T cell 
proliferation was measured by CFSE dilution as detected by flow cytometry. Only OTI 
T cells isolated from mice that had been injected with DC and neutrophils that had 
phagocytosed OVA showed signs of proliferation above background levels, demonstrating 
that secondary presentation can also occur in a more physiologically relevant setting. 
Work by Kambayashi et al looking in to the involvement of mast cells in antigen-specific 
T cell responses has shown that antigen taken up via Fc receptor-mediated endocytosis 
can also undergo secondary presentation by APC [300]. Murine mast cells were 
incubated first with anti OVA-IgE to allow binding of the IgE by surface Fcε receptors 
expressed by the mast cells, followed by incubation with OVA protein. This resulted in 
opsonisation of the OVA protein by the Fcε receptor-bound anti OVA-IgE, leading to 
intracellular uptake of the antigen. These preloaded mast cells were then co-cultured 
with unsorted splenocytes from OTII mice, and the activation of OTII OVA-specific 
T cells assessed by flow cytometry. Activation was determined by CD69 up-regulation on 
the OTII T cells, with increased expression observed on T cells originating from the co-
cultures involving OVA preloaded mast cells, but not from co-cultures involving 
untreated mast cells. When OVA preloaded mast cells were cultured with purified OTII 
T cell populations, minimal levels of T cell activation were seen, demonstrating that the 
T cell CD69 up-regulation observed in the mast cell-splenocyte co-cultures did not result 
from direct antigen presentation by the mast cells, but was the result of presentation 
by APCs within the splenocyte population. This was confirmed by addition of DCs to 
preloaded mast cell-OTII T cell co-cultures, resulting in enhanced CD69 expression by 
the T cells. This secondary presentation model was then further tested in an in vivo 
setting. This was done by the injection of CFSE labelled OTII T cells and OVA preloaded 
mast cells into C57BL/6 mice. The spleens and draining lymph nodes were harvested 
from the mice 5 days later, and analysed via flow cytometry for proliferation of the 
CFSE stained T cells as measured by CFSE dilution. Proliferation of the OTII T cells was 
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observed in mice injected with OVA preloaded mast cells, but was not in mice injected 
with untreated mast cells. This finding demonstrates that mast cells that have 
previously taken up antigen by receptor-mediated endocytosis can serve as a source of 
antigen for presentation to T cells in vivo. 
These studies, along with the work presented in this chapter, serve to illustrate that 
successful secondary presentation of antigen is indeed possible in a variety of settings. 
The up-regulation of CD69 by OVA-specific T cells, along with the cellular proliferation 
and IL-2 production observed, demonstrate that successful antigen presentation has 
occurred. However, these results do not indicate the nature of the T cell response in 
this setting. Although CD69 is generally considered an early activation marker, work by 
Sancho et al. in CD69-deficient mice has highlighted a potential role for this molecule as 
a negative regulator of immune responses [301,302]. In addition, T cell proliferation 
does not necessarily imply the generation of effector cell populations. Activation-
induced cell death is a process in which activation through the T cell receptor results in 
a period of cell proliferation followed by apoptosis of the T cell [303], with exposure of 
T cells to IL-2 shown to be critical to this form of induced cells death [304]. Due to this, 
it cannot be conclusively stated that the T cell activation seen in this assay will result in 
the generation of effector populations.  
To start to dissect the impact of secondary OVA presentation in this assay, the 
generation of specific T cell subsets in response to this secondary presentation was 
investigated. Cytokine ELISAs were undertaken, with the levels of IFNγ, IL-17A and IL-10 
investigated, as CD4+ T cell subsets can be identified by their production of signature 
cytokines [reviewed in [305]. IFNγ production is indicative of the presence of pro-
inflammatory Th1 cells [281], and in the BMDM+B conditions no significant change in the 
levels of IFNγ were seen compared to the un-treated BMDM+B controls, for any of the B 
cell pre-treatments used. These results indicate that antigen presentation did not result 
in the generation of a substantial population of Th1 cells under these conditions. Levels 
of the anti-inflammatory cytokine, IL-10, also did not change for any of the B cell pre-
treatments used compared to the BMDM+B(nt) group. IL-10 can be produced by a variety 
of immune cells, in the case of T cells it is most commonly associated with the Treg 
subsets [35], and acts on APCs to suppress their antigen presenting capacity [306] and 
inhibit the production of pro-inflammatory cytokines [307]. Generation of a population 
of iTregs could have been a mechanism of tolerance induction, however this lack of a 
change in IL-10 concentration indicates that secondary presentation in this system did 
not generate a significant regulatory population. IL-17A, is characteristic of the Th17 
cell subset [34,272], and a significant increase in IL-17A production was seen in the 
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BMDM+B(RTX:OVA) compared to the BMDM+B(nt) group. These data indicate that under 
the conditions used, the secondary presentation of OVA resulted in expansion of the 
Th17 cell population, with no corresponding effects in the Th1 cell or iTreg populations.  
The generation of an inflammatory Th17 population in response to antigen presentation 
in this system may not be a result of the method of secondary presentation, but rather 
a reflection of the broader assay conditions used. Before co-culture with B cells, the 
BMDM were stimulated overnight with IFNγ and then treated with LPS. This stimulation 
protocol mimics a pro-inflammatory environment, resulting in a pool of activated 
macrophages expressing the co-stimulatory molecules required to initiate T cell 
responses. This in vitro treatment could be said to better reflect the inflammatory RA 
environment, however we hypothesize that on RTX-treatment in vivo, APCs will obtain 
antigen from apoptotic B cells. The immunomodulatory signals from the large number of 
apoptotic B cells would potentially be able to overcome the inflammatory environment. 
Although B cells will constitutively undergo apoptosis at low levels within the body, this 
sudden increase in the number of apoptotic B cells present in the system may be enough 
to tip the balance toward an anti-inflammatory environment, and combined with the 
potential increased levels of secondary presentation, could be enough to result in 
tolerance to the arthritogenic auto-antigen. In this version of the assay, non-irradiated 
B cells were used, rather than those that had been irradiated to induce apoptosis. As 
mentioned previously, B cells in culture have a very short life span without the addition 
of growth factors, and therefore a proportion of the B cells present in culture would be 
expected to be apoptotic or undergoing apoptosis, however the number of apoptotic 
cells present in the assay system may not have been enough to override the 
inflammatory stimulus given to the macrophages, resulting in an active immune 
response toward OVA. Also, as previously shown in this thesis and by previous studies, 
the response of macrophages to AC differs depending on the macrophage subset 
(Chapter 3, sections 3.2.7 - 3.2.9) and the inflammatory milieu present at the time of 
uptake (Chapter 3, section 3.2.2) [175]. This suggests that different outcomes would 
result from the inclusion of different macrophage populations, or different activatory 
stimuli, something that would be interesting to investigate in more detail. 
In light of earlier work in this thesis looking into the interaction of AC and BMDM, and 
the finding that in certain culture conditions viable cells seem to have the same 
immunomodulatory capacity as AC, it would be interesting to include a group of truly 
viable B cells into the secondary presentation assay. This is something that could be 
done by the addition of B cell survival factors, such as IL-4 or a CD40L-CD8α fusion 
protein [308], into the overnight pre-treatment stage. Another potential alteration to 
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the assay would be the inclusion of a control conjugate at the B cell pre-treatment 
stage. If the modified OVA peptide used in the RTX:OVA conjugate was instead 
conjugated to a RTX isotype, this would control for the uptake mechanism of the OVA in 
this condition. However, with the questions raised as to whether the RTX:OVA conjugate 
is needed for this assay to work, or whether the use of OVApro is sufficient, this control 
may not be of use.  
Together these results demonstrate that successful secondary presentation of OVA by 
BMDM is possible in this assay system, and that with the conditions used this 
presentation may result in the generation of a Th17 cell population. Although these 
results cannot definitively state whether tolerance or activation would result from such 
antigen presentation in vivo, they are first step toward understanding this interaction 
and encourage the pursuit of this line of investigation. 
  
 
 
 
 
 
Chapter 6: Human CD20 Transgenic Mice 
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6.1 Introduction 
Transgenic mice are valuable tools for biomedical research, and are extensively used in 
the study of autoimmune diseases. Human CD20 transgenic (hCD20tg) mice specifically 
express the human CD20 molecule on the surface of their B cells. The amino acid 
sequence of CD20 is well conserved between humans and mice [309], however human-
specific anti-CD20 antibodies do not detect the mouse homologue. The transgenic 
expression of hCD20 on the surface of murine B cells enables the study of human-
specific anti-CD20 monoclonal antibodies (mAbs), such as RTX, in animal models of 
disease. Rituximab was originally developed for the treatment of B cell lymphomas 
[310], but its use in the clinic has now spread to encompass the treatment of 
autoimmune disorders such as SLE [311], and RA [80], and is being considered for use in 
Multiple Sclerosis (MS) [312-314]. As use of these biologics increases, and as the search 
for improved efficacy continues, hCD20tg mice are a vital tool to facilitate the study of 
the complex interaction between anti-CD20 monoclonal antibodies and B cells, as well 
as the significant consequences B cell depletion has on the immune system as a whole. 
CD20, previously known as the B1 molecule [315], is a transmembrane protein belonging 
to the MS4A family, sharing structural similarities with the β chain of the Fc receptor 
FcεRI, found on mast cells [316]. It is a stable B cell-specific marker, with expression 
lost on terminal differentiation of cells into plasma cells [317]. It is thought that CD20 is 
involved in B cell proliferation, with binding of CD20 by anti-CD20 antibodies resulting 
in the inhibition of cell cycle progression following activation [318], and extensive cross-
linking of CD20 leading to apoptosis [235]. It has also been suggested that CD20 may 
have a role in the generation of optimal B cell responses [319]. Several studies have 
highlighted a role for CD20 in the regulation of the transmembrane movement of 
calcium in B cells. In the 1993 paper by Bubien et al, it was demonstrated that the 
binding of CD20 by anti-CD20 antibodies results in enhanced transmembrane calcium 
conductance [320]. In this same paper, the authors went on to show that transfection of 
CD20 cDNA into a variety of human and murine cells also results in an increased 
transmembrane Ca2+ conductance [320]. Despite these findings, the endogenous ligand 
for CD20 is still currently unknown, and B cells in CD20 knockout mice develop and 
function normally [321].  
The hCD20tg colonies maintained at the University of Glasgow were originally 
established from mice obtained from Dr. Mark Shlomchik (Yale University School of 
Medicine). The hCD20tg founder lines were generated by the introduction of a bacterial 
artificial chromosome (BAC) carrying the gene for human CD20 into the pronuclei of 
mouse embryos. BAC inserts have been used to produce a variety of transgenic mouse 
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strains since the late 1990s [322], and are highly stable, allowing the introduction of 
genomic inserts up to 300kb in length [reviewed in [323]. 
Several groups have previously characterized hCD20 expression in hCD20tg mice 
[242,324,325], however the animals used in the current work were from a separately 
maintained colony, with a new hCD20tg DBA strain created from the original hCD20tg 
C57BL/6 strain via backcrossing and therefore it was decided to validate these mice in-
house prior to their use. 
Chapter objectives: 
• To confirm the expression of hCD20 by B cells in the blood and secondary 
lymphoid organs 
• To characterize the ability of RTX to bind to hCD20 expressed by hCD20tg mice 
• To investigate the ability of RTX to deplete B cells in hCD20tg mice 
 
6.2 Results 
6.2.1 Genotyping of hCD20tg mice 
It has been previously noted in other hCD20tg colonies that hCD20tg female mice do not 
breed well, and so breeding pairs at the University of Glasgow have been consistently 
set up using wild-type (WT) females and hCD20tg males. As this type of mating results in 
both hCD20tg heterozygous offspring and WT littermates, all pups were genotyped by 
PCR prior to use. Two sets of primers were used to ensure the presence of the transgene 
in the animals: one that amplifies part of the un-translated exon 2 region within the 
hCD20 gene; and one that amplifies a sequence near the end of the BAC. A band of 
100kbp for 5’Bac, and 400kbp for Exon 2, indicated the presence of the hCD20 
transgene [324]. 
The hCD20 transgene could be readily detected in a proportion of the pups bred from 
both the C57BL/6 and DBA colonies. In no samples tested was a positive result detected 
for one primer but not the other, with all pups either showing bands for both the Exon 2 
and 5’ Bac primers, or no bands at all, as can be seen in Figure 6.1. Mice expressing the 
transgene were termed hCD20tg, while those with no expression were termed WT 
littermates. 
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Figure 6.1 Genotyping of hCD20tg mice using primers for the 5’ Bac region and Exon 2 of 
the hCD20 gene 
PCR was performed on DNA extracted from tail tips taken from 3-4 week old pups. The numbers 
across the top of the gel represent the identification numbers of various pups. A band of 100kbp for 
5’Bac, and 400kbp for Exon 2, indicated the presence of the hCD20 transgene. 
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6.2.2 2H7 anti-hCD20 antibody titration 
To verify the presence of the hCD20 protein on the surface of B cells in those mice that 
tested positive for the hCD20 transgene flow cytometry was used.  
A variety of anti-hCD20 antibodies are commercially available for use in flow cytometry, 
with the majority of these coming from the 2H7 clone. The ability of a selection of 
these antibodies to detect hCD20 was investigated. Peripheral blood mononuclear cells 
(PBMCs) were separated from human buffy coats and stained for lineage specific 
markers, along with various amounts of either anti-hCD20 FITC, anti-hCD20 PE, anti-
hCD20 PerCPCy5 or anti-hCD20 APC, all clone 2H7. Analysis of hCD20 expression in this 
context was performed on CD3-CD19+ B cells (Figure 6.2a). 
When used at 2.5µl/test, all the anti-hCD20 antibodies tested could detect a similar 
quantity of hCD20+ peripheral blood B cells (Figure 6.2b). For all antibodies, the 
percentage of B cells seen to be expressing hCD20 increased as the amount of antibody 
used per test increased, up to 10µl/test. For both the anti-hCD20 FITC and anti-hCD20 
PE, using 15µl/test did not increase the percentage of hCD20+ B cells detected above 
the 10µl/test level, however for the anti hCD20-PECy5 and anti-hCD20 APC 15µl/test 
increased the levels of detection still further. 
The amount of hCD20 detected on the surface of hCD20+ human B cells by the various 
antibodies was also looked at (Figure 6.2c). The MFI value was noticeably higher for all 
antibodies tested when used at 15µl/test compared to when used at 10µl/test (FITC 
MFI: 230 vs. 295 respectively; PE MFI: 98 vs. 129; PECy5 MFI: 213 vs. 390; and APC MFI: 
159 vs. 251, respectively), indicating that a greater level of hCD20 was detected on the 
cell surface when the anti-hCD20 antibodies were used at this higher concentration. 
Although the MFI value was consistently highest for each antibody at 15µl/test, the MFI 
values varied greatly between the different conjugated antibodies at this concentration 
(MFI range: 129 – 390). It was decided that anti-hCD20 PECy5 would be used for 
phenotypic characterization of the hCD20tg colonies, as although all antibodies tested 
bound similar proportions of B cells, the strength of the PECy5 signal was considerably 
greater than that for either FITC, PE or APC. 
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Figure 6.2 Titration of 2H7 anti-hCD20 antibodies 
PBMCs were separated from human buffy coats and stained for lineage specific markers, and 
either anti-hCD20 FITC, anti-hCD20 PE, anti-hCD20 PerCPCy5 or anti-hCD20 APC, all clone 2H7. 
(A) Representative dot plats demonstrating the gating strategy used to define B cells. First panel: 
SSC vs. FSC. Second panel: CD3 vs. CD19. (B) Representative FACS histograms showing hCD20 
detection by each anti-hCD20 antibody when used at 2.5, 5, 10 or 15µl per test. Panels: % of Max 
vs. hCD20. (C) Graphs showing the hCD20 MFI for each of the anti-hCD20 antibodies at all the 
concentrations tested. (n=1) 
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6.2.3 Phenotypic characterization using 2H7 anti-hCD20 antibodies 
To investigate the expression of hCD20 on the surface of cells from hCD20tg mice, tail 
bleeds were performed on hCD20tg C57BL/6 mice in which the presence on the hCD20 
transgene had been verified by PCR. WT littermates were used as controls. Cells were 
stained with cell lineage markers, along with anti-hCD20 PECy5 (clone 2H7), and 
analyzed using flow cytometry. 
In the blood samples tested, viable cells were gated on using FSC and SSC, and within 
this population B cells were defined as CD3-CD19+ cells (Figure 6.3a). hCD20 could not 
be detected on B cells from either the hCD20tg mice or the WT littermates using the 
2H7 anti-hCD20 (Figure 6.3b). This result was unexpected, as B cells from the hCD20tg 
mice were expected to express hCD20 on the surface of their mature B cells. The level 
of hCD20 expression on T cells and monocytes was also investigated for comparison. 
Within the viable cell population T cells were defined as CD3+CD19-, and monocytes as 
CD11b+ (Figure 6.3a). As expected, neither population expressed detectable levels of 
hCD20 (Figure 6.3b).  
This lack of hCD20 staining on transgenic B cells could be due to a lack of expression of 
hCD20 on the surface of these cells, or it could be a result of an inability of the 2H7 
anti-hCD20 antibody used to detect transgenic hCD20. Although in the previous binding 
tests for this antibody staining of cell surface hCD20 was observed, these tests were 
performed on human B cells, not transgenic murine cells.  
6.2.4 Comparison of transgenic hCD20 staining by 2H7 and L27 anti-
hCD20 antibodies 
The anti-hCD20 2H7 antibody did not detect hCD20 expression on B cells from hCD20tg 
mice. To try to verify if this was an accurate representation of the levels of hCD20 on 
the surface of these transgenic B cells, or if this finding was simply a result of a lack of 
compatibility of the 2H7 anti-hCD20 antibody with transgenic hCD20, another antibody 
clone, L27, was used. As it was seen with the 2H7 clone that the ability of an anti-CD20 
antibody to detect hCD20 in human samples did not correlate to detection of transgenic 
hCD20 in murine samples, the L27 antibody was not validated on human cells prior to 
use on hCD20tg B cells. 
Tail bleeds were performed on mice in which the presence on the hCD20 transgene had 
been verified by PCR. WT littermates were used as controls. Samples were stained with 
antibodies to lineage specific markers, and either the 2H7 anti-hCD20 antibody, or the
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Figure 6.3 hCD20 expression cannot be observed in hCD20tg C57BL/6 mice with the 2H7 
anti-hCD20 antibody clone 
Tail bleeds were performed on WT and hCD20tg C57BL/6 mice. Blood samples were stained with 
2H7 anti-hCD20 PECy5 along with cell lineage markers, and analyzed using a FACSCalibur. 
(A) Representative FACS plots showing the gating strategy used to identify the B cell, T cell and 
monocyte populations. Left panel: SSC vs. FSC. Top right panel: CD3 vs. CD19. Bottom right 
panel: CD11b vs. FSC. (B) Representative FACS histograms showing hCD20 expression by 
hCD20tg mice as detected by 2H7 anti-hCD20 PECy5. WT littermates are shown for comparison. 
Panels: % of Max vs. hCD20. (n=4, data from a single experiment) 
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L27 anti-hCD20 antibody. Stained samples were subsequently analyzed by flow 
cytometry. Viable CD3-CD19+ B cells were gated on (Figure 6.4a), and the expression of 
hCD20 in this population evaluated.  
Nominal levels of B cells stained positive for hCD20 in both hCD20tg and WT littermates 
with the 2H7 anti-hCD20 antibody (Figure 6.4b). However, at the same concentrations, 
the L27 anti-hCD20 antibody was able to detect hDC20 expression in blood samples from 
the same transgenic animals, with 72.9±3.4% of hCD20tg B cells staining positive for 
hCD20, compared to 1.9±0.7% of B cells from wild-type littermates (Figure 6.4b and 
Figure 6.4c). Minimal levels of hCD20 staining could be seen on B cells from non- 
transgenic WT littermates, however once non-specific background staining was 
deducted from the results using values obtained from FMO (fluorescence minus one) 
tests, it could be concluded that C57CL/6 WT littermates mice do not express hCD20 on 
the surface of their B cells, while hCD20tg C57BL/6 express hCD20 on the majority of 
their circulating B cells (Figure 6.4b, d). 
Although both clones of anti-hCD20 antibody are seen to bind endogenous CD20 in 
human samples [326,327], these results demonstrate that the 2H7 clone is unable to 
detect the transgenic hCD20 expressed in this colony of hCD20tg mice. As an outcome of 
this, L27 anti-hCD20 antibodies were utilized for all further flow cytometric analyses 
undertaken. 
6.2.5 Phenotypic characterization using L27 anti-hCD20 antibodies 
6.2.5.1 Evaluation of hCD20 expression in the blood and secondary 
lymphoid organs of hCD20tg mice 
Once an antibody able to detect hCD20 in hCD20tg mice was identified, a more in depth 
investigation of the pattern of hCD20 expression in these transgenic mice was 
undertaken. Spleens, peripheral LNs and blood were isolated from hCD20tg C57BL/6 
mice and single cell suspensions made. Cells were then stained with L27 anti-hCD20 
along with cell lineage markers, and analyzed using a MACSQuant. 
Viable cells were gated on using FSC and SSC. Within this population B cells were 
defined as CD19+ cells, and T cells as CD3+ cells. Within the CD19+ B cell population, 
B cell subsets were further classified on the basis of their CD21 and CD24 expression, 
allowing the differentiation of follicular (Fo) B cells, Transitional 1 (T1) B cells and 
Transitional 2/Maginal Zone (T2-MZ) B cells, as shown in Figure 6.5a. Viable neutrophils 
and monocytes were defined as CD45+ viable cells, with high levels of CD11b expression, 
and were distinguished from one another by their expression of GR1 and Ly6C. Monocyte
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Figure 6.4 L27 anti-hCD20 antibody is able to detect hCD20 in hCD20tg mice  
Tail bleeds were performed on hCD20tg C57BL/6 mice and WT littermates. Blood samples were 
stained for lineage specific markers, and either 2H7 anti-hCD20 or L27 anti-hCD20. CD3-CD19+ 
cells were gated on, and the expression of hCD20 in this population analyzed. (A) Representative 
FACS plots demonstrating the gating strategy used to define total B cells and hCD20+ B cells. First 
panel: SSC vs. FSC. Second panel: SSC vs. CD19, Third panel: hCD20 vs. CD19. 
(B) Representative FACS plots showing the detection of hCD20 by the 2H7 anti-hCD20 antibody 
and the L27 anti-hCD20 in WT littermates and hCD20tg mice. Panels: hCD20 vs. CD19. (C) Graph 
of pooled data showing the percentage hCD20+ B cells as detected by the 2H7 and L27 anti-
hCD20 antibodies. (D) Graph of pooled data showing the percentage of hCD20+ B cells in WT 
littermates and hCD20tg C57BL/6 mice. (WT littermate n=3, hCD20tg n=4, data from a single 
experiment) Statistics used: Unpaired t-tests performed on (C) and (D), with *** = p<0.001. 
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could then be further distinguished into Ly6C negative (Ly6Cneg), Ly6C intermediate 
(Ly6Cint) and Ly6C high (Ly6Chi) monocyte subsets (Figure 6.5b). 
The majority of B cells in the spleen, regardless of their subset, expressed hCD20 on 
their surface (Total B cells 62±8.8%; Fo B cells 59.9±10.3%; T1 B cells 55.6±10.7%; T2-MZ 
B cells 76.7±7% hCD20+) (Figure 6.6a – left and middle panels). Overall, very low levels 
of hCD20 expression were seen in all other cell types investigated, with 3.4±0.5% of T 
cells, 4.7±0.1% of neutrophils, and 10.6±4.3% of monocytes in the spleen staining 
positive for hCD20 (Figure 6.6a, left panel). When the monocyte subsets were examined 
individually, it could be seen that a notable percentage of the Ly6Cneg monocyte subset 
showed hCD20 expression (25.4±8.5% hCD20+) (Figure 6.6a, right panel), however the 
levels of surface hCD20 expression on this cell subset was considerably lower than that 
on B cells in the same tissue (mean MFIs of 117 and 245, respectively) (Figure 6.6d, e).In 
the peripheral LN 50.1±0.8% of B cells expressed hCD20, with minimal staining on T cells 
(4.9±0.8%) in this tissue (Figure 6.6b). Similar patterns of hCD20 expression were seen in 
the blood, with B cells expressing high levels of hCD20 on their surface (63.8±9%), and 
all other cell types expressing minimal hCD20 overall (<10% hCD20+) (Figure 6.6c, left 
panel). The Ly6Cneg monocyte subset in the blood also showed a greater percentage of 
hCD20 expression than the other subsets, with 15.8±6.3% of the population staining 
positive for hCD20 (Figure 6.6c, right panel). The levels of surface expression of hCD20 
on B cells and Ly6Cneg monocytes also showed the same pattern as in the spleen (mean 
MFIs of 256 and 81, respectively) (Figure 6.6d and e). 
Together this data confirms that mice genotyped as being hCD20tg express hCD20 on 
the surface of their B cells, and indicates that this expression is mostly limited to B cell 
populations in the tissues tested. However Ly6Cneg monocytes, in both the spleen and 
blood, seemed to have an unexpected, moderate hCD20 surface expression. These 
results may accurately reflect the levels of hCD20 seen on surface of hCD20tg Ly6Cneg 
monocytes, however, it is important to note that due to the technical aspects of the 
study this positive population could be B cell contamination in the Ly6Cneg monocyte 
gate. No B cell marker was used in the monocytes staining panel and thus it cannot 
categorically ruled out that B cells are not part of the Ly6Cneg subset. 
6.2.5.2 Evaluation of hCD20 expression in the Ly6Cneg monocyte population 
after B cell exclusion 
To allow a full understanding of the expression of hCD20 in hCD20tg mice, and whether 
the Ly6Cneg monocyte subset aberrantly express hCD20 in these transgenic animals, a 
new monocyte FACS panel was developed with an additional B cell marker added to
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Figure 6.5 Gating strategy for analysis of hCD20 expression in hCD20tg mice 
Spleen, LN and blood were isolated from hCD20tg C57BL/6 mice, and analysed by flow cytometry, 
with the expression of hCD20 investigated using a L27 anti-hCD20 antibody. (A) Representative 
dot plots demonstrating the gating strategy used to define total T cells, total B cells and the 
Follicular (Fo), Transitional 1 (T1) and Transitional 2/Marginal zone (T2-MZ) B cell subsets. Left 
panel: SSC vs. FSC. Top middle panel: SSC vs. CD3. Bottom middle panel: SSC vs. CD19. 
Bottom right panel: CD21 vs. CD24. (B) Representative dot plots detailing the gating strategy used 
to define total neutrophils, total monocytes and the Ly6C high (Ly6Chi), Ly6C intermediate (Ly6Cint) 
and Ly6C negative (Ly6Cneg) monocyte subsets. First panel: SSC vs, CD45. Second panel: SSC 
vs. FSC. Third panel: FSC vs. CD11b. Fourth panel: GR1 vs. Ly6C. Fifth panel: Ly6C vs. GR1. 
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Figure 6.6 Expression of hCD20 by hCD20tg C57BL/6 mice 
Tissues were isolated from hCD20tg C57BL/6 mice and single cell suspensions made. Cells were 
then stained with anti-hCD20 v450 (L27) along with cell lineage markers and analyzed using a 
MACSQuant. (A) Graphs showing the percentage of hCD20+ cells within different cell populations 
in the spleen. (B) Graph showing the percentage of hCD20+ B cells and T cells in the peripheral 
lymph nodes (LN). (C) Graphs showing the percentage of hCD20+ cells within different cell 
populations in the blood. (D) Representative FACS plots showing hCD20 expression by B cells and 
Ly6Cneg monocytes in the spleen and blood. Panels: hCD20 vs. SSC. (E) Graphs of pooled data 
showing the hCD20 MFI of B cells and Ly6Cneg monocytes in the spleen (top) and blood (bottom) 
on hCD20tg C57BL/6 mice. (n= 3, data from 2 independent experiments) Statistics used: For (B) 
and (E) students T test; all others, One way ANOVA performed on each complete data set (splenic 
cell populations, splenic B cell subsets, splenic monocyte subsets, blood cell populations, blood 
monocyte subsets) followed by Bonferroni’s post test, with * = p<0.05, ** = p<0.01 and *** = 
p<0.001. 
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allow definite exclusion of this population before further analysis. A hCD20tg DBA strain 
has been generated in house from the original hCD20tg C57BL/6 strain, and once the 
issues with the staining panel had been amended the expression of hCD20 was 
investigated in both populations. 
Cells isolated from the spleens, peripheral LNs and blood of both hCD20tg C57BL/6 and 
DBA mice were analyzed. T cells, total B cells and the Fo, T1 and T2-MZ B cell subsets 
were gated as previously shown (Figure 6.5). The neutrophil/monocyte-staining panel 
was expanded, and the gating strategy modified to reflect this (Figure 6.7). In detail, 
viable cells within the CD45+ population were identified and then gated for CD19 
expression. CD19- cells were selected, to ensure removal of any B cell contamination 
from the final analysis, and the CD11b+ cells within this population considered to be a 
mix of neutrophils and monocytes. These populations were then distinguished by their 
differential expression of GR1 and Ly6C. The monocyte population can be then further 
subdivided into Ly6Cneg, Ly6Cint, and Ly6Chi subsets for analysis. 
In the spleens of hCD20tg C57BL/6 mice the majority of B cells express hCD20 
(66.1±7.7%). WT littermates do not express hCD20, and as such were included in the 
study to allow discrimination of true hCD20 expression from non-specific background 
staining, with B cells from WT littermates demonstrating minimal levels of hCD20 
staining (4.8±0.3%) (Figure 6.8a and b). In the hCD20tg mice, no hCD20 staining above 
background was detected in the splenic T cells (hCD20tg: 5.6±2.9%; WT littermates: 
4.3±0.5%), monocyte (hCD20tg: 0.1±0.2%; WT littermates: 0.01±0.01%) or neutrophil 
(hCD20tg: 1.3±0.3%; WT littermates: 1±0.4%) populations (Figure 6.8a and b). When the 
B cell subsets in the spleen were investigated further, a large proportion of the Fo, T1 
and T2-MZ B cells subsets could be seen to express hCD20, with no differences found in 
the percentage of cells expressing hCD20 in each of these three groups (Figure 6.8c). 
However the data indicates that with a larger sample pool an increased proportion of 
hCD20+ cells may be found with within the T2-MZ subset (68±9.6%) compared to the Fo 
and T1 subsets (51.1±10.4% and 51.8±8.7%, respectively). Again, low-level background 
staining was seen in the B cell subsets investigated in WT littermates (Fo: 0.9±0.9%; T1: 
1.7±0.7%; T2-MZ: 2.4±1.3%). The exclusion of B cells from the monocyte-staining panel 
considerably reduced the amount of hCD20 expression detected within the Ly6Cneg 
monocyte subset in the spleen (Figure 6.8d). With the previous panel 25.4±8.5% of 
Ly6Cneg monocytes were positive for hCD20 expression in hCD20tg C57BL/6 mice, 
however with the new panel, only 0.1±0.2% of this subset were positive for hCD20 
staining, which is equivalent to the background levels of hCD20 staining seen in this 
subset in WT littermates (0.2±0.4%). 
   
203 
The cells isolated from the peripheral LN and blood of hCD20tg C57BL/6 mice show 
similar levels of hCD20 expression as their counterparts in the spleen. The majority of 
LN B cells from hCD20tg C57BL/6 mice express hCD20 (55.1±5.5%). Very few hCD20tg 
T cells stain as hCD20+ (5±1.2%) (Figure 6.9a), with comparable levels in WT littermate 
T cells (4±0.9%) indicating this staining is an artifact of the assay, rather than actual 
expression of hCD20. Significantly less WT littermate B cells stained positive for hCD20 
(5±0.4%), with only minimal non-specific staining seen compared to hCD20tg B cells. In 
the blood of hCD20tg C57BL/6 mice, 50±13.8% of B cells express hCD20, with only 
background staining of 3.7±1.1% in WT littermate B cells (Figure 6.9b). The T cell, 
monocyte and neutrophil populations from both hCD20tg mice and WT littermates show 
background staining only (<5%), as do all monocyte subsets investigated, with no hCD20 
expression detected. 
The expression of hCD20 in hCD20tg DBA mice was also investigated using the revised 
FACS panels. As with the C57BL/6 transgenic mice, a significant proportion of B cells 
from the spleen (65.6±9.6% - Figure 6.10a and b), LN (59±9.3% - Figure 6.11a) and blood 
(49.9±14.8% - Figure 6.11b) express hCD20 on their surface compared to the background 
levels of staining seen in WT littermates (spleen: 4.4±0.3%, LN: 7.6±2.5% and blood: 
3.9±0.7% hCD20+) (Figures 6.10b, 6.11a and 6.11b, respectively). In the hCD20tg DBA 
mice, the T cell, monocyte and neutrophil populations in these tissues did not show any 
hCD20 staining above the levels seen in the WT littermates, with extremely low 
percentages of hCD20+ cells (<5%) in all populations. The majority of all splenic B cell 
subsets investigated in the hCD20tg DBA mice expressed hCD20 (Figure 6.10c), with no 
notable difference in the expression levels between subsets (Fo: 60.9±28.3%; T1: 
57.5±18%; T2-MZ: 61.9±27.7%), although the hCD20 staining in these populations showed 
a higher level of variation than in others looked at. WT littermates had minimal 
background hCD20 staining for all splenic B cell subsets (Fo: 2.1±0.6%; T1: 2.8±0.6%; T2-
MZ: 1.7±0.3%). No expression of hCD20 by monocyte subsets in the spleens of hCD20tg 
DBA animals was seen, with comparable levels of hCD20 staining seen as in the WT 
littermates (hCD20tg: 1.6±0.4% of Ly6Chi, 3.6±1.1% of Ly6Cint and 1.7±1.5% of Ly6Cneg, 
vs. WT littermates: 1.3±0.4% of Ly6Chi, 4.8±0.1% of Ly6Cint and 1.5±1.3% of Ly6Cneg). 
Unfortunately, due to a technical issue, the monocyte subsets in the blood of the DBA 
hCD20tg mice could not be investigated. However, due to the similarities seen in the 
expression pattern of hCD20 by the monocyte subsets of the spleen and blood in the 
hCD20tg C57BL/6 mice, and the comparable levels of hCD20 seen on all populations of 
cells investigated in the hCD20tg C57BL/6 mice and the hCD20tg DBA mice, it can be 
supposed that all monocyte subsets in the blood of hCD20tg DBA mice would not express 
hCD20 on their surface. 
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Figure 6.7 Revised monocyte gating strategy for analysis of hCD20 expression in hCD20tg 
mice 
Spleen, LN and blood were isolated from hCD20tg mice, and analysed by flow cytometry, with the 
expression of hCD20 investigated using a L27 anti-hCD20 antibody. Representative dot plots are 
shown, detailing the gating strategy used to define total neutrophils, total monocytes and the Ly6C 
high (Ly6Chi), Ly6C intermediate (Ly6Cint) and Ly6C negative (Ly6Cneg) monocyte subsets, with an 
additional CD19- gating step added. First panel: SSC vs, CD45. Second panel: SSC vs. FSC. Third 
panel: FSC vs. CD19. Fourth panel: FSC vs. CD11b. Fifth panel: GR1 vs. Ly6C. Sixth panel: Ly6C 
vs. GR1. 
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Figure 6.8 Transgenic hCD20 is expressed on splenic B cells from hCD20tg C57BL/6 mice 
Spleens were isolated from hCD20tg C57BL/6 mice and WT littermates, and single cell 
suspensions made. Cells were then stained with L27 anti-hCD20 along with cell lineage markers 
and analyzed using a MACSQuant. (A) Representative FACS plots showing hCD20 staining on 
each splenic cell population investigated. B cell panels: hCD20 vs. CD19. T cell panels: hCD20 vs. 
CD3. Monocyte panels: hCD20 vs. CD45. Neutrophil panels: hCD20 vs. Ly6C. (B) Graph of pooled 
data showing the percentage of hCD20+ B cells, T cells, monocytes and neutrophils in the spleens 
of hCD20tg mice and WT littermates. (C) Graph of pooled data showing the percentage of hCD20+ 
follicular (Fo), transitional-1 (T1) and transitional-2/marginal zone (T2-MZ) B cells in the spleens of 
hCD20tg mice and WT littermates. (D) Graph of pooled data showing the percentage of hCD20+ 
Ly6Chi, Ly6Cint and Ly6Cneg monocytes in the spleens of hCD20tg mice and WT littermates. 
(hCD20tg n=5, WT littermates n=3, data from a single experiment) Statistics used: One way 
ANOVA performed on each complete data set (splenic cell populations, B cell subsets, monocyte 
subsets) followed by Bonferroni’s post test, with *** = p<0.001. 
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Figure 6.9 Transgenic hCD20 is expressed on B cells from the lymph nodes and blood of 
hCD20tg C57BL/6 mice 
Tissues were isolated from hCD20tg C57BL/6 mice and WT littermates, and single cell 
suspensions made. Cells were then stained with L27 anti-hCD20 along with cell lineage markers 
and analyzed using a MACSQuant. (A) Graph of pooled data showing the percentage of hCD20+ 
B cells and T cells in the peripheral lymph nodes of hCD20tg mice and WT littermates. (B) Graph 
of pooled data showing the percentage of hCD20+ B cells, T cells, monocytes and neutrophils in 
the blood of hCD20tg mice and WT littermates. (C) Graph of pooled data showing the percentage 
of hCD20+ Ly6Chi, Ly6Cint and Ly6Cneg monocytes in the blood of hCD20tg mice and WT 
littermates. (hCD20tg n=5, WT littermates n=3, data from a single experiment) Statistics used: 
lymph nodes - unpaired T test; blood - One way ANOVA performed on each complete data set 
(splenic cell populations, monocyte subsets) followed by Bonferroni’s post test, with *** = p<0.001. 
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Figure 6.10 Transgenic hCD20 is expressed on splenic B cells from hCD20tg DBA mice 
Spleens were isolated from hCD20tg DBA mice and WT littermates, and single cell suspensions 
made. Cells were then stained with L27 anti-hCD20 along with cell lineage markers and analyzed 
using a MACSQuant. (A) Representative FACS plots showing hCD20 staining on each splenic cell 
population investigated. B cell panels: hCD20 vs. CD19. T cell panels: hCD20 vs. CD3. Monocyte 
panels: hCD20 vs. CD45. Neutrophil panels: hCD20 vs. Ly6C. (B) Graph of pooled data showing 
the percentage of hCD20+ B cells, T cells, monocytes and neutrophils in the spleens of hCD20tg 
mice and WT littermates. (C) Graph of pooled data showing the percentage of hCD20+ follicular 
(Fo), transitional-1 (T1) and transitional-2/marginal zone (T2-MZ) B cells in the spleens of hCD20tg 
mice and WT littermates. (D) Graph of pooled data showing the percentage of hCD20+ Ly6Chi, 
Ly6Cint and Ly6Cneg monocytes in the spleens of hCD20tg mice and WT littermates. (n=3, data 
from a single experiment) Statistics used: One way ANOVA performed on each complete data set 
in (B) (C) and (D), followed by Bonferroni’s post test, with *** = p<0.001. 
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Figure 6.11 Transgenic hCD20 is expressed on B cells from the lymph nodes and blood of 
hCD20tg DBA mice 
Tissues were isolated from hCD20tg DBA mice and WT littermates, and single cell suspensions 
made. Cells were then stained with L27 anti-hCD20 along with cell lineage markers and analyzed 
using a MACSQuant. (A) Graph of pooled data showing the percentage of hCD20+ B cells and 
T cells in the peripheral lymph nodes of hCD20tg mice and WT littermates. (B) Graph of pooled 
data showing the percentage of hCD20+ B cells, T cells, monocytes and neutrophils in the blood of 
hCD20tg mice and WT littermates. (n=3, data from a single experiment) Statistics used: lymph 
nodes - unpaired T test; blood - One way ANOVA performed on the complete data set, followed by 
Bonferroni’s post test, with *** = p<0.001. 
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Together this data supports the previous FACS data showing that C57BL/6 hCD20tg mice 
express significant levels of hCD20 on the surface of their B cells, and that this 
expression is limited to the B cell populations in all tissues tested. It also clarifies the 
pattern of expression of hCD20 on monocytes in both the spleen and blood, showing that 
the previous hCD20 expression seen in the Ly6Cneg monocyte populations was indeed due 
to B cell contamination during analysis, rather than a true reflection of the expression 
by these cells. The characterization of the DBA hCD20tg strain confirms that these mice 
also express significant levels of hCD20 on the surface of their B cells, although the 
proportion of hCD20 expressing cells varies more than in the original hCD20tg C57BL/6 
colony, and this expression is specific to the B cell populations in the tissues tested. 
6.2.6 Binding of Rituximab to hCD20tg B cells  
RTX is a chimeric anti-hCD20 antibody, derived from the murine parent 2B8 clone 
(C2B8). After the discovery that anti-CD20 antibodies of different clones vary greatly in 
their ability to bind transgenic hCD20, studies were undertaken to confirm the ability of 
RTX to bind B cells from hCD20tg mice. To do this, RTX was conjugated to the 
fluorochrome AlexaFluor-488 (RTX-488), allowing detection of the monoclonal antibody 
by flow cytometry. 
An initial comparison of RTX binding to total splenocytes from hCD20tg mice and WT 
littermates was undertaken (Figure 6.12). Cells were stained with CD19 to allow 
detection of B cells and incubated with the RTX-488 conjugate. While no notable RTX-
488 staining was observed in WT littermates (2.1% of CD19+ cells), 97.5% of CD19+ 
splenocytes in hCD20tg mice were RTX-488 positive.  
Once it was seen that the RTX-488 conjugate was indeed able to bind to CD19+ hCD20tg 
cells, a comparison between the binding of RTX-488 and the commercially available 
anti-hCD20 antibodies was made (Figure 6.13a). Cells were stained with cell lineage 
markers, and either 2H7 anti-hCD20, L27 anti-hCD20, or RTX-488. Significantly more 
hCD20+ B cells were detected with RTX-488 than either commercially available antibody 
in both the spleens and peripheral LNs of hCD20tg C57BL/6 mice (Figure 6.13b). When 
using RTX-488 (1µg/test), 96.1±0.9% of splenic CD19+ B cells stained positive for hCD20, 
while only 51.9±7.6% and 0.6±0.2% of B cells were hCD20+ with the L27 and 2H7 anti-
hCD20 antibodies, respectively. A similar level of hCD20+ B cells was detected using 2µg 
of RTX-488 per test (hCD20tg C57BL/6, spleen: 96.1±0.9% vs. 97.2±0.7%). In the LNs of 
C57BL/6 hCD20tg mice, 98±0.1% of B cells were positive for hCD20 when using RTX-488 
staining (1µg/test), compared to 40.9±6.7% with L27 anti-hCD20 and 1.24±0.3% with 2H7 
anti-hCD20. In DBA hCD20tg mice a similar staining pattern was observed (Figure 6.13c),  
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Figure 6.12 Rituximab-488 binds to B cells in hCD20tg mice but not WT littermates 
Spleens were harvested from hCD20tg DBA mice and WT littermates. Total splenocytes were 
stained for lineage specific markers and RTX-488, and analyzed using a MACSQuant. 
Representative FACS plots showing the binding of RTX to lymphocytes in the spleens of WT 
littermates and hCD20tg mice. Top panels: SSC vs. FSC. Bottom panels: RTX-488 vs. CD19. 
(n=1) 
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Figure 6.13 A greater percentage of hCD20+ B cells can be detected in hCD20tg mice using 
RTX-488, compared to both L27 and 2H7 antibodies 
Tissues were isolated from hCD20tg mice and single cell suspensions made. Cells were then 
stained for lineage specific markers, and either L27 anti-hCD20, 2H7 anti-hCD20, or RTX-488, and 
analyzed by flow cytometry. CD3-CD19+ cells were gated on, and the staining of hCD20 evaluated. 
(A) Representative FACS histograms showing staining of hCD20 on B cells isolated from spleens 
and LNs of hCD20tg mice. Coloured lines represent the anti-hCD20 antibody used, with grey 
histograms representing FMO staining. First row panels: % of Max vs. L27 anti-hCD20, Second 
row panels: % of Max vs. 2H7 anti-hCD20. Third row panels: % of Max vs. RTX-488 (1ug/test). 
Fourth row panels: % of Max vs. RTX-488 (2µg/test). (B) Graphs of pooled data showing the 
percentage of hCD20+ B cells in the spleen (left) and LN (right) of hCD20tg C57BL/6 mice. 
(C) Graphs of pooled data showing the percentage of hCD20+ B cells in the spleen (left) and LN 
(right) of hCD20tg DBA mice. (hCD20tg C57BL/6 n=3, hCD20tg DBA n=4, data from a single 
experiment) Stats used: One way ANOVA performed on each complete data set (hCD20tg 
C57BL/6 spleen, hCD20tg C57BL/6 LN, hCD20tg DBA spleen, hCD20tg DBA LN) followed by 
Bonferroni’s post test, with ** = p<0.01 and *** = p<0.001. 
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with 96.5±0.7% of splenic B cells staining positive for hCD20, compared to only 
60.7±9.6% and 0.5±0.07% with L27 and 2H7 anti-CD20, respectively. RTX-488 was also 
able to detect far greater levels of hCD20+ B cells in peripheral LN samples from DBA 
hCD20tg mice, with 96±1.3% of B cells staining positive for hCD20 compared to 50±9.2% 
with L27 anti-hCD20 and 1.5±0.2% with 2H7 anti-hCD20. 
Together this data confirms that RTX is able to bind to B cells from both hCD20tg 
C57BL/6 and DBA hCD20tg mice, and that this binding is specific for transgenic hCD20, 
as minimal RTX binding was detected on B cells from WT littermates. 
6.2.7 RTX-mediated B cell depletion in hCD20tg mice 
Once the ability of RTX to bind B cells from hCD20tg mice had been confirmed, the 
ability of RTX to deplete B cells in hCD20tg mice was investigated. To do this, healthy 
animals were injected i.v. with 100µg RTX or control IgG. On day 6 mice were bled from 
the tail vein, red blood cells lysed, and the samples stained for flow cytometry and 
analysed on a FACSCalibur. On day 7 the mice were sacrificed, and the spleens, 
peripheral lymph nodes, mesenteric lymph nodes, and peyers patches harvested and 
single cell suspensions made. All tissue samples were stained for lineage markers and 
run on a FACSCalibur. Results were normalized and expressed as a ratio of B cells:T cells 
in the relevant tissue. 
RTX treatment resulted in a varying degree of depletion of B cells, with significant 
levels of depletion seen in all tissues tested, bar the spleen. In the spleen, no 
significant B cell depletion was detected, with RTX-treated animals having 0.62±0.1 
B cells to every T cell, compared to 0.92±0.01 in the control animals. Significant B cell 
depletion was seen the peripheral LNs, mesenteric LNs and peyers patches. In RTX-
treated mice 0.13±0.04 B cells:1 T cell were seen in the peripheral LNs, compared to  
0.26±0.04 B cells:1 T cell in the control animals, in the mesenteric LN, RTX-treated 
animals had 0.09±0.01 B cells:1 T cell, compared to 0.41±0.09, and in the peyers 
patches treated mice had 0.68±0.07 B cells:1 T cell, compared to 1.78±1 B cell:1 T cell. 
The greatest level of B cell depletion was seen in the blood, with a reduction from 
2.1±0.34 B cells:1 T cell in control animals to 0.21± 0.01 B cells:1 T cell. 
These results demonstrate that RTX effectively depletes B cells in the blood of hCD20tg 
mice, with significant depletion also seen in the majority of secondary lymphoid organs 
investigated. 
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Figure 6.14 RTX-mediated B cell depletion in hCD20tg mice 
Healthy hCD20tg C57BL/6 mice were injected i.v. with either 100µg RTX or 100µg IgG on day 0. 
On day 6 mice were bled from the tail vein, and on day 7 sacrificed, with spleens, peripheral lymph 
nodes (LNs), mesenteric lymph nodes (MLNs), and peyers patches (PP) harvested and single cell 
suspensions made. All tissue samples were stained for lineage markers and run on a FACSCalibur 
on the day of collection. (A) Representative FACS plots demonstrating the gating strategy used to 
define total B cells and total T cells. Top panel: SSC vs. FSC. Bottom panel: CD3 vs. CD19. 
(B) Representative FACS plots showing the levels of B cells depletion in various tissues of the 
body. Panels: CD3 vs. CD19. (C) Graph of pooled data showing the ratio of B cells:T cells in the 
spleen, LN, MLN, PP and blood of RTX-treated and IgG-treated mice. (n=3, data from a single 
experiment) Statistics used: Unpaired t-test (RTX-treated vs. IgG-treated), with * = p<0.5, 
** = p<0.01 and *** = p<0.001. 
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6.3 Discussion 
• The in-house colonies of hCD20tg C57BL/6 and DBA mice were characterised in 
order to determine their suitability for use in RTX-mediated depletion studies. 
• Both hCD20tg strains express hCD20 on the surface of their B cells, with RTX 
able to bind this transgenic hCD20 resulting in B cell depletion in the peripheral 
blood and secondary lymphoid organs. 
• These results demonstrate that the hCD20tg C57BL/6 and DBA strains are 
suitable for use in studies employing RTX-mediated B cell depletion. 
To allow the use of Rituximab in our experiments, rather than a mouse specific anti-
CD20 antibody, transgenic C57BL/6 mice expressing hCD20 on the surface of their 
B cells have been obtained and bred in house. From this parent strain a hCD20tg DBA 
strain has also been generated. To do this, the MAX-BAXsm (Marker-Assisted Accelerated 
Backcrossing) program of speed congenics from Charles River was utilized to backcross 
the founder line to DBA/1J over 9 generations. With this method, the genetic 
background of each offspring was determined by microsatellite analysis, allowing the 
percentage congenicity to be assessed throughout backcrossing, resulting in the rapid 
production of the DBA congenic strain.  
In the majority of the literature utilizing hCD20tg mice the 2H7 clone of anti-hCD20 
antibody has been used. All 2H7 antibodies tested for their ability to bind hCD20 in 
human buffy coat samples were able to detect hCD20 expression, with the percentage 
of B cell identified as hCD20+ increasing with the amount of antibody used. However, 
when using 2H7 anti-hCD20 antibodies on samples from hCD20tg mice, transgenic hCD20 
was detected in very low levels, if at all, on the surface of primary hCD20tg B cells. This 
finding caused some concern initially as it indicated the hCD20tg mice might not express 
the hCD20 protein on the surface of their B cells even though the transgene was 
present. Once it was determined that this result was not due to the concentration of 
antibody or the particular vial of antibody used (results not shown), an anti-hCD20 
antibody of clone L27 was evaluated. The L27 antibody was able to detect considerable 
hCD20 on the surface of B cells isolated from hCD20tg mice, indicating that the previous 
lack of detection was due to the clone of antibody used, and not a lack of hCD20 
expression.  
Although the expression of hCD20 on transgenic B cells was detected after this reagent 
change, the lack of binding of transgenic hCD20 by the 2H7 antibodies raises some 
questions about the molecule expressed by the hCD20tg mice, and its similarity to 
endogenous hCD20. Three isoforms of CD20 are expressed on the surface of human 
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B cells, with the 33,000 Mr isoform accounting for 75-80% of surface CD20 [328,329]. 
Although the commercially available anti-hCD20 antibodies do not specify a target CD20 
isoform, it may be the case that certain clones are more readily able to detect one 
isoform over the others, and that the prominent isoform expressed by hCD20tg mice 
differs from that expressed in humans. SDS-polyacrylamide gel electrophoresis was 
originally utilized to identify the relative expression of the different hCD20 isoforms on 
human B cells, and this technique could also be employed to identify the specific 
isoform/s of hCD20 expressed by hCD20tg mice. Another explanation for the lack of 
binding could be related to the fact that different clones of antibody of the same 
specificity will detect different epitopes on the target molecule. Potentially, the 
transgenic expression of hCD20 on murine B cells somehow alters epitopes on the 
molecule, resulting in a loss or masking of the epitope 2H7 antibodies bind. The gene 
encoding endogenous murine CD20 is not disrupted on insertion of the hCD20-containing 
BAC, and therefore is expressed alongside hCD20 on the surface of the transgenic B cells 
[242]. As such it is possible that some level of steric hindrance between the two forms 
of CD20 is occurring. 2H7 anti-hCD20 antibodies are structurally similar to RTX [330], 
with almost identical core contact regions [85], however studies have shown that 
differences in the H3 loop of the two antibodies result in a lower affinity of 2H7 for 
hCD20 and fewer binding interactions when compared to RTX [330]. On investigation of 
the binding of RTX to transgenic hCD20 it could be seen that RTX was capable of binding 
the vast majority of transgenic B cells. In the tests undertaken, a RTX-488 conjugate 
bound over 90% of primary hCD20tg B cells from both the spleen and peripheral LNs of 
C57BL/6 and DBA hCD20tg mice, a far higher percentage than either the 2H7 or L27 
antibodies. RTX binding was not seen in WT littermates, confirming that RTX was 
binding to the hCD20 and not endogenous CD20 on murine B cells. These results 
highlights the fact that although the percentage of hCD20+ detected using the L27 
antibody was far greater than that with the 2H7 clone, it was still far less able to bind 
to transgenic hCD20 than RTX.  Titration of the L27 antibody was not undertaken, and 
so the reduced levels of binding seen with this antibody compared to RTX may be an 
intrinsic trait of the antibody, however it could potentially be due to the use of sub-
optimal concentrations during staining. The ability of RTX to bind transgenic hCD20 on 
the surface of the vast majority of transgenic B cells, along with the, albeit reduced, 
ability of the L27 clone, indicates that the lack of binding of 2H7 is due to the antibody, 
rather than a lack of hCD20 expression.  
The L27 anti-hCD20 antibody was used to undertake a more in depth investigation of the 
pattern of hCD20 expression in hCD20tg C57BL/6 mice. Some issues with the staining 
panel used were highlighted during analysis, specifically the inability to fully gate out 
B cells from the Ly6Cneg monocyte population, and as a result modifications to the 
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monocyte-staining panel were made. Using this revised staining panel, the hCD20tg 
C57BL/6 and hCD20tg DBA strains were characterized, with cells from the spleens, 
peripheral LNs and blood from these animals analyzed by flow cytometry. In both the 
hCD20tg C57BL/6 and hCD20tg DBA bred in-house, it could be seen that the majority of 
B cells in the spleen, LNs and blood expressed hCD20, and this expression was consistent 
across all B cell subsets investigated. All other cell types looked at (T cells, neutrophils 
and monocytes) showed minimal hCD20 expression, including the Ly6Cneg monocyte 
population, confirming that the previously detected hCD20 expression was due to 
transgenic B cell contamination within this gate, rather than aberrant expression by this 
monocyte subset. Work by Mark Shlomchik’s group has previously shown that hCD20tg 
MRL/lpr mice, hCD20tg BALB/c mice and hCD20tg MRL+/+ mice all express high levels of 
transgenic hCD20 on the surface of their B cells as detected by flow cytometry [324]. 
The expression of hCD20 in these mice is first seen in the bone marrow at the late pre-B 
cell stage, with only background levels of hCD20 staining detected on the non-B cell 
populations tested [324]. Flow cytometric characterization of splenocytes from hCD20tg 
NOD mice has also confirmed expression of hCD20 on the surface of B cells, with this 
expression occurring from the pre-B cell stage to mature B cells [325]. B cell function in 
these hCD20tg NOD mice was shown to be unaffected by hCD20 expression compared to 
WT NOD mice, with no difference in CD40 and CD86 up-regulation seen after stimulation 
with either anti-Ig or anti-CD40 antibodies [325]. The levels of natural IgA, IgG1 and 
IgG2 in the serum of hCD20tg and WT NOD mice were also found to be comparable, as 
detected by ELISA [325]. The hCD20 expression patterns seen in the in-house hCD20tg 
C57BL/6 and hCD20tg DBA colonies are in line with the characterizations of numerous 
hCD20tg strains previously undertaken by other researchers, and confirm the expression 
patterns expected in these strains. 
The ability of RTX to deplete B cells in hCD20tg C57BL/6 mice was then investigated. 
Some level of B cell depletion was detected in all tissues investigated, however the 
extent of depletion varied between tissues. It has been previously been documented 
that in patients, B cell depletion in solid tissues shows considerable variation between 
individuals and is frequently not complete [108,331-333], with work in primate models 
showing that increasingly higher doses of anti-CD20 mAbs are needed to deplete B cells 
in the bone marrow, LNs and spleen [92]. Interestingly, previously work has generally 
indicated that splenic B cells are cleared more readily by RTX-mediated depletion than 
LN B cells [241], however in the present study that was found not to be the case. 
Although some differences arose in the pattern of B cell depletion seen in the hCD20tg 
mice compared to other work, depletion was in line with that expected, and as such it 
was decided that the hCD20tg strain would be an appropriate model for RTX-depletion 
studies.  
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These results show that transgenic mice bred from our C57BL/6 and DBA hCD20tg 
colonies can be readily detected via PCR, and that these mice express the hCD20 
molecule on the surface of their B cells in the spleen, peripheral LNs and blood. This 
expression is restricted to the B cell population, and not seen in transgene-negative WT 
littermates. The hCD20 molecule expressed by both the C57BL/6 and DBA hCD20tg mice 
can be bound by RTX, with no binding of endogenous murine CD20 seen in WT 
littermates. RTX treatment of hCD20tg mice resulted in the depletion of vast majority 
of B cells from the blood, and substantial numbers from secondary lymphoid organs. 
Together, these data demonstrate that the hCD20tg mice are a suitable model to use 
for studies into RTX-mediated B cell depletion. 
  
 
 
 
 
 
Chapter 7: Modelling Inflammatory 
Responses  In Vivo 
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7.1 Introduction 
Due to the complexity of the processes involved in autoimmune diseases, animal models 
are widely used to facilitate their study, and have been instrumental in countless 
advances within the field of RA research.  
Many rodent models of arthritis have been developed over the years. Some models 
utilize genetically manipulated animals that spontaneously develop arthritis over the 
course of their lifetime, such as the K/BxN mouse model. These mice express transgenic 
TcR receptors that recognize peptides deriving from a ubiquitously expressed protein, 
resulting in a severe, chronic arthritis, which typically develops at 4-5 weeks of age 
[reviewed in [334]. More commonly, models rely on the induction of disease either 
through the administration of an inducing agent, such as type-II collagen (CII) [335] 
aggrecan [336], or the soluble auto-antigen G6PI (glucose-6-phosphate isomerase) [337], 
or the passive transfer of disease via autoantibody transfer [338].  
Collagen induced arthritis (CIA) was first described in the late 1970s [339], and is one of 
the most prevalent models of rheumatoid arthritis in use today. This model relies on the 
immunization of genetically susceptible strains of mice [340] with an emulsion of 
heterologous type-II collagen (CII) and Complete Freund’s Adjuvant (CFA) to initiate 
disease, followed by a CII challenge on day 21. Clinical symptoms normally begin to 
present 21-28 days after initial disease induction, and can be evaluated by both clinical 
arthritis scoring systems and paw and ankle measurements [335]. Sub-clinical disease 
parameters can also be assessed, with CII-specific T cell proliferative responses and 
titres of serum CII-specific IgG subclasses often investigated. 
CIA is characterized by synovial hyperplasia and the progressive destruction of cartilage 
and bone, with disease induction requiring both T cell and B cell activation, as well as 
the infiltration of joint tissue by populations of inflammatory cells. Genetic 
susceptibility to CIA is associated with the expression of particular MHC II haplotypes, 
with mice expressing H-2Aq readily susceptible to disease induction. This MHC II 
association highlights the role of CD4+ T cells in disease pathology, with a dominant Th1 
response established early on in disease and characterized by the production of IFNγ 
during the onset of arthritis [341]. This early T cell response is vital to CIA 
development, with administration of monoclonal antibodies toward CD4 [342], the TcR 
[343], or MHC II molecules [344] at the time of disease induction able to suppress 
disease pathogenesis. However, a direct role for T cells in mediating disease pathology 
is uncertain. The Th1 response initiates inflammation by recruiting polymorphonuclear 
cells, to the joint and providing B cell help. Infiltrating polymorphonuclear cells 
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produce a range of pro-inflammatory cytokines including TNFα [345], IL-1β [346] and IL-
6 [347]. TNFα induces the up-regulation of adhesion molecules on the endothelium, 
further enhancing the infiltration of inflammatory cells, with IL-1β promoting 
neutrophilia and the production of collagenases, the enzymes responsible for the break 
down of collagen. IL-6 stimulates myelopoiesis, and is involved the development of 
activated B cells, with the production of anti-CII antibodies by B cells a hallmark of CIA 
pathogenesis. In DBA mice, the Th1-associated IgG2a subclass is the predominant 
pathogenic isotype, with a positive correlation seen between the serum levels of CII-
specific IgG2a and clinical pathology [348]. These CII-specific autoantibodies are 
considered to be the primary mechanism of disease immunopathogenesis, binding to 
articular cartilage and initiating the complement cascade [349]. Activation of 
complement contributes to the recruitment of innate immune cells, such as neutrophils 
and macrophages, further promoting joint inflammation. Innate cell infiltration 
eventually leads to the development of oedema and synovial hyperplasia [350], with 
subsequent pannus formation at the synovium-cartilage interface. On disease 
progression a down-regulation of IFNγ production results in a skewing of the immune 
response toward a Th2 phenotype, with an associated increase in the Th2 cytokines IL-
10 and IL-4 [341]. CIA is a transient model of arthritis, with this increase in IL-10 
production helping to down-regulate the pathogenic inflammatory response, and 
resulting in eventual disease remission. 
The pathogenesis of CIA shares multiple features with human disease, such as the 
development of synovial hyperplasia, autoantibody production by B cells [351], and 
joint infiltration by inflammatory cells [350]. However, differences between CIA and 
human arthritis are also apparent. Disease progresses far more rapidly in CIA, and, 
unlike RA, is of a transient nature. The pattern of joint involvement also differs 
between the diseases, and periostial reactions are common in the mouse model but not 
in human arthritis. Despite the various differences, CIA is a valuable tool for 
understanding the pathogenesis of human disease, as well as for testing the efficacy of 
new therapies [352] and better understanding the mode of action of those already in 
use [353]. 
Along with the study of specific diseases, animal models can be utilized to explore 
varying aspects of the immune response to particular antigens. Delayed-type 
hypersensitivity (DTH) assays are used to investigate antigen-specific, cell-mediated 
immunity in response to a chosen antigen, and have been frequently used in studies of 
oral tolerance [354-357], as well as in those looking into the re-introduction of systemic 
tolerance in autoimmune disorders [182,358]. 
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To induce DTH responses, mice are systemically immunized with the selected antigen, 
followed by a challenge 14-21 days later, in either the ear pinna [359] or footpad [183]. 
Local swelling is assessed 24 hours post challenge, with antigen-specific T cell responses 
[182] and serum antibody levels also commonly examined. DTH responses are dependent 
on local T cell-mediated responses to the model antigen [360], leading to cellular 
infiltration and oedema at the site of antigen challenge, with tolerance in this model 
defined as a lack of inflammation in response to this controlled re-exposure. 
In this chapter both the CIA and DTH models have been utilized in an effort to dissect 
the complex interactions taking place on RTX-mediated B cell depletion in RA.  
Chapter objectives: 
• To investigate whether apoptotic B cells are able to ameliorate disease 
symptoms in a murine model of CIA 
• To investigate whether RTX treatment of hCD20tg mice can improve disease 
outcome in a murine model of CIA 
• To set up a DTH model in the lab for future use to explore tolerance induction 
after RTX treatment 
7.2  Results 
7.2.1 Prophylactic treatment of CIA with apoptotic B cells 
Rituximab treatment causes the depletion of CD20-expressing B cells in the blood and 
lymphoid tissues of the body in both humans and mice [81,361]. This depletion is 
thought to occur through several mechanisms including, but not limited to, direct 
apoptosis of B cells [238]. There is a vast body of literature demonstrating the 
immunosuppressive effects of apoptotic cells on the immunes system, and it has 
previously been shown by Gray et al that apoptotic thymocytes protect mice from CIA 
[172]. The current study aimed to investigate the effect of apoptotic B cells on 
arthritis. To do this, either 5x106 or 0.5x106 apoptotic B cells were adoptively 
transferred via the tail vein into WT DBA mice on day 0, with control mice receiving PBS 
only or 5x106 viable B cells. CIA was induced with chicken CII in all mice on day 0, and 
boosted on day 21, following the protocols outlined in section 2.4.3, and disease 
progression and severity was evaluated. Using this protocol to induce arthritis, disease 
is not generally seen before the boost on day 21, and so clinical scoring, ankle, and paw 
measurements, were not started before this time.  
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Similar levels of general inflammation, as measured by the 16-point clinical scoring 
system (Chapter 2, Table 2.1), could be detected in all groups (Figure 7.1a), with 
average cumulative scores of 12±12 for the PBS treated group, 22±26 for the group that 
received 5x106 B cells, 18±22 for the group that received that 5x106 apoptotic B cells, 
and 15±21 for the group that received 0.5x106 apoptotic B cells. The general 
inflammation scores of individual animals were also investigated on d39 and d42 (Figure 
7.1b), and it can be seen that in both groups receiving apoptotic B cells the average 
score is brought up by only one or two highly arthritic animals, in comparison to the PBS 
and B cell groups which contain a greater proportion of highly arthritic animals. Joint 
inflammation scores followed the same pattern of progression as the general 
inflammation scores (Figure 7.1c), with no differences detected between any of the 
groups. Again, the joint inflammation scores of individual animals were investigated on 
d39 and d42 (Figure 7.1d). With this mode of visualisation it can be seen that as with 
the general inflammation scores, both groups receiving apoptotic B cells contain only 
one or two highly arthritic animals, in comparison to the PBS and B cell groups which 
contain a greater proportion of highly arthritic animals. 
Ankle size changed little over the course of the experiment (Figure 7.2a), and no 
difference was observed between treatment groups. A greater variation in paw size was 
seen, although again, no difference was detected between any group (Figure 7.2b). 
Averaging 52±6%, the incidence of disease was considerably lower than expected (Figure 
7.2c), with incidence levels of 80-100% anticipated in DBA mice [335]. 
The general-inflammation and joint-inflammation scores, along with paw and ankle 
measurements, allow quantification of clinical disease, however there may be sub-
clinical disease in animals that do not present with visible symptoms. To allow 
investigation of this potential sub-clinical disease, blood was collected from all mice on 
day 42 and ELISAs undertaken to quantify total serum titres of IgG and IgG1, as well as 
relative levels of CII-specific IgG1 and IgG2a. No difference was seen in the 
concentration of either total IgG (Figure 7.3a) or total IgG1 (Figure 7.3b) between the 
treatment groups. Titres of CII-specific IgG1 and IgG2 were also comparable in all 
groups (Figure 7.3c and d, respectively). 
To determine whether the scoring of paw inflammation was accurately representing 
sub-clinical disease in the mice, the correlation between maximal joint score and CII-
specific antibody titres was investigated. The groups receiving 5x106 B cells, and 5x106 
apoptotic B cells showed a significant correlation between maximal joint score and CII-
specific IgG1 levels, with serum antibody titres increasing with increased score (Figure 
7.4a). The groups administered either PBS or 0.5x106 apoptotic B cells did not show any 
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correlation between clinical score and CII-specific IgG1. No correlation between joint 
inflammation scores and serum CII-specific IgG2a was seen in any treatment group 
(Figure 7.4b).  
As an additional read out of sub-clinical disease, T cell proliferation in response to re-
stimulation with collagen was measured by quantifying the incorporation of radioactive 
tritiated-thymidine (3H-thymidine) into newly synthesized cells (Figure 7.5). LN cells 
were harvested from all mice on day 42, and cells cultured in vitro with collagen 
protein for 72-96hr, before pulsing with 3H-thymidine. Significantly more proliferation 
was seen in the T cells from mice receiving 5x106 B cells, compared to those given PBS 
regardless of the concentration of CII re-stimulation. However, this increased 
proliferation was not significant when compared to either of the other treatment 
groups. There was also an increase in proliferation of cells from mice given 5x106 
apoptotic B cells compared to PBS controls, when cultured with 60µg/ml of collagen. 
Again, this increase was not significant when compared to the proliferation levels of the 
other groups when cultured with 60µg/ml collagen.   
With the experimental protocol used, no effect of apoptotic B cell administration on CIA 
progression or severity could be detected, as measured by either clinical scores or 
serum CII-specific antibody levels. However, unexpectedly, an increase in collagen-
induced T cell proliferation was seen in cells from mice that received 5x106 apoptotic 
B cells compared to PBS control animals. 
7.2.2 Effects of hCD20tg B cell transfer and subsequent RTX treatment 
on CIA severity and progression 
In parallel to this study, the effects of RTX-mediated B cell apoptosis on CIA were 
investigated. It is known that RTX treatment directly induces apoptosis in a proportion 
on the B cell population [235-237], and this is a potential mechanism by which RTX 
exerts its beneficial effects. A strain of hCD20tg DBA mice have been generated in-
house to allow the use of RTX in an animal model of arthritis, however at this point in 
time our hCD20tg DBA colony was not fully established and therefore not available in 
the numbers required for disease models. As an interim solution, it was decided to 
adoptively transfer hCD20tg DBA B cells into WT DBA mice, allowing apoptosis to be 
induced in this defined B cell population. The adoptive transfer of hCD20tg B cells and 
subsequent RTX treatment took place on day 0, with induction of CIA using chicken CII 
undertaken later the same day. This allowed the study of the effects of RTX-mediated 
B cell apoptosis specifically, rather than an alternate method of B cell apoptosis. 
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Figure 7.1 Clinical scores of collagen induced arthritis in WT DBA mice adoptively 
transferred with apoptotic B cells  
On day 0 WT DBA mice were adoptively transferred with either: 5x106 B cells (); 5x106 apoptotic 
B cells (); or 0.5x106 apoptotic B cells () via the tail vein. Control mice received PBS only (). 
CIA was then induced in these animals. (A) Graph showing the general inflammation scores (16-
point scoring system) for all treatment groups. (B) Scatter graph showing the general inflammation 
scores for each animal on days 39 and 42. (C) Graph showing the joint inflammation scores (24-
point scoring system) for all treatment  (D) Scatter graph showing the joint inflammation scores for 
each animal on days 39 and 42. (n=13, data from 2 independent experiments) Statistics used: 
Two-way ANOVA, followed by Bonferroni’s post-test, with p<0.05 considered statistically 
significant.  
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Figure 7.2 Swelling and incidence of collagen induced arthritis in WT DBA mice adoptively 
transferred with apoptotic B cells  
On day 0 WT DBA mice were adoptively transferred with either: 5x106 B cells (); 5x106 apoptotic 
B cells (); or 0.5x106 apoptotic B cells () via the tail vein. Control mice received PBS only (). 
CIA was then induced in these animals. (A) Graph showing the change in ankle size for all 
treatment groups. (B) Graph showing the change in paw size for all treatment groups. (C) Graph 
showing the incidence of disease in all treatment groups. (n=13, data from 2 independent 
experiments) Statistics used: Two-way ANOVA performed on complete data sets in (A) (B) and (C), 
with p<0.05 considered significant.  
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Figure 7.3 Serum antibody titres in WT DBA mice adoptively transferred with apoptotic 
B cells 
Mice were culled on d42, blood samples collected and serum IgG titres quantified by ELISA. 
(A) Graph showing the concentration of total serum IgG (mg/ml) for all treatment groups (B) Graph 
showing the concentration of total serum IgG1 (mg/ml) for all treatment groups. (C) Graph showing 
the concentration of CII-specific serum IgG1 (RU = relative units) for all treatment groups. 
(D) Graph showing the concentration collagen type-II specific IgG2a (RU = relative units) for all 
treatment groups. (n=13, data from 2 independent experiments) Statistics used: One-way ANOVA 
performed on the complete data sets in (A) (B) (C) and (D), followed by Bonferroni’s post-test, with 
p<0.05 considered statistically significant. 
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Figure 7.4 Correlation of maximal joint inflammation score with serum titre of collagen-
specific IgG1 or IgG2a 
(A) Graphs showing the correlation of maximal joint inflammation score (24-point clinical score) and 
CII-specific IgG1 for each treatment group. (B) Graphs showing the correlation of maximal joint 
inflammation score and CII-specific IgG2a for each treatment group. (PBS only  (n=12); 5x106 
B cells  (n=12); 5x106 apoptotic B cells  (n=12); or 0.5x106 apoptotic B cells  (n=11, data 
from 2 independent experiments). Statistics used: Linear regression and Spearman r tests where 
shown , with * = p<0.05.  
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Figure 7.5 Collagen re-stimulation responses 
Mice were culled on d42 and peripheral LNs were harvested to allow the investigation of cellular 
proliferation in response to collagen re-stimulation was investigated.  LN cells were cultured in vitro 
with 3H-thymdine and either 30µg/ml or 60µg/ml collagen protein to look at specific proliferation 
responses. Values are normalized to media only controls. CPM = counts per minute. (0.5x106 
apoptotic B cells: n=6, all other groups: n=7, data from a single experiment) Statistics used: One-
way ANOVA performed on complete data set, followed by Bonferroni’s post-test, with * = p<0.05, 
and *** = p<0.001. 
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No difference was seen in the levels of either general inflammation or joint specific 
inflammation between the treatment groups (Figure 7.6a and b, respectively). The 
general and joint inflammation scores of individual animals was also plotted, to attempt 
to visualise any differences between the treatments groups (Figure 7.6b and d). All 
groups, except the hCD20 B cell + RTX group, show a clear separation between a highly 
arthritis group and a minimally arthritis group, however the numbers of responders and 
non-responders did not differ between groups. The hCD20 B cell + RTX group show a 
more uniform spread of scores, which could indicate that the treatment was able to 
reduce the clinical score of animals which would have otherwise become highly 
arthritic. However, it may also be a sign of a more consistent disease induction within 
this group, and without further work would be needed to discern the cause. A more 
severe arthritis was seen in this run of CIA compared to the runs undertaken in which 
irradiated apoptotic B cells were adoptively transferred into WT DBA mice, with average 
cumulative scores of: 27±28 for mice receiving hCD20tg B cells + RTX; 23±25 for mice 
receiving RTX alone: 27±23 for mice receiving hCD20tg B cells + IgG; and 25±19 for mice 
receiving IgG alone. An increase in both ankle and paw size was observed in all groups 
after day 37, however the levels of swelling did not differ between the treatment 
groups (Figure 7.7a and b). Disease incidence averaged 83±14% for the run, falling 
within the range expected for DBA/1 mice [335] (Figure 7.7c).  
In the IgG treated group a significantly higher concentration of total serum IgG was 
found compared to the RTX treated group (Figure 7.8a), with this groups also having a 
significantly higher concentration of total serum IgG1 compared to all other treatment 
groups (Figure 7.8b). No difference in the levels of total IgG or total IgG1 was seen 
between any of the other treatment groups. Relative levels of serum CII-specific IgG1 
and IgG2a were unchanged between the groups (Figure 7.8c and d, respectively). 
The correlation between maximal joint inflammation score and serum levels of CII-
specific IgG1 and IgG2a was investigated (Figure 7.9). A significant positive correlation 
was seen between maximal inflammatory score, and both CII-specific IgG1 and IgG2a 
subclasses, in the mice given hCD20tg B cells + RTX. A significant correlation was also 
seen in the IgG control group between maximal joint inflammation score and levels of 
CII-specific IgG2a, with higher levels of IgG2a seen as maximal scores increased. 
T cell proliferation in response to re-stimulation with collagen was also measured. 
Significantly more proliferation was seen in T cells from mice receiving IgG alone, than 
those receiving either hCD20tg B cells + IgG, or RTX alone, when cultured with 60µg/ml 
of CII (Figure 7.10). No other variation in the levels of T cells proliferation was seen
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Figure 7.6 Clinical scores of collagen induced arthritis in WT DBA mice adoptively 
transferred with hCD20tg B cells and treated with Rituximab 
On day 0, hCD20tg B cells were adoptively transferred into WT DBA mice via the tail vein, which 
were then given a single dose of RTX (), or hIgG (). Further control mice received RTX of hIgG 
only ( and , respectively). CIA was then induced in these animals the same day. (A) Graph 
showing the general inflammation scores (16-point scoring system) for all groups. (B) Scatter graph 
showing the general inflammation scores for each animal on days 42 and 42. (C) Graph showing 
the joint inflammation scores (24-point scoring system) for all groups. (D) Scatter graph showing 
the joint inflammation scores for each animal on days 42 and 44. (hCD20tg B cells + RTX group: 
n=8, for all other groups: n=7, data from a single experiment) Statistics used: Two-way ANOVA 
performed on complete data sets in (A) and (C), with p<0.05 considered statistically significant.  
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Figure 7.7 Swelling and incidence collagen induced arthritis in WT DBA mice adoptively 
transferred with hCD20tg B cells and treated with Rituximab 
On day 0, hCD20tg B cells were adoptively transferred into WT DBA mice via the tail vein, which 
were then given a single dose of RTX (), or hIgG (). Further control mice received RTX of hIgG 
only ( and , respectively). CIA was then induced in these animals the same day. (A) Graph 
showing the change in ankle size for all groups. (B) Graph showing the change in paw size for all 
groups. (C) Graph showing the incidence of disease in all treatment groups. (hCD20tg B cells + 
RTX group: n=8, for all other groups: n=7, data from a single experiment) Statistics used: Two-way 
ANOVA performed on complete data sets in (A) (B) and (C), with p<0.05 considered statistically 
significant.  
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Figure 7.8 Serum antibody titres in WT DBA mice adoptively transferred with hCD20tg 
B cells and treated with RTX 
Mice were culled on d44, blood samples taken and serum IgG titres quantified by ELISA. (A) Graph 
showing the concentration of total serum IgG (mg/ml) for all treatment groups (B) Graph showing 
the concentration of total serum IgG1 (mg/ml) for all treatment groups. (C) Graph showing the 
concentration of CII-specific serum IgG1 (RU = relative units) for all treatment groups. (D) Graph 
showing the concentration collagen type-II specific IgG2a (RU) for all treatment groups. (hCD20tg 
B cells + RTX group: n=8, for all other groups: n=7, data from a single experiment) Statistics used: 
One-way ANOVA performed on each complete data set in (A) (B) (C) and (D), followed by 
Bonferroni’s post-test, with * = p<0.05, ** = p<0.01, and *** = p<0.001. 
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Figure 7.9 Correlation of maximal joint inflammation score with serum titre of collagen-
specific IgG1 or IgG2a 
(A) Graphs showing the correlation of maximal joint inflammation score (24-point clinical score) and 
CII-specific IgG1 for each group. (B) Graphs showing the correlation of maximal joint inflammation 
score and CII-specific IgG2a for each group. (hCD20tg B cells + RTX  (n=8); RTX only  (n=6); 
hCD20tg B cells + IgG  (n=7); IgG only  (n=5), data from a single experiment). Statistics used: 
Linear regression and Spearman r tests where shown, with * = p<0.05.  
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Figure 7.10 Collagen re-stimulation responses 
Mice were culled on d42 and peripheral LNs were harvested to allow the investigation of cellular 
proliferation in response to collagen re-stimulation was investigated.  LN cells were cultured in vitro 
3H-thymdine and varying concentrations of collagen protein to look at specific proliferation 
responses. Values are normalized to media only controls. CPM = counts per minute. (hCD20tg 
B cells + RTX group: n=8, for all other groups: n=7, data from a single experiment) Statistics used: 
One-way ANOVA performed on complete data set, followed by Bonferroni’s post-test, with 
* = p<0.05, and ** = p<0.01. 
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between the groups when cells were cultured with 60µg/ml CII, and no differences in 
proliferation could be detected when the cells were cultured with 30µg/ml of CII. 
In this model system, RTX-mediated B cell apoptosis had no effect on the symptoms of 
CIA as determined by clinical scoring of general- and joint specific inflammation, as well 
as measurement of ankle- and paw swelling. In the IgG control group, an increase in 
T cell proliferation was seen, as well as higher levels of total serum IgG and IgG1, 
however no difference was detected in levels of CII-specific antibodies between any of 
the groups investigated. 
7.2.3 Rituximab treatment of CIA in hCD20tg DBA mice 
Once the hCD20tg DBA colony was established, the effects of RTX-mediated B cell 
depletion on CIA was investigated in this transgenic mouse model. hCD20tg mice have 
previously been used to explore RTX-mediated B cell depletion in a range of in vivo 
disease models [324,325,358], however this transgenic strain has not yet been used to 
study RTX-mediated B cell depletion in the context of arthritis. To do this, hCD20tg DBA 
mice were given a single dose of RTX on day 0, with CIA induced later the same day. 
WT littermates were included in the run for comparison of disease kinetics. 
General inflammation of the paws was detected from day 28 (Figure 7.11a), with joint 
inflammation being observed from the same time-point (Figure 7.11c). The severity of 
this inflammation increased over the course of the experiment in all treatment groups. 
The level of inflammation seen in the hCD20tg mice + IgG was lower than in the other 
groups, however this difference was not significant. The general inflammation scores 
and joint inflammation scores of individual animals were also investigated on d40 and 
d42 (Figure 7.10b, d). All groups contain both high and low responders, with no great 
difference seen in the numbers between the groups for either scoring system. 
Ankle size fluctuated in all groups (Figure 7.11a), with a significant increase in the ankle 
size of the WT littermates + RTX group seen on day 33, compared to that of the hCD20tg 
mice + IgG, and on d37 compared to both hCD20tg groups. Paw size peaked on day 37, 
with the WT littermates + RTX group having significantly more paw swelling than the 
hCD20tg mice + IgG on days 33, 35, 37 and 40 (Figure 7.11b). Again, the hCD20tg + IgG 
group were seen to have the least evidence of disease. Although there was no 
significant differences in disease incidence between the groups, the data indicated that 
disease incidence may be higher in WT littermates than in hCD20tg mice, with 86% of 
WT littermates showing signs of arthritis compared to 63% in the hCD20tg mice, falling 
below the expected levels for DBA mice (Figure 7.11c). 
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Serum was collected from all mice on day 42, and the absolute concentration of total 
polyclonal IgG and IgG1 assessed. Relative levels of CII-specific IgG1 and CII-specific 
IgG2a were also measured. No difference was detected in the concentration of total IgG 
or total IgG1 between any of the groups (Figure 7.12a, b). Collagen-specific IgG1 and 
IgG2a levels also showed no difference between groups, however the titres of CII-
specific IgG2a seen were more varied in both WT littermate groups compared to the 
groups consisting of hCD20tg mice (Figure 7.12d). 
 
In order to compare the clinical disease observed in the mice with any sub-clinical 
pathology the correlation between maximal clinical score for joint inflammation and 
CII-specific serum antibodies was examined (Figure 7.13). A significant positive 
correlation was seen between clinical score and CII-specific IgG1 levels in the WT 
littermates treated with IgG. No other group showed a significant correlation between 
these parameters. 
As a further measurement of sub-clinical disease, post-mortem x-rays were taken of the 
left hind paw to determine the level of radiographic pathology incurred during the 
model. Images were captured using a Kodak Fx Pro, and were scored for radiological 
bone damage. Figure 7.15a shows an overview of the joints included in the scoring 
system, as well as representative x-rays of a healthy and an arthritic mouse paw. With 
this scoring system, a score of 1 assigned for evidence of erosions, osteopenia, 
periostial reactions and loss of joint space in various joints of the paw, and a score of 0 
in the absence of evidence of each parameter. A maximal score of 27 was possible. 
Radiographic scores did not differ between the groups (Figure 7.15b), and no correlation 
was seen between the radiographic scores and the maximal joint inflammation scores 
for any of the groups in the run (Figure 7.15c). 
From these data it can be concluded that with the treatment regimen used, RTX-
mediated B cell depletion in hCD20tg had no effect on CIA severity or progression.  
7.2.4  Rituximab treatment prior to induction of CIA in hCD20tg DBA 
mice 
B cell depletion studies have been undertaken in multiple murine models of arthritis, 
each utilizing a different treatment regimen, with both the dosing and timing of anti-
CD20 mAbs administration varying [71,362-364]. In studies using the murine anti-CD20 
mAb MB20-16, Yanaba et al showed that B cell depletion before induction of CIA in DBA 
mice resulted in a different disease course and severity, compared to animals treated 
after disease onset [362]. We wanted to investigate whether the timing of RTX 
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Figure 7.11 Clinical scores of collagen induced arthritis in hCD20tg DBA mice and WT 
littermates treated with Rituximab  
CIA was induced in hCD20tg DBA mice and WT littermates on day 0. The RTX treated hCD20tg 
and WT littermate groups were given an i.v. injection of RTX on day 0  ( and , respectively), 
while control hCD20tg and WT littermate groups received IgG only ( and , respectively). 
(A) Graph showing the general inflammation scores (16-point scoring system) for all treatment 
groups. (B) Scatter graph showing the general inflammation scores for each animal on days 40 and 
42. (C) Graph showing the joint inflammation scores (24-point scoring system) for all treatment 
groups. (D) Scatter graph showing the joint inflammation scores for each animal on days 40 and 
42. (hCD20tg + RTX n=5. hCD20tg + IgG n=6, WT littermate groups: n=7, data from a single 
experiment) Statistics used: Two-way ANOVA performed on complete data sets in (A) and (C), 
followed by a Bonferroni’s post-test, with * = p<0.05, and ** = p<0.01.  
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Figure 7.12 Swelling and incidence of collagen induced arthritis in hCD20tg DBA mice and 
WT littermates treated with Rituximab  
CIA was induced in hCD20tg DBA mice and WT littermates on day 0. The RTX treated hCD20tg 
and WT littermate groups were given an i.v. injection of RTX on day 0  ( and , respectively), 
while control hCD20tg and WT littermate groups received IgG only ( and , respectively). 
(A) Graph showing the change in ankle size for all treatment groups. (B) Graph showing the 
change in paw size for all treatment groups. (C) Graph showing the incidence of disease in all 
treatment groups. (hCD20tg + RTX n=5. hCD20tg + IgG n=6, WT littermate groups: n=7, data from 
a single experiment)  Statistics used: Two-way ANOVA performed on complete data sets in (A) (B) 
and (C), followed by Bonferroni’s post-test, with * = p<0.05  and ** = p<0.01.  
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Figure 7.13 Serum IgG antibody titres in hCD20tg DBA mice and WT littermates treated with 
Rituximab 
Mice were culled on d42 and blood samples collected to assay for serum IgG titres by ELISA. 
(A) Graph showing the serum titres of total serum IgG (mg/ml) for all groups. (B) Graph showing 
the serum titres of total serum IgG1 (mg/ml). (C) Graph showing the serum titres of CII-specific 
IgG1 (RU = relative units) (D) Graph showing the serum titres of CII-specific IgG2a (RU) 
(hCD20tg + RTX n=5. hCD20tg + IgG n=6, WT littermate groups: n=7, data from a single 
experiment) Statistics used: One-way ANOVA, performed on each complete data set in (A) (B) (C) 
and (D), with p<0.05 considered statistically significant. 
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Figure 7.14 Correlation of maximal joint inflammation score and serum titre of collagen-
specific IgG in hCD20tg mice and WT littermates 
(A) Graphs showing the correlation of maximal joint inflammation score (24-point clinical score) and 
CII-specific IgG1 for each group. (B) Graphs showing the correlation of maximal joint inflammation 
score and CII-specific IgG2a for each group. (hCD20tg mice + RTX () n=5, WT littermates + RTX 
() n=7, hCD20tg mice + IgG () n=6 and WT littermates + IgG () n=7). Statistics used: Linear 
regression and Spearman r tests where shown, with * = p<0.05.  
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Figure 7.15 Radiographic pathology in hCD20tg mice and WT littermates treated with 
Rituximab 
Mice were culled on d42 and the left hind leg fixed in formalin for 2 weeks. After fixation, legs were 
x-rayed using a Kodak In-Vivo FX PRO. (A) A hind paw x-ray with the joints used for scoring 
highlighted, followed by a representative x-ray of a healthy animal and an animal with arthritis. 
(B) Graph showing the radiographic scores for each of the experimental groups. (C) Graphs 
showing the correlation of radiographic score and maximal joint inflammation score (24-point 
clinical scores) for each of the four experimental groups, with the legend shown in (B). (hCD20tg + 
RTX: n=5, hCD20tg + IgG: n=6, WT littermate groups: n=7) Statistics used: One-way ANOVA 
performed on complete data set in (B); linear regression and Spearman r tests where shown in (C), 
with a value of p<0.05 considered statistically significant. 
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treatment would affect the outcome of B cell depletion in CIA. To do this, hCD20tg 
mice were given a single dose of RTX, four days prior to CIA induction using bovine CII.  
Unfortunately, for these runs of CIA the levels of disease incidence was so low in both 
the treatment group and the control groups that no conclusions about the effectiveness 
of the treatment regimen could be made. Between the groups an average incidence of 
only 23% was seen (Figure 7.16e), and no paw swelling detected by either the scoring 
systems used or measurements taken (Figure 7.16a-d). 
After speaking to colleagues about the minimal disease incidence level seen with the 
initial study undertaken using bovine CII in hCD20tg mice, it was decided to modify the 
induction protocol used. Previously, mice had been given one single injection of CII/CFA 
at the base of the tail, while awake. For the second study using this treatment regimen, 
mice were given the same total amount of CII/CFA but over two injection sites, while 
anaesthetized. However, this modification did not affect incidence levels seen. 
Serum ELISAs were undertaken to detect any potential sub-clinical disease that may 
have been present in the mice (Figure 7.17), however no differences were detected in 
the levels of total serum IgG, total serum IgG1, CII-specific IgG1 or CII-specific IgG2a 
levels between the treatment groups.  
With the minimal levels of disease seen in these runs, no conclusions could be made 
about the effectiveness of RTX-mediated B cell depletion prior to CIA induction in 
hCD20tg mice. 
7.2.5 Effect of the species and supplier of collagen on CIA Induction 
In standard CIA protocols available, bovine CII is used for CIA induction in DBA/1 mice, 
with incidence rates of 80-100% expected [335], while chicken CII is generally only used 
for disease induction in the less susceptible C57BL/6 mouse strain [365]. For the initial 
runs of CIA undertaken as part of this project, chicken CII was used due to its 
availability in the lab. It was then decided to replace this with bovine CII, in an attempt 
to keep our experiments in line with those previously undertaken by other groups, 
allowing for a more direct comparison of results. On the transition to bovine CII 
incidence rates fell dramatically, and so it was decided to more closely examine the 
effect of the species and supplier of collagen on CIA induction in hCD20tg mice. CIA was 
induced in hCD20tg mice using either chicken CII, bovine CII from MD Bioscience, or 
bovine CII from Sigma. Over the two runs undertaken with this variation in disease 
induction, virtually no disease was seen with only one animal included in the study 
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Figure 7.16 Collagen induced arthritis in hCD20tg mice treated with a single dose of 
Rituximab prior to disease induction 
On day -4, hCD20tg DBA mice given a single dose of 100µg of RTX (), while control mice 
received polyclonal hIgG (), and CIA induced in these animals on day 0. (A) Graph showing the 
general inflammation scores (16-point scoring system) for both treatment groups. (B) Graph 
showing the joint inflammation scores (24-point scoring system) for both treatment groups. 
(C) Graph showing the change in ankle size for both treatment groups. (D) Graph showing the 
change in paw size for both treatment groups. (E) Graph showing the incidence of disease in both 
treatment groups. (RTX: n=12; IgG: n=14, data from 2 independent experiments). Statistics used: 
Two-way ANOVA performed on each compete data set in (A) (B) (C) (D) and (E), with values of 
p<0.05 considered significant. 
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Figure 7.17 Serum antibody titres in hCD20tg mice treated with a single dose of Rituximab 
prior to disease induction 
Mice were culled on d44 and blood samples collected, and serum IgG titres quantified by ELISA. 
(A) Graph showing the serum titres of total serum IgG (mg/ml) for all groups. (B) Graph showing 
the serum titres of total serum IgG1 (mg/ml). (C) Graph showing the serum titres of CII-specific 
IgG1 (RU = relative units) (D) Graph showing the serum titres of CII-specific IgG2a (RU) (n=6, data 
from a single experiment) Statistics used: unpaired T test (RTX-treated vs. IgG-treated) for each 
data set, with values of p<0.05 considered significant. 
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Figure 7.18 Progression of CIA induced with either chicken CII or bovine CII in hCD20tg DBA 
mice 
CIA was induced in hCD20tg DBA mice using either chicken CII (), bovine CII from MD 
Bioscience (), or bovine CII from Sigma (). (A) Graph showing the general inflammation scores 
(16-point scoring system) for all treatment groups. (B) Graph showing the joint inflammation scores 
(24-point scoring system) for all treatment groups. (C) Graph showing the change in ankle size for 
all treatment groups. (D) Graph showing the change in paw size for all treatment groups. (E) Graph 
showing the incidence of disease in all treatment groups. (chicken CII: n=8, MD bovine CII: n=5, 
Sigma bovine CII: n=6, data from 2 independent experiments) Statistics used: Two-way ANOVA 
performed on each compete data set in (A) (B) (C) (D) and (E), with values of p<0.05 considered 
significant. 
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showing any signs of arthritis (Figure 7.18). Between these runs, the person performing 
the injections was changed to a more experienced investigator to remove the possibility 
that sub-optimal dosing with collagen was responsible for the reduced incidence seen, 
however this did not have any effect on disease induction in this setting. 
This continued lack of disease in hCD20tg animals induced with CIA meant that no 
information could be garnered from the runs, and any conclusions on the effectiveness 
of the various species or suppliers of CII used could not be made. 
7.2.6 Comparison of disease in hCD20tg mice and WT DBA mice 
In order to examine whether the limited arthritis incidence observed in hCD20tg mice 
could be due, at least to some extent, to an intrinsic feature of this transgenic strain. 
CIA was induced in hCD20tg DBA mice bred in house, and WT DBA mice bought in from 
Charles River, following the same general protocol as previously, with bovine CII used in 
both the induction and boost injections. However, the protocol used to generate the 
CII/CFA emulsion was altered, with the emulsion for the initial injections made the day 
before disease induction, stored overnight at 4oC, and re-emulsified just prior to use. 
This protocol for emulsion preparation had been seen to increase the effectiveness of 
CIA induction in C57BL/6 mice (Dr. Darren Asquith, personal communication), and so the 
decision was made to employ this method for this run. No treatment was given to either 
group of mice, and no attempt was made to modify the disease course in any way. 
The general inflammation scores (Figure 7.19a) and joint inflammation scores (Figure 
7.19b) of both groups show very similar disease progression until day 35. After this point 
the data indicates an increased severity of disease in the WT DBA mice compared to the 
hCD20tg mice, with the cumulative general inflammation score of 12±10 for the 
hCD20tg mice, and 20±19 in the WT DBA mice. However due to the variability seen and 
group sizes used, this increase was not significant. Very little change in hind ankle size 
(Figure 7.19c) or hind paw size (Figure 7.19d) was observed, and these measurements 
did not differ between the groups. The incidence of disease was noticeably lower in 
hCD20tg mice, with 50% of the hCD20tg mice showing signs of arthritis, compared to 
75% of the WT DBA mice, however this difference was not statistically significant.  
Blood was collected from all mice on day 42 and serum ELISAs undertaken to look at the 
antibody response in disease. The hCD20tg mice had significantly higher levels of total 
serum IgG, compared to the WT DBA mice (Figure 7.20a), but levels of total IgG1 were 
no different between the groups (Figure 7.20b). The relative serum titres of collagen-
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specific IgG1 and collagen-specific IgG2a were also investigated (Figure 7.20b and c), 
with concentration of CII-specific IgG1 and IgG2a similar for both groups.  
The correlation of maximal joint score with serum titres of collagen-specific IgG1 and 
IgG2a was examined. Both hCD20tg and WT DBA mice showed an increase in CII-specific 
IgG1 on increased disease score (Figure 7.21a), however this correlation was only 
significant in the WT DBA mice. Surprisingly, in the hCD20tg mice the data indicated a 
decrease in CII-specific IgG2a on increased disease score, while in WT DBA there was an 
increase in CII-specific IgG1 on increased disease score, however neither group showed 
a significant correlation between maximal joint score and CII-specific and serum IgG2a 
(Figure 7.21b).  
Collagen re-stimulation responses were also investigated. Peripheral LNs were harvested 
on day 42 and cultured in vitro in media alone or with either 30µg/ml or 60µg/ml 
collagen peptide. 3H-thymdine was then added to the cultures and CII-specific 
proliferation responses quantified. There was no difference in the proliferative 
responses between the hCD20tg and WT DBA mice at either concentration of collagen 
used (Figure 7.22), and proliferation did not increase with additional CII in the culture 
system. 
Although a lower incidence of disease in the hCD20tg DBA mice was indicated compared 
to the WT DBA mice, from these data it cannot be concluded whether hCD20tg DBA 
mice are less susceptible to CIA than WT DBA mice, with comparable clinical scores and 
CII-specific serum antibody levels observed in both strains.  
7.2.7 T cell priming in hCD20tg mice on CIA induction 
With the repeated issues experienced with collagen-induced arthritis in hCD20tg mice, 
we wanted to understand what may be causing this reduced response. It is known that 
T cells play a crucial role in disease pathogenesis in experimental arthritis [366,367], 
and therefore it was decided to look into the levels of T cell priming occurring in 
hCD20tg mice on disease induction. To do this, hCD20tg mice were injected with 
bovine CII/CFA on day 0, as in CIA induction, and LN harvested on day 7, with cells used 
for in vitro 3H-thymidine proliferation assays. 
LN cells were cultured with either 30µg/ml or 60µg/ml of CB11 CII peptide for 72hr 
prior to pulsing with 3H-thymidine (figure 7.23). The CB11 peptide is a cyanogen 
bromide-cleaved fragment of CII, and it has been shown that in experimental arthritis 
induced with heterologous collagen, the majority of T cell responses are directed 
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Figure 7.19 Comparison of CIA disease course in hCD20tg DBA and WT DBA mice 
CIA was induced in hCD20tg DBA mice bred in-house () and WT DBA mice purchased from 
Charles River (). No treatment was administered to either group. (A) Graph showing the general 
inflammation scores (16-point scoring system) for both treatment groups. (B) Graph showing the 
joint inflammation scores (24-point scoring system) for both treatment groups. (C) Graph showing 
the change in ankle size for both treatment groups. (D) Graph showing the change in paw size for 
both treatment groups. (E) Graph showing the incidence of disease in both treatment groups.  
(hCD20tg mice n=6, WT DBA mice: n=8, data from a single experiment) Statistics used: Two-way 
ANOVA performed on each compete data set in (A) (B) (C) (D) and (E), with values of p<0.05 
considered significant. 
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Figure 7.20 Serum antibody titres in hCD20tg DBA and WT DBA mice 
Mice were culled on d42, blood samples collected and serum IgG titres quantified by ELISA. 
(A) Graph showing the titres of total serum IgG (mg/ml). (B) Graph showing the titres of total serum 
IgG1 (mg/ml). (C) Graph showing the serum titres of CII-specific IgG1 (RU = relative units) (D) 
Graph showing the serum titres of CII-specific IgG2a (RU). (hCD20tg mice n=6, WT DBA mice: 
n=7, data from a single experiment) Statistics used: unpaired T test (WT DBA vs. hCD20tg mice) 
on each data set, with * = p<0.05. 
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Figure 7.21 Correlation of joint inflammation scores with serum CII-specific IgG1 and IgG2a 
titres 
(A) Graphs showing the correlation of maximal joint inflammation score (24-point clinical score) and 
CII-specific IgG1 for each group. (B) Graphs showing the correlation of maximal joint inflammation 
score and CII-specific IgG2a for each group. (hCD20tg mice () n=6, and WT DBA mice () n=7, 
data from a single experiment)  
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Figure 7.22 Collagen re-stimulation responses in hCD20tg DBA and WT DBA mice 
Cellular proliferation in response to in vitro collagen re-stimulation was investigated. Peripheral LNs 
were harvested and cultured in vitro with 3H-thymdine and varying concentrations of collagen 
protein for 72hrs to look at CII-specific proliferation responses. Values normalized to media only 
controls. CPM = counts per minute. (hCD20tg mice: n=6, and WT DBA mice: n=7, data from a 
single experiment) Statistics used: One-way ANOVA performed on complete data set, with p<0.0.5 
considered significant. 
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Figure 7.23 T cell recall responses after induction of CIA 
CIA was induced in hCD20tg DBA mice on day 0 by i.d. injection of CII/CFA. Mice were culled on 
day 7, peripheral LNs collected and the LN cells cultured for 72hr with either 30µg/ml or 60µg/ml 
collagen type-II. Cell proliferation in response to CII-stimulation was quantified using a 3H-
thymidine based proliferation assay. PMA/Ionomycin stimulation was used as a positive control. 
CPM = counts per minute. (n=7, data from a single experiment) Statistics used: One-way ANOVA 
performed on complete data set, with a value of p<0.05 considered significant. 
   
253 
toward epitopes on this particular section of CII [277]. In the hCD20tg mice, no increase 
in T cell proliferation above background levels was seen in response to CB11 stimulation 
after induction of CIA (Figure 7.23). This lack of proliferation was not due to an intrinsic 
defect in the hCD20tg cells, as cells cultured in the presence of PMA and Ionomycin 
showed a 230-fold increase in proliferation, compared to those cultured in media alone. 
These data show that T cell priming did not occur in the hCD20tg DBA mice on CII/CFA 
injection, indicating that insufficient priming may occur in this transgenic strain at the 
time of CIA induction. However, without directly comparing this finding with the levels 
of priming seen in WT DBA mice on CIA induction this cannot be conclusively stated at 
present.  
7.2.8 Expression of MHC I-Aq in hCD20tg mice 
The hCD20tg DBA colony used throughout this work was originally generated by 
backcrossing the hCD20 transgene from hCD20tg C57BL/6 animals onto the DBA 
background. It is known that susceptibility to CIA is dependant on the MHC haplotype 
expressed by a strain, with mice expressing either the H-2Aq or H-2Ap haplotypes 
susceptible to disease induction [368]. WT DBA mice express the MHC I-Aq haplotype, 
conferring susceptibility to CIA, while C57BL/6 mice express I-Ab. Due to the lack of 
T cell priming seen in the hCD20tg DBA mice, it was asked whether these transgenic 
animals shared the same MHC expression profile as WT DBA mice, or if they had 
retained an element of the original C57BL/6 MHC haplotype. To do this, WT DBA mice, 
hCD20tg DBA mice, WT DBA littermates and hCD20tg C57BL/6 mice were bled, and the 
samples analysed for cell surface expression of MHC I-Aq by flow cytometry. 
In the blood of WT DBA mice, 98±0.2% of B cells expressed MHC I-Aq (Figure 7.24a and 
b), with a small but significant decrease in the hCD20tg DBA mice (83±3.4% of B cells 
MHC I-Aq+). A more variable expression pattern was seen in the WT littermates, and as 
such, the decreased expression seen in the WT littermates was not significant. 
hCD20tg C57BL/6 mice were included as a negative control, with minimal levels of 
background staining seen (0.5±0.68% of B cells MHC I-Aq+). Although substantial 
proportions of B cells from both the hCD20tg mice and WT littermates expressed MHC I-
Aq, a significant and considerable decrease in the levels of surface expression of MHC I-
Aq by these B cells was detected, compared to B cells from WT DBA mice (801±460) 
(Figure 7.24c), with an MHC I-Aq MFI of 116±18 on B cells from hCD20tg DBA and 185±134 
on those from WT littermates.  
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Figure 7.24 hCD20tg DBA mice and WT littermates express significantly less MHC I-Aq than 
WT DBA mice 
Tail bleeds were performed on WT DBA mice, hCD20tg DNA mice, DBA WT littermates and 
hCD20tg C57BL/6 mice. Cells were stained for lineage markers and MHC I-Aq and analysed by 
flow cytometry. (A) Representative FACS plots showing the relative levels of MHC I-Aq staining in 
each of the four mouse genotypes. Panels: MHC I-Aq vs. CD19. (B) Graph of pooled data showing 
the percentage of total B cells expressing MHC I-Aq. (C) Graph of pooled data showing the relative 
levels of MHC I-Aq expression on MHC I-Aq+ B cells. (WT DBA and hCD20tg DBA: n=4, WT 
littermates and hCD20tg C57BL/6: n=3) Statistics used: One way ANOVA performed on each 
complete data set in (B) and (C), followed by Bonferroni’s post test, with * = p<0.05, ** = p<0.01 
and *** = p<0.001. 
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These findings demonstrate that there is minimal MHC I-Aq expression in hCD20tg DBA 
mice compared to WT DBA mice, which could explain the poor T cell priming seen on 
CIA induction in this transgenic strain. 
7.2.9 Delayed-type hypersensitivity responses in hCD20tg mice 
Due to the challenges encountered with the induction of reliable and reproducible CIA 
in hCD20tg DBA mice, it was decided to explore the option of using a more general 
model of inflammation; a delayed-type hypersensitivity (DTH) assay. To induce a DTH 
response, hCD20tg DBA mice were immunized systemically with OVA/CFA in the scruff 
and then challenged with heat-aggregated OVA (HAO) in the left footpad 14 days later 
(OVA/HAO group). Before the introduction of any treatment regimens intended to 
modify the course of the DTH response, a basic protocol was established in the lab, with 
control mice receiving only the initial OVA/CFA injection (OVA/PBS group), only the 
HAO challenge (PBS/HAO group), or left naïve. The change in paw thickness was 
measured at 24 and 48hr post challenge using calipers, and cells from the draining LN 
harvested at the 48hr time-point and used to assess T cell cytokine production in 
response to OVA re-stimulation in vitro. 
At 24hr post footpad challenge, the OVA/HAO group showed an average increase in 
footpad size of 0.34±0.2mm (Figure 7.25a). This increase was larger than that seen for 
any of the control groups (naïve: 0.05±0.13mm; PBS/HAO: 0.18±0.16mm; OVA/PBS; 
0.13±0.1mm), however it did not reach significance with the number of animals used. 
By 48hr post challenge, paw inflammation had resolved back to baseline levels in all 
groups.  
When cytokine production in response to in vitro OVA re-stimulation was investigated, it 
could be seen that T cells from the OVA/HAO group produced significantly more IL-2 
than those from any of the control groups (Figure 7.25b), with an average IL-2 increase 
of 65.5±41.4pg/ml above background levels, compared to 10.1±19.9pg/ml in the naïve 
group, 21.1±10.7pg/ml in the PBS/HAO group and 15.3±18.8pg/ml in the OVA/PBS 
group. 
These data demonstrate that a DTH response can be elicited in hCD20tg mice as 
detected by paw swelling and antigen-specific IL-2 production, however larger group 
sizes are needed in order to achieve significance for all parameters assessed. 
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Figure 7.25 Basic DTH model in hCD20tg DBA mice 
Mice were immunized with OVA/CFA s.c. in the scruff and 14 days later challenged with heat-
aggregated OVA (HAO) in the left footpad. Control mice received only the initial OVA/CFA 
injection, only the HAO challenge, or were left naïve. Hind paw thickness was measured at 24 and 
48hr post challenge using calipers. Mice were euthanized 2 days after HAO challenge, and cells 
from the draining lymph node harvested and used to assess in vitro re-stimulation responses. 
(A) OVA-specific increase in footpad thickness (mm) at baseline (0hr) and 24hr and 48hr post 
challenge for all groups. (B) IL-2 production (pg/ml) by draining LN cells after in vitro re-stimulation 
with OVA. Levels of IL-2 normalized to media only controls. (n=9, data from two independent 
experiments) Statistics used: One-way ANOVA performed on complete data sets in (A) and (B), 
followed by Bonferroni’s post-test, with * = p<0.05. 
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7.3 Discussion 
• To investigate our hypothesis that RTX-mediated B cell depletion introduces 
temporary tolerance to the immune system, in vivo disease models were 
utilised. 
• Due to technical issues no conclusions could be made about the ability of 
apoptotic B cells or RTX treatment to ameliorate CIA, with the discovery that 
hCD20tg DBA mice express very little MHC I-Aq on the surface of their cells a 
possible explanation for this. 
• These results demonstrate that although the hCD20tg DBA mice are suitable for 
use in RTX-mediated B cell depletion studies, due to their MHC haplotype they 
are not ideal for use in CIA. As such, an alternate in vivo model is needed for 
future studies, with a DTH model successfully established in the lab. 
Many hypotheses have been put forward to explain how RTX treatment exerts its 
beneficial effects in RA, however a definitive answer has still not been reached, and it 
is probable that there will not be one single mechanism, but several, which when 
combined help to re-introduce a balance to the immune system. In this chapter, two 
different in vivo models were utilized in an attempt to investigate the complex, and 
potentially wide-reaching effects of RTX-mediated B cell depletion in a more 
physiological setting. 
Treatment with RTX results in the long-lasting depletion of CD20+ B cells [81], with 
several mechanisms involved including complement-dependent cytotoxicity (CDC), 
antibody-dependent cellular cytotoxicity (ADCC), and direct apoptosis of B cells [238]. It 
is known that apoptotic cells can have an immunosuppressive effect on the immune 
system [157,158], and it was this aspect of RTX-mediated B cell depletion we wanted to 
investigate. 
It has previously been shown that apoptotic cells (AC) can modulate the immune 
response and have a protective effect in rodent models of arthritis. Intra-articular 
injection of apoptotic thymocytes prior to arthritis induction is able to inhibit the onset 
of immune complex-mediated arthritis in BALB/c mice [369]. This inhibition is 
attributed the decreased production of chemo-attractant proteins by synovial lining 
macrophages after ingestion of the AC, resulting in reduced immune cell infiltrates in to 
the joints and decreased joint inflammation. It has also been shown that systemic 
administration of apoptotic thymocytes can markedly suppress disease in several models 
of arthritis. Work by Gray et al has shown that apoptotic thymocytes, given 
intravenously (i.v.) up to 1 month before the induction of CIA, have a protective effect 
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on WT DBA mice and inhibit the development of severe arthritis in this model [172]. 
Systemic treatment with apoptotic thymocytes can also suppress antigen-induced 
arthritis in C57BL/6 mice, and it has been shown that this suppression is dependent on 
natural IgM [370]. In the rat model of streptococcal cell wall arthritis, intraperitoneal 
injection of apoptotic thymocytes at the time of arthritis induction results in decreased 
proinflammatory responses by macrophages, and reduced disease severity [188]. These 
studies demonstrate the beneficial effects of AC administration on disease severity in 
arthritis models, however apoptotic thymocytes are utilized as the model AC for all of 
these investigations. To examine whether apoptotic B cells have the same ability as 
apoptotic thymocytes to modulate disease course in a model of arthritis, WT DBA mice 
were adoptively transferred with apoptotic B cells on the day of CIA induction, and 
disease progression monitored. 
In this experimental set up, no effect on CIA severity or progression was seen on i.v. 
irradiated apoptotic B cell administration. These results could indicate several things. 
The first, and perhaps most obvious, is that apoptotic B cells do not have the same 
modulatory capacity as apoptotic thymocytes in this disease model. However, we have 
shown in previous chapters that in an in vitro system, the interaction of apoptotic 
B cells with bone marrow derived macrophages (BMDM) has comparable effects on BMDM 
function as the interaction of apoptotic thymocytes with BMDM, indicating that 
apoptotic B cells do not differ from apoptotic thymocytes in their immunomodulatory 
ability. The reductionist nature of in vitro assays means that the results gained in these 
settings can differ from those seen in vivo, and so it could be argued that the ability of 
apoptotic B cells to modify BMDM is purely an artefact of the in vitro culture system. 
However, without the inclusion of an apoptotic thymocyte treatment group in the 
present study, it is impossible to know whether the lack of effect seen on apoptotic 
B cell administration is due to an inability of apoptotic B cells to modulate the immune 
system, or if the previous findings using apoptotic thymocytes cannot be replicated 
using this model in our hands.  
Although several different arthritis models have been utilized previously to investigate 
the effects of apoptotic thymocytes on disease all with similar outcomes, the diverse 
findings between this and previous studies may still be explained by differences in 
experimental protocols. As CIA was used for the work being discussed in the current 
chapter, I will limit comparisons of experimental protocol to the 2007 paper by Gray et 
al, who also used the CIA model in DBA mice [172]. In their paper, the investigators 
gave a series of three injections of AC, totalling 20x106 apoptotic thymocytes, with the 
first injection given on the day of disease induction and the others on the following 
2 days. In our study, a maximum of 5x106 AC were given in one single injection, just 
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prior to disease induction. It may be the case that the numbers of apoptotic B cells 
given in this study were not enough to suppress the immune response on disease 
induction, and that with a larger number of cells an effect would be noticeable. Giving 
AC in multiple injections over the course of several days, rather than in one single dose, 
may also increase the efficacy of this type of treatment. AC are rapidly cleared from 
the system, with professional phagocytes initiating uptake of AC immediately on 
contact, and full digestion of ingested cells occurring within 2hr of initial uptake [371]. 
Even in settings where professional phagocytes are overwhelmed by the number of AC 
present, clearance will still occur in time periods of less than 10hr as non-professional 
phagocytic cells are also able to ingest AC, although only after they have undergone 
further cell surface changes [371]. This means that when AC are administered over 
several days, they will be present in the system for a longer period of time, allowing 
more AC-immune cell interactions before clearance occurs, and therefore increasing the 
opportunity for immunomodulation to occur. In order to fully state whether these 
experimental differences could account for the variation in responses seen, a further 
study would need to be undertaken, modifying the present protocol to fit that of the 
previous work undertaken, allowing a direct comparison of the effects of apoptotic 
thymocytes and apoptotic B cells. 
CIA is affected by environmental issues, and this sensitivity may have obscured potential 
findings. Within all groups included in this study, a relatively low disease incidence was 
observed. As previously stated, incidence levels of 80-100% are expected on induction of 
CIA in DBA mice [335], however in this run incidence above 60% was not seen in any 
treatment or control group, contributing to the variability seen in clinical inflammation 
scores. In those animals in which disease was observed, the severity within each group 
was not consistent between animals, indicating that even in those animals where 
induction of disease was successful, the efficiency of induction was inconsistent. It has 
previously been observed that serum levels of CII-specific IgG2a positively correlates 
with CIA pathology in both mice [372] and rats [373]. In this study, a correlation 
between CII-specific IgG2a serum titres and maximal inflammation score was only noted 
in the PBS control, with all other groups only showing a positive correlation between 
CII-specific IgG1 serum titres and clinical pathology. This indicates that the majority of 
animals included in the study did not have a pathogenic humoral response toward CII 
taking place, even if clinical symptoms were apparent, as although these animals 
showed increased levels of CII-specific IgG1, this subclass of IgG is non-pathogenic and 
therefore not indicative of an arthritogenic response. This general lack of correlation 
between CII-specific IgG2a and clinical pathology highlights the inconsistency of disease 
induction within this run. Together, these findings suggest that with larger treatment 
groups, there is the potential that differences between groups may be resolved. Due to 
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these concerns, drawing a firm conclusion as to the ability of apoptotic B cells to 
modulate the immune responses in CIA may be premature at this time. 
We next went on to model the effect of RTX-mediated apoptosis of B cells in a CIA 
setting. To do this, B cells isolated from hCD20tg mice were adoptively transferred into 
WT DBA mice, which were subsequently treated with a single dose of RTX. Once cell 
transfer and treatment were complete, disease was induced. As shown in the previous 
chapter, RTX, a human-specific anti-CD20 mAb, is not able to bind murine CD20, and 
therefore does not bind B cells from WT littermates, or any WT mice. This model, 
therefore, allows selective depletion of the transferred hCD20tg B cells, while leaving 
the endogenous WT B cell population intact.  
No differences between the treatment and control groups were seen in clinical 
inflammation scores or measurement of swelling, however the control groups given IgG 
alone had significantly higher serum levels of both total IgG and total IgG1. The half life 
of endogenous IgG in the serum of mice ranges from 4-8 days [374], and in humans from 
7-21 days [375]. Although in this study human polyclonal IgG was administered to mice, 
it can be expected that the clearance of the exogenous immunoglobulin would not 
exceed that of endogenous IgG. The long half-life of IgG in the blood is dependant on 
the interaction of IgG with the neonatal Fc receptor (FcRn), with binding inhibiting the 
break down of IgG, and it has been shown that excess concentrations of IgG in the blood 
lead to saturation of available FcRn, resulting in the degradation of unbound excess IgG 
in the lysosomes [376,377].  In this way, elevated levels of serum IgG lead to increased 
IgG catabolism, and therefore a shortened half-life [378]. As serum was collected from 
the mice 42 days after the administration of polyclonal IgG, this increase in serum IgG 
levels was not likely to be due to the administration of exogenous IgG. This increase in 
serum IgG, as well an increased proliferative response to collagen re-stimulation, 
indicates that some level of sub-clinical response occurred in this group of mice after 
CIA induction. However, as increased levels of CII-specific IgG subclasses were not 
detected, it can be concluded that this response was not specifically directed at 
collagen, as would be expected in CIA, and was a general inflammatory response, 
possibly due to the continued presence of CFA at the original injection site. The lack of 
disease modulation in the hCD20tg B cell + RTX group indicates that RTX-mediated 
B cell apoptosis on this scale is not sufficient to alter the course of arthritis in WT DBA 
mice. 
The effect of RTX treatment of CIA in hCD20tg DBA mice was then investigated. RTX 
treatment in this transgenic mouse strain results in depletion of the majority of B cells 
from the body, and is therefore a closer representation of what would occur in the 
   
261 
treatment of rheumatoid arthritis patients. To date, the depletion of B cells with 
Rituximab in CIA has not previously been undertaken. Huang et al utilized hCD20tg 
K/BxN mice to investigate RTX mediated B cell depletion in a spontaneous model of 
murine inflammatory arthritis. The hCD20tg K/BxN were given weekly doses of RTX, 
commencing at 5-8weeks of age, after the onset of arthritis, with treatment resulting in 
the depletion of short-lived CD20-expressing plasma cells, and decreased serum titres of 
pathogenic auto-antibodies directed toward glucose-6-phosphate isomerase, however no 
improvements in clinical scores and ankle swelling were seen compared to controls 
[364]. In all other available literature, B cells depletion studies in murine arthritis 
models have utilized anti-mouse CD20 antibodies [71,267,362,379], or have targeted 
other B cell-specific markers, such as CD22 [380]. Using RTX rather than a mouse 
homologue, allows the study of the interactions between this monoclonal antibody and 
B cells, and the resulting effects of the B cell depletion which may not be correctly 
represented by the use of anti mouse-CD20 antibodies. When hCD20tg DBA mice were 
administered a single dose of RTX on the day of CIA induction, no improvement of 
disease severity or progression could be detected when compared to control groups.  
Previous work by Yanaba et al has shown that in mice, B cells depletion prior arthritis 
induction, resulting in a lack of B cells at the time of CIA initiation, will delay disease 
onset. However, depletion of B cells at the time of arthritis onset (day 35 in the model 
used) rather than on CIA induction, did not significantly ameliorate clinical disease 
compared to control animals [362]. Due to these findings, it was decided to modify the 
RTX treatment regimen used in the hCD20tg DBA mice to explore whether RTX mediated 
B cell depletion prior to, rather than at the time of, arthritis induction would have a 
beneficial effect on CIA severity. For these experiments, hCD20tg DBA mice were given 
a single dose of RTX on day -4, with disease induced on day 0. Unfortunately in both 
runs undertaken with this treatment regimen, a lack of disease incidence was seen in all 
groups, and therefore no conclusions could be drawn as to the effectiveness of this 
treatment protocol. These runs of CIA were both induced using bovine CII, rather than 
chicken CII, as previously used. This change in induction protocol should not have 
resulted in this severe drop in incidence levels, as bovine CII is the standard species 
used for induction of CIA in DBA mice [335], with chicken CII generally only used in the 
less susceptible C57BL/6 mouse strain [365] and was only chosen initially due to its 
availability in the lab. To investigate whether this dramatic decrease in incidence was 
due to the CII species used, CIA was induced in hCD20tg DBA mice using either chicken 
or bovine CII. As with the runs undertaken to look at RTX treatment prior to disease 
induction, extremely low incidence rates were observed in all of the groups, with the 
majority of mice showing no disease symptoms whatsoever in both test runs 
undertaken. As relatively good incidence levels had previously been achieved using 
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chicken CII in hCD20tg mice, these results were unexpected. Varying aspects of the 
disease induction process were altered throughout the CII test runs, as well as the runs 
intended to investigate RTX treatment prior to disease induction to try to figure out 
what was causing these problems with incidence: mice were given their initial CII dose 
over two i.d. injections rather than just one; mice were anaesthetised during the initial 
CII/CFA injection rather then left conscious; the investigator performing the injections 
was changed; along with the species and supplier of collagen used being altered. Mice 
used for all runs were of the recommended age for use in CIA models [335], and were 
kept on an anti-pinworm diet, as it is known that infection with helminths, such as 
pinworms, can alter the immune response in mice resulting in an lessening of symptoms 
in a variety of disease models including CIA [reviewed in [381]. However, disease 
induction remained minimal.  
In previous runs using the chicken CII to induce CIA in both hCD20tg DBA mice and 
WT littermates, it was noted that the hCD20tg DBA mice tended toward a lesser severity 
of disease, as well as a lower disease incidence. When hCD20tg DBA mice and 
WT littermates were treated with RTX on the day of CIA induction, with IgG used as a 
control, a significant increase in both ankle and paw size was observed in the 
WT littermates treated with RTX, compared to the hCD20tg DBA mice treated with IgG. 
As these were both control groups, and neither treatment in those particular genotypes 
should have modified disease course in any way, this altered disease severity could be 
attributed to intrinsic differences between these mice. Although decreased disease 
severity was not evident in the group of hCD20tg DBA mice treated with RTX compared 
to WT littermates, the data does indicate a lower incidence of disease in both hCD20tg 
DBA groups compared to the WT littermate groups. Along with these findings, it was 
noted that all the CIA runs undertaken which resulted in minimal incidence of disease 
were carried out in hCD20tg DBA mice. It was decided to attempt one last run of CIA to 
compare arthritis induction in hCD20tg DBA mice with WT DBA mice bought in from 
Charles River. Bovine CII was again used for disease induction, the protocol for emulsion 
preparation was altered to one used by other members of the department to induce CIA 
in the less susceptible C57BL/6 mice (Dr Darren Asquith, personal communication). 
Instead of emulsifying the CII and CFA on the day of injection and using it straight away, 
it was prepared the day before injection and then re-emulsified just prior to use. This 
technique helps to ensure that a fully homogenized emulsion is prepared, reducing the 
chance of the components of the emulsion separating out after injection, which can 
result in lower disease incidence and contributes to the formation of ulcers at the site 
of injection. Although a large variability in disease was seen for both strains of mice, 
and no significant difference was seen in disease severity or incidence between the 
groups, the data does suggest that hCD20tg mice show a decreased severity of arthritis 
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and a lower incidence of disease compared to the WT mice. If repeats were undertaken 
to increase group sizes these differences may well become significant.  
We then went on to explore possible reasons for this reduced response to CIA induction 
in hCD20tg DBA mice. It is known that T cell responses are vital to disease pathogenesis 
in rodent models of arthritis [366,367], and also play a major role in the pathogenesis 
and perpetuation of RA [382]. Our data show that after CII/CFA injection, T cells from 
hCD20tg DBA mice on do not proliferate in response to in vitro CII re-stimulation, 
indicating that insufficient T cell priming may occur on induction of CIA in this 
transgenic strain. T cell priming in CIA is dependent on the successful presentation of 
immunodominant peptides derived from CII by MHC molecules of specific haplotypes 
[368], with WT DBA mice expressing the MHC I-Aq haplotype, conferring susceptibility to 
CIA. Flow cytometry was used to investigate whether hCD20tg DBA had a reduced level 
of MHC I-Aq expression compared to WT DBA mice. The proportion of B cells from 
hCD20tg mice expressing MHC I-Aq was only slightly less than that of B cells from WT 
DBA mice, however when the expression levels of MHC I-Aq on these cells was 
investigated it could be seen that the hCD20tg B cells expressed this MHC II molecule at 
severely reduced levels, compared to their WT counterparts. Along with the T cell 
recall responses seen in hCD20tg mice, this finding points toward the possibility of there 
being an issue with T cell priming on CIA induction in this transgenic strain.  
This lack of expression of a susceptible MHC haplotype also helps to explain the drop in 
incidence seen on transition from chicken CII to bovine CII in the induction protocol. 
Chicken CII is used to induce CIA in less susceptible C57BL/6 mice, and so the use of this 
species of collagen in the initial runs undertaken using the hCD20tg mice allowed a 
relatively good level of disease induction to be achieved. Once the collagen species was 
changed to the less potent bovine CII, incidence rates fell rapidly. However, when the 
CIA runs comparing collagen species in disease induction were undertaken, chicken CII 
was also unable to induce disease in hCD20tg mice. The most likely explanation for this 
sudden lack of disease on induction with chicken CII is that a sub-standard emulsion was 
prepared for the initial injections. This theory is supported by the fact that when bovine 
CII was used for the final CIA run comparing disease in hCD20tg and WT DBA mice, 
moderate arthritis was inducible in this transgenic strain when using an adapted 
protocol for emulsion preparation which had previously been shown to improve 
incidence levels in the less susceptible C57BL/6 mice. 
Although an understanding of the complications involved in inducing arthritis in hCD20tg 
DBA mice had been reached, due to the lack of reliability and reproducibility with CIA, 
it was decided to move to an alternate mouse model. The model chosen was a DTH 
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assay, as although it is not an arthritis model, it would allow the investigation of our 
hypothesis in an in vivo model of inflammation. A basic DTH protocol was set up in the 
lab, with the aim of ultimately using it to investigate the potential re-establishment of 
tolerance after RTX treatment. A DTH response could be elicited in the hCD20tg DBA 
mice as detected by paw inflammation and swelling, however the change in footpad 
size seen was not significant compared to controls with the numbers of animals used. If 
a treatment group were to be included in this model, much larger group sizes would 
need to be used in order for any change in swelling to reach significance. To ascertain 
the group sizes needed, a power calculation was undertaken, with a two-sided alpha of 
5%, and a power of 0.9 used. The mean value for paw swelling entered into the 
calculation was 0.18mm, with 0.34mm as the expected mean paw swelling after DTH, 
and a SD of 0.2mm. The values used were taken from the initial DTH assays undertaken. 
With these parameters it was calculated that a minimum of 17 mice per group would be 
required to detect a change in paw swelling. This means that for each DTH run 
undertaken, a minimum of 34 mice would be needed to allow inclusion of a treatment 
group plus one control group, with numbers rapidly rising with each subsequent control 
group deemed necessary. The hCD20tg mice used throughout this work are not 
commercially available, and arise from a heterozygous colony maintained in house. This 
means that breeding such a number of age-matched animals would be a huge 
undertaking, with multiple new breeding pairs needing to be set up, and a high number 
of unwanted WT littermates also generated alongside the desired transgenic animals. As 
a result, it was decided that this would not be feasible in the time frame left and no 
further DTH models were set up. 
The aim of this chapter was to investigate our hypothesis that RTX-mediated B cell 
depletion may introduce a temporary tolerance to the immune system in an in vivo 
system, by utilizing animal models. The arthritis model was initially chosen for this, 
however after initial variability in runs, incidence levels became so low as to make the 
results meaningless. The reasons for this sharp decline in incidence, as well as a 
continued partial resistance of the hCD20tg mice to CIA induction, were explored, and 
the decision was made to move away from this model. DTH assays were successfully 
established in the lab, however due to the high number of animals needed to allow 
detection of significance and the time remaining in the project, this protocol was not 
pursued. Due to the challenges encountered while working with these animal models, 
no real progress was made in regards to furthering our understanding of RTX-mediated 
B cell depletion and the effects this has on the immune system in an in vivo setting. 
However, I was able to gain extensive experience in working with a range of in vivo 
models, including one not previously established in the lab, as well as broadening the 
understanding of the hCD20tg DBA strain used throughout this project. 
  
 
 
 
 
 
Chapter 8: Summary 
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AC are able to modulate the immune system, dampening inflammation and eliciting 
anti-inflammatory responses by phagocytes as a consequence of interaction and uptake. 
RTX is an anti-CD20 monoclonal antibody used as a treatment in several autoimmune 
diseases, including RA. Treatment results in B cell depletion, with B cell apoptosis 
known to contribute to RTX-mediated B cell death. However the simple removal of 
pathogenic B cells from the system does not seem to account for all the beneficial 
effects of this biologic in the treatment of autoimmunity.  
Multiple theories have been put forward to explain the beneficial effects of RTX 
treatment in autoimmunity, however a full understanding of all the processes involved 
has still not been reached. It is plausible that there will not be one single mechanism, 
but several, which, when combined, help to re-introduce a balance to the immune 
system. We have hypothesized that one of the potential mechanisms of action of RTX is 
the re-introduction of temporary tolerance to the immune system.  
If apoptosis of B cells is caused as a result of RTX-mediated B cell depletion, these 
apoptotic B cells will be cleared by APC, with the binding and engulfment of apoptotic 
B cells inducing a range of anti-inflammatory responses in the APC. The phagocytosed 
B cell, and any antigens it has previously internalized, will be degraded, and presented 
by the APC in a local environment that is now anti-inflammatory, and therefore skewed 
toward tolerance. If the apoptotic B cell is an autoreactive cell which had previously 
taken up antigen, specifically auto-antigens the RA response is directed toward, 
presentation of this arthritogenic antigen in a non-inflammatory, tolerizing environment 
may result in the re-introduction of temporary tolerance in a dysregulated system, akin 
to the resolution stage of a non-chronic immune response. 
In the preceding chapters steps were taken to begin to investigate the possibility of this 
hypothesis, with a focus on the role of apoptotic B cells and their immunomodulatory 
capacity. 
Throughout this work, apoptotic B cells underwent similar levels of interaction with 
macrophages, and had comparable ability to alter macrophage phenotype and function, 
as the other apoptotic cells examined. Although the effects of AC are now known to be 
more complex than originally anticipated, this finding indicates that apoptotic B cells 
have the capacity to modulate the immune response, with the potential to exert anti-
inflammatory effects on the system. Although far from conclusive, these preliminary 
results open up the possibility that in the setting of RTX-mediated B cell depletion, the 
generation of sufficient numbers of apoptotic B cells may be able to dampen down 
inflammation and help to halt the progression of autoimmunity. 
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The ability of RTX treatment to alter B cell interactions prior to depletion, and the 
possibility that these altered interactions could regulate responses by macrophages was 
also investigated. It has previously been shown that RTX stimulation alters the 
interaction of viable B cells with T cells, and can directly affect the subclass of 
immunoglobulin produced by B cells. In the current in vitro system, RTX pre-treated 
B cells underwent increased levels of interaction with macrophages, with enhanced 
phagocytosis of RTX-coated B cells also observed. However, this increased interaction 
did not affect the macrophage phenotype or function according to any of the 
parameters tested, indicating that RTX bound B cells do not modulate immune 
responses prior to their becoming apoptotic. 
A key feature to understanding the hypothesis is the question of whether self-antigen 
taken up by autoreactive B cells could potentially be presented by other APCs after 
phagocytosis of the B cells. We found that successful secondary presentation of antigen 
was possible in this in vitro assay system, however the current results cannot answer 
the question of whether tolerance or activation would result from such antigen 
presentation in vivo. Nevertheless, they are a first step toward understanding this 
interaction, highlighting this as an interesting area for further investigation. 
Importantly, one of the main findings throughout this thesis was the ability of viable 
cells to recapitulate the AC-driven modulation of macrophage phenotype and function. 
This finding was unexpected, and in comparison to the overwhelming AC data in the 
literature, would suggest that either the previous literature has not performed the 
correct controls or that this capacity of viable cells is specific to our experimental 
system. Regardless of the explanation, further work would be needed to fully explain 
this result. 
In summation, to help enable a better understanding of the role B cells play in RA 
pathogenesis, we need to elucidate the mode of action of effective agents targeted at 
this cell population, such as RTX. The experiments presented in this thesis have begun 
to explore the immunomodulatory capacity of apoptotic B cells, and attempted to 
further the understanding of the mechanisms of action of RTX-mediated B cell depletion 
in autoimmunity and how they exert their beneficial effects. Additional work is needed 
before it can be concluded whether or not RTX-mediated B cell apoptosis and the re-
introduction of tolerance plays a key role in the clinical efficacy of RTX treatment in 
autoimmunity. However, this is an interesting area of research, warranting further 
investigation. 
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Appendix 
 
Media 
 
Complete RPMI: 
 500ml incomplete RPMI (Gibco, Invitrogen) 
 50ml heat-inactivated foetal bovine serum  
 5ml penicillin-streptomycin (Sigma) 
 5ml L-Glutamine (Sigma) 
 5ml non-essential amino-acids (Invitrogen) 
 500µl beta-2-mercaptoethanol (Gibco, Invitrogen)  
 
Peritoneal Wash Solution: 
 100mls 1x PBS  
 250mM EDTA  
 
Buffers 
 
General buffers 
 
10x PBS: 
 10L dH2O 
 800g NaCl 
 20g KCl 
 20g KH2PO4 
 290g Na2HPO4.12H20 
 
Genotyping buffers 
 
Tris-acetate-EDTA (TAE) buffer: 
 242g Tris Base 
 57.1ml Glacial Acetic Acid 
 100ml 0.5M EDTA 
 make up to 1L with dH20 
 
Alkaline Lysis Buffer, pH 12: 
 25mM NaOH 
 0.2 mM EDTA 
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Neutralization buffer, pH 5: 
 40mM Tris HCl 
 
FACS buffers 
 
FACS Buffer: 
 1L 1x PBS   
 3% BSA  
 1mM EDTA 
 0.05% Sodium Azide 
 
Sodium Phosphate Buffer, pH 8.0: 
 100mM sodium phosphate 
 
ELISA buffers  
 
Cytokine ELISA coating buffers: 
a) 0.2M Sodium Phosphate, pH 6.5: 
 1L dH20 
 12.49g Na2HPO4 
 15.47g NaH2PO4 
 
b) 0.1M Sodium Carbonate, pH 9.5: 
 1L dH20 
 7.13g NaHCO  
 1.59g NaCO  
 
Cytokine ELISA Assay Diluent/Blocking Buffer: 
 1x PBS 
 10% FBS 
 
Serum ELISA Blocking Buffer: 
 1x PBS 
 3% BSA 
 
Serum ELISA Assay Diluent: 
 1x PBS 
 1% BSA 
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PBS-Tween (ELISA wash buffer): 
 1x PBS 
 0.5% Tween 
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